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Abstract  
 
Diffuse Large B-Cell Lymphomas (DLBCL) are common, aggressive malignancies of 
mature B-lymphocytes that represent ~40% of lymphomas. Despite the widespread use 
of combined immunochemotherapy, approximately 50% of patients with DLBCL die 
from their disease. The two main DLBCL subgroups resemble activated B cells (ABC) 
or germinal centre B cells (GCB), where patients with ABC-DLBCL have significantly 
worse outcome. There is urgent need for novel therapeutic strategies in the treatment of 
DLBCL, which requires a better understanding of the molecular pathways upon which 
tumours depend.    
Accumulating evidence suggests that the signalling networks promoting and sustaining 
DLBCL derive from dysregulation of the normal pathways controlling B-lymphocyte 
activation and differentiation. There is increasing evidence indicating important roles for 
the NFAT family of transcription factors in DLBCL. Constitutively-active nuclear 
NFAT2 has been demonstrated in approximately 40% of primary DLBCL samples and 
NFAT has been shown to regulate a small number of genes associated with DLBCL 
growth/survival. 
This project investigated the role of NFAT in DLBCL. Nuclear localisation and activation 
of NFAT family members were characterised in a panel of DLBCL cell lines and 
chemical inhibition of calcineurin/NFAT, using Cyclosporin A (CsA), indicated 
dependency on the calcineurin/NFAT pathway for survival. Gene expression microarray 
analysis performed in DLBCL cell lines treated with CsA revealed potential NFAT target 
genes involved in the tumour microenvironment and anergy.  
These data revealed that the cytokine TNFα was downregulated by CsA in ABC, but not 
GCB cell lines. TNFα expression has recently been reported a significant prognostic 
factor for OS and PFS in DLBCL and evidence suggests dependency of some DLBCL on 
autocrine TNFα signalling for survival. Biologically active TNFα was produced by 
DLBCL cell lines, however inhibition of TNFα signalling using Infliximab and 
Etanercept had no effect on cell viability, suggesting that TNFα may be functionally 
important in DLBCL by other mechanisms.   
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1. Introduction 
 
1.1. Lymphoma  
 
Cancer is a disease caused by the uncontrolled division and survival of abnormal cells, 
leading to the formation of malignant growths or tumours in specific parts of the body. 
There are over 200 different types of cancer, with over 300,000 new cases being 
diagnosed each year in the UK (CRUK, 2015). Most cancers develop as solid tumours at 
a primary site and may spread, or metastasise, to other tissues, such as through the blood 
or lymphatic system. Spread of cancer throughout the body is often life-threatening, 
sometimes preventing the function of vital organs.  
For a cell to transform from a normal cell to a cancerous cell, it is believed that specific 
biological capabilities are required. These were summarised by Hanahan and Weinberg 
in 2000, who proposed six hallmarks of cancer, forming a framework for understanding 
the diverse characteristics of neoplastic disease (Hanahan et al., 2000). The hallmarks 
included sustaining proliferative signals, evading growth suppressors, enabling 
replicative immortality, resisting cell death, inducing angiogenesis and activating 
invasion and metastasis (Hanahan et al., 2000). More recently, an additional two traits 
have been added to the list of hallmarks: the ability to evade immune destruction and the 
ability to reprogram energy metabolism (Hanahan et al., 2011). A better understanding 
of the common traits shared by various malignancies is key to deciphering the multistep 
process of tumour pathogenesis. 
Lymphomas are cancers of lymphocytes and their immediate precursors which form solid 
masses within the lymphatic system, such as within lymph nodes or spleen, or in 
extranodal tissues throughout the body. Similar neoplasms based in blood and bone 
marrow are considered leukaemias, however this is a generalisation, with some myelomas 
also being located in the bone marrow and some lymphomas being present in the blood. 
There are two main types of lymphoma, the largest group being the non-Hodgkin 
lymphomas (NHL), which are the fifth most common cancer in the UK, with around 
12,000 new cases being diagnosed each year (Macian, 2005; Cancer Research UK, 2012). 
Named after Dr Thomas Hodgkin, who first diagnosed the disease, a less common group 
are the Hodgkin lymphomas (Burkitt, 1958). The abnormal cells in classical Hodgkin 
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lymphomas are large, often multinucleate, Hodgkin/Reed-Sternberg cells (Küppers et al., 
2012).  
1.2. B-Cell Non-Hodgkin Lymphoma 
 
Since their first recognition, the classification of lymphomas has evolved considerably as 
our understanding of the underlying biology has increased. NHL can derive from B cells, 
T cells or natural killer-cells (NK-cells). Less common are the T/NK-cell lymphomas, 
which include peripheral T-cell lymphoma not otherwise specified, cutaneous T-cell 
lymphomas, anaplastic large cell lymphomas and T-cell lymphoblastic lymphoma. B-cell 
NHL (B-NHL) on the other hand are the most common NHL, representing a very diverse 
group of malignant diseases.   
Briefly, mantle cell lymphomas (MCL) account for 5-10% of lymphoma cases and are 
derived from a naïve pre-germinal centre B-cell, localising to the mantle region of 
secondary follicles (Shaffer et al., 2002b; Nogai et al., 2011). MCL are typically 
aggressive lymphomas and patients with this disease have a median survival of only 3 to 
4 years (Goy et al., 2011; Vose, 2013). Follicular lymphomas (FL) are the most frequent 
indolent, low-grade B-NHL, accounting for roughly 20% of all lymphomas (Nogai et al., 
2011). FL are derived from germinal centre B cells (GCB) and localise principally to the 
germinal centres (GC) of follicles where they undergo somatic hypermutation (Nogai et 
al., 2011). Also derived from the GC, Burkitt lymphoma (BL) is an aggressive type of B-
NHL found in mainly children and young adults (Shaffer et al., 2002b).  
The B-NHL of interest in this study were the diffuse large B-Cell lymphomas (DLBCL), 
which are aggressive malignancies of mature B cells. DLBCL are the most common type 
of NHL, representing around 40% of lymphomas in adults in the UK (Staudt, 2010). 
Although cures are achieved in approximately 60% of patients, outcome is largely 
unpredictable due to substantial disease heterogeneity (Shipp, 2007). Over 30% of 
patients do not respond to conventional first-line therapies or relapse, highlighting the 
requirement for a better understanding of the biology underlying lymphoma (Pasqualucci, 
2013).  
Examples of other, less common B-cell lymphoid malignancies include extranodal 
marginal zone B-cell (MALT) lymphomas, primary mediastinal large B-cell lymphomas 
(PMBL) and nodal marginal zone lymphomas (NMZL).  
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1.3. Diagnosis, prognosis and treatment of DLBCL 
 
Patients with DLBCL present with solid tumours, most commonly in the lymph nodes 
but also in extranodal sites. Following initial clinical consultation, DLBCL is typically 
diagnosed by a biopsy from an involved site, which is examined microscopically. 
Immunophenotyping by immunohistochemistry or flow cytometry is used to confirm B-
cell lineage, exclude other diagnoses and determine their phenotypic subgroup. Genetic 
analysis for chromosomal translocations and mutations is now increasingly clinically 
important. Accordingly, DLBCL is currently sub-classified based on a combination of 
morphological, immunophenotypic, clinical and genetic features.  
The prognosis of DLBCL depends upon both clinical and intrinsic biological and genetic 
features. The International Prognostic Index (IPI) has been the main method for predicting 
patient response to therapy for the past 20 years (Unknown, 1993; Zhou et al., 2014). 
Based on analysis of more than 2000 patients with aggressive lymphomas, the IPI 
integrates five negative prognostic factors at diagnosis into a risk score (Unknown, 1993). 
These factors are age (>60 years), stage (extent) of disease, elevated lactate 
dehydrogenase (LDH) level, Eastern Cooperative Oncology Group (ECOG) performance 
status (≤2) and whether the lymphoma is present at more than one extranodal site 
(Unknown, 1993). Patients are then put into four separate outcome groups, identified 
initially as having a 5-year overall survival from 26%-73% (Unknown, 1993). Two 
modifications to the IPI have been introduced recently, in response to changes in therapy 
and outcome: an age-adjusted IPI (aaIPI) and a revised IPI (r-IPI) with only three risk 
factors (Sehn et al., 2007).  
Conventional methods of treatment for various cancers include local surgery, 
radiotherapy or chemotherapy. As a cancer frequently disseminated throughout the 
lymphoid system, DLBCL is treated principally with chemotherapy. In the UK, DLBCL 
is usually treated with moderately aggressive combined immunochemotherapy using the 
R-CHOP regimen. The chemotherapeutic agents that make up this drug combination 
include cyclophosphamide (an alkylating agent), doxorubicin (an anthracycline) and 
vincristine (an alkaloid). Prednisolone on the other hand, is a glucocorticoid drug, 
whereas rituximab is an anti-CD20 monoclonal antibody. 
The addition of Rituximab to the standard CHOP regimen has been shown to be beneficial 
in many trials and has significantly improved the survival of patients with DLBCL 
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(Habermann et al., 2006; Coiffier et al., 2010; Pfreundschuh et al., 2011). Nevertheless, 
clinical responses vary considerably depending on a patient’s genetic profile and stage of 
disease, meaning that further improvements are required for patients who are poor-risk or 
chemo-refractory, or who relapse after treatment (Coiffier et al., 2002; Zhang et al., 
2013b). Second-line chemotherapy regimes, haematopoietic stem cell transplantation and 
radiotherapy have important roles in certain clinical contexts, but when the diagnosis of 
DLBCL is known, surgery is rarely utilised.  
1.4. Sub-classification of DLBCL by cell of origin (COO) 
 
Genomic analysis has shown DLBCL to harbour a high degree of complexity when 
compared to other haematological malignancies (Pasqualucci, 2013). This is largely due 
to significant variability between patients, which is one of the main obstacles to 
therapeutic success in DLBCL (Pasqualucci, 2013). Studies investigating the molecular 
heterogeneity of DLBCL have enabled identification of three molecularly distinct 
subgroups of DLBCL, which arise from B cells at different stages of differentiation 
(Alizadeh et al., 2000; Wright et al., 2003). Genome-scale gene-expression microarrays 
have demonstrated unique gene-expression signatures for each disease subtype, where 
one expressed genes characteristic of germinal centre B cells (GCB type) including 
BCL6, CD10 and LMO2, and a second type expressed genes induced during the activated 
B-cell state (ABC type) such as IRF4/MUM1, FOXP1 and CCND2 (Alizadeh et al., 
2000). Interestingly, the gene expression subgroups were shown to differ by the 
expression of more than 1000 genes, proving how distinct these lymphomas really are 
(Alizadeh et al., 2000; Rosenwald et al., 2002).  
GCB DLBCLs are thought to derive from germinal centre centroblasts, expressing high 
levels of genes characteristic of normal germinal centre B cells (Alizadeh et al., 2000). In 
contrast, the gene expression profile of ABC DLBCLs suggests that these lymphomas are 
derived from B cells that are in the process of differentiating into plasma cells (Alizadeh 
et al., 2000). Importantly, multiple genetic lesions of pathogenic significance are 
correlated with different subgroups of DLBCL (Shaffer et al., 2012a). This suggests that 
these tumours depend on specific oncogenic pathways, which may be therapeutically 
targetable.  
The third type of DLBCL, which also arose from gene expression profiling, is PMBL 
(Alizadeh et al., 2000) . This disease mostly occurs in young females, with a median age 
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of only 30 to 35 years (Nogai et al., 2011). It is thought that PMBL originates from a rare, 
post-germinal B-cell population that resides in the thymus, showing different 
characteristics to other types of DLBCL, but similarities to Hodgkin lymphomas by gene 
expression profiling (Rosenwald et al., 2003; Yuan et al., 2015).  
Approximately 15% of DLBCLs cannot be assigned to a molecular subgroup as they 
exhibit gene expression profiles not typical of GCB DLBCL, ABC DLBCL or PMBL 
subtypes. These are referred to as ‘unclassifiable’ or ‘Type 3’ DLBCL, (Lenz et al., 
2008b).  
Immunohistochemistry has been used in attempts to stratify DLBCL into COO subgroups 
in diagnostic practice as genome-scale expression profiling is not clinically practical. 
Various immunohistochemical algorithms have been used to try to reproduce the cell of 
origin subgroups found by gene expression profiling. The Hans classification system, for 
example, distinguishes GCB and non-GCB subgroups according to expression of CD10, 
BCL6 and IRF4/MUM1 (Hans et al., 2004). CD10-positive and CD10-negative/BCL6-
positive/MUM1-negative tumours are classed as GCB tumours, and the remainder as non-
GCB (Hans et al., 2004). Recently, additional antibodies (including FOXP1, LMO2, 
GCET1 and BCL2), have been incorporated into additional algorithms which has 
increased the accuracy of the approach (Choi et al., 2009) (Meyer et al., 2011). 
Nevertheless, immunostaining remains an imperfect substitute for gene expression 
profiling, fails to identify Type 3 DLBCLs, and suffers from poor inter-laboratory 
reproducibility. More recently, new platforms for molecular profiling of fixed diagnostic 
tissue such as NanoString have been used for COO classification with promising results 
(Scott et al., 2015; Xue et al., 2015). Importantly, when treated with current standard 
therapies, patients with GCB DLBCL have a significantly better overall survival than 
those with the ABC subtype. Patients with ABC DLBCL have a 5-year overall survival 
rate of only 35%, compared to 60% in patients with GCB DLBCL (Shaffer et al., 2002b; 
Dunleavy et al., 2009; Meyer et al., 2011).  
Despite recognition of two very different DLBCL phenotypes by gene expression 
analysis, at present, patients with either ABC or GCB DLBCL receive the same therapy. 
It is therefore not surprising that there are differences between response and cure rates 
between these disease subgroups. Future therapies would ideally target the disease in a 
subgroup-specific manor, which first requires a better understanding of the molecular 
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machinery to which they depend. Indeed, several agents targeting subgroup-selective 
pathogenic mechanisms, (as discussed below) are currently in clinical trials.  
1.5. Pathogenesis of DLBCL 
 
1.5.1. Genetic abnormalities in DLBCL 
 
Similar to other types of cancer, B-cell lymphomas arise from the multistep accumulation 
of genetic abnormalities such as translocations, point mutations and deletions (Shaffer et 
al., 2012a). Multiple genetic lesions in DLBCL are often associated with the genes and 
molecular pathways which affect behaviours in relation to the hallmarks of cancer.  
B-cell development is initiated in the primary lymphoid organs and differentiation occurs 
in the secondary lymphoid tissues such as the spleen, lymph nodes or tonsils. During these 
stages of development a number of DNA modifications occur which can predispose to 
various genetic aberrations (figure 1) (Nogai et al., 2011). Initiation of normal B-cell 
development occurs in the bone marrow whereby formation of the BCR occurs by the 
rearrangement of genes which encode the immunoglobulin heavy and light chains 
(Hozumi et al., 1976). This process, called V(D)J recombination, involves double-
stranded DNA breaks by the recombination activating genes 1 (RAG1) and 2 (RAG2), 
followed by end-joining repair processes (Hozumi et al., 1976). Cells that do not acquire 
heavy and light chain variable regions correctly undergo apoptosis at this stage, whereas 
cells expressing the BCR become mature naïve B cells which leave the bone marrow and 
enter the periphery.  
Until B cells encounter an antigen, they are considered naïve B cells, as shown in figure 
1 (Bertoni et al., 2007). Following contact with an antigen, the BCR becomes activated 
and naïve B cells are stimulated, resulting in their proliferation and migration to the 
secondary lymphoid tissues such as the lymph nodes, where they form the germinal centre 
(Steinhardt et al., 2012). Here, B cells differentiate into germinal centre cells (centrocytes 
and centroblasts) and subsequently into plasma cells (MacLennan, 1994). Centrocytes 
and centroblasts cycle through the light and dark zones of the germinal centre, where they 
rapidly proliferate, differentiate, and revise their antigen receptors (Berek et al., 1991; 
Jacob et al., 1991). This occurs by somatic hypermutation (SHM) of the immunoglobulin 
heavy chain variable region (IGHV) genes, as well as by the process of class switch 
recombination (CSR) which involves DNA double strand breaks (Steinhardt et al., 2012). 
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Both of these processes are mediated by activation-induced cytidine deaminase (AID), 
which deaminates cytosine to uracil (Muramatsu et al., 1999; Muramatsu et al., 2000). 
Although highly controlled, V(D)J recombination, SHM and CSR each lead to an 
inevitable degree of collateral damage to other genes, resulting the accumulation of 
various somatic genetic changes which may promote lymphomagenesis (Nogai et al., 
2011). During SHM for example, activating or inactivating mutations and small 
insertions/deletions can occur in numerous key non-immunoglobulin genes involved in 
B-cell differentiation (Nogai et al., 2011). In addition, chromosomal translocations can 
occur as a result of misrepair of DNA breaks that occur during V(D)J recombination in 
the bone marrow and class-switch recombination in the germinal centre (Nogai et al., 
2011). AID-induced DNA lesions during SHM also predispose to double strand DNA 
breaks and promote translocation formation. Unfortunate consequences of these initial 
recombination events are the development of select chromosomal aberrations, affecting 
specific oncogenes and tumour suppressors. In fact, up to 50% of DLBCLs have 
translocations involving immunoglobulin loci (Shipp, 2007).  
Figure 1. Stages of B-cell differentiation and the specific events that can lead to various lymphomas. 
Image adapted from (Nogai et al., 2011) 
1.5.2. Deregulation of BCL2 activity  
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B-cell lymphoma 2 (BCL2) is the founding member of a family of regulatory proteins 
which regulate apoptosis (Tsujimoto Y, 1984 ). First discovered for its role in t(14;18) 
translocations in follicular lymphoma, BCL2 is now regarded as a central anti-apoptotic, 
pro-survival protein of oncogenic nature (Aukema et al., 2011). Recurrent t(14;18) 
(q32;q21): BCL2-IGH translocations lead to upregulation of BCL2, causing it to be 
aberrantly regulated and constitutively expressed (Willis et al., 2000; Rui et al., 2011) 
(Huang et al., 2002; Kuppers, 2005). This translocation occurs in 20% of DLBCL, where 
it is more common in the GCB subtype (Willis et al., 2000; Iqbal et al., 2004). In fact, 
RNA-sequencing data has recently shown that BCL2 is the most highly mutated gene in 
GCB DLBCL (Schuetz et al., 2012). BCL2 deregulation can also occur in ABC DLBCL; 
however this is usually by amplification of the BCL2 gene or transcriptional upregulation 
through constitutive activation of NF-κB (Iqbal et al., 2006).  
1.5.3. Deregulation of BCL6 activity 
 
Another recurrent translocation in DLBCL involves the transcription factor and master 
regulator of the germinal centre reaction, B-cell lymphoma 6 (BCL6). BCL6 is a zinc 
finger transcriptional repressor which has essential roles in B cells and T cells in normal 
antibody responses and regulates genes involved in the cell cycle, differentiation and 
inflammation (Shaffer et al., 2000). BCL6 principally functions to allow cells in the 
germinal centre to differentiate and sustain rapid proliferation, while tolerating DNA 
breaks (without initiating DNA damage responses) during SHM and class switch 
recombination (Rui et al., 2011). BCL6 therefore prevents premature differentiation of B 
cells and their escape from the germinal centre before selection of clones producing high 
affinity antibodies (Basso et al., 2012).  
BCL6 in DLBCL is frequently deregulated by chromosomal rearrangements of the BCL6 
locus, which occurs in around 20% of DLBCL patients, where a higher frequency is 
observed in patients with the ABC subgroup of DLBCL (Iqbal et al., 2007; Basso et al., 
2012; Shaffer et al., 2012a). Often deregulated by t(3;14) (q27;q32) BCL6-IGH 
translocations, recombination events place the coding domain of BCL6 downstream of 
heterologous regulatory regions from over 20 chromosomal partners (Ye et al., 1993; 
Willis et al., 2000; Pasqualucci, 2013). BCL6 translocations therefore ultimately prevent 
the normal downregulation of BCL6 during differentiation of cells into post-GCB cells 
(Basso et al., 2012).  
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Gene expression profiling experiments have been a useful tool for understanding the role 
of BCL6 in lymphomagenesis, where BCL6 has been demonstrated to block plasmacytic 
differentiation and promote progression of the cell cycle (Shaffer et al., 2000). Moreover, 
BCL6 has also been shown to block the DNA-damage response by repressing ATR and 
TP53 (Phan et al., 2004; Ranuncolo et al., 2007). In addition, another important target of 
BCL6 is the previously described pro-survival factor BCL2, which is also frequently 
amplified on locus 18q24 in patients with the GCB subgroup of DLBCL (Iqbal et al., 
2004; Ci et al., 2009; Saito et al., 2009). The fundamental role of BCL6 in 
lymphomagenesis has been highlighted by the promotion of human-like lymphoma 
development in mouse models with deregulated BCL6 expression and BCL6 now 
represents an attractive therapeutic target in lymphoma (Cattoretti et al., 2005). 
1.5.4. Disruption of terminal differentiation 
 
A significant role for BCL6 is in the control of differentiation to plasma cells via 
suppression of PR domain zinc finger protein 1 (PRDM1), which is also known as 
BLIMP1 (Shapiro-Shelef et al., 2003). BLIMP1 is a tumour suppressor gene that 
functions a transcriptional repressor by binding to DNA and acting as a scaffold to recruit 
multiple core-repressor proteins (Bikoff et al., 2009). Its role is to promote terminal 
differentiation of B cells into plasma cells by repressing genes important in B-cell 
receptor signalling and proliferation (Lin et al., 1997; Shaffer et al., 2002a) . This was 
demonstrated by Shapiro-Shelef et al (2003), where conditional knockout of Blimp-1 in 
the B cells of mice failed to produce plasma cells and serum immunoglobulins (Shapiro-
Shelef et al., 2003).  
In 25% of cases of DLBCL, aberrant loss of expression of BLIMP1 is due to constitutive 
repression by deregulated BCL6 (Pasqualucci et al., 2006; Mandelbaum et al., 2010). A 
consequence of these events is that ABC DLBCLs escape from terminal differentiation 
and cell cycle arrest (Pasqualucci, 2013). This pathogenic block in the differentiation 
pathway may also be due to inactivating mutations and deletions of the BLIMP1 gene, 
which have also been detected in one quarter of ABC DLBCLs (Mandelbaum et al., 
2010). The importance of correctly functional BLIMP1 in ABC DLBCL has been 
demonstrated in mouse models with conditional deletion of BLIMP1 in the germinal 
centre, where mice developed an ABC DLBCL-like disease (Mandelbaum et al., 2010).  
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1.5.5. Alterations in epigenetic modifiers 
 
In recent years there have been increasing studies reporting recurrent genetic lesions in 
histone/chromatin modifiers such as acetyltransferases and histone methyltransferases 
(Morin et al., 2010; Béguelin et al., 2013; Pasqualucci, 2013). Inactivating mutations and 
deletions of CREB Binding Protein (CREBBP) and less frequently, E1A Binding Protein 
P300 (EP300) have been detected in up to 35% of DLBCL, and found to occur more 
commonly in GCB DLBCLs (Morin et al., 2011; Pasqualucci et al., 2011b).  These 
proteins modify lysine residues on both histone and non-histone nuclear proteins, 
functioning as transcriptional coactivators for many transcription factors (Pasqualucci et 
al., 2011a). CREBBP and EP300 enhance transcription by mechanisms such as by 
acetylation of chromatin and transcriptional activators, such as p53, and acetylation-
mediated inactivation of repressors of transcription such as BCL6 (Pasqualucci et al., 
2011a). Mutations of CREBBP and EP300 cause disruption of their ability to acetylate 
substrates such as p53 and BCL6, which consequently leads to constitutive active BCL6 
and decreased tumour suppressor activity from p53 (Pasqualucci et al., 2011a). There is 
no surprise that CREBBP and EP300 have become attractive therapeutic targets for 
DLBCL. Current attempts have targeted these proteins by histone deacetylase inhibitors 
(HDACs), which have had growth inhibitory effects in DLBCL cell lines and patients 
with chemotherapy-resistant DLBCL (Cai et al., 2013; Xue, 2015).     
Mixed-lineage leukaemia 2 (MLL2) is an example of a gene which encodes a highly 
conserved histone methyltransferase, its role being to control gene transcription by 
modification of lysine-4 on histone 3 (Shilatifard, 2012). Interestingly, MLL2 is the most 
commonly mutated gene in B-NHL, representing over 30% of DLBCL and 89% of 
follicular lymphomas (Morin et al., 2011; Pasqualucci et al., 2011b). Inactivating 
mutations of MLL2 in DLBCL generate truncated proteins that lack the catalytic activity 
that is required for methyltransferase activity, suggesting that this gene acts as a tumour 
suppressor in both ABC and GCB DLBCL (Morin et al., 2011; Pasqualucci et al., 2011a).     
Moreover, a particularly striking difference between ABC and GCB DLBCL is the 
presence of somatic gain-of-function mutations in the histone methyltransferase enhancer 
of zeste homolog 2 (EZH2), which occurs in approximately 22% of GCB DLBCL patient 
samples, but not in ABC DLBCL (Morin et al., 2010). EZH2 is the catalytic subunit of 
the chromatin regulator polycomb repressive complex 2 (PRC2) and mediates 
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transcriptional repression using its methyltransferase activity (Velichutina et al., 2010). 
EZH2 is critical for normal embryo development and important for V(D)J recombination 
in pre-B cells (Su et al., 2003). Normally, after the pre-B-cell stage, EZH2 expression 
decreases as B cells exit the GC reaction, allowing expression of genes that control 
terminal differentiation (Velichutina et al., 2010). However, when EZH2 is somatically 
mutated, suppression of GC exit genes and checkpoints continues, resulting in 
hyperplasia (Béguelin et al., 2013). Several recent studies have investigated the effects of 
selective small molecule inhibitors of EZH2, which were shown to effectively induce cell 
cycle arrest and apoptosis in EZH2-mutated DLBCL cells (Knutson et al., 2012; McCabe 
et al., 2012). 
Overall, these studies suggest a critical role for epigenetic remodelling in the malignant 
setting, highlighting new therapeutic opportunities for these lymphomas (Morin et al., 
2010; Pasqualucci et al., 2011a; Lohr et al., 2012).  
 
Figure 2. The origin of human lymphoid malignancies and the underlying genetic aberrations 
commonly associated with ABC and GCB DLBCL. Image adapted from (Rui et al., 2011) 
In summary, the pathogenesis of DLBCL is caused by a combination of chromosomal 
translocations, mutations and deletions that disrupt normal B-cell proliferation, survival 
and differentiation. While GCB DLBCLs are associated with translocations of BCL2, 
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mutations within the BCL6 autoregulatory domain and mutations of epigenetic regulators 
such as EZH2, patients with ABC DLBCL often harbor BCL6 translocations and 
amplifications of BCL2 (Ye et al., 1993; Huang et al., 2002; Iqbal et al., 2004; Iqbal et 
al., 2007; Morin et al., 2010). In addition to the underlying genetic abnormalities 
previously described (and shown in figure 2), it is common for ABC DLBCLs to harbor 
mutations associated with BCR signalling, such as within the NF-κB pathway, as 
discussed in the following sections. 
1.6. B-Cell Receptor signalling 
 
1.6.1. Normal B-Cell receptor signalling 
 
Signals propagated through the BCR are critical for the development of normal B cells 
and the survival of mature B cells  (Kraus et al., 2004). In summary, upon ligand 
stimulation, BCRs aggregate in microclusters, which recruit Src family tyrosine kinases, 
which phosphorylate tyrosine residues within the immunoreceptor tyrosine-based 
activation motif (ITAM) of the BCR components CD79A and CD79B (Rickert, 2013). 
This causes recruitment of the spleen tyrosine kinase (SYK), which phosphorylates the 
B-cell linked (BLNK) protein, engaging Bruton’s tyrosine kinase (BTK) (Rickert, 2013). 
In turn, phosphatidylinositol -4, 5-bisphosphate 3-kinase (PI3K) activation allows 
recruitment of BTK to the plasma membrane by binding to phosphatidylinositol (3, 4, 5)-
trisphosphate (PIP3) (Shaffer et al., 2012a). This enables activation of phospholipase C 
gamma 2 (PLCγ2), which hydrolyses phosphatidylinositol (4,5)-bisphosphate (PIP2) into 
diacylglycerol (DAG) and inositol trisphosphate (IP3) (Shaffer et al., 2012a). IP3 induces 
release of calcium stores via the IP3 receptor on the endoplasmic reticulum. Together, 
calcium and DAG activate protein kinase C beta (PKCβ), leading to activation of NF-κB 
via activation of the CARD11-BCL10-MALT1 (CBM) complex (Shaffer et al., 2012a).  
B cells use antigen-dependent BCR signalling to induce their differentiation and 
proliferation during an immune response. This occurs through the initiation of a set of 
signalling pathways (figure 3), including the NF-κB, NFAT, PI3K and MAPK pathways, 
as reviewed by Dar Porto et al (2004) (Dal Porto et al., 2004). Upon activation, NF-κB 
and NFAT bind to the promoters, enhancers and other regulatory regions of copious genes 
and regulate their expression. As a result, these transcription factors are responsible for 
controlling the growth, proliferation and function of peripheral lymphocytes. 
PhD Thesis  Holly White 
 
14 
 
 
Figure 3. The B-cell receptor and the key signalling pathways initiated by BCR stimulation.  
 
1.6.2. B-Cell receptor signalling in DLBCL 
 
Despite the numerous somatic hypermutation events and IG translocations that occur 
during lymphomagenesis, there is rarely loss of the BCR in the malignant setting, 
indicating that continued BCR signalling is important for B-cell lymphoma maintenance 
(Kuppers, 2005). Indeed, signals from the BCR are known to be critical promoters of 
lymphoma cell proliferation and survival (Shaffer et al., 2012b). Interestingly, prominent 
BCR clusters, resembling those on normal B cells following stimulation by an antigen, 
were identified on cell lines and patient samples of ABC DLBCL, suggesting that this 
subtype resembles normal, activated B cells (Davis et al., 2010). In contrast, BCRs in 
GCB cell lines were likened to those of a normal resting B-cell, where BCRs were evenly 
distributed across the plasma membrane (Davis et al., 2010).  
1.6.3. Chronic active BCR signalling 
 
There is accumulating evidence that ABC DLBCL are sustained by dysregulation of 
normal BCR signalling pathways that regulate B-cell activation and survival (Lenz et al., 
2010). This may be a consequence of ligand-independent BCR signalling due to 
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mutations in components of the B-cell receptor, such as somatic mutations of the Igα or 
Igβ subunits (Davis et al., 2010). This altered BCR surface expression is described as 
‘chronic-active BCR signalling’, which can lead to constitutive activation of downstream 
signalling events, as described in the sections below. 
1.7. The NF-κB signalling pathway 
 
Constitutive activation of NF-κB is a hallmark of numerous malignancies, where the 
functional consequences of its activation have a striking correlation with the hallmarks of 
cancer (Hanahan et al., 2000; Perkins, 2012). NF-κB can drive the malignant phenotype 
in a number of ways, such as by inhibiting apoptosis, driving cell proliferation and 
promoting migration and invasion (Kumar et al., 2004; Karin, 2006; Kim et al., 2006). 
The oncogenic nature of the NF-κB pathway and its many roles have now been 
extensively reviewed (Baldwin, 2001; Karin et al., 2002).  
Deregulation of NF-κB in cancer, leading to nuclear NF-κB-localisation and aberrant NF-
κB target gene expression, may be due to oncogenes such as Harvey Rat Sarcoma Viral 
Oncogene Homolog (HRAS), or by positive regulation from upstream components such 
as mutated Caspase Recruitment Domain Family Member 11 (CARD11) (Lenz et al., 
2008a; Staudt, 2010; Perkins, 2012). Alternatively, constitutively active NF-κB may be a 
consequence of the inability of negative regulators of NF-κB, such as the intracellular 
ubiquitin-editing protein A20 (also known as TNFAIP3) to switch off NF-κB (Compagno 
et al., 2009; Kato et al., 2009; Perkins, 2012) 
Many types of B-cell lymphoma harbour constitutive activation of NF-κB, such as 
DLBCL and multiple myeloma, which is likely to stem from the fact that NF-κB 
signalling has a major role in the differentiation, proliferation and maturation of normal 
B cells (Gerondakis et al., 2010; Staudt, 2010).  
1.7.1. Biology of NF-κB/primary structure of NF-κB 
 
NF-κB was first identified as a transcription factor that binds to the enhancer of the kappa 
immunoglobulin light chain gene in B cells (Sen et al., 1986). Soon after, NF-κB was 
recognised as a major regulator of immune function and the inflammatory response 
(Karin, 2009; Vallabhapurapu et al., 2009). The NF-κB transcriptional pathway has since 
been associated with the regulation of hundreds of genes involved in a vast array of 
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cellular processes such as apoptosis, the cell cycle, inflammation and immunoregulation 
(Jost et al., 2007).   
NF-κB belongs to the evolutionarily conserved Rel family of proteins (figure 4), which 
includes c-Rel, RelA (p65), RelB, NF-κB1 (p50) and NF-κB2 (p52). NF-κB1 and NF-
κB2 encode longer precursor proteins that can be processed to active p50 and p52 
respectively (Hayden et al., 2008).  In resting cells, NF-κB proteins are sequestered in the 
cytoplasm in association with inhibitory IκB proteins including IκBα, IκBβ and IκBε. 
Ankyrin repeats found in IκB proteins are also present in p100 and p105, allowing them 
to also function as IκB proteins (Vallabhapurapu et al., 2009).  
 
Figure 4. The primary structure of the NF-κB subunits. The NF-κB subunits share a DNA binding 
domain and dimerization domain called the REL homology region (RHR). RelA, RelB and c-Rel contain 
transactivation domains whereas RelB has an amino-terminal leucine zipper-like (LZ) motif. Image adapted 
from (Perkins, 2012)  
1.7.2. Activation of the NF-κB signalling pathway 
 
NF-κB is activated by many different stimuli, including antigen-binding to immune 
receptors and by binding of inflammatory cytokines, such as TNFα, to toll-like receptors 
(TLR) and the TNFα receptor. Many stimuli activate the canonical NF-κB pathway, 
which specifically requires the catalytic IKKα and IKKβ and the regulatory IKKγ 
(NEMO) subunits, (which comprise the heterotrimeric IKK complex) (Perkins, 2007). 
Phosphorylation of IκBα on serine 32 or serine 36 causes IκBα to be targeted for 
polyubiquitination and degradation by the 26S proteasome, allowing release of NF-κB 
subunits (Karin et al., 2000; Karin, 2009), as shown in figure 5. There is the potential for 
the formation of 15 different NF-κB dimers, which for the canonical pathway are typically 
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p50/p65 and p50/c-Rel heterodimers, (Staudt, 2010; Vincent Feng-Sheng Shih, 2011). 
Following release of NF-κB subunits from inhibitory IκB proteins, dimers translocate to 
the nucleus and bind to κB sites on DNA, leading to transcriptional activation of genes 
with a broad spectrum of roles. 
 
Figure 5. The NF-κB signalling pathway.  NF-κB signalling can be initiated by activation of the B-cell 
receptor, leading to activation of the CBM complex via recruitment of TRAF6 (not shown) and subsequent 
activation of IKK subunits and the NF-κB signalling cascade.  
The non-canonical pathway on the other hand, is initiated by other stimuli and is engaged 
specifically by TNF-family receptors such as CD40, BAFF receptor and the lymphotoxin 
β receptor (Bonizzi et al., 2004). The pathway is dependent on phosphorylation of 
homodimers of IKKα by activation of the upstream kinase NIK. In non-stimulated cells 
NIK is subject to rapid turnover, however stimulation of the pathway causes stabilisation 
of NIK and IKKα activation, which in turn regulates the processing of the p100 precursor 
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protein to p52, leading to nuclear translocation of the p52-RelB heterodimer (Liao et al., 
2004).  
1.7.3. NF-κB signalling in DLBCL  
 
Mutations in several upstream components of the NF-κB pathway have been identified in 
ABC DLBCL tumours, leading to sustained activation of the NF-κB pathway, which is 
now a well-known hallmark of this subgroup of DLBCL (Lam et al., 2005). This was first 
recognised by Davis et al (2001) where small molecule inhibitors of IκB Kinase were 
found to be toxic for ABC DLBCL cell lines (Lam et al., 2005). Their data indicated that 
specifically DLBCLs of the ABC subgroup were addicted to constitutive NF-κB 
signalling and require it for their survival (Davis et al., 2001; Lam et al., 2005). Moreover, 
as described previously, gene expression profiling has shown that many genes 
upregulated in ABC DLBCL are known NF-κB target genes, such as BCL2 and IL6, 
suggesting that these lymphomas utilise the transcriptional activity of NF-κB to express 
genes detrimental for patient survival (Davis et al., 2001; Lenz et al., 2008c).  
1.7.4. CD79A/B mutations  
 
Constitutive NF-κB activation in approximately 20% of ABC DLBCLs appears to be due 
to somatic mutations in the CD79A and CD79B genes which encode components of the 
B-cell receptor (Davis et al., 2010). Mutations are usually non-synonymous missense 
substitutions that affect the N-terminal tyrosine of CD79B. Therefore ABC DLBCL 
mutated cases retain an intact ITAM region of either CD79A or CD79B, so that at least 
one docking site for SYK signalling is functional (Davis et al., 2010). Mutations 
ultimately lead to ligand-independent chronic active BCR signalling, enhancing BCR 
signalling in two ways; first by enhancing the surface expression of the BCR, therefore 
enhancing the duration of BCR-dependent signalling and second by making the BCR 
resistant to negative regulation by the tyrosine-protein kinase LYN (Davis et al., 2010; 
Rossi et al., 2013). Mutations in CD79A and CD79B are rare or absent in other types of 
lymphoma and have been described as being the genetic ‘smoking gun’ that links the 
pathogenesis of ABC DLBCLs with chronic active BCR signalling (Rui et al., 2011; 
Shaffer et al., 2012b).  
1.7.5. Alterations in positive regulators of NF-κB 
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In an attempt to identify novel oncogenes, Ngo et al (2006) used RNA interference 
techniques in a loss-of-function ‘Achilles heel’ screen of DLBCL cell lines (Ngo et al., 
2006). They identified components of the antigen receptor – NF-κB signalling pathway 
such as CARD11, BCL10 and MALT1 (components of the CBM complex) as essential 
for the survival of ABC DLBCL cell lines, a dependency which was not shared by other 
DLBCL types (Ngo et al., 2006). The CBM complex is formed following antigenic 
stimulation of the BCR and acts as a signalling scaffold, responsible for the recruitment 
of TRAF6, TAK1 and the IKK complex to activate the canonical NF-κB pathway (Nogai 
et al., 2011). In normal lymphocyte activation, CBM complex formation is transient, 
whereas in ABC DLBCL the complex is constitutively active, which is likely due to 
mutations in the complex that function oncogenically (Nogai et al., 2011).  
The pro-tumour function of the CARD11 scaffold protein was first confirmed by the 
observation of constitutive NF-κB activation in lymphoma cell lines into which CARD11 
mutants had been introduced (Lenz et al., 2008a). It is now established that mutations in 
CARD11 are present in approximately 10% of ABC DLBCL cases, causing a 
conformational change in CARD11 (Lenz et al., 2008a). CARD11 encodes a 
multidomain signalling scaffold protein consisting of an N-terminal CARD motif, an 
inhibitory domain, a coiled-coil domain and a C-terminal MAGUK domain (Thome et 
al., 2010). In resting B cells, CARD11 exists in a latent closed conformation, but upon 
engagement of the BCR the inhibitory domain of CARD11 is phosphorylated by PKCβ 
(Thome et al., 2010). In turn, this effectively results in the spontaneous opening of 
CARD11, which subsequently relocalises to the plasma membrane to recruit MALT1 and 
BCL10 into the CBM complex, activating the IKK2 kinase and initiating NF-κB activity 
(Lenz et al., 2008a; Thome et al., 2010). Interestingly, the active conformation of the 
CBM complex has been identified in ABC DLBCLs with wild-type CARD11, where this 
is due to mutations of components of the BCR itself, for example in CD79A or CD79B, 
as described previously in section 1.8.4 (Davis et al., 2010).  
Although the CBM complex represents a key area of study in the field of DLBCL 
research, a recent study screened for additional components of the CBM complex in 
lymphocytes, where the linear ubiquitin chain assembly complex (LUBAC) was found to 
bind to and preassemble the CBM complex following engagement of the BCR, governing 
NF-κB activation (Dubois et al., 2014). Knockdown of LUBAC hampered NF-κB activity 
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and was lethal to ABC DLBCL cell lines, suggesting that targeting LUBAC may also be 
important for the treatment of ABC DLBCL (Dubois et al., 2014).  
1.7.6. Alterations in negative regulators of NF-κB 
 
Interestingly, an alternative mechanism of constitutive active NF-κB in ABC DLBCL 
was detected by several research groups investigating genetic lesions in the genes 
encoding NF-κB regulatory proteins. 30% of cases of ABC DLBCL have inactivating 
mutations of A20, which negatively regulates NF-κB (Compagno et al., 2009; Kato et al., 
2009). Biallelic inactivation of TNFAIP3 (which encodes A20), further enhances NF-κB 
signalling in ABC DLBCL, inhibiting apoptosis and promoting cell proliferation 
(Compagno et al., 2009). 
1.7.7. Targeting NF-κB in DLBCL 
 
Although there is now vast information supporting the role of NF-κB signalling in 
DLBCL, inhibition of this pathway for the treatment of DLBCL has been a difficult task. 
Due to the requirement of NF-κB for the function of normal, non-cancerous cells, and the 
ability of this signalling cascade to crosstalk with many other pathways, inhibition of NF-
κB can cause many unwanted side effects.  
Some success has been achieved in the clinic using the proteasome inhibitor Bortezomib 
(Velcade®) for the treatment of various NHLs such as multiple myeloma (Palumbo et al., 
2011; Bose et al., 2014). Bortezomib inhibits NF-κB activation by blocking proteasomal 
degradation of IκBα (therefore preventing the release of NF-κB subunits to the nucleus) 
(Bose et al., 2014). Although known to have many other effects in the cell, Bortezomib 
has been shown to have efficacy in relapsed/refractory DLBCL when combined with 
chemotherapy (Dunleavy et al., 2009; Chen et al., 2011a; Bose et al., 2014). A 
significantly higher response and median overall survival was observed in ABC DLBCL 
compared to GCB DLBCL, which was expected due to their dependency on  NF-κB 
(Dunleavy et al., 2009).  
In recent years, the immuno-modulatory agent Lenalidomide (Revlimid®) has shown 
potential for treatment of patients with haematological malignancies, including DLBCL 
(Rajkumar, 2014; Abou Zahr et al., 2015; Ghosh et al., 2015). Patients with 
relapsed/refractory ABC DLBCL have shown a 52% response rate to lenalidomide 
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monotherapy, compared to 8.7% in patients with GCB DLBCL (Hernandez-Ilizaliturri et 
al., 2011). The molecular mechanism through which lenalidomide is active in ABC 
DLBCL was found to be by downregulating the transcription factors IRF4 and SPIB, 
which together repress IRF7, thereby preventing production of IFN-β, which in turn 
reduces amplification of NF-κB signalling (Yang et al., 2012). The selectivity of in vitro 
activity of lenalidomide against ABC DLBCL cell lines has led to phase I and II clinical 
trials using lenalidomide as a monotherapy (Hernandez-Ilizaliturri et al., 2011). 
Moreover, subsequent trials have now been conducted using R-CHOP + lenalidomide 
(R2CHOP), which has been shown to be safe for both ABC and GCB patients in two 
phase I trials (Nowakowski et al., 2011; Chiappella et al., 2013).  
Chronic active BCR signalling in DLBCL also provides an opportunity for therapeutic 
targeting upstream of IKK (Davis et al., 2010). Inhibition of Bruton’s tyrosine kinase 
(BTK) using Ibrutinib, has been shown to kill ABC DLBCL with chronic active BCR 
signalling, but not other types of lymphomas (Pan et al., 2007; Davis et al., 2010). This 
potent, covalent inhibitor has been well-tolerated and shown significant anti-tumour 
activity in CLL and MCL and combination therapies are currently being tested in DLBCL 
(Herman et al., 2011; Wang et al., 2015). Interestingly, a recent study investigated the 
effects of combined treatment of ABC DLBCLs using the BTK inhibitor ibrutinib and 
lenalidomide (Yang et al., 2012). These therapies were reported to synergise in killing 
ABC DLBCLs and were described as being a synthetically lethal drug combination by 
also blocking IRF4 induction by oncogenic NF-κB signalling. Finally, peptide inhibition 
of the MALT1 paracaspase of the CBM complex has demonstrated selective toxicity for 
ABC DLBCL, which may represent a future therapy for these lymphomas (Ferch et al., 
2009; Hailfinger et al., 2009; Fontan et al., 2012). 
Despite progress being made in these fields, future targeting of NF-κB is likely to benefit 
from a better understanding of the contribution of individual NF-κB subunits to the 
pathogenesis of DLBCL and the genes they target, which is currently unclear. c-Rel has 
been shown to have oncogenic potential in a number of B-cell cancers and some evidence 
suggests a role for c-Rel in the pathogenesis of DLBCL, where REL is amplified in 
approximately 25% of GCB DLBCL (Gilmore, 1999; Gilmore et al., 2004). Moreover, 
knockdown of c-Rel expression was shown to impair cell survival in a GCB DLBCL cell 
line (Pham et al., 2005; Lenz et al., 2008c).   
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Constitutive NF-κB signalling may not be restricted to the ABC subtype. For example, 
engagement of both the classical and alternative NF-κB pathways in DLBCL patient 
tumour samples were observed in 61% of ABC DLBCL tumour samples and a smaller 
fraction (30%) of GCB DLBCL (Compagno et al., 2009). In vitro studies are in agreement 
with these findings, whereby heterogeneous expression of p52 (as a marker for 
noncanonical NF-κB activity) was detected in DLBCL cell lines of both ABC and GCB 
subgroups (Compagno et al., 2009). Oncogenic lesions that specifically activate the 
alternative NF-κB pathway in DLBCL have not been reported until recently, whereby 
mutations of the TRAF3 negative regulator of the NF-κB pathway was found in ~15% of 
DLBCL, often coexisting with BCL6 translocations (Zhang et al., 2015).   
1.8. Tonic BCR signalling and the PI3K/AKT signalling pathway 
 
While some lymphomas remain antigen-dependent throughout their history, some 
DLBCL have been identified by gene expression profiling as depending on "low level" 
BCR survival signals in the absence of antigen engagement (Kraus et al., 2004; Monroe, 
2004; Srinivasan et al., 2009). Continuous signals delivered by the BCR in an antigen-
independent manor is a mechanism termed ‘tonic signalling’ and has been shown to 
enable long term B-cell survival throughout their lifespan (Gauld et al., 2002; Monroe, 
2004). Tonic BCR signalling was first identified in murine models where ablation of the 
BCR or mutation of Igα caused apoptosis of normal mature B cells (Lam et al., 1997; 
Kraus et al., 2004). Unlike chronic active BCR signalling, which is reminiscent of 
antigen-stimulated B cells, tonic BCR signalling is typical of a resting B-cell and is 
CARD11-independent (Rossi et al., 2013).  
In a study investigating the BCR-mediated survival signals upon which mature B cells 
depend, constitutively active PI3K/AKT signalling was found to rescue the survival of 
mature BCR-deficient B cells (Srinivasan et al., 2009). Interestingly, this was not the case 
for the NF-κB or MAPK pathways, highlighting differences between tonic BCR 
signalling pathways and pathways downstream of an activated BCR (Srinivasan et al., 
2009).  
Activation of PI3K/AKT signalling is a hallmark of many cancer types, targeting a 
number of cellular processes linked to tumourigenesis including the promotion of cell 
survival, proliferation and cell growth (Song et al., 2012; Pfeifer et al., 2013b). Although 
some BCR-dependent ABC DLBCLs with chronic active BCR signalling exhibit 
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constitutive PI3K activation, their main mechanism for survival is through the NF-κB 
pathway (Kloo et al., 2011). In contrast, in BCR-dependent GCB DLBCL, tonic BCR 
signalling promotes survival predominantly by utilising the phosphatidylinositol-4,5-
bisphosphate 3-kinase/protein kinase B (PI3K/AKT) pathway (Gauld et al., 2002; Davis 
et al., 2010). This group of DLBCL utilise tonic BCR signalling by retaining normal 
expression of the BCR, but with higher relative expression of BCR signalling 
components, such as the spleen tyrosine kinase SYK, leading to activation of the 
PI3K/AKT pathway (Srinivasan et al., 2009; Kenkre et al., 2012; Chen et al., 2013).  
Of note, BCR dependent DLBCLs had, in fact, already been predicted by Monti et al 
(2005), using a different classification system for detecting disease subtype to the COO 
system described in section 1.4 (Monti et al., 2005). Using multiple, comprehensive 
consensus clustering (CCC-defined) algorithms, Monti et al (2005) identified three 
separate subgroups defined by the expression of genes involved in oxidative 
phosphorylation (OxPhos subgroup), genes involved in proliferation (BCR subgroup) and 
genes involved in the tumour microenvironment/host inflammatory response (Monti et 
al., 2005). The BCR subtype was shown to have higher expression of BCR signalling 
components such as CD19, IgH, CD79a, BLK, SYK, PLCγ2 and genes associated with 
tumourigenesis such as c-Myc and BCL6 (Monti et al., 2005). Although comprehensive 
consensus clustering classification of DLBCL is highly reproducible, the subgroups 
derived from COO-defined and CCC-defined methods of analysis do not overlap and the 
BCR-type thus includes both ABC and GCB DLBCL (Pasqualucci, 2013).  Clearly the 
complexity of DLBCL must not be underestimated, where the success of future therapies 
likely lies in a targeted, patient-specific approach.  
Chemical inhibition of SYK, using the ATP-competitive inhibitor R406, has been shown 
to decrease aberrant BCR signalling and induce apoptosis in BCR-type DLBCL cell lines 
regardless of COO type (Chen et al., 2008). Follow-up studies investigating the role of 
SYK in DLBCL led to the discovery of SYK amplifications in BCR-type DLBCLs (Chen 
et al., 2013). Clinical trials using the oral SYK inhibitor fostamatinib (R788) have since 
showed a 22% response rate in patients with DLBCL, and clinical efficacy has been 
demonstrated in vivo using lymphoma mouse models (Young et al., 2009; Friedberg et 
al., 2010). 
A characteristic feature specifically found in GCB DLBCL is deregulation of the 
phosphatase and tensin homolog (PTEN) pathway (Pfeifer et al., 2013a). Normally, 
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PTEN is an antagonist of the oncogenic PI3K/AKT pathway, therefore playing an 
important tumour suppressive role (Song et al., 2012). In a screen for the expression of 
PTEN in primary DLBCL patient samples, loss of PTEN was identified in approximately 
50% of GCB DLBCL but only approximately 15% of ABC DLBCL (Pfeifer et al., 
2013a). Loss of PTEN in GCB DLBCL was correlated with constitutive activation of the 
PI3K/AKT pathway, which was not apparent in PTEN positive samples (Pfeifer et al., 
2013a) while ABC DLBCL showed PI3K/AKT pathway activation independent of PTEN 
status. Functional analysis demonstrated a dependency of PTEN negative cells on this 
pathway for their survival, therefore suggesting their addiction to PI3K/AKT (Pfeifer et 
al., 2013a).  
The underlying genetic abnormalities behind PTEN loss in some GCB DLBCL are mostly 
unknown; however deletions of the PTEN locus on chromosome 10q23 have been 
reported, including somatically acquired PTEN mutations and downregulation of PTEN 
by various microRNA (Lenz et al., 2008c; Song et al., 2012; Chen et al., 2013; Pfeifer et 
al., 2013a). For example, amplifications of the PTEN suppressor miR-17-92 have also 
been found in roughly 15% of GCB DLBCL (Xiao et al., 2008). 
Importantly, the studies described suggest that only patients with abnormal expression of 
PTEN may respond to inhibition of the PI3K pathway, which interestingly, was found 
evident in an in vitro setting, using DLBCL cell lines (Pfeifer et al., 2013a). From a 
clinical perspective this is of key importance, where stratification of treatment may 
benefit many patients with GCB DLBCL.   
Although not fully comprehensive, figure 6 summarises some of the genes and pathways 
disrupted in ABC and GCB DLBCL.  
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1.9. Pathway lesions downstream of TLR signalling 
 
TLRs are key receptors in the BCR-independent response to infectious organisms which 
sense a plethora of molecules from pathogens including lipoproteins, double stranded 
RNA/DNA and many other foreign components, collectively termed pathogen-associated 
molecular patterns (Rawlings et al., 2012). Ligand binding to TLRs leads to engagement 
of various cytoplasmic adaptor molecules such as myeloid differentiation primary 
response gene 88 (MYD88). Upon stimulation of the TLR, MYD88 triggers the activation 
Figure 6. The genes and pathways disrupted in ABC and GCB DLBCL. The stars indicate genetic 
aberrations in common DLBCL signalling pathways where red = ABC DLBCL, green = GCB DLBCL 
and yellow = aberrations affecting both subgroups (but more common in GCB DLBCLs). Mutations of 
the BCR components CD79A/B cause chronic active signalling of downstream pathways, such as the 
NF-κB pathway and potentially other pathways downstream of the BCR, such as the NFAT pathway. 
Mutations in the coiled-coil domain of CARD11 also causes constitutive activation of the NF-κB 
pathway, which is a hallmark of ABC DLBCLs. Mutations in the negative regulator of NF-κB, A20 
leads to further promotion of the NF-κB pathway and cell survival in these lymphomas. Activation of 
NF-κB leads to the transcriptional activation of IRF4, which in turn downregulates BCL6 expression, 
allowing the release of the plasma cell master regulatory PRMD1. In a normal cell, this leads to the 
development of the cell into a differentiated plasma cell, however this circuit is disrupted in DLBCL, 
blocking terminal B-cell differentiation. Some DLBCLs rely on survival signals independent of antigen 
engagement of the BCR. Some of these lymphomas depend on the PI3K/AKT pathway for survival, 
which has been shown to be constitutively activated in GCB DLBCLs with loss of the negative regulator 
of the PI3K/AKT pathway, PTEN. TLR signalling is also another pathway which is aberrantly 
expressed in ABC DLBCL cells due to mutations in the MYD88 adaptor, leading to activation of NF-
κB. Finally, dysregulation of epigenetic modifiers are frequent in DLBCL, particularly in the GCB 
DLBCL. Mutations of EP300 and CREBBP, for example, have been shown to cause constitutive 
activation of BCL6 and TP53.    
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of NF-κB via assembly of the interleukin-1 receptor-associated (IRAK) kinases IRAK4, 
IRAK1, and IRAK2, followed by activation of TRAF6 and polyubiquitination of the 
MAP3K7 kinase, which in turn phosphorylates IKK2 (Lin et al., 2010; Rawlings et al., 
2012).   
Dysregulation of BCR-independent immune signalling pathways, such those triggered by 
the TLRs have been demonstrated in the pathogenesis of DLBCL. For example, 
components of the TLR – NF-κB signalling pathway (such as MyD88 and IRAKs) are 
essential for NF-κB activation in various ABC DLBCL cell lines (Ngo et al., 2006; Ngo 
et al., 2011). Moreover, recurrent somatic mutations of MYD88 occur in 39% of ABC 
DLBCLs, where 29% have a specific single nucleotide substitution of L265P (Ngo et al., 
2011). Located in the C-terminal TIR domain of the MYD88 protein, L265P mutations 
allow spontaneous and activation-independent interaction with IRAK4 and IRAK1 (Lin 
et al., 2010; Rossi et al., 2013). Targeting MYD88 is a potential therapeutic strategy for 
DLBCL and other B-cell NHL with MYD88 mutations. MYD88 knockdown for 
example, has been shown to induce death in ABC cell lines, which was rescued by a 
MYD88 mutant, but not by wild-type MYD88 (Ngo et al., 2011). Moreover recent studies 
have successfully targeted mediators of MYD88, such as TAK-1, effectively decreasing 
cell proliferation (Ansell et al., 2014).  
1.10. Lymphoma summary 
 
The recognition of comprehensive molecular signatures for ABC and GCB DLBCL has 
enabled the identification of genetic aberrations associated with each subgroup (Alizadeh 
et al., 2000). Many genetic aberrations lead to dysregulated activity of specific signalling 
pathways that drive tumour formation and progression. It is important that these pathways 
and the cellular dependencies that result from them are identified so that new therapeutic 
strategies, based on specific drugs which effectively and specifically target cancer cells 
and spare normal cells, can be developed.  
The BCR and pathways downstream of the BCR are proving to be central for DLBCL 
cell survival, thus representing excellent novel targets for therapy. Although considerable 
progress has been made in understanding the involvement of pathways such as the NF-
κB and PI3K/AKT signalling pathways in DLBCL, there remains potential for other 
pathways downstream of the BCR to play an important role. For example, increasing 
evidence supports a role for the Nuclear Factor of Activated T cells (NFAT) transcription 
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pathway in many cancers, including DLBCL (Pham et al., 2005; Fu et al., 2006; Pham et 
al., 2010; Qin et al., 2014). Moreover, recent studies have indicated that the NF-κB and 
NFAT pathways may functionally intersect in DLBCL, together regulating the expression 
of combined target genes important for lymphoma growth and survival (Pham et al., 
2005; Pham et al., 2010).  
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1.11. Nuclear factor of activated T-cell (NFAT) family of proteins 
 
Nuclear Factor of activated T cells (NFAT) was discovered over two decades ago as an 
inducible nuclear protein binding to the antigen receptor response element-2 (ARRE-2) 
of the interleukin-2 (IL-2) promoter in activated human T cells (Shaw, 1988). The role of 
NFAT in the immune system has now been extensively reviewed (Macian, 2005; Müller 
et al., 2010; Fric et al., 2012) although novel roles for NFAT continue to emerge in the 
literature, particularly in the field of T-cell tolerance, the mechanisms underlying T-cell 
anergy and in the function of regulatory T cells (TReg) (Serfling et al., 2006b; Noemi Soto-
Nieves, 2009).  
 Following its initial discovery, a plethora of studies established that NFAT family 
members are not only important for T-cell activation and differentiation, but are 
ubiquitously expressed in many mammalian tissues, implying a broader role for NFAT 
isoforms than was originally thought (Müller et al., 2010). In addition to regulating the 
function of cells of the immune systems, such as B cells, dendritic cells and 
megakaryocytes, the NFAT signalling axis has a key role in vertebrate-specific 
development of the heart, bones, skin, blood vessels, skeletal muscle and pancreas 
(Yaseen et al., 1993; Hogan et al., 2003; Heit et al., 2006; Winslow et al., 2006; Crist et 
al., 2008; Oro, 2008; Negishi-Koga et al., 2009; Shukla et al., 2009; Zanoni et al., 2009).  
Dysregulation of NFAT signalling is now know to be associated with a broad range of 
diseases including autoimmune and inflammatory disorders such as Alzheimer’s disease 
and pathological cardiac hypertrophy (Ferraccioli et al., 2005; Heineke et al., 2006). It 
has long been suspected that NFAT signalling may also be dysregulated in cancer, but 
this has only been reported recently (Jauliac et al., 2002). Aberrant NFAT signalling has 
now been associated with malignant transformation and tumour progression in a number 
of cancers, including solid tumours such as breast, pancreatic, lung, and colon cancers 
(Jauliac et al., 2002; Holzmann et al., 2004; Duque et al., 2005; Maxeiner et al., 2009). 
NFAT has also demonstrated a role in cancers of the haematopoietic system, for example 
in Chronic Lymphocytic Leukaemia (CLL), DLBCL, Burkitt’s lymphoma and some T-
cell lymphomas (Marafioti et al., 2005; Pei et al., 2012). However, the respective 
contribution of specific NFAT family members and their function in various cancer 
phenotypes is not known. Further research on the role of NFAT in tumourigenesis would 
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allow us to evaluate potential targeting of NFAT for therapy but also to gain a greater 
understanding for the molecular machinery driving cancer types.   
1.12. Biology of NFAT/primary structure of NFAT 
 
The human NFAT family consists of five members (table 1) including NFAT1 
(NFATc2/NFATp), NFAT2 (NFATc1/NFATc), NFAT3 (NFATc4), NFAT4 
(NFATc3/NFATx) and NFAT5 (TonEBP/OREBP). When compared to other 
transcription factors, a unique feature of NFAT members 1-4 is their dependency on an 
influx of Ca2+ by the PLC-γ pathway or via store-operated Ca2+ entry. This distinguishing 
factor requires Ca2+ binding sites present on NFAT1-NFAT4, but not NFAT5, which is 
insensitive to Ca2+ stimulation. Exclusively important for cellular responses to osmotic 
stress, NFAT5 is expressed in almost all cells and is known as the primordial NFAT 
family member, emerging as early as Drosophila spp. (López-Rodríguez et al., 1999; 
Miyakawa et al., 1999; López-Rodrı́guez et al., 2001; Mancini et al., 2009). Table 1 
summarises the alternative names for NFAT family members, their mechanisms of 
regulation and whether they are expressed in immune and cancer cells.  
NFAT 
family 
member 
Alternative 
names 
Regulation Expressed in 
immune cells 
References Expressed 
in tumour 
cells 
NFAT1 NFATc2/NFATp Calcium-
calcineurin 
Yes (McCaffrey PG, 1993) Yes 
NFAT2 NFATc1/NFATc Calcium-
calcineurin 
Yes (Northrop et al., 1994) Yes 
NFAT3 NFATc4 Calcium-
calcineurin 
No (Hoey T, 1995) Yes 
NFAT4 NFATc3/NFATx Calcium-
calcineurin 
Yes (Ho et al., 1995; Hoey 
T, 1995; Masuda et al., 
1995) 
Yes 
NFAT5 TonEBP/OREBP Osmotic 
stress 
Yes (Miyakawa et al., 1999) Yes 
 
Table 1. The NFAT family of transcription factors are expressed in cells of the immune system and 
in tumour cells. 
Structurally, NFAT members contain three main tandem domains; a regulatory domain 
known as the NFAT homology region (NHR), a highly conserved Rel-homology region 
(RHR) (which binds DNA) and a carboxy-terminal domain, as illustrated in figure 7. The 
NHR is moderately conserved between NFAT family members and contains an amino-
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terminal transactivation domain (TAD) which initiates gene transcription by binding gene 
promoter elements. The NHR contains docking sites for both calcineurin and NFAT 
kinases which control NFAT activation by regulating its phosphorylation status. In resting 
cells, the NHR is heavily phosphorylated at multiple serine residues within several 
conserved serine-rich sequence motifs. The RHD is a unifying characteristic of NFAT 
family members which is structurally related to the DNA binding domain of NF-κB REL-
family of transcription factors, classifying NFATs as extended members of the NF-κB 
family. Characterised by a set of 300 evolutionary conserved amino acid residues, the 
RHR confers the DNA binding specificity of NFAT transcription factors and is a well 
characterised mode of DNA binding (Ghosh et al., 1995; Muller et al., 1995). Of the five 
NFATs, NFAT5 has the highest structural similarity to NF-κB, however NFAT5 lacks a 
calcineurin binding site, making it insensitive to calcium-calcineurin activation (López-
Rodríguez et al., 1999). 
 
 
Figure 7. General structure of NFAT family members. The primary structure of a typical NFAT family 
member consists of the NFAT homology region (NHR), Rel-homology region (RHR) and a C-terminal 
domain. The NHR contains a transactivation domain (TAD), two calcineurin binding sites, a nuclear 
localisation sequence (NLS) and a nuclear export sequence (NES). Also contained in the NHR are multiple 
serine-rich motifs including SRR1, SRR2, SP1, SP2 and SP3. The RHR consists of a DNA binding domain 
and areas for recognition with other transcription factor partners, such as the Jun and Fos members of the 
AP-1 transcriptional family. The structure of NFAT family members are highly comparable, however 
NFAT5 does not possess a NHR, making it calcium insensitive. Image adapted from (Qin et al., 2014). 
 
1.13. NFAT isoforms 
 
TAD 
NFAT 
NHR RHR 
Calcineurin binding site Calcineurin binding site 
C-terminal domain 
SRR1 SP1 SP2 SRR2 NLS SP3 NES 
Jun Fos Jun 
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NFAT complexity is also increased since the subunits are comprised of several isoforms 
generated by alternative splicing or by use of individual promoters. Table 2 shows the 
various NFAT transcription factor genes and their isoform variants. For most NFATs, 
each protein has two or more alternatively spliced forms, which result in variations at the 
amino (N) and carboxyl (C) termini. However, the core region, containing the regulatory 
domain, NHR and RHR remains conserved (Park et al., 1996; Imamura et al., 1998; 
Chuvpilo et al., 1999a).  
Among the three NFAT proteins expressed in immune cells (NFAT1, NFAT2 and 
NFAT4), NFAT1 and NFAT2 are most prominently expressed in peripheral T cells 
(Chuvpilo et al., 1999b). These two family members differ in their mode of expression in 
peripheral effector lymphocytes. The three NFAT1 variants and five of the six NFAT 
variants are constitutively expressed, whereas the transcription of the NFAT2 isoform 
NFAT2/αA is strongly induced following stimulation of T or B-lymphocytes (Chuvpilo 
et al., 1999b; Serfling et al., 2006a; Rudolf et al., 2014).  
NFAT isoform Protein variant Chromosomal loci Proteins (amino acids) 
NFAT1 
A 20q13 1064 
B 20q13 921 
C 20q13 925 
NFAT2 
αA 18q23 716 
βA 18q23 703 
αB 18q23 825 
βB 18q23 812 
αC 18q23 943 
βC 18q23 930 
NFAT3  14q11 902 
NFAT4 
 16q22 1075 
 16q22 1068 
 16q22 1065 
NFAT5 
 16q22 1531 
 16q22 1455 
 
Table 2. The protein variant forms of the NFAT family of transcription factors, their chromosomal 
loci and length in amino acids.  
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In peripheral lymphocytes, the synthesis of six NFAT2 proteins is directed by the 
existence of two promoters (P1 and P2), coupled with two poly A sites and alternative 
splicing events (figure 8) (Park et al., 1996; Sherman et al., 1999). P1 transcripts begin at 
exon 1 and encode NFAT2 proteins with an N-terminal α-peptide whereas P2 transcripts 
start at exon 2 and encode β-peptide proteins (Park et al., 1996; Sherman et al., 1999). 
The C-termini of individual proteins defines the A, B or C isoforms which differ in amino 
acid length, where a short stretch of 19aa comprises the A isoform, 128aa in the B isoform 
or 126aa in the C isoform (Chuvpilo et al., 1999b). Alternative splicing and poly A 
addition at the distal site pA2 gives rise to the B and C isoforms, whereas formation of 
the short isoform A uniquely results from polyadenylation at the proximal poly A site 
pA1 (Chuvpilo et al., 1999b).  
 
Figure 8. Expression of the NFAT2 gene. Alternative splicing events and use of different promoters 
allows the expression of six NFAT2 RNAs. The two promoters (P1 and P2) and two poly A addition sites 
(pA1 and pA2) are shown. Exons are indicated by number below the gene model. Red blocks indicate 
sequences specific for NFAT2/αA, green are sequences occurring in β isoforms and blue are sequences 
common to all isoforms. In resting T cells, transcription of exon 2 is achieved by activation of promoter 
P2, followed by splicing to exon 3 to generate three β isoforms. During T-cell activation, a promoter switch 
from P2 to P1 results in the transcription of exon 1, followed by splicing to exon 3, therefore synthesising 
three α isoforms. NFAT2/αA is the predominant isoform generated, by the use of the proximal poly A site 
pA1. Image adapted from (Serfling et al., 2006a) 
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In resting T and B cells, the P2 promoter is primarily active (resulting in the generation 
of three β isoforms), however during T-cell activation a promoter switch from P2 to P1 
allows the generation of the α isoforms, in particular a strong induction of the 
predominant shorter isoform (Chuvpilo et al., 1999b). In fact, a 15-20 fold induction of 
NFAT2/αA RNA was detected in primary effector T cells and human T-cell lines upon 
T-cell activation, compared to a 2.5 fold increase for the NFAT2/αB and NFAT2/αC 
isoform RNAs (Chuvpilo et al., 1999b). Induction results in the predominant synthesis of 
NFAT2/αA, which differs in length, compared to other isoforms, lacking a 250aa residue 
long C-terminal and a second transactivation domain that is present in other NFAT 
isoforms. Absence of this domain prevents sumoylation of NFAT2/αA, which has been 
reported to inhibit induction of IL-2 by NFAT2/C (Nayak et al., 2009). Moreover, 
NFAT2/αA also differs from other family members in that its half-life is 2-4 hours 
(compared to around 8 hours for other isoforms), suggesting it to be less stable (Hock et 
al., 2013). 
1.14. NFAT2 autoregulation 
 
Of the five NFAT family members, NFAT2 is uniquely regulated by a positive 
autoregulatory feedback loop (Zhou et al., 2002a). In a study characterising the structure 
of the murine NFAT2 gene and its 5’-flanking region, a CsA-sensitive consensus NFAT-
binding site was located and identified in the promoter region of the inducible NFAT2 
short isoform (NFAT2A) (Zhou et al., 2002a). Promoter activity was increased when 
NFAT1 was overexpressed, indicating that NFAT2/αA expression is under the control of 
a distinct inducible promoter (Chuvpilo et al., 2002). As mentioned previously, NFAT1 
is found abundantly in the cytoplasm of resting T cells, whereas NFAT2 expression is 
induced during T or B-cell activation (Chuvpilo et al., 1999a). The auto-regulatory 
feedback circuit described is therefore beneficial to T and B-lymphocytes during an 
immune response, allowing high levels of NFAT2/αA synthesis to be kept constant during 
lymphocyte induction (Serfling et al., 2006a). Despite original research findings reporting 
that NFAT2 autoregulation was due to heightened NFAT1 expression, other studies have 
revealed that NFAT2 induction may not depend on just NFAT1 (Zhou et al., 2002a). This 
has come to light since reports showing that NFAT2/αA remains strongly induced in T 
cells deficient in both NFAT1 and NFAT3 (Hock et al., 2013).   
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Interestingly, positive auto-regulation of NFAT2 is likely a common strategy during cell 
linage commitment, ensuring accumulation of an isoform of particular biological 
importance (Serfling et al., 2006a). Moreover, this regulatory mechanism  explains why 
deletion of NFAT2 during development is more lethal than other NFAT isoforms (Qin et 
al., 2014). The architecture and expression of the NFAT2 gene in lymphocytes is clearly 
a complex system that is highly researched. NFAT2/αA induction, however, is not limited 
to immune cells. In fact, studies have shown that induction is a crucial step in determining 
the fate of the cell in many systems, including osteoclastogenesis and cardiac valve 
development (Asagiri et al., 2005; Zhou et al., 2005). Recent reports have highlighted 
dysregulation of NFAT2/αA in immune cells that are suggestive of its contribution to 
lymphoid disorders, including lymphomagenesis (Asagiri et al., 2005). However, these 
will be discussed in a later section. 
1.15. The NFAT signalling pathway 
 
The activation of NFAT by calcium signalling is a well-studied mechanism. Upon ligand 
binding to immunoreceptors (such as the BCR), receptor tyrosine kinases (RTK) or G-
protein-coupled receptors (GPCR) activate phospholipase C gamma (PLCγ), as shown in 
figure 9, which leads to the hydrolyse of phosphatidyl-4,5-bisphosphate (PtdIns(4,5)P2) 
to diacylglycerol (DAG) and ionositol-1,4,5-trisphosphate (InsP3) (Pan et al., 2013). In 
turn, InsP3 binds to the InsP3 receptor (InsP3R) on the ER membrane and initiates calcium 
release from endoplasmic reticulum Ca2+ stores. In many cell types, this initial release of 
calcium is not sufficient to activate NFAT target genes (Müller et al., 2010). Store-
operated Ca2+ entry (SOCE) is activated by detection of calcium by STIM1 and STIM2, 
which communicate with the CRAC channel ORAI1 at the plasma membrane and trigger 
its conformational change (Müller et al., 2010). Essential for lymphocyte activation and 
NFAT activation, this process is termed “inside-out” signalling and leads to the opening 
of CRAC channels and an influx of extracellular calcium (Putney Jr et al., 1993). A 
sustained calcium signal is required for NFAT activation, where binding of calcium to 
calmodulin leads to activation of the serine/threonine phosphatase calcineurin.  
In the basal state, the calcium-responsive NFAT isoforms exist in a hyperphosphorylated 
inactive conformation in the cytoplasm. NFAT1 for example, demonstrates a high level 
of complexity, harbouring more than 20 phosphorylation sites, 18 of which are located in 
the regulatory region (Okamura et al., 2000). Dephosphorylation by activated calcineurin 
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occurs on multiple serine-proline rich (SP) motifs, serine rich regions (SSR1) and the 
SPXX (X represents any amino acid) (figure 7) (C R Beals, 1997; Okamura et al., 2000). 
Dephosphorylation of SP motifs (SP1, SP2 or SP3) reveal a nuclear localisation sequence 
and also leads to masking of the nuclear export sequence, allowing NFAT isoforms to 
translocate to the nucleus and bind either as monomers, homodimers or heterodimers to 
DNA elements (Zhu et al., 1998; de Lumley et al., 2004). In the nucleus, NFAT 
transcriptionally regulates an array of genes in a cell-type and context-dependent manor. 
Transcriptional activity is terminated by the rephosphorylation of NFAT and exposure of 
a nuclear export sequence.  
 
Figure 9. The NFAT signalling pathway and its regulatory factors. Immunoreceptors, receptor tyrosine 
kinases (RTK) and G-protein-couple receptors (GPCR) activate PLCγ which hydrolyses 
phophatidylinositol-4-5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol trisphosphate (IP3). 
IP3 binds to Ca2+-permeable receptors on the endoplasmic reticulum (ER) and stimulates the release of 
calcium into the cytosol. ER store depletion is detected by STIM receptors, resulting in the opening of 
calcium release-activated channels (CRAC)  at the plasma, allowing entry of additional calcium. An influx 
of calcium allows activation of calmodulin, which induces the phosphatase calcineurin to dephosphorylate 
NFAT proteins, causing them to translocate to the nucleas bind to DNA as monomers, dimers or with other 
transcription factors to initiate gene trascription such as IL-2 in T cells. NFAT is regulated by multiple 
levels of control. The NFAT kinase glycogen synthase kinase 3 beta (GSK3β) acts as an export kinase by 
rephosphorylating NFAT, leading to its nuclear exit. Dual specificity tyrosine phosphorylation-regulated 
kinases (DYRK) and casein kinase 1 (CK1) are multi-functional, behaving as both export kinases and 
maintainance kinases which retain fully phosphorylated NFAT in the cytoplasm. Another level of NFAT 
pathway regulation is by endogenous inhibition of calcineurin by the calcineurin-binding protein 1 
(CABIN1), Down’s syndrome critical region 1 (DSCR1) and A-kinase anchor protein 79 (AKAP79). 
PhD Thesis  Holly White 
 
36 
 
1.16. Regulation of NFAT 
 
1.16.1. Kinase regulation of NFAT 
 
In addition to control of NFAT activation by their unique sensitivity to intracellular 
calcium and by autoregulation of the short NFAT2 isoform, the complexity of NFAT 
signalling is further increased by additional levels of regulation. Serine/threonine kinases, 
for example are fundamental in controlling the precise subcellular location of NFAT 
isoforms and their transcriptional activity. Subdivided into maintenance and export 
kinases, these key regulators effectively retain NFAT in the cytoplasm, or promote NFAT 
nuclear export. The export kinase glycogen synthase kinase 3 beta (GSK3β) 
phosphorylates the SP2 and SP3 motifs of NFAT2, terminating transcriptional activity 
and promoting nuclear exit (Beals et al., 1997; Neal et al., 2003). In contrast, kinases such 
as casein kinase 1 (CK1) and the dual specificity tyrosine phosphorylation-regulated 
kinases (DYRKs) are multi-functional, behaving as either export kinases or as 
maintenance kinases by retaining fully phosphorylated NFAT in the cytoplasm, 
preventing nuclear translocation (Okamura H, 2004; Arron et al., 2006; Gwack et al., 
2006). It is likely that additional kinases are yet to be discovered, highlighting a key area 
of unexplored research. Kinase activity may explain the differential activation or 
deregulation of specific NFAT isoforms in various cellular and pathological contexts. 
1.16.2. Regulation of NFAT by calcineurin 
 
The use of the pharmacological immune-suppressant drugs CsA and FK506 to antagonise 
calcineurin activity have been a useful resource to aid our understanding of the 
endogenous role of calcineurin and NFAT signalling. In addition to its role as an activator 
of NFAT in the cytoplasm, calcineurin has been identified as a regulatory protein in the 
nucleus of stimulated cells, maintaining the dephosphorylated state of NFAT and 
consequently sustaining active transcription (Zhu et al., 1999). Moreover, direct control 
of calcineurin activity by endogenous calcineurin inhibitors has become evident, such as 
by calcineurin-binding protein 1 (CABIN1), Down’s syndrome critical region 1 (DSCR1) 
and A-kinase anchor protein 79 (AKAP79) (Lai et al., 1998; Lin et al., 1999; Fuentes et 
al., 2000; Jurado et al., 2010).  
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1.16.3. Post-translational modifications 
 
In addition to regulation by phosphorylation, other post-translational modifications have 
been identified for NFAT proteins. For example, nuclear retention of NFAT1 and NFAT2 
can be regulated by sumoylation (Terui et al., 2004; Nayak et al., 2009). Distinct isoform 
specific effects have been reported (Terui et al., 2004; Nayak et al., 2009). The long 
NFAT2/C isoform (but not the NFAT2/A short inducible isoform) is modified by Small 
ubiquitin-like modifier 1 (SUMO1), causing its nuclear translocation and transformation 
from a transcriptional activator to a transcriptional repressor by recruitment of histone 
deacetylases (HDACs) and induction of transcriptionally inactive chromatin (Nayak et 
al., 2009). Other examples of post-translational modifications include the ubiquitination 
of NFAT1 by the E3 ubiquitin ligase MDM2 in breast cancer cells and the binding of 
Poly-ADP-ribose polymerase (PARP) to NFAT, inducing adenosine di-phosphate (ADP) 
–ribosylation, hence increasing NFAT binding activity (Wyszomierski et al., 2005; 
Yoeli-Lerner et al., 2005; Olabisi et al., 2008; Yoeli-Lerner et al., 2009).  
1.17. NFAT transcriptional partners 
 
Although calcium is one of the broadest signalling molecules, having a wide range of 
cellular effects, very few gene targets are activated by a calcium signal alone (Crabtree et 
al., 2002). It is likely that NFAT binds DNA with the assistance of other proteins. 
Summarised nicely by Crabtree et al (2002) ‘NFAT genes are probably not “master” 
genes that wear camouflage clothes and live in caves, but rather that they function within 
the community of proteins in a cell when a calcium signal is given’ (Crabtree et al., 2002). 
Studies investigating the mechanism of NFAT contact with DNA have revealed 
significant NFAT conformational flexibility. NFAT isoforms 1-4, for example, can bind 
DNA as monomers to specific (GGAA) sites or bind as dimers at kappa B-like (κB-like) 
sites; however this is with fairly weak affinity (Chen et al., 1998; Hogan et al., 2003). 
Cooperation with partner transcription factors to form heterodimeric complexes enhances 
DNA contact and is the mechanism by which NFATs regulate most of their target genes 
(Chen et al., 1998). The Activator Protein 1 (AP-1) transcription factors (comprised of 
Fos-Jun complexes) represent the most well established NFAT binding partner (Jain et 
al., 1992; Macian, 2001). AP-1 and NFAT cooperatively bind a composite DNA binding 
site to synergistically activate the expression of genes involved in an immune response, 
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where formation of a quaternary DNA complex achieves high affinity binding (Jain et al., 
1992; Chen et al., 1998).   
The biological implications of NFAT activity are further enhanced by interaction with 
many other transcription factor proteins, for example, zinc finger proteins such as GATA 
(globin transcription factor 1), helix-turn-helix domain proteins such as Oct and other 
transcription factors including FOXP3 (forkhead box P3), EGR (early growth response) 
proteins and MEF2 (myocyte enhancer factor 2)  (Decker et al., 1998; Bert et al., 2000; 
Nemer et al., 2002; Rengarajan et al., 2002; Wada et al., 2002; Decker et al., 2003; Tone 
et al., 2008; Li et al., 2012). Although the interaction between NFAT and IRF4 (interferon 
regulatory factor 4) is not well characterised, an IRF4/NFAT complex modelled on a 
putative composite binding site from the IL-4 promoter suggested that IRF4 and NFAT2 
may potentially bind to DNA simultaneously, with their DNA binding interacting (Hu et 
al., 2002). NFAT transcription factors form stable nuclear complexes with a plethora of 
partners to perform an array of biological functions (Qin et al., 2014). These may range 
from immunotolerance (FOXP3), to proliferation (GATA) and even the malignant 
transformation. For example, shRNA depletion of the NFAT binding partner STAT3 
(signal transducer and activator of transcription 3), decreased the transforming ability of 
NFAT2 in 3T3-L1 fibroblasts (Tone et al., 2008; Lagunas et al., 2009; Li et al., 2012). 
1.18. Role of NFAT in Cancer 
 
NFAT proteins transactivate downstream targets that support the development of cancer 
and tumour progression, as reviewed in (Mancini et al., 2009; Müller et al., 2010; Pan et 
al., 2013; Qin et al., 2014; Shou et al., 2015). Consequently, constitutive activation and 
overexpression of NFAT has been reported in an increasing number of both solid tumours 
and haematological malignancies, as highlighted in table 3. NFAT family members have 
been shown to regulate key cellular processes involved in malignant transformation, 
including cell survival, differentiation, migration, angiogenesis and the tumour 
microenvironment, which will be discussed in the subsequent sections (Mancini et al., 
2009; Pan et al., 2013; Qin et al., 2014).  
The first implication that NFAT had oncogenic potential came from a study showing the 
involvement of NFAT in promoting carcinoma invasion downstream of the α6β4 integrin, 
resulting in enhanced cell migration (Jauliac et al., 2002). Soon after, another study 
demonstrated a proliferative role for NFAT in cancer, where the expression of a 
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constitutively active NFAT2 mutant in murine fibroblasts caused cells to adopt a 
transformed cell phenotype (Neal et al., 2003). Since these discoveries, activated and/or 
overexpressed NFAT has identified in several types of cancer, including pancreatic 
cancer, breast cancer, Burkitt’s lymphoma and aggressive T-cell lymphomas (Marafioti 
et al., 2005; Pham et al., 2005; Yoeli-Lerner et al., 2005; Buchholz et al., 2006; Yoeli-
Lerner et al., 2009; Pham et al., 2010).  
Although NFATs often perform redundant functions, distinct isoform-specific roles are 
also emerging with cell-type and context dependent effects being observed in cancer 
(Hogan et al., 2003; Robbs et al., 2008). Despite the highly conserved sequence 
similarities between NFAT isoforms (and assumed functional redundancy), specific 
oncogenic or tumour suppressive functions have been correlated with particular NFAT 
family members. These distinct roles have particularly been identified between NFAT1 
and NFAT2, which although share 72% sequence similarity in their C-terminal DNA 
binding domains, appear to have strikingly opposing roles (Robbs et al., 2008). It is likely 
that NFAT1 and NFAT2 induce a non-overlapping selection of gene targets, which either 
suppress or promote cell growth (Mancini et al., 2009). However, Rudolf et al (2014) 
suggest that functional differences between NFATs may be due to the synthesis of the 
NFAT2/αA short isoform of NFAT2 (Rudolf et al., 2014). Aberrant expression of this 
isoform may be influenced by the autoregulatory mechanisms of NFAT2 and this may 
explain its oncogenic nature (Chuvpilo et al., 2002).   
Mutations of NFAT proteins have not been associated with human cancers, in fact, recent 
cancer genome sequencing suggests that mutations and amplifications in NFAT genes 
may only occur at very low frequencies (Macian, 2005). Aberrant NFAT signalling in 
cancer is reportedly by overexpression and/or hyperactivity, which is likely due to drivers 
of NFAT activity or retention of NFAT in the nucleus (Müller et al., 2010). Differential 
regulation of NFATs in specific cell types may be due to the selective activation of export 
kinases such as GSK3β, which in cancer may become dysregulated; however these areas 
remained largely unexplored. 
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Cancer type NFAT 
isoform 
Proposed mechanism Clinical/biological 
outcomes 
Reference 
T-cell leukaemia NFAT1-
4 
Activation of calcineurin 
and NFAT nuclear 
translocation 
Chemoresistance (Glud et al., 2005; 
Pham et al., 2005; 
Medyouf et al., 2007) 
Chronic 
lymphocytic 
leukaemia 
NFAT2 Overexpressed and 
constitutively active 
Increased cancer 
progression 
(Le Roy et al., 2012; 
Pei et al., 2012) 
Chronic 
myelogenous 
leukaemia 
NFAT2 Constitutively activated Chemoresistance to 
TKI treatment  
(Gregory et al., 2010) 
Diffuse Large B-
cell lymphoma 
NFAT2 Constitutively activated. 
Interacts with NF-κB to 
synergistically activate 
CD54 gene transcription 
Increased tumour 
growth. Maintaining 
cell survival and 
counteracting 
apoptosis by induction 
of CD40 and BLYS 
survival factors 
(Pham et al., 2005; Fu 
et al., 2006; Pham et 
al., 2010) 
Breast cancer NFAT1, 
NFAT5 
Overexpressed Increased migration 
and invasion by 
induction of COX2 
(Yoeli-Lerner et al., 
2005; Yoeli-Lerner et 
al., 2009) 
Pancreatic cancer NFAT2 Overexpressed  Increased tumour 
growth by induction 
of MYC expression 
(Buchholz et al., 
2006) 
Prostate cancer NFAT Activated NFAT promoter 
by TRPV6-mediated Ca2+ 
influx 
Increased cancer cell 
proliferation 
(Lehen'Kyi et al., 
2007) 
Colon cancer NFAT1 Constitutively activated Induces tumour 
progression 
(Gerlach et al., 2012) 
Melanoma NFAT Increased NFAT activity 
via BRAF-MEK-ERK 
pathway and a TGF-β 
dependent pathway 
Increased migration 
and invasion by 
induction of COX2 
(Flockhart et al., 
2009; Werneck et al., 
2011) 
Angiosarcoma NFAT4 Activated by SFRP2 Increased 
angiogenesis 
(Courtwright et al., 
2009) 
Ewing sarcoma NFAT1 Amplified chimera due to 
chromosomal translocation 
Not known (Szuhai et al., 2009; 
Sankar et al., 2011; 
Arbajian et al., 2013) 
Endometrial 
cancer 
NFAT Regulation of IL11 and 
CXCL8 expression 
Increased migration (Sales et al., 2009; 
Cook et al., 2010) 
Glioblastoma NFAT1 Overexpressed Increased invasiveness (Wu, 2010; Tie et al., 
2013) 
Non-small cell 
lung cancer 
NFAT Overexpressed Decreased post-
operative survival 
(Zhang, 2007; Chen et 
al., 2011c) 
Table 3. Evidence linking NFAT isoforms with different malignancies, including biological and 
clinical outcomes. Image adapted from (Qin et al., 2014) 
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It is becoming clear that therapeutic targeting of the NFAT pathway is a desirable 
approach for cancer treatment; however with the increasingly level of complexity of 
NFAT regulation and function, it is essential that we gain a greater level of understanding 
of the molecular mechanisms involved.  
1.18.1. Study of NFAT using mouse models 
 
Mice with single NFAT isoform knockouts show mild phenotypes, which may be due to 
a high degree of redundancy (Mancini et al., 2009). However, a few effects have been 
observed, including defective cardiac valve formation with embryonic lethality in mice 
with a NFAT2 deletion and reduced mast cell cytokine production in mice with a NFAT1 
deletion (de la Pompa et al., 1998; Ranger et al., 1998). Importantly, until at least two 
NFAT proteins are absent no distinct physiological effects are seen (Macian, 2005). 
Deletion of multiple NFAT family members can result in abolished cytokine production 
in T cells (NFAT1 and NFAT2 deletion), lethal defects in formation of the vasculature 
system (NFAT3 and NFAT4 deletion) and impairment of nervous system growth 
(NFAT1, NFAT3 and NFAT4 deletion). The deleterious effects of double knockout mice 
substantiate the pivotal role of NFAT proteins in the immune system and vertebrate 
development and have been reviewed comprehensively (Macian, 2005; Müller et al., 
2010; Fric et al., 2012; Pan et al., 2013) 
Using NFAT knockout in mouse knockout models of cancer would allow a better 
understanding of the individual roles of NFAT isoforms; however research on NFAT in 
cancer has largely been restricted to in vitro studies. This is mostly due to the fact that the 
use of in vivo mouse models are hampered by the extreme immunological disorders that 
occur in NFAT double knockout mice, as described above. Despite a lack of in vivo 
evidence, several recent studies have been of particular value. NFAT1 null mice, for 
example, were shown to be susceptible to chemically induced carcinogenesis when 
compared to wild-type mice, supporting the tumour suppressive role for NFAT1 
demonstrated in in vitro studies (Robbs et al., 2008; Werneck et al., 2011). Moreover, 
mice deficient in NFAT1 and NFAT4 show decreased activation-induced cell death 
(AICD), increased proliferation and impaired induction of Fas ligand, adding to its 
potential anti-tumour effects (Oukka et al., 1998; Ranger et al., 1998).  Importantly, the 
research findings of in vivo studies overall have largely complemented in vitro studies. 
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Further examples of NFAT mouse model studies will be described throughout the rest of 
the chapter.  
1.18.2. Roles of NFAT in cancer development and progression 
 
As described in the sections below, increasing evidence supports a role for NFAT in the 
underlying principles of Hanahan and Weinberg’s hallmarks of cancer, providing cancer 
cells with characteristic traits such as the ability to sustain angiogenesis, invade 
surrounding tissues and metastasise (Hanahan et al., 2000). 
1.18.3. Role of NFAT in the malignant transformation and cell proliferation 
 
Following Neil and Clipstone’s discovery that NFAT2 proteins induce malignant 
transformation and increase cell proliferation in fibroblasts (Neal et al., 2003), other 
research groups have revealed contrasting effects of NFAT1. In 2008 for example, Robbs 
et al reported that induction of constitutively active NFAT1 mutants in fibroblasts induced 
cell cycle arrest and apoptosis, whereas NFAT2 increased proliferation and 
transformation (Robbs et al., 2008). This apoptotic role for NFAT1 is likely due to the 
inhibition of cyclin dependent kinase 4 (CDK4) and cyclin A2 expression, which are 
previously documented roles for this NFAT family member (Baksh et al., 2002; Carvalho 
et al., 2007; Robbs et al., 2008). Interestingly, NFAT1 was recently shown to cooperate 
with the oncogenic Ras/Raf/MEK/ERK pathway (but not with JNK, p38 or NF-κB) 
(Robbs et al., 2013). Its role was found to shift signalling from an oncogenic to a tumour 
suppressive pathway by the induction of TNFα (Robbs et al., 2013).  
However, in other studies, the expression of NFAT1 is correlated with aggressive and 
invasive behaviour in various malignancies, suggesting that the predominant role for 
NFAT1 is the promotion of cell migration (Yoeli-Lerner et al., 2005; Yoeli-Lerner et al., 
2009; Tie et al., 2013; Zhang et al., 2013a; Qin et al., 2014). In breast cancer cells for 
example, NFAT1 has been shown to induce MDM2 transcription, increasing p53 
inactivation and therefore functioning in a pro-proliferation manner (Qin, 2012). 
Moreover, induction of NFAT1 has been reported in advanced stages of pancreatic 
cancer, a malignancy where NFAT1 was shown to aid silencing of the p15(INK4b) 
tumour suppressive pathway, promoting pancreatic cancer cell growth (Baumgart et al., 
2012). NFAT1 has also demonstrated oncogenic behaviours in colon and breast cancer 
(Zheng et al., 2011; Gerlach et al., 2012).      
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A number of studies have found oncogenic functions for NFAT2. For example, NFAT2 
has been shown to work cooperatively with TGF-β to promote breast cancer cell 
proliferation (Sengupta et al., 2013; Sengupta et al., 2014). Moreover, overexpression of 
NFAT2 was identified in 70% of pancreatic carcinomas where the c-myc oncogene was 
found to be a direct target gene of NFAT2 (Buchholz et al., 2006). Binding of active 
NFAT2 to a specific element in the c-myc promoter caused upregulation of c-myc 
transcription, increasing cell proliferation and growth in a calcium/calcineurin dependent 
manor (Buchholz et al., 2006). Interestingly, activated MYC subsequently interacted with 
NFAT complexes to transactivate genes involved in cell cycle progression such as 
cyclinD1/D3 (Buchholz et al., 2006). Of further significance is the ability of NFAT2 to 
regulate the switch between dormancy of stem cells to a proliferative state (Horsley et al., 
2008; Oro, 2008). NFAT2 maintains a state of quiescence in the stem cell population by 
inhibiting the CDK4 checkpoint kinase downstream of bone morphogenetic protein 4 
(BMP4) signalling (Horsley et al., 2008). By promoting a tumour cell population that 
possesses stem cell characteristics, NFAT2 can provide tumour cells (which are 
potentially metastasising) with a capacity for self-renewal (Horsley et al., 2008; Mani et 
al., 2008; Oro, 2008; Qin et al., 2014).  
1.18.4. Role of NFAT in cell invasion and metastasis 
 
The ability of tumour cells to acquire migratory and invasive characteristics during the 
epithelial-mesenchymal transition is fundamental to metastatic progression. NFAT 
family members have been shown to play important roles in this process, particularly in 
breast cancer (Thiery, 2002). Isoform specific roles have been identified, for example, the 
migration and invasion of breast cancer cells through matrigel in vitro is promoted by 
expression of active NFAT1, whereas NFAT5 promotes migration but not invasion 
(Jauliac et al., 2002). As mentioned previously, a significant positive correlation between 
NFAT1/NFAT5 and expression of the integrin α6β4 was observed in patients with 
invasive breast cancer and ductal breast carcinoma cell lines (Jauliac et al., 2002). The 
α6β4 integrin is released from hemi-desmosomes in cancer cells, associating with the 
actin cytoskeleton to activate transcription of NFAT5, which in turn activates metastasis-
associated target genes such as COX-2 (Rabinovitz et al., 1997; Yiu et al., 2006; 
Vázquez-Cedeira et al., 2012). COX-2 is required for NFAT proteins to promote invasive 
migration, by catalysing the synthesis of prostaglandin E2 (PGE2), a mitogen known to 
promote invasion though the extra-cellular matrix (Yiu et al., 2006; Greenhough et al., 
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2009). In addition to COX-2, NFAT family members also target other genes that promote 
invasive properties. In breast epithelial cells NFAT induces the expression of autotoxin, 
a protein involved in synthesis of the potent mitogen and motogen lysophosphatidic acid 
(Chen et al., 2005) 
Due to their pro-invasive properties, it is reasonable to predict that NFATs are involved 
with the transcription or secretion of matrix metalloproteinases (MMPS) which regulate 
proteolytic degradation of the basement membrane during tumour invasion (Mott et al., 
2004). Although this has been highlighted in a number of NFAT review papers, only 
recently has a study reported an oncogenic association between NFAT and MMPs in lung 
cancer (Mancini et al., 2009; Minami et al., 2013; Qin et al., 2014).  
1.18.5. Role of NFAT in angiogenesis and lymphangiogenesis  
 
Establishment of a tumour vasculature allows solid malignancies to be provided with the 
oxygen and nutrients essential for cancer cells to thrive and proliferate. Angiogenesis is 
a key hallmark of cancer, since it also provides tumour cells with a pathway for 
dissemination to other bodily organs. The importance of NFAT in formation of the 
vasculature was first recognised in mice lacking both NFAT3 and NFAT4, which was 
lethal for mouse development during stage E11 (Graef et al., 2001). Mechanistically, 
NFAT is known to control the expression of vascular endothelial growth factor (VEGF), 
by regulating the expression of the VEGF receptor (VEGFR) (Jinnin et al., 2008). VEGF 
is an important molecule that induces angiogenesis by stimulating endothelial cell 
proliferation (Dvorak, 2006). In a positive feedback loop, NFAT induction of VEGF also 
enables VEGF to increase calcium signalling via PLCγ, hence activating NFAT and 
promoting transcription of downstream pro-angiogenic targets such as COX2, PGE2 and 
granulocyte-macrophage colony-stimulating factor (GM-CSF) (Cockerill et al., 1995; 
Schulz et al., 2004; Ferrara, 2005; Yiu et al., 2006; Jinnin et al., 2008; Vázquez-Cedeira 
et al., 2012).  
Isoform-specific roles for NFAT family members have also emerged in the field of 
lymphangiogenesis where NFAT2 has been shown to modulate the formation of 
lymphatic vessels, which some cancers (such as breast, lung and gastrointestinal) utilise 
for effective metastasis (Graef et al., 2001; Karpanen et al., 2001; Skobe et al., 2001; 
Kulkarni et al., 2009). NFAT2 functions downstream of vascular endothelial growth 
factor C (VEGFC) by interacting with other lymphangiogenesis factors such as forkhead 
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box C2 (FOXC2) and prospero-homeobox 1 (PROX1), a mechanism that Qin et al 2014 
suggest may contribute to the tumourigenic activity of NFAT2 in haematological cancers 
(Kulkarni et al., 2009; Norrmén et al., 2009; Qin et al., 2014). In summary, NFAT family 
members regulate both angiogenesis and lymphangiogenesis, further supporting their role 
in the malignant setting.  
1.18.6. Role of NFAT in the tumour microenvironment 
 
Stephen Paget proposed the ‘seed and soil’ hypothesis in 1889 to explain the behaviour 
of tumour cells when they metastasise (Paget, 1889; Mathot et al., 2012). Paget described 
the cancer cells as ‘seeds’ which metastasise to areas that are biochemically and 
physiologically favourable (the ‘soil’) for implantation and further growth (Paget, 1889). 
Considering that metastasis is a leading cause of death in cancer patients, over a century 
later, this phenomenon has become one of the main focuses of cancer research (Mathot 
et al., 2012). 
The tumour microenvironment is an intricate system of many cell types, including 
immune cells, fibroblasts, endothelial cells and the extracellular matrix. A close 
relationship between cancer cells and the cells of the microenvironment can potentiate 
tumourigenesis by providing optimal conditions for cancer cells (the seeds) to thrive. 
Tumour cells themselves for example, release extracellular signals to the 
microenvironment to promote angiogenesis and induce peripheral immune tolerance. 
Furthermore, infiltrating immune cells in the microenvironment can also benefit cancer 
cell survival by the release of factors which promote cell growth. The molecular 
mechanisms involved in these processes are yet to be fully understood, however it is 
becoming increasingly apparent that future strategies for cancer treatment will be to target 
both the seed and the soil.  
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In the past, the study of lymphoma involved analysis of isolated malignant lymphocytes, 
however recent studies suggests that the tumour microenvironment should also be 
considered. Research, for example, has shown that the tumour microenvironment in B 
cell malignancies is crucial for promotion of survival and proliferation signals, 
contributing to disease progression and relapse (Burger et al., 2014). Intercellular stromal 
and immune cell crosstalk in the tissue microenvironment has been demonstrated to allow 
some malignant B cells to escape from the host anti-tumour response by switching on 
immune evasion mechanisms. Examples of such include altered expression of surface 
molecules that are involved in immune cell recognition (allowing escape from immune 
surveillance) and hijacking of the immune checkpoint network by the tissue 
microenvironment (Nicholas et al., 2016).  
Compared to other malignancies, such as CLL, the precise contributions of the cells 
associated with the tumour microenvironment in DLBCL are less well defined. Generally 
speaking, malignant B cells have been shown to dampen down the T cell mediated 
response and suppress the anti-tumour effects of cytotoxic T lymphocytes (Nicholas et 
al., 2016). 
The tumour microenvironment in DLBCL has been shown to involve a plethora of cells, 
including tumour-associated macrophages, T cells, endothelial stromal cells, dendritic 
cells and mesenchymal stem cells (Burger et al., 2014, Nicholas et al., 2016). Of those 
characterised, there is evidence suggesting that some may have an anti-tumour effect, 
which contrasts the functions identified in other haematological cancers such as CLL. An 
influx of CD4+ T cells in CLL for example, has been shown to promote tumour 
proliferation, whereas immunohistochemical analysis of DLBCL diagnostic tissue 
biopsies showed a correlation between CD4+ T-cell infiltration and response to therapy, 
increasing overall survival (Nicholas et al., 2016). Moreover, in CLL, tumour-associated 
macrophages have been shown to inhibit apoptosis and attract other immune cells, such 
as T cells (Burger et al., 2009, Zucchetto et al., 2010). The effect of tumour-associated 
macrophages on the prognosis of DLBCL is not well understood and requires a better 
understanding of their phenotype and precise function (Kridel et al., 2015).  
Aside from the cell specific effects on prognosis, histopathological analysis of the degree 
of microvessel density surrounding the tumours of DLBCL patients has been shown to 
correlate with significantly worse overall survival (Cardesa-Salzmann et al., 2011). 
Moreover, analysis of the molecular signatures associated with the tumour 
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microenvironment in DLBCL has revealed specific genes in the microenvironment which 
are associated with a poorer outcome (Puvvada et al., 2013). Gene expression profiling 
of 787 DLBCL patients for example, showed that the tumour necrosis factor receptor 
superfamily member 9 (TNFRSF9) was associated with the DLBCL microenvironment 
and correlated with adverse outcomes in GCB DLBCL (Alizadeh et al., 2011). Overall, 
it is becoming clearer that the clinically exploitable immune sensitivity of haematological 
malignancies makes their tumour microenvironment a sensible target for immunotherapy 
and should be considered a primary target for research in this field.  
Recently, several studies have shown that NFAT signalling has an important role in the 
microenvironment, particularly by enhancing inflammatory chemokine production 
(Gwack et al., 2007). Chemokines function as chemo-attractants for leukocytes, enabling 
recruitment of cells (such as monocytes and neutrophils) to the site of tissue damage or 
in the context of cancer towards the tumour (Allavena et al., 2008). Often highly 
expressed in advanced stages of cancer, chemokines promote chemotaxis and migration 
of epithelial cells, which can also promote cancer cell dissemination (Allavena et al., 
2008). In advanced breast cancer, chemokines such as CXCL12 (chemokine (C-X-C) 
motif) and CCL21 (chemokine (C-C) motif ligand 21) are highly upregulated by NFAT, 
mediating metastasis by promoting chemotaxis of epithelial cells and therefore cancer 
cell invasion (Muller et al., 2001). In turn, infiltration of macrophages to the tumour 
microenvironment facilitates tumour proliferation and migration by macrophage 
secretion of epidermal growth factor (EGF) and colony-stimulating factor 1 (CSF1) 
(Wyckoff et al., 2004). Tumour cells expressing epidermal growth factor receptors 
(EGFR) respond to EGF secretion, which consequently activates store-operated calcium 
entry into cells, stimulating NFAT signalling (Wang et al., 2012). NFAT further 
integrates into this feedforward paracrine loop between inflammation, immune activation 
and cancer progression by inducing CSF1 in both immune and tumour cells (Cockerill et 
al., 1993; Masuda et al., 1993). Functioning alongside infiltrating macrophages, which 
often localise adjacent to tumour vasculature, NFAT is likely to promote epithelial cell 
migration and tumour progression (Wyckoff et al., 2004; Shou et al., 2015). 
Until recently, evidence showing that NFAT activation initiates primary tumour 
formation was lacking. Tripathi et al (2013) recently reported, for the first time, direct 
evidence of primary tumour induction by NFAT2 in vivo, through establishment of the 
tumour microenvironment (Tripathi et al., 2013). Using inducible transgenic mouse 
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systems, in which NFAT2 activation could be controlled by the administration of 
doxycycline, they showed that constitutively active NFAT2 caused tumours to form in 
specific sites and tissues, including the ovaries and the skin (Tripathi et al., 2013). Their 
data indicated that NFAT functions oncogenically in a cell-type and tissue-dependent 
manner, where NFAT2 induction was found to promote production of cytokines to 
produce an inflammatory microenvironment (Tripathi et al., 2013). Interestingly, they 
found that cells expressing constitutively active NFAT2, as well as wild-type 
neighbouring the tumour cells, had upregulated expression of tumour-promoting STAT3 
and c-Myc (Tripathi et al., 2013).  
In summary, NFAT is likely to have a complex role in the tumour microenvironment, 
demonstrating both cell autonomous and non-autonomous mechanisms. Further studies 
are required regarding the disease-specific roles for NFAT in the microenvironment, 
including a greater understanding of the molecular mechanisms behind its recently 
reported role in tumour-associated anergy (Serfling et al., 2006b; Abe et al., 2012). 
1.19. Targeting the NFAT pathway in cancer therapy 
 
NFATs have long been considered good targets for the treatment of immune related 
disorders. However, with an increasing number of studies also reporting of a role for 
NFAT in cancer, therapeutic intervention in this pathway may also prove useful for anti-
tumour therapy. Research on NFAT activity in immune function largely stemmed from 
recognition that NFAT induction was inhibited by the potent immunosuppressants 
cyclosporin A (CsA) and FK506. Derived from fungal metabolites, these drugs have 
revolutionised the field of transplant medicines. CsA and FK506 are widely used in the 
clinic to prevent organ transplant rejections but also serve as a useful research tool for 
understanding the role of NFAT in various systems (Kiani et al., 2000).   
Mechanistically, CsA and FK506 both prevent the nuclear translocation of NFATs by 
preventing calcineurin activation (Liu et al., 1991; Matsuda et al., 2000). Lacking 
structural similarity, CsA binds to the immunophillin protein cyclophilin A (CyPA) 
whereas FK506 bindings to FKBP12 respectively. Used in this PhD study, CsA binds to 
cyclophilin A (CyPA) (an immunophillin peptidyl-prolyl cis-trans isomerase (PPIase)), 
effectively preventing its PPIase activity which usually enables calcineurin activation. 
CsA-CyPA complexes bind between the catalytic and regulatory regions of calcineurin, 
forming a stable ternary complex (Barik, 2006; Sieber, 2009 ). Formation of respective 
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CsA or FK506 complexes with calcineurin effectively inhibits its phosphatase activity 
(Liu et al., 1991; Matsuda et al., 2000). This prevents the dephosphorylation of substrates 
downstream of calcineurin, including NFAT, therefore preventing the transcription of 
multiple genes, such as a cytokines and chemokines. (Liu et al., 1991; Matsuda et al., 
2000).  
Inhibition of calcineurin activity blocks the dephosphorylation of many other substrates 
(in addition to NFAT), which is likely to explain the neurotoxicity and nephrotoxicity 
experienced by patients administered these drugs (Kiani et al., 2000; Rezzani, 2004). 
Although valuable agents for transplant therapy, patients on long term treatment have a 
significant increase in the incidence of cancer due to suppression of tumour 
immunosurveillance mechanisms (Dantal et al., 2005). Despite this observation, short 
term CsA treatment of mouse models with human T-cell leukaemia results in anti-
leukaemic effects (Medyouf review 2008). CsA in combination with other agents has also 
been used successfully in the treatment of some T-cell lymphomas (Advani et al., 2007; 
Chen et al., 2011b).     
For NFAT therapy to be effective for the treatment of cancer, a targeted approach is 
essential. Selective inhibitors of NFAT have also been developed in the form of peptide 
sequences that interfere with the interaction between calcineurin and NFAT, blocking 
NFAT dephosphorylation and nuclear translocation. The VIVIT peptide for example, 
with a Pro-Val-Ile-Val-Ile-Thr sequence, has a high affinity for NFAT’s docking site on 
calcineurin (Aramburu et al., 1998; Aramburu et al., 1999). Developed in 1998, VIVIT 
was valued for its enhanced selectivity when compared to CsA (Aramburu et al., 1998; 
Aramburu et al., 1999). VIVIT was shown to attenuate breast cancer cell invasion in vitro 
(Jauliac et al., 2002), however the efficacy of VIVIT in mouse models of cancer 
progression remain to be evaluated. Furthermore, the use of peptides in the clinic 
introduces issues of delivery and stability, whereas development of effective small 
molecule inhibitors is likely a more promising strategy. Analogues of CsA and FK506 
(L-732531 and ISATX47 respectively), have shown less side effects than CsA and FK506 
themselves, however their efficacy in mouse models of cancer have not yet been 
performed (Karanam et al., 1998; Aspeslet et al., 2001).  
1.20. Role of NFAT in haematological malignancies 
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NFAT1, 2 and 4 are the NFAT family members expressed in lymphoid tissues. Increasing 
evidence suggests a role for NFAT1 and NFAT2 in haematological malignancies, 
although less is known about the role of NFAT4. First implicated in blood malignancies 
by Marafioti et al (2004), a comprehensive analysis of 300 biopsies of human lymphomas 
showed the overexpression and nuclear activation of NFAT2 in a range of disease types, 
including DLBCL, Burkitt’s lymphoma, aggressive T-cell lymphoma and chronic 
lymphocytic leukaemia (Marafioti et al., 2005; Pei et al., 2012). In this study, active 
nuclear NFAT2 was observed in 70% of Burkitt lymphomas and 30% of DLBCL 
(Marafioti et al., 2005). Nuclear localisation of NFAT2 or dephosphorylation of both 
NFAT2 and NFAT1 has also been observed in sample material from patients with 
DLBCL and aggressive T-ALL (T-cell acute lymphoblastic leukaemia) (Fu et al., 2006; 
Medyouf et al., 2007). It is possible that overexpression of NFAT may be due to genomic 
amplification, owing to the fact that approximately 5% of ABC DLBCL have 
amplification of a 1.9Mb region of chromosome 18q containing NFAT2, suggesting an 
effect of gene dosage in these cells (Lenz et al., 2008c; Müller et al., 2010).  
NFAT activation was also demonstrated to be calcineurin-dependent in cell lines derived 
from DLBCL and T-ALL, where treatment with CsA or FK506 suppressed NFAT 
activation (Pham et al., 2005; Medyouf et al., 2007). Moreover, from an in vivo 
standpoint, sustained activation of calcineurin/NFAT signalling, in leukaemia cells of 
mouse models of human T-ALL, could also be inhibited using CsA or FK506 and this 
resulted in leukaemia regression and induction of apoptosis (Medyouf et al., 2007). 
Leukaemic progression was also enhanced by transduction of cells with a constitutively 
active calcineurin mutant, further demonstrating the oncogenic nature of activating this 
pathway (Medyouf et al., 2007). Furthermore, it was recently reported that activation of 
the NFAT signalling pathway has an important role in the development of resistance to 
tyrosine kinase inhibitors in CML, providing further evidence that NFAT may be of key 
functional relevance in haematological malignancies (Gregory et al., 2010).  
1.21. Evidence for cooperative roles of NFAT and NF-κB in DLBCL 
 
Because NFAT-dependent transcription commonly requires assistance from other DNA 
binding proteins, this suggests a transcription factor that functions amongst a community 
of proteins that together promote tumourigenesis. Indeed, there is increasing evidence for 
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a cooperative role of the NF-κB and NFAT transcriptional pathways in the pathogenesis 
of DLBCL. 
A number of key studies have shown a small number of genes that may enhance tumour 
growth and survival are regulated co-ordinately by NF-κB and NFAT in lymphocytes (Fu 
et al., 2006). Pham et al (2005) investigated mechanisms that explain the abnormal 
expression of CD40 ligand (CD40L) in B-cell lymphomas (Pham et al., 2005). They 
demonstrated constitutive activation of NFAT2, which directly interacted with the NF-
κB subunit c-Rel, resulting in both cooperatively binding to the CD40L promoter, 
activating CD40L gene transcription and enhancing cell survival (Pham et al., 2005). NF-
κB and NFAT bound to two sites, including the distal CD40 ligand promoter kB sites -
1180 and the proximal NFAT site -250, where cooperation between these two key 
transcription factors was compared to the formation of an enhanceosome –like complex 
(Pham et al., 2005).  
Another study investigated regulation of the cell-survival factor BLyS in B-cell non-
Hodgkin lymphomas and found that constitutive NF-κB and NFAT regulated its 
expression through at least one NF-κB and two NFAT binding sites in the BLyS promoter 
(Fu et al., 2006).  
1.22. Importance of the BCR and NFAT signalling  
 
As described previously, signalling pathways downstream of the BCR are fundamental 
for the survival of many lymphomas, including ABC and some GCB DLBCLs. Chronic-
active BCR signalling leads to activation of the NF-κB pathway, for example, which is a 
well-established, critical pathway used for the survival of ABC DLBCL. Interestingly, in 
a recently study, clinical outcomes were predicted based on the degree of BCR and NFAT 
activation in Chronic Lymphocytic Leukaemia (CLL) (Le Roy et al., 2012). Although 
resistant to cell death in vivo, most CLL cells quickly become apoptotic when cultured in 
vitro (Le Roy et al., 2012). Remarkably, some CLL cells avoid apoptosis in vitro by 
survival responses that result from BCR stimulation. Le Roy et al (2012) show that B 
cells isolated from patients with unfavourable prognostic forms of CLL, had a survival 
advantage in vitro due to the degree of BCR and NFAT activation (Le Roy et al., 2012). 
In cells with an activated BCR, phosphorylation of SYK, activation of phospholipase Cγ2 
and intracellular calcium mobilisation demonstrated upregulation and constitutively 
active NFAT2 (Le Roy et al., 2012). Interestingly, when induced with IgM, responding 
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cells were converted to an unresponsive state when also treated with the VIVIT peptide 
NFAT inhibitor, whereas Ionomycin-induced NFAT activation caused non-responding 
cells to survive (Le Roy et al., 2012). The degree to which NFAT activation correlates 
with engagement of the BCR has not been studied in DLBCL. However, given the 
importance of the previously described forms of chronic and tonic BCR signalling for 
survival of DLBCL, this is an interesting and unexplored area of research.   
1.23. NFAT summary  
 
These studies collectively provide compelling evidence for the pathogenicity of the 
calcineurin-NFAT signalling pathway in haematological malignancies such as DLBCL. 
The presence of nuclear, active NFAT in DLBCL patients suggests that NFAT is 
transcriptionally active in these cells; however its function in this disease setting has not 
been fully investigated.  
At present, we have little understanding of the mechanisms that drive constitutive 
activation of NFATs, such as regulation by the BCR. It is possible that similar to NF-κB, 
NFAT signalling is critical for the survival of a specific subgroup of DLBCL, a hypothesis 
that if proven true could allow more targeted treatments for DLBCL.  
NFAT may exert its function in DLBCL by direct regulation of specific target genes, 
however these have surprisingly not yet been defined. Given the diverse roles of NFAT 
isoforms highlighted previously in other forms of cancer, is it possible that specific NFAT 
family members function differently, perhaps as oncogenes or tumour suppressors. 
Moreover, NFAT may not be a master regulator of DLBCL, but rather work in synergy 
with other transcription factors such as NF-κB to co-ordinately regulate genes encoding 
survival factors. 
 
 
 
1.24. Aims 
 
Accumulating evidence suggests that the signalling networks promoting and sustaining 
DLBCL derive from dysregulation of the normal pathways controlling B-lymphocyte 
activation and differentiation. There are increasing studies supporting a role for the NFAT 
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family of transcription factors in the malignant setting, where NFAT family members 
have demonstrated characteristics which represent many of the hallmarks of cancer 
(Macian, 2001; Qin et al., 2014). Constitutively-active nuclear NFAT2 has been 
demonstrated in approximately 40% of primary DLBCL samples, however a fully 
comprehensive analysis of its expression and activation in different subgroups of DLBCL 
has not yet been investigated (Marafioti et al., 2005). Moreover, although NFAT has been 
shown to regulate a small number of genes associated with DLBCL growth/survival, a 
broader analysis of the genes to which NFAT targets in DLBCL has not been explored 
(Pham et al., 2005; Fu et al., 2006; Pham et al., 2010).  
In addition to the NFAT family of transcription factors, the NF-κB pathway is also 
individually important for the pathogenesis of DLBCL. A small number of genes in 
lymphocytes have been shown to be regulated by NFAT and NF-κB in combination, 
suggesting that these pathways functionally intersect to drive lymphomagenesis (Pham et 
al., 2005; Fu et al., 2006). 
Together, there is convincing evidence supporting a role for NFAT in DLBCL. Therefore, 
the central hypothesis tested in this PhD study was if ‘the NFAT family of transcription 
factors play an important role in the survival and maintenance of DLBCL’.  
This hypothesis will be investigated as follows: 
 Aim 1: To investigate the expression and activation of NFAT in DLBCL 
 Aim 2: To determine novel NFAT target genes in DLBCL 
 Aim 3: To investigate cooperativity between the NFAT and NF-κB signalling 
pathways in DLBCL 
 
 
 
 
Chapter 2. 
Materials and Methods 
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2. Materials and Methods 
2.1. Culture of mammalian cell lines 
The human DLBCL cell lines U2932, SUDHL-4, Farage, WSU-NHL, SUDHL-6, OCI-
LY18, OCI-LY19, Pfeiffer, Toledo and Karpas-422 were purchased from DSMZ or 
ATCC. The ABC DLBCL cell lines HLY-1, RIVA and OCI-Ly3 were generously 
provided by Dr Alison Banham, Nuffield Department of Clinical Laboratory Sciences 
(University of Oxford). The specific molecular subgroups of the panel of human DLBCL 
cells are indicated in table 4. HLY-1 cells (not commercially available) were validated as 
an ABC subtype DLBCL cell line with expression of BCR components by a combination 
of flow cytometric and immunohistochemical immunotyping performed by the 
Department of Pathology, Newcastle Upon Tyne NHS Foundation Trust. Cells were 
cultured in plastic 75cm2 flasks and maintained in Gibco Roswell Park Memorial Institute 
(RPMI) 1640 medium with either 10% or 20% (as indicated in table 4) Gibco foetal calf 
serum (FCS). They were sustained in a humidified atmosphere at 37ºC with 5% CO2. 
Cultures were split every 2-3 days at a ratio of 1:3-1:6 in order to maintain a cell density 
of less than 1x10⁶cells/ml.  
U2OS cells were kindly cultured by Dr Alex Sfikas and were maintained at 37oC, 5% 
CO2 in DMEM medium (Lonza), supplemented with 10% FCS and 1% penicillin, 
streptomycin and L-Glutamine. Cells were grown to a maximum confluency of 90% and 
were split every 2-3 days. 
 
Table 4. Cell lines and culture medium. Mammalian cell lines used throughout the study are listed above, 
indicating cancer type and appropriate culture medium. ABC (Activated B-Cell), GCB (Germinal Centre 
B-Cell), DLBCL (Diffuse Large B-Cell Lymphoma). 
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2.1.1. Thawing of cryopreserved cell lines 
 
Cells frozen in freezing medium (section 2.1.3) were removed from liquid nitrogen stores 
and were thawed at 37oC before being combined with 5ml warm cell culture medium. To 
remove Dimethyl Sulfoxide (DMSO) (contained in the freezing media), cells were 
centrifuged (300g, 5mins) before the media was removed and replaced with an 
appropriate volume of fresh media and incubated at 37ºC, 5% CO2.  
2.1.2. Counting of cells using a haemocytometer  
Equal volumes of 0.4% Trypan Blue stain (Sigma) and cell suspension were mixed and 
pipetted under the cover slip of the haemocytometer e.g. 20µl Trypan Blue and 20µl cell 
suspension. Under the microscope, live cells (colourless and bright) were counted from 
all four large corner grids (1mm2). To calculate the cell concentration per/ml the 
following calculation was made;  
 
Total cell count
 Number of 1mm2 grids counted
   x dilution factor (2) = cells/ml x 104 
 
2.1.3. Freezing of cryopreserved cell lines  
 
Cells growing in the exponential phase were counted using 0.4% Trypan Blue and a 
haemocytometer (as described in section 2.1.2). A total of 107 cells were collected and 
centrifuged (300g, 5mins) before the supernatant was removed and the remaining pellet 
dissolved in freezing medium (1ml cell culture medium, 10% DMSO). Cells were 
transferred to cryovial tubes and stored at -80oC for 24 hours before transportation into 
liquid nitrogen tanks (-195oC).    
2.1.4. Mycoplasma testing 
 
Mycoplasma is a genus of bacteria that lack a cell wall around their cell membrane, 
meaning that they are often unaffected by many common antibiotics. Known to alter the 
DNA, RNA and protein synthesis of infected host cells, mycoplasma are difficult 
microorganisms to detect. The MycoAlert® (Lonza) test for mycoplasma infection used 
in this project exploits the activity of mycoplasmal enzymes. Enzymes are found in all 
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six of the main mycoplasmal cell culture contaminants and the majority of 180 species of 
mycoplasma, but are not present in eukaryotic cells. Viable mycoplasma are first lysed, 
before addition of the MycoAlert® substrate, which reacts with mycoplasmal enzymes, 
converting ADP to ATP. The level of ATP in a sample is measure before and after 
addition of the substrate, providing a ratio which is indicative of the presence or absence 
of mycoplasma.  
2.2. Protein Methods 
 
2.2.1. Preparation of whole cell extracts 
 
Untreated or treated cells were pelleted by centrifugation and washed twice in 1ml cold 
PBS. Lysis buffer was prepared by addition of 10µl of EDTA-free Halt™ Protease and 
Phosphatase Inhibitor (100x) (1mM Aminoethyl benzenesulfonyl hydrochloride, 800nM 
Aprotinin, 50µM Bestatin, 15µM E-64, 5uM EDTA, 20µM Leupeptin, 10µM Pepstatin 
A) single-use cocktail (Thermo-Scientific) to 1ml radioimmunoprecipitation (RIPA) 
Lysis and Extraction Buffer (Thermo-Scientific). 40µl lysis buffer per 1 million cells was 
added to samples and mixed by pipetting up and down until a clump of cellular material 
was formed. Samples were then incubated on ice for 30 minutes to ensure total lysis of 
cells. Samples were subsequently centrifuged (15mins, 16,000g at 4oC) and the 
supernatant removed and decanted into eppendorfs. Samples were stored at -20oC.     
2.2.2. Preparation of nuclear and cytoplasmic extracts 
 
The NE-PER™ Nuclear and Cytoplasmic Extraction Kit (Thermo-Scientific, catalogue 
number 78833) was used to perform nuclear and cytoplasmic extractions as per the 
manufacturer’s protocol. Addition of two cytoplasmic extraction reagents (CERI and 
CERII) to cell pellets causes disruption of cell membranes and the release of cytoplasmic 
components. The nuclei remain intact and are removed from the cytoplasmic extract by 
centrifugation. Addition of the nuclear extraction reagent (NER) lyses the nuclei, yielding 
a nuclear extract with less than 10% contamination between fractions. For experiments 
analysing the subcellular localisation of proteins and NFAT2 binding (ELISA), 107 
untreated or treated cells were harvested for each sample and (following centrifugation) 
the volumes of kit reagents used were based upon an approximate packed cell volume of 
20µl. For experiments using nuclear extracts to investigate NF-κB DNA binding 
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(ELISA), 5x106 cells were harvested and kit reagent volumes were based on a packed cell 
volume of 10µl.       
Optimisation experiments for this assay indicated that an additional wash step was 
beneficial to remove cytoplasmic contamination of the nuclear fraction. Following 
removal of the cytoplasmic extract, the nuclear pellet was washed in 1ml PBS, followed 
by centrifugation (5mins, 16,000g at 4oC) and removal of the PBS wash before the 
addition of the NER. This adjustment to the protocol was included throughout the study.   
2.2.3. Protein quantification 
 
2.2.3.1. Pierce™ BCA Protein Assay  
 
The Pierce™ BCA Protein Assay Kit (Thermo-Scientific, catalogue number 23225) was 
used to determine the concentration of protein in cell lysates. This method makes use of 
the biuret reaction (Cu+2 cations are reduced to Cu+1 cations by the presence of protein 
peptide bonds in an alkaline medium) and is quantified colourimetrically by using a 
reagent containing bicinchoninic acid (BCA). Chelation of two molecules of BCA with 
one cuprous Cu1+ cation produces a purple-coloured reaction product which exhibits 
strong absorbance at 562nm. The degree of colour change reflects the relative 
concentration of protein in a sample.  
Protein lysate samples were diluted 1:5 in 10μl RIPA buffer and added to a 96-well plate 
in triplicate alongside a series of dilutions of bovine serum albumin (BSA) protein 
standards (ranging from 0.125-2mg/ml) and a column of RIPA buffer blanks. Working 
reagent was prepared by mixing BCA Reagent A with BCA reagent B in the ratio 50:1. 
In turn, 200μl of working reagent was added to all wells and the plate incubated for 
30mins at 37oC, 5% CO2.  Absorbance readings were recorded using the FLUOstar 
Omega plate reader (BMG Labtech) at a wavelength of 562nm. The protein concentration 
of samples was subsequently determined, based on a standard curve produced by protein 
standards.   
 
 
2.2.3.2. BioRad protein assay (Bradford Assay) 
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The BioRad Protein Assay (catalogue number 500-0006) is based on the method of the 
Bradford assay, which is a colourimetric assay used for the determination of solubilised 
protein. The assay is based on an absorbance shift of Coomassie® Brilliant Blue G-250 
dye. The dye binds primarily to basic and aromatic amino acid residues and under acidic 
conditions is red in colour, occurring as a doubly protonated cationic form (Amax = 
470nm). When the dye binds to protein it is converted to a stable, unprotonated form 
which is blue in colour (Amax = 595nm) and can be detected using a spectrophotometer at 
this wavelength.   
For experiments investigating NF-κB activity using the NF-κB luciferase reporter assay 
(as described in section 2.8), the Bradford assay was performed in order for Relative Light 
Units (RLU) to be normalised to the respective protein concentrations of samples. First, 
the dye reagent was prepared by diluting 1 part dye with 4 parts distilled, de-ionised water 
(DDI H2O). To a 96-well plate, 10µl of supernatant from cell lysates or BSA protein 
standard was pipetted in duplicate and 200µl of diluted dye reagent was mixed into wells. 
The plate was incubated at room temperature for 5 minutes before absorbance 
measurements were taken using the POLARstar Omega spectrophotometer (BMG, 
Labtech) at 596nm. The protein concentration of samples was determined based on a 
standard curve of protein concentrations produced by protein standards (ranging from 
0.05-0.5mg/ml).  
2.2.4. Western blotting 
 
Western blotting is a technique used for the detection of specific proteins in a cell extract 
or tissue homogenate. Proteins are first denatured by heating to 100oC in a solution of 
SDS sample loading buffer. The 2-β-Mercaptoethanol contained in the sample buffer aids 
the denaturing process by breaking disulphide bonds, whereas the SDS adds a negative 
charge to proteins so that proteins will migrate through the acrylamide gel to the positive 
charged electrode during SDS-PAGE electrophoresis. Proteins are separated according to 
their molecular weight, for example, smaller, lower molecular weight proteins migrate 
further down the gel. Following electrophoresis, the separated protein bands on the gel 
are transferred to a nitrocellulose or polyvinylidene difluoride (PDVF) membrane by 
using an electric current to pull proteins from the gel onto the membrane. To avoid non-
specific binding of antibodies, the membrane is then blocked using a solution of diluted 
protein from either 5% BSA in PBS or 5% milk in TBS-Tween. In turn, the membrane is 
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probed with antibodies specific to a protein of interest, followed by exposure to a 
secondary antibody specific to the species of the primary antibody. Attached to the 
secondary antibody is usually a reporter enzyme such as alkaline phosphatase or 
horseradish peroxidase which cleaves a chemoluminescent agent to produce 
luminescence which is relative to the amount of protein present. The protein bands are 
visualised by placing photographic film on top of the membrane, exposing the light 
emitted from the chemoluminescent reaction in the areas of antibody binding.     
2.2.4.1. Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE)  
 
Electrophoresis gels were poured in-house, using the recipes in table 5. To achieve 
optimal resolution of NFAT transcription factors, an 8% acrylamide concentration was 
used for NFAT detection, due to NFAT isoforms being of high molecular weight (90-
160kDa). In contrast, 10% resolving gels were poured for all other proteins which were 
smaller in size, such as for NF-κB subunits. A 6% stacking gel was used for all gels.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Ingredients 
Volume for x1 
gel (10ml) 
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8% Resolving Gel 
Protogel: 30% acrylamide, 0.8% bisacrylamide 
(National Diagnostics) 
2.7ml 
4x Resolving Gel Buffer: 1.5M Tris-HCL, 0.4% 
SDS, pH8.8 (National Diagnostics) 
2.6ml 
Tetramethylenediamine (TEMED) (Sigma) 10µl 
Ammonium Persulphate (APS) (Sigma)) 30µl 
DiH2O (Gibco) 4.7ml 
10% Resolving Gel 
Protogel: 30% acrylamide, 0.8% bisacrylamide 
(National Diagnostics) 
3.3ml 
4x Resolving Gel Buffer: 1.5M Tris-HCL, 0.4% 
SDS, pH8.8 (National Diagnostics) 
2.6ml 
TEMED (Sigma) 10µl 
APS (Sigma) 30µl 
DiH2O (Gibco) 4.1ml 
6% Stacking Gel 
Protogel: 30% acrylamide, 0.8% bisacrylamide 
(National Diagnostics) 
1ml 
Protogel Stacking Buffer: 0.5M Tris-HCL, 0.4% 
SDS, pH6.8 (National Diagnostics) 
1.25ml 
TEMED (Sigma) 5µl 
APS (Sigma) 50µl 
DiH2O (Gibco) 2.75ml 
 
Table 5. Material information and recipe for pouring SDS-PAGE gels. 
While gels were setting, cell lysates were diluted in RIPA buffer and 4x SDS sample 
buffer so that the final amount of protein added to individual wells was 12-20µg. Protein 
lysates were then denatured by heating samples to 100oC in a heat block for 5 minutes 
and then centrifuged at full speed for one minute (to collect condensation) and then 
pipetted into wells. 10µl Spectra™ Multicolour Broad Range Protein Ladder standards 
(Thermo-Scientific) were run alongside samples. Once loaded, Mini-PROTEAN® 3 
system tanks (BioRad) were filled with 500ml running buffer (table 6) and electrophoresis 
was performed at 120V for approximately 90 minutes. 
 Ingredients to make stock Preparation of 1x solution 
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4x SDS Sample 
Buffer (50ml) 
250mM Tris pH 6.8 (12.5ml) 
Dilute 1:4 with sample lysate 
and RIPA buffer  
40% Glycerol (20ml) 
8% SDS (4g) 
Sterile diH2O to 40ml, pH to 6.8, then 
make up to 50ml. with diH2O 
2.86M 2-β-Mercaptoethanol (2ME) 
(200µl/ml)  
0.04% saturated aqueous Bromophenol 
Blue solution (40µl/ml) 
10x Running 
Buffer (2L) 
25mM Tris (60g) 
For 500ml: Dilute 100ml 10x 
running buffer with 900ml 
sterile diH2O 
192mM Glycine (288g) 
0.1% SDS (20g) 
Sterile diH2O to 2L 
5x Transfer 
Buffer (2L) 
25mM Tris (30g) 
For 1L: 200ml 5x transfer 
buffer, 200ml Methanol, 600ml 
sterile diH2O 
192mM Glycine (144g) 
0.0075% SDS (7.5g) 
Sterile diH2O to 2L 
10x TBS pH 7.6 
(2L) 
20mM Tris (175.32g) 
For 1L 1xTBS 0.1% Tween: 
Dilute 100ml 10x TBS with 
900ml sterile diH2O plus 1ml 
Tween® 20 (Sigma) 
150mM NaCl (87.66g) 
Sterile DiH2O to 1.8L, pH to 7.6, 
then make up to 2L with diH2O 
 
Table 6. Material information and recipes for preparing Western blotting buffers and washing 
agents. 
 
 
2.2.4.2. Transfer and Immunoblotting 
 
Proteins were transferred to an Immobilon-P PDVF transfer membrane (Millipore) using 
the BioRad Mini Trans-Blot system. The gel and methanol-activated membrane were 
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placed between two sponges and two pieces of filter paper that had been soaked in transfer 
buffer (table 6). The transfer was run at 100V for 1 hour with a block of ice inserted in 
the tank, which was replaced with another block of ice halfway through the transfer 
process. Following protein transfer, the membrane was blocked with TBS-Tween 5% 
milk solution for 1 hour to prevent non-specific binding. The membrane was then washed 
(2x10mins) in TBS-Tween 5% milk before being incubated for 1 hour or overnight in the 
specified concentration of primary antibody, as indicated in table 7. A further 2x10min 
washes with TBS-Tween 5% milk were made followed by incubation of the membrane 
in the specified concentration of secondary antibody for 1 hour. The membrane was then 
washed for 4x10mins in TBS-Tween 5% milk.  
2.2.4.3. Protein detection 
 
Proteins were detected using the Amersham enhanced chemiluminescence (ECL) 
Western Blotting Detection Reagents (GE Healthcare) by adding 1ml of ECL per 
membrane for 1 minute. The membrane was wrapped in Saran wrap and fastened into an 
X-Ray film cassette. Autoradiography film (Amersham Hyperfilm) was exposed to the 
membrane and developed using a D3300 X-Ray system (Gulmay Medical Ltd, Surrey, 
UK).  
2.2.4.4. Stripping membranes 
 
When required, membranes were stripped to remove bound antibodies by incubation in 
20mls stripping buffer solution (6.25ml 0.5M Tris pH 6.8, 5ml 20% SDS, 350μl 2-β-
mercaptoethanol (Sigma) and 38.5ml sterile H2O) in a shaking water bath at 70
oC for 30 
minutes. Membranes were washed for 4x10min in TBS-Tween and subsequently blocked 
in TBS-Tween 5% milk for 1 hour before re-probing with the primary antibody of interest.  
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2.3. Cell viability/proliferation methods 
 
2.3.1. Trypan blue exclusion  
 
The Trypan Blue exclusion assay was used to determine the number of viable cells in a 
cell suspension. Dead cells are visually identified as blue in colour, where their disrupted 
cell membranes have allowed the dye to be taken up into the cytoplasm of cells. Live cells 
with intact membranes will not absorb the dye and appear visually as having a clear 
cytoplasm. Cell suspensions were mixed in a 1:1 ratio with 0.4% Trypan Blue (Sigma) 
solution (e.g. 20µl cells: 20µl Trypan Blue) and pipetted onto a haemocytometer before 
counting (as described in section 2.1.2). The following calculation was made to determine 
cell viability in samples; 
 
No. of viable cells counted
Total cells counted (viable and dead)
 x 100 = % viable cells 
2.3.2. Growth curves   
 
To obtain optimal cell seeding densities for subsequent cell viability assays, the growth 
of cell lines was analysed over 4 days and recorded using the resazurin assay, as described 
in section 1.6.3. Cells were first counted using trypan blue staining and seeded out at a 
range of densities (0.05x106/ml to 1x106/ml) in 100µl volumes. Samples were assayed in 
triplicate and for each cell line 4x96-well plates were filled, one to be assayed each day. 
To avoid evaporation of cells, the outer wells were filled with 100µl PBS. Cells were 
incubated (37oC, 5% CO2) for 24, 48, 72 and 96 hours before 11µl resazurin agent was 
added to each well and the plates incubated for 2 hours. Viable cells were quantified using 
the FLUOstar Omega plate reader (BMG Labtech) at an excitation wavelength of 560nm 
and emission wavelength of 590nm and growth curves were plotted using Microsoft 
Excel.  
2.3.3. Resazurin cell viability assay 
 
To analyse the effects of specified chemical inhibitors, peptides and anti-TNFα agents on 
cell viability, the resazurin assay (Sigma, catalogue number R7017) was used. The assay 
estimates the number of viable cells present in multi-well plates by using the indicator 
dye resazurin to measure the metabolic activity of cells. Resazurin is readily reduced into 
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the fluorescent compound resorufin in viable cells, shifting the colour from a dark blue 
to a pink, fluorescent colour (579Ex/584Em), which can be measured using a 
spectrophotometer. The fluorescent signal is directly proportional to the number of viable 
cells. In contrast, non-viable cells without the capacity to metabolise, are unable to reduce 
the resazurin dye and so do not generate a fluorescent signal.   
Upon arrival, the resazurin sodium salt was reconstituted in sterile H2O (Gibco) to a 
concentration of 100µg/µl and stored in 1ml aliquots at -20oC. Immediately prior to 
performing the assay (after the desired time point), the resazurin was thawed in the 
absence of light. For the assay setup, cells were first counted and seeded out into 96-well 
plates at a cell-specific density, as indicated in chapter 3, figure 16k. A volume of 50μl 
of cells was added to wells in triplicate, including triplicates of control wells (cells with 
or without DMSO/agent diluents) and triplicates of blank media control wells. To avoid 
evaporation of outer wells, these were loaded with 100μl PBS. Specific concentrations of 
chemical inhibitor, peptide or anti-TNFα agent were prepared at double the final desired 
concentration and 50μl of each added to wells accordingly (1:2 dilution to achieve final 
concentration). Plates were incubated at 37ºC, 5% CO2 for the specified time point, 
followed by addition of 11ul of resazurin reagent (final concentration in wells 100µg/ml) 
and incubated at 37ºC, 5% CO2 for 2 hours. Fluorescence readings were recorded using 
the FLUOstar Omega plate reader (BMG Labtech) at an excitation wavelength of 560nm 
and emission wavelength of 590nm. The percentage cell viability was determined by 
comparing fluorescence values to the untreated control and IC50 values (when reached) 
were established using cell viability curves on GraphPad Prism 6 software.      
2.3.4. Propidium Iodide (PI) assay for cell cycle analysis 
 
Flow cytometry is a useful technique used for many research applications including cell 
counting, sorting and for the detection of biomarkers of interest. The physical and 
chemical properties of cells (such as their granularity, size and fluorescence intensity) can 
be characterised. Cells are typically resuspended in a stream of fluid and passed through 
at least one laser, exciting fluorescently labelled components of cells, therefore emitting 
light at various wavelengths. An electronic detection apparatus is used to record 
fluorescence and how the light is scattered from the laser.   
During the phases of the cell cycle, levels of DNA change, which can be detected using 
a DNA-staining dye such as propidium iodide (PI). PI binds to DNA by intercalating 
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between bases and is stoichiometric, binding in direct proportion to the amount of DNA 
present in the cell. The binding property of the dye therefore allows the different stages 
of the cell cycle to be identified. Cells in S-phase for example, will have more DNA than 
cells in G1 and fluorescence intensity will further increase when cells are in the G2 growth 
phase.  
For the experimental assay, following the appropriate treatment, cells were counted using 
a haemocytometer and centrifuged (300g, 5mins) and washed in 1ml PBS. Cells were 
spun down again (300g, 5mins) and fixed in 1ml of cold 70% ethanol (prevents lysis and 
degradation of cells). To ensure fixation of all cells, the ethanol was added to eppendorfs 
drop-wise while vortexing at a low speed. Samples were placed on ice for 30 minutes (or 
at this stage stored at 4oC for several days) before being washed in 1ml PBS (300g, 
5mins). To prevent the binding of PI to RNA, RNA was degraded by resuspending pellets 
in 50µl of 100µg/ml RNaseA. To stain the DNA, 200µl of propidium iodide (Sigma) was 
added to the pellet to a final concentration of 50µg/ml. Samples were subsequently 
protected from light by tin foil and taken for flow cytometry analysis using the 
FACSCalibur (BD Biosciences). A total of 10,000 events were analysed using the 
CellQuest Pro software (BD Biosciences). For data analysis, cell cycle phase distribution 
was determined using Cyflogic flow cytometry software (version 1.2.1), as described in 
Appendix Figure 22.  
 
 
 
 
 
 
 
 
2.3.5. Preparation of calcineurin/NFAT chemical inhibitors and peptides 
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Cyclosporin A (CsA), Tolypocladium 
Inflatum 
 
 
 
Source: www.merckmillipore.com 
 
Calcineurin inhibitor Cyclosporin A 
(molecular weight 1202.6) was purchased 
from Merck Chemical Ltd. (Calbiochem, 
catalogue number 239835) in a powder form 
and was dissolved in DMSO (Sigma) to a 
concentration of 100mg/ml and stored at 4ºC.  
 
Figure 10. Molecular structure and preparation of calcineurin inhibitor CsA.  
 
 
FK506, Tacrolimus 
 
 
 
Source: www.enzolifesciences.com 
 
Calcineurin inhibitor FK506 (molecular 
weight 804.03) was purchased from Cell 
Signalling (catalogue number 9974) in a 
powder form and was dissolved in DMSO 
(Sigma) to a concentration of 12.4µM and 
stored at -20ºC.  
 
Figure 11. Molecular structure and preparation of calcineurin inhibitor FK506. 
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11R-VIVIT Peptide 
 
 
Cell permeable NFAT inhibitor 11R-VIVIT peptide (molecular weight 3573.1) was 
purchased from Merck Chemicals Ltd (Calbiochem, catalogue number 480401). It was 
obtained in a lyophilised solid, salt form and was dissolved in sterile distilled water to a 
concentration of 250µM and stored at -20ºC. Peptide sequence; H-Arg-Arg-Arg-Arg-
Arg-Arg-Arg-Arg-Arg-Arg-Arg-Gly-Gly-Gly-Met-Ala-Gly-Pro-His-Pro-Val-Ile-Thr-
Gly-Pro-His-Glu-Glu-OH. 
 
 
 
Maleimido-conjugated VIVIT 1 (MCV-1) 
 
Cell permeable NFAT inhibitor MCV-1 (HP-VIVIT) peptide (molecular weight 1020.2) 
was purchased from Merck Chemicals Ltd (Calbiochem, catalogue number 480404) in 
a salt form and was dissolved in DMSO (Sigma) to a concentration of 40mM and stored 
at -20oC.  
 
Source: www.merckmillipore.com  
 
Figure 12. Molecular structure and preparation of MCV-1 VIVIT peptide.  
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Inhibitor of NFAT-Calcineurin Activation 6 
(INCA-6)  
 
 
 
Source: www.tocris.com 
 
The NFAT inhibitor INCA-6 (molecular weight 
284.31) was purchased from Tocris Biosciences 
(catalogue number 2162) in a powder form and 
was dissolved in DMSO (Sigma) to a 
concentration of 18mM and stored at room 
temperature.   
 
Figure 13. Molecular structure and preparation of the NFAT inhibitor INCA-6. 
2.3.6. Preparation of NF-κB chemical inhibitors 
 
 
IKK2 inhibitor IV (TPCA-1)  
 
 
Source: ww.sigmaaldrich.com 
 
The IKK2 (NF-κB) inhibitor 2-[amino 
carbonyl) amino]-5-(4-fluorophenyl)-3-
thiophenecarboxamide (TPCA-1) (molecular 
weight 279.29) was purchased from 
Selleckchem (catalogue number S2824 and 
was dissolved in DMSO (Sigma) to a 
concentration of 35mM and stored at -80oC. 
 
Figure 14. Molecular structure and preparation of the IKK2 inhibitor TPCA-1. 
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2.3.7. Preparation of anti-TNF-α agents 
 
 
Etanercept (Enbrel®)  
 
The TNF-α fusion protein Etanercept was a kind gift from Dr Anja Krippner (University 
of Newcastle, UK) and was diluted in PBS with 5% FCS to a concentration of 10mg/ml 
and stored at 4oC. 
 
 
Infliximab (Remicade®) 
 
The TNF-α neutralising antibody Infliximab was a kind gift from Dr Anja Krippner 
(University of Newcastle, UK) and was diluted in PBS with 5% FCS to a concentration 
of 10mg/ml and stored at 4oC. 
 
 
Human Immunoglobulin G (IgG)  
 
The human IgG was a kind gift from Dr Anja Krippner (University of Newcastle, UK) 
and was diluted in PBS with 5% FCS to a concentration of 10mg/ml and stored at 4oC.  
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2.4. RNA Methods 
 
2.4.1. GeneFlow EZ-RNA total RNA isolation  
 
RNA extraction was performed by using the EZ-RNA Total RNA Isolation Kit 
(GeneFlow, catalogue number 20-400-100) which uses a denaturing solution comprised 
of guanidine thiocyanate to disrupt cells, followed by a phenol-based organic extraction 
and isopropanol-based precipitation of RNA. The assay procedure was followed 
according to the manufacturer’s protocol. RNA pellets were dissolved in 20μl sterile, 
RNAse/DNase free H2O (Gibco) and stored at -80
oC.  
2.4.2. Qiagen RNeasy RNA extraction  
 
RNA extraction of samples used for gene expression microarray analysis was performed 
using the RNeasy Mini Kit (Qiagen, catalogue number 74106). The assay procedure was 
followed according to the manufacturer’s protocol, where samples are first lysed with 
guanidine-isothiocyanate and washed in ethanol. A series of steps to remove 
contaminants are subsequently followed by loading samples into silica membrane spin 
columns. Samples were eluted in 30μl RNase-free H2O (Gibco) and were stored at -80oC 
before further use. 
2.4.3. Reverse Transcription of RNA to cDNA 
 
The NanoDrop ND1000 spectrophotometer (LabTech International) was used to 
determine the quantity of RNA in each sample. Samples were diluted in sterile 
DNase/RNase free water (Gibco) to a concentration of approximately 500ng/µl. The 
260:230 and 260:280 ratios were recorded as an indication of contaminant absorption e.g. 
phenol. The RevertAid H Minus First Strand cDNA Synthesis Kit (Fermentas) was used 
for the reverse transcription of RNA to cDNA. First, 500ng RNA was added to 
Fisherbrand PCR tubes (Fisher Scientific) and the volume made up to 11μl with RNase 
free water (Gibco). 1μl of random hexamer primers was then added to the cDNA followed 
by denaturing of the samples at 65oC using the GeneAmp PCR system 2700 (Applied 
Biosystems). 8μl of master mix (4μl reaction buffer, 2μl 10nM dNTP mix, 1μl Ribolock 
RNase Inhibitor and 1μl RevertAid H Minus M-MulV Reverse Transcriptase per sample) 
was added to each of the cDNA samples which were then incubated in the GeneAmp 
PhD Thesis  Holly White 
 
73 
 
PCR system 2700 (Applied Biosystems) for 10mins at 25oC, 60mins at 42oC and 75oC 
for 10mins. Samples were then stored at -20oC until further use.   
2.4.4. Quantitative Real-Time PCR (qRT-PCR) 
 
qRT-PCR is a quantitative method used for the determination of a relative expression of 
a gene. In this study the SYBR green dye based-method was used, whereby SYBR green 
acts as a reporter dye by binding to newly synthesised double-stranded DNA causing a 
green fluorescent signal to be emitted. For signals to be detectable the PCR reaction is 
repeated 40 times, amplifying the DNA each time and increasingly fluorescence intensity, 
which can be detected at 520nm. The absolute and relative DNA quantities can therefore 
be measured and compared between samples.  
First, a master mix for each Sigma primer set was prepared using 0.3μl of forward and 
reverse primers (final concentration of primer 100nM), 5μl 2X SYBR-Green master mix 
(Invitrogen) and 3.2μl RNase/DNase free H2O (Gibco). For Qiagen primers, 1µl of 10x 
primer was used per reaction, 5µl 2X SYBR-Green master mix and 3µl H2O. The master 
mix was mixed by vortexing and 8μl was added into wells of a 384-well plate 
respectively. 1μl of cDNA was added (using a multistep electronic pipette) to wells 
accordingly and a row of non-template controls (Gibco sterile distilled H2O) were run 
alongside samples. Samples were run in triplicate so that a mean cycle threshold (Ct) 
value could be calculated after the qRT-PCR step. The plate was then sealed and 
centrifuged at 300g for 1 minute. Quantitative Real-time PCR was subsequently 
performed using the ABI Prism 7900HT sequence detections system (Applied 
Biosystems).  
The PCR reaction was run for 90mins and used specific conditions to allow the 
amplification of specific genes as follows. First, samples were heated to 95oC for 10mins 
causing denaturation of DNA and separation of strands. The reaction temperature was 
then reduced to the annealing temperature (60oC) for 1min and increased to 95oC for 15 
seconds for 40 cycles to allow forward and reverse primers to anneal to complementary 
regions of single-stranded DNA and begin synthesising DNA for genes of interest. 
 
2.4.5. Primers used for qRT-PCR 
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SYBR green-based Quantitect primers were purchased from Qiagen, as indicated in table 
8a and 8b. Each primer set was supplied as a lyophilised mix of forward and reverse 
primers and had been bioinformatically validated to ensure high specificity and 
sensitivity. Primers were reconstituted to make a 10x stock solution by adding 1.1ml TE, 
pH 8.0 to individual vials of primers. Primers were stored at -20oC in small aliquots to 
avoid repeated freezing and thawing.  
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Sequences for the SYBR green-based primers for the house-keeping gene GAPDH and 
reference genes TBP, BCL-6 and MYC (Sigma) are shown in table 8c. Sequences were 
designed using the Ensembl Genome Browser and PrimerQuest (Integrated DNA 
Technologies). The criteria for primer design were for sequences to span at least 2 exons 
and contain no intronic sequence, PCR amplicon length 75-150bp, Primer length 19-
25bp, percentage GC content 45-55%, melting temperature 60-65oC. The specificity of 
primers was checked using the online PrimerBlast tool (NCBI). 100μM stock 
concentrations were made for all Sigma primers by reconstitution in sterile DNase/RNase 
free diH2O (Gibco) and were stored at -20
oC. Before use in qRT-PCR experiments, 
primers were diluted into 2.5µM aliquots in RNase/DNase H2O (Gibco). The quality of 
all primers was checked by analysis of their dissociation curves where the presence of 
one single peak indicated that primers did not form dimers and non-specific products had 
not been amplified.   
Using the ABI SDS 2.3 system software, amplification plots and dissociation curves were 
constructed (SYBR selected as the reporter gene and ROX as the reporter dye) in order 
for Ct values to be calculated. The Ct value indicates the intersection between the 
amplification plot and the threshold line and represents the relative concentration of the 
target gene. The relative level of gene expression was calculated using the 2-ΔΔCt method. 
Accordingly, the mean Ct value of the gene of interest (GOI) was normalised to the mean 
Ct value of the endogenous control gene GAPDH or for each sample to give a ΔCt value 
(Ct (GOI) – Ct (GAPDH) = ΔCt). The ΔCt values of the treated samples were then further 
normalised to the ΔCt values of the control samples such as the untreated DMSO sample 
(ΔCt treated sample – ΔCt control sample = ΔΔCt). As every Ct unit represents a 2-fold 
change (=log2), the ΔΔCt values were subsequently linearised to give the relative RNA 
expression / fold difference (2-ΔΔCt = relative RNA expression). Although not shown 
throughout this thesis, the human TATA-box binding protein (TBP) was also used as an 
additional control gene. Following these calculations, data was input into Microsoft Excel 
for graph interpretation.  
2.5. Illumina gene expression microarray  
 
Gene expression arrays for expression analysis are a powerful approach for comparing 
gene activity in biological samples. Providing genome-wide transcriptional coverage of 
well-established genes (including splice variants), arrays can be used for a wide range of 
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experimental purposes, such as to compare treated versus untreated cell culture 
experiments or to profile tissue samples.    
Typically, RNA is isolated from samples, followed by conversion to fluorescently 
labelled cDNA via reverse transcription. The cDNA is subsequently hybridised to the 
array and any unhybridised cDNA is removed. The cDNA that has hybridised to the 
complementary DNA on the array is detected by the excitation of molecules in the 
fluorescent dye using a laser. Photons emitted from the array are measured by scanning a 
digital image of the dye which is then analysed to locate probes on the array and to record 
the intensity of their fluorescence.  
To investigate changes in gene expression induced by CsA treatment, three cell lines 
(U2932, HLY-1 and WSU-NHL) were treated with their respective IC50 concentration 
for 2 timepoints (2 hours and 6 hours) in 4 independent biological repeat experiments. 
Following treatment, RNA was isolated from all 48 samples using the RNeasy Mini Kit 
(Qiagen), as described in section 2.4.2. Samples were then randomised and reassigned a 
numerical sample ID before being shipped to The Welcome Trust Centre for Human 
Genetics (Oxford Genomics Centre, UK) on dry ice.  
Samples were subsequently hybridised to Illumina Human HT-12v4 Expression 
BeadChip arrays, which deliver high-throughput processing of 12 samples per BeadChip, 
therefore using a total of 4 BeadChips in this particular study. Arrays on the expression 
BeadChip target approximately 47,231 probes derived from the National Centre for 
Biotechnology Information Reference Sequence (NCBI) RefSeq Release 38 (November 
7th, 2009) and other sources.   
2.5.1. Data analysis 
 
Paired and unpaired data analysis was analysed by Dr Simon Cockell (Bioinformatic 
Support Unit, University of Newcastle, UK), using R Software (version 3.1.2). 
2.6. Gene Set Enrichment Analysis (GSEA) 
 
GSEA is a useful analytical method for extracting meaning from genome-wide expression 
arrays, which often yield an extremely large amount of data. Classes of genes that are 
over-represented in the dataset (such as by being significantly enriched or depleted) are 
identified and compared to existing prior biological knowledge from previously published 
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gene sets. Gene sets, for example, may be groups of genes that share similar biological 
function, biochemical pathways or regulation. The ultimate aim of this powerful 
computational technique is to determine whether a set of genes show statistically 
significant differences between phenotypes, however this will be described in greater 
detail in the results section.  
Parameter Settings used in study 
Number of permutations 1000 
Phenotype labels  Vehicle_versus_treatment 
Collapse dataset to gene values True 
Permutation type Gene_set 
Chip platform Ilmn_HumanHT_12_V4_0_R1_15002873_B.chip 
Enrichment statistic Weighted 
Metric for ranking genes Log2_Ratio_of_Classes 
Gene list sorting mode Real 
Gene list ordering mode Descending  
Max size: exclude large sets 500 
Min size: exclude smaller sets 15 
Collapsing mode for probe sets => 1 gene Max_probe 
Normalisation mode Meandiv 
Randomisation mode No_balance 
Omit features with no symbol match True 
Make detailed gene set report  True 
Median for class metrics False 
Number of markers 100 
Plot graphs for the top sets of each phenotype 50 
Seed for mutation  Timestamp 
 
Table 9. Parameters used for GSEA. 
GSEA was performed using the Broad Institute of Harvard and MIT GSEA software 
(http://www.broadinstitute.org/gsea/index.jsp) and the Molecular Signatures Database 
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v5.0 (MSigDB) (Subramanian, Tamayo 2005), which was used to provide a collection of 
annotated gene sets. Data from the Illumina gene expression microarray was uploaded 
into the GSEA software to investigate expression profiles between CsA-treated and 
untreated samples using the parameters indicated in table 9. 
2.7. Enzyme-Linked Immunosorbent Assay (ELISA) 
 
An ELISA is a technique used to measure the concentration of an analyte or hormone in 
solution, relying on the basic principle of an interaction between an antigen and an 
antibody with a complimentary binding site. Samples are first immobilised onto a solid 
surface (such as a 96-well plate) either directly by adsorption or indirectly using a capture 
antibody already bound to the plate. Addition of a specific detection antibody forms an 
analyte-antibody complex, where the antibody may be covalently linked to an enzyme, 
or detected itself by a secondary antibody linked to an enzyme. Between binding steps, 
the plates are washed with a detergent to remove non-specific binding. Following the final 
wash, an enzymatic substrate solution is added to produce a detectable signal, commonly 
a change in colour. The end product colour is relative to the amount of analyte being 
investigated and can be measured using spectrophotometry.   
2.7.1 TransAM® DNA-binding ELISA  
 
The TransAM® NFAT2 (Active Motif, catalogue number 40296) and TransAM® NF-
κB family assays (Active Motif, catalogue number 43296) are ELISA-based kits 
specifically designed to quantify NFAT2 and NF-κB subunit transcriptional activity. 
The TransAM® kit contained 96-well plates to which a specific double-stranded 
oligonucleotide containing the NFAT2 consensus binding site (5’-AGGAAA-3’) or NF-
κB consensus binding site (5’-GGGACTTTCC-3’) had been immobilised. NFAT2 or NF-
κB contained in nuclear extracts bound specifically to the oligonucleotide, which was 
detected upon DNA binding by an antibody directed against an accessible epitope on the 
NFAT2, p65, p50, p52, c-Rel or RelB protein that is accessible only when NFAT or NF-
κB are active and bound to their DNA target. Addition of a secondary antibody 
(conjugated to horseradish peroxidase) produced colourimetric readouts which were 
quantified by spectrophotometry. Inclusion of competitive binding experiments allowed 
the specificity of the assay to be monitored. The wild-type consensus oligonucleotide 
should prevent NFAT2 or NF-κB from binding to the immobilised probe by acting as a 
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competitor for their binding, whereas the mutated oligonucleotide should have no effect 
on NFAT2 or NF-κB binding. 
For experiments measuring the relative NFAT2 transcription factor activation in a panel 
of cell lines, cells were collected one day after being split and nuclear extracts were 
prepared, as described in section 2.2.2. For experiments measuring the effect of a 
chemical inhibitor on NFAT2 binding activity, treated and untreated DLBCL cells were 
incubated at 37ºC, 5% CO2 for the specified duration before being harvested and nuclear 
extracts prepared. The experimental procedure for the NFAT2 ELISA was followed 
according to the TransAM protocol in the Active Motif manual. Samples were assayed in 
duplicate at a concentration of 5µg per well, including the PHA-treated Jurkat nuclear 
extract (provided by kit). Samples were incubated in developing solution for 12 minutes 
before addition of stop solution, as advised for the particular kit lot number. The 
experimental procedure for the NF-κB ELISA was also followed according to the 
TransAM protocol in the Active Motif manual. Samples were assayed in duplicate at a 
concentration of 4µg per well, including the Raji nuclear extract (provided by kit). 
Samples were incubated in developing solution for 5 minutes before addition of stop 
solution, as advised for the particular kit lot number. Absorbance for both assays was 
recorded using the FLUOstar Omega plate reader (BMG Labtech) at 450nm with a 
reference wavelength of 655nm. Data was analysed using GraphPad Prism 6 software. 
2.7.2. Quantikine® TNFα Colourimetric Sandwich ELISA 
 
The human TNF-alpha (TNFα) Quantikine® HS ELISA SixPak kit (R&D Systems, 
catalogue number STA00C) was used to measure human TNFα in cell culture 
supernatants. Employing a sandwich enzyme immunoassay technique, Quantikine® 
solid-phase ELISA plates contained pre-coated monoclonal antibody specific for human 
TNFα. E.coli-derived recombinant human TNFα standards and samples were pipetted 
into wells and any TNFα present was immobilised by the antibody. Following a series of 
wash steps to remove unbound substances, an enzyme-linked polyclonal antibody 
specific for human TNFα was added to wells, followed by addition of a substrate solution 
to initiate colour development in proportion to the amount of TNFα. The measurement of 
TNFα in the kit detected the total amount of TNFα in samples (the total amount of free 
TNFα plus the amount of TNFα bound to soluble receptors).  
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For experiments measuring the relative mass values of human TNFα produced in a cell 
line panel, cells were split as normal and cultured for 2 days without addition of fresh 
medium. This incubation period enabled sufficient time for cells to produce TNFα 
adequate for detection within the linear range of standards used in the ELISA. Following 
incubation, samples were centrifuged (5mins, 300g) and the supernatant transferred into 
fresh eppendorf tubes. Samples were stored on ice temporarily before addition to the 
TNFα ELISA 96-well plate accordingly.  
For experiments measuring the effect of a chemical inhibitor on TNFα production, 
DLBCL cells were counted and washed in 1ml PBS before 2mls of cells (per sample) 
were seeded into 6-well plates at a density of 1x106/ml.  The PBS wash was included to 
sufficiently remove the cell culture medium in which TNFα may have built-up as a result 
of normal TNFα production. In turn, cells were treated with the appropriate 
concentrations of small molecule inhibitors and an untreated DMSO control sample was 
included into each experiment. Cells were incubated for 2 hours before centrifugation 
(5mins, 300g) and the supernatant transferred into fresh eppendorf tubes. Samples were 
stored on ice temporarily before addition to the TNFα ELISA 96-well plate accordingly. 
The assay procedure for the Quantikine TNFα ELISA was followed according to the 
manufacturer’s protocol. Optimal density readings were taken using the FLUOstar 
Omega plate reader (BMG Labtech) at 450nm and wavelength correction set at 570nm. 
The concentration of TNFα produced by samples was calculated based on a standard 
curve produced by TNFα Standards. Data was analysed using GraphPad Prism 6 software.  
For the TNFα ELISA experiment shown in chapter 6, figure 65c, a new Quantikine kit 
(R&D Systems, catalogue number DTA00C) was purchased. The assay procedure was 
followed according to the manufacturer’s protocol, however some reagents differed and 
the protocol in this kit had been updated. This kit did not contain an amplifier solution 
step and washes were reduced from six to four repetitions.  
2.8. NF-κB luciferase reporter assay 
 
Luciferase reporter assays are a useful tool for measuring gene expression and cellular 
events associated with gene expression. A typical reporter assay involves cloning the 
regulatory region of the gene of interest upstream of the firefly luciferase gene in an 
expression vector. The vector is then transfected into the DNA of cells (such as U2OS 
cells); followed by an incubation period where cells are selected to ensure the whole cell 
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line population expresses the vector. Following an experimental procedure/treatment, 
cells are lysed and luciferase is added, initiating the following reaction process; 
 
 
The Luciferase enzyme is expressed under the control of the promoter of interest and is 
therefore directly proportional to the transcriptional activity of the gene being studied, 
such as NF-κB. Enzymatic activity is subsequently measured in the form of light emission 
using a luminometer. 
 
The U2OS cell reporter system was generated previously in Sonia Rocha’s laboratory 
(Dundee) by using a pGL4.32 [luc2P/NF-κB-RE/Hygro] vector (Promega, catalogue 
number E849A) containing five copies of an NF-κB response element, which drives 
transcription of the luciferase reporter gene luc2P (Photinus pyralis). To allow selection, 
the vector contains a mammalian selectable marker for hygromycin resistance. Cells were 
cultured for 2-3 months in selection media to ensure formation of stable cell lines 
expressing the NF-κB response element. 
 
For experiments confirming the function of the TNFα neutralising antibody Infliximab 
and the TNFα antagonist Etanercept, U2OS cells were split 1 day before the assay 
procedure to a confluency of 70-80% and were seeded into 6-well plates. The next day, 
media from U2OS cells was replaced with fresh media and cells were treated with 
10ng/ml human TNFα (to positive control wells), followed by immediate addition of 
10µg/ml Etanercept or Infliximab to wells accordingly. Following 2 hours incubation 
(37ºC, 5% CO2), media from U2OS cells was aspirated and cells washed with ice cold 
PBS. Cells were subsequently lysed using 200µl 1x lysis buffer (Promega) and lysates 
collected. Samples were then transferred into eppendorfs and stored overnight at -80oC to 
achieve optimal lysis. The following day, samples were thawed, vortexed and centrifuged 
at maximum speed for 1 minute. 20µl supernatant was then assayed using the Luciferase 
Assay System (Promega) in a Lumat LB9507 Luminometer (Bethold Technologies). Due 
to the short half-life of the luciferase reagent, 100µl luciferase reagent (Promega) was 
added to tubes one at a time, immediately before each sample reading. Relative light units 
were recorded and results were normalized to the respective protein concentrations of 
samples (quantified by the Bradford assay), as described in section 2.2.3.1.   
 
Luciferin + O2 + ATP                                        Oxyluciferin + CO2 + AMP + PPi + Light 
                                               Luciferase  
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For experiments investigating TNFα production and the effects of TNFα production by 
DLBCL cells on NF-κB transcriptional activity, DLBCL cells were incubated (37ºC, 5% 
CO2) for 2 days (following splitting as normal) before the assay procedure commenced. 
This period of growth enabled sufficient time for the production of TNFα by DLBCL 
cells and secretion into the surrounding media. U2OS cells were split 1 day before the 
assay procedure to a confluency of 70-80% and were seeded into 6-well plates. On the 
day of the assay, DLBCL cells were centrifuged (5mins, 300g) and the supernatant 
(containing TNFα media) decanted into fresh tubes. Media from U2OS cells was removed 
by aspiration and replaced with 2mls of DLBCL cell media or 2mls RPMI 1640, 10% 
FCS for untreated control wells. U2OS cells were treated accordingly with Etanercept 
and Infliximab to a concentration of 10µg/ml, followed by immediate addition of 10ng/ml 
human TNFα to appropriate positive control wells. Cells were incubated for either 2 or 6 
hours (37ºC, 5% CO2) before the remainder of the assay performed as described 
previously.    
 
2.9. Statistical analysis 
 
Paired and unpaired statistical analysis for the gene expression microarray was performed 
by Dr Simon Cockell (Bioinformatic Support Unit, Newcastle University, UK). For other 
all other data analysis, P-values were calculated for respective experiments using the 
Minitab 16 statistical software using paired t-test analysis.   
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Chapter 3. 
Investigation of NFAT expression, 
activation and dependency in DLBCL 
cell lines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Investigation of NFAT expression, activation and dependency in DLBCL 
cell lines 
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3.1.Introduction 
 
One of the initial aims of this study was to confirm the findings of other groups reporting 
constitutive expression and activation of NFAT family members in DLBCL. 
Constitutively active nuclear NFAT2 had previously been reported in 30% of DLBCL 
patient samples and in a small selection of DLBCL cell lines (Marafioti et al., 2005; Pham 
et al., 2005; Fu et al., 2006; Pham et al., 2010). Although these reports demonstrated clear 
correlations between DLBCL and NFAT expression, they were not fully comprehensive. 
Due to a lack of effective antibodies for immunohistochemistry, Marafioti et al (2005) 
were only able to detect NFAT2 in patient samples, however the expression of other 
isoforms such as NFAT1 were not recorded (Marafioti et al., 2005). Additionally, studies 
illustrating a role for NFAT-mediated regulation of lymphocyte survival factors in 
DLBCL were mostly restricted to cell lines established in-house and were not 
commercially available (Pham et al., 2005; Fu et al., 2006; Pham et al., 2010). Therefore, 
although the scientific evidence for a role of NFAT in DLBCL was clear, the relative 
expression of individual NFAT family members in a comprehensive panel of 
representative ABC and GCB DLBCL cell lines had not been explored.  
In addition, although it is well known that NFAT activation is a result of events preceding 
engagement of the BCR, the distinct nature of NFAT regulation in DLBCL has not been 
investigated. Signalling pathways downstream of the BCR represent promising treatment 
targets for the treatment of DLBCL and other B-cell malignancies, some of which have 
been studied in great detail (Kuppers, 2005; Gupta et al., 2007; Chen et al., 2008). As 
described previously, ABC DLBCLs exhibit constitutive activation of NF-κB and NF-κB 
pathway components (Davis et al., 2001; Rosenwald et al., 2002; Compagno et al., 2009). 
DLBCLs in this subgroup also harbour increased BCR surface expression and frequent 
somatic mutations of components of the BCR itself, including the Igα or Igβ subunits 
(Davis et al., 2001; Davis et al., 2010). The BCR is critical for the survival of ABC 
DLBCLs, which are described as having ‘chronic active’ BCR signalling, whereby the 
BCR and downstream pathways (such as NF-κB) are constitutively activated (Davis et 
al., 2001; Davis et al., 2010). Whether NFAT signalling is also a pathway upregulated as 
a result of increased BCR expression currently remains unexplored and was a question I 
aimed to address in this study.   
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GCB DLBCL, on the other hand, are known to utilise their BCR more akin to normal B 
cells, which rely on low level antigen dependent ‘tonic’ BCR-dependent survival signals 
(Kraus et al., 2004; Monroe, 2004; Srinivasan et al., 2009). BCR ablation in murine 
models has been shown to cause apoptosis of normal mature B cells (Lam et al., 1997; 
Kraus et al., 2004). Interestingly, when the PI3K/AKT signalling cascade was activated, 
the survival of BCR-deficient B cells was rescued, although this was not apparent for 
activation of the NF-κB or MAPK pathways (Srinivasan et al., 2009). These studies 
suggest that there are dissimilarities between tonic BCR survival signals and signals 
propagated from pathways downstream of the BCR, such as NF-κB (Chen et al., 2013). 
Moreover, in consensus clustering methods to define DLBCL transcriptional profiles, 
Shipp et al (2013) defined two GCB DLBCL tumour groups which were defined as ‘BCR’ 
or ‘non BCR’ (Chen et al., 2008; Chen et al., 2013). Unlike non-BCR DLBCLs, BCR 
DLBCL had increased expression of multiple components of the BCR, such as high 
expression of SYK and were responsive to blockade of SYK in BCR-dependent DLBCLs 
(Chen et al., 2008; Friedberg et al., 2010).  
Analysis of DLBCL expression and dependency on the NFAT signalling axis may define 
NFAT as an additional, targetable pathway in GCB DLBCL, but could also reveal 
interesting insights into the upstream regulation of NFAT. Hypothetically, NFAT 
expression would likely be highest in ABC cell lines with chronic active BCR signalling 
and GCB BCR cell lines with increased expression of BCR components. Alternatively, 
NFAT expression and activation in GCB non-BCR cell lines is suggestive of BCR-
independent activation of NFAT, which could be an interesting avenue to explore.   
Although targeting BCR signalling pathways is a rational therapeutic approach for 
treatment of DLBCL, the subtype-specific pathways and their core genetic mechanisms 
are not fully understood. Identification of a potential role for NFAT in a particular 
subgroup of DLBCL would enhance our knowledge of the molecular mechanisms of this 
aggressive disease while allowing opportunity for future therapies to be more targeted.  
Lastly, based on expression, activation and chemical sensitivity data, one of the key goals 
of this chapter was to strategically select a small number of DLBCL cell lines for use in 
gene expression array analysis. In brief, the purpose of the microarray was to investigate 
potential NFAT target genes by comparing differentially expressed genes upon treatment 
with/without a suitable inhibitor of NFAT. It was therefore necessary that model cell lines 
PhD Thesis  Holly White 
 
88 
 
expressed detectable levels of active NFAT and were shown to respond to inhibition of 
the NFAT pathway.     
3.2.Results 
 
3.2.1. NFAT transcription factors are heterogeneously expressed in DLBCL cell 
lines 
 
To gain a general understanding of the expression and activation of NFAT family 
members in DLBCL and to help determine appropriate cell lines models for future 
experiments, NFAT isoforms and their respective activation status were analysed by 
Western blot in a comprehensive panel of ABC and GCB DLBCL cell lines with defined 
BCR status. The total expression of individual NFAT family members from samples 
prepared as whole cell extracts was heterogeneous across the panel (figure 15), where 
some cell lines had markedly high or low expression of specific isoforms. Due to the 
multiple serine residues on NFAT that can be phosphorylated or dephosphorylated, 
detection of active NFAT is best analysed by SDS-PAGE, where phosphorylated NFAT 
proteins are slower migrating and dephosphorylated NFAT proteins are faster migrating. 
For NFAT1, these principally represent differentially phosphorylated species, for 
example the lower band in the Toledo cell line indicates that NFAT1 is in the 
dephosphorylated, active form. However, in some cell lines however (such as HLY-1 and 
U2932) both the inactive and active forms of NFAT1 were expressed at high levels, 
indicating that only a certain degree of NFAT1 activation is important in these cell lines. 
OCI-Ly19 did not appear to express either the hyperphosphorylated or dephosphorylated 
form of NFAT1, suggesting this isoform is of little functional importance in this cell line.   
For NFAT2, the three broad groupings of bands seen represent different protein products, 
resulting from alternative mRNA splicing, while the closely spaced bands within each 
cluster represent different phospho-isoforms. Given the predicted sizes of the A, B and C 
isoforms of NFAT2, the lower band represents the NFAT2/A α and β isoforms, the middle 
band the NFAT2/B α and β variants, while the upper band represents the NFAT2/C α and 
β isoforms (www.ensembl.org, NFAT2). HLY-1 cells, for example showed striking 
expression of all splice products, whereas SUDHL-4 lacked expression of the upper and 
lower proteins (NFAT2/C α and β and NFAT2/Aα and β). NFAT2 expression across the 
panel of cells was highly variable; with some cell lines (particularly those in the GCB 
non-BCR subgroup) expressing little to no NFAT2. NFAT4 was also differentially 
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expressed between cell lines, however the identity of the two NFAT4 species observed is 
not known. 
Although the NFAT1, NFAT2 and NFAT4 family members are known to be the three 
main isoforms expressed in lymphocytes, the expression of the NFAT3 isoform was also 
analysed (Rudolf et al., 2014) (figure 15). Unexpectedly, all DLBCL cell lines expressed 
moderate levels of NFAT3 with the upper band representing the hyperphosphorylated 
form and the lower band being in its dephosphorylated, active form (www.ensembl.org, 
NFAT3). NFAT3 was activated in a small number of cell lines including RIVA, U2932, 
SUDHL-4, SUDHL-6, OCI-Ly18 and Toledo.                                                                                                                
The expression of NFAT isoforms generally did not correlate with any particular 
subgroup of DLBCL. This was especially apparent for NFAT1, NFAT3 and NFAT4; 
however the expression of NFAT2 in the GCB non-BCR group was noticeably lower than 
the ABC and GCB-BCR subgroups. Pfeiffer and Toledo appeared to express NFAT2 at 
very low levels while expression was non-existent in OCI-Ly19 and Toledo cell lines.   
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Deregulated MYC expression due to MYC translocations, amplifications or mutations is 
a negative prognostic indicator in DLBCL (Klapper et al., 2008). Moreover, the c-Myc 
oncoprotein was recently reported to be an NFAT target gene in DLBCL cell lines, with 
its expression correlating with the nuclear levels of NFAT2 (Pham et al., 2010). 
Interestingly, c-Myc is known to regulate the NFAT pathway in B-lymphocytes by 
amplifying calcium signalling, therefore maintaining NFAT nuclear translocation (Habib 
et al., 2007). c-Myc and NFAT are therefore proposed to function in DLBCL by providing 
a positive regulatory feedback loop where NFAT2 and c-Myc reinforce each other’s 
expression, including the expression of their respective target genes (Pham et al., 2010). 
To assess whether this mutual regulatory relationship was reflected in my DLBCL cell 
lines, the relative expression of c-Myc protein was evaluated. c-Myc expression was 
Figure 15. NFAT transcription factors are heterogeneously expressed in DLBCL cell lines. Whole 
cell extracts were taken from a panel of ABC and GCB DLBCL cell lines and the expression of NFAT 
family members analysed by Western blot. Cell lines are categorised into their respective DLBCL 
subgroups where ABC = activated B-cell, GCB = germinal centre B-cell, BCR = B cell receptor. 
Molecular weight marker lines to the right of the Western blot indicate the approximate size of detected 
bands (KDa). α-tubulin was included as a loading control. Data is representative of three biological 
repeat experiments apart from NFAT3, NFAT4 and MYC which were analysed in two repeat 
experiments.   
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heterogeneous between cell lines but did not correlate with the expression of NFAT2 or 
with any other NFAT isoform (figure 15).   
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3.2.2. Growth curves for DLBCL cell lines 
 
To analyse the growth of cell lines in subsequent resazurin proliferation assays, it was 
essential that optimal seeding densities were obtained, to take account of the growth 
behaviour of individual cell lines. The growth of cells plated out at a range of seeding 
densities was analysed over a period of 24, 48, 72 and 96 hours before data analysed in 
the form of growth curves (figure 16). The shape of the growth curves for some cell lines 
indicated their particularly slow growth rates, such as Toledo (figure 16j), whereas most 
other cell lines began multiplying after 2 days (48 hours) of culture. Keeping in mind that 
future experiments aimed to use the resazurin assay to investigate the effects of chemical 
inhibitors on cell viability over a 72 hour period of incubation, the growth of cells at this 
timepoint were carefully considered. To accurately capture the physiological effects of 
inhibitors at this timepoint it is important that cells are growing in their exponential phase. 
For most cell lines, a seeding density less than 0.9-1x105/ml did not allow cells to form 
an exponential growth curve over 96 hours, with some cells unable to multiply at all in 
these conditions. On the other hand, seeding densities above 3x105/ml were generally too 
high for most cell lines, where cells reached their stationary and death phases of growth 
Figure 16 (Continued from previous page). Growth curves for DLBCL cell lines. a-j) To find the 
optimal cell seeding density of cells for resazurin proliferation assays, the growth of DLBCL cell lines 
was analysed over 4 days and recorded using the resazurin assay. Cells were seeded out at a range of 
densities (0.05x10
6
/ml
 
to 1x10
6
/ml) and incubated for 24, 48, 72 or 96 hours before viable cells were 
quantified. k) Table showing the optimal cell seeding densities chosen for resazurin proliferation assays. 
Data is representative of one experiment. Error bars indicate standard deviation between triplicate wells 
of cells.   
k) 
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at early stages of incubation. The table in figure 16k indicates the seeding densities chosen 
for subsequent resazurin assay experiments, based on their exponential growth at 72 hours 
incubation. Optimal seeding densities were considerably similar between cell lines, 
indicating similar growth behaviours between these DLBCL cells.  
3.2.3. DLBCL cell lines have heterogeneous expression and activation of NFAT 
family members  
 
To further investigate the expression and activation of NFAT family members in DLBCL 
cell lines, Western blot analysis of nuclear protein extracts (figure 17a) allowed a 
comparative analysis of subcellular location and hence activation status of NFAT 
between cell lines. Most cell lines expressed moderate to high levels of nuclear NFAT 
and expression typically reflected whole cell extract expression (figure 15). For example, 
(as indicated previously) Toledo cells demonstrated striking expression of active NFAT1 
compared to OCI-Ly19, while HLY-1 cells were the highest expressers of NFAT2. The 
Western blot in figure 17b shows that nuclear samples in figure 17a were absent of 
cytoplasmic contamination, as demonstrated by detection of α-tubulin.  
Interestingly, in U2932 cells, the expression of the lower molecular weight band in 
NFAT1 in nuclear extract is considerably lower than the whole cell lysate. An explanation 
for this may be due to the fact that two stable tumour clones have been identified in this 
cell line. This was identified by Quentmeier et al (2013), whereby they found that one 
subclone overexpressed genes such as BCL6, whereas the other subclone overexpressed 
MYC (Quentmeier et al., 2013). In fact, microarray analysis showed that around 200 genes 
were differentially expressed between the clones, including transcriptional targets of the 
aberrantly expressed oncogenes (Quentmeier et al., 2013). The variability between 
experiments discussed above may therefore be due to differences in the ratios of these 
two U2932 clones.   
Although cells lines of the GCB non-BCR subgroup appeared to express very little NFAT 
in whole cell extracts (figure 15), expression is visibly higher in nuclear extracts, perhaps 
due to the preparation of concentrated/enriched NFAT2 in nuclear samples. However, 
overall there is no distinctive correlation between ABC and GCB subgroups, indicating 
that NFAT may be of importance in all subtypes of DLBCL.  
To further compare NFAT activity in DLBCL cell lines, the DNA-binding activity of 
NFAT2 was analysed using an ELISA assay (figure 17c). Despite differential activity of 
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NFAT1 in figure 17a, only NFAT2 was assayed for activity because TransAM assay kits 
were not available for the other NFATs. The nuclear samples used in figure 17a were run 
alongside a PHA-stimulated Jurkat positive control extract and to monitor assay 
specificity, a mutated (MT) consensus oligonucleotide and wild-type (WT) consensus 
oligonucleotide were included as competitors for NFAT2 DNA-binding. The Jurkat 
control performed as expected, showing a high level of NFAT2 activity. Also as expected, 
the MT oligo had little effect on NFAT2 activity, whereas the WT oligo effectively 
competed with NFAT2 for binding. A clear trend was observed between NFAT2 DNA 
binding activity and protein expression, demonstrating consistency between two different 
experimental techniques. The NFAT2 ELISA, for example, highlighted the elevated 
activity of NFAT2 in cell lines such as HLY-1 and WSU-NHL but was also sensitive 
enough to measure low levels of NFAT2 activity in cell lines with very little protein 
expression, such as OCI-Ly3, OCI-Ly18 and Toledo.  
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a) 
c) 
b) 
Purple = ABC  
Orange = GCB BCR  
Blue = GCB non-BCR 
Grey = T-ALL control 
Figure 17. DLBCL cell lines have heterogeneous expression and activation of NFAT family 
members and are sensitive to chemical inhibition of the calcineurin-NFAT pathway by CsA a) 
nuclear extracts were taken from a panel of ABC and GCB DLBCL cell lines and the expression of 
NFAT family members analysed by Western blot. Nuclear-cytoplasmic preparations illustrate the 
comparative subcellular localisation and activation of family members. Cell lines are categorised into 
their respective DLBCL subgroups where ABC = activated B-cell, GCB = germinal centre B-cell, BCR 
= B cell receptor. PARP was included as a nuclear loading control. b) To check for cytoplasmic 
contamination in nuclear extracts, samples in (a) were probed for the cytoplasmic loading control α-
tubulin. Molecular weight marker lines to the right of Western blots indicate the approximate location 
of antibody binding, therefore confirming antibody specificity for proteins of a particular size (KDa). 
Data is representative of two individual experiments apart from NFAT2 expression in GCB non-BCR 
extracts which was performed in a single experiment. c) The DNA binding activity of NFAT2 was 
analysed by ELISA using nuclear extract samples in (a). PHA-treated Jurkat nuclear extracts were 
included as a positive control for NFAT2 activation. To monitor the specificity of the assay, samples 
were run alongside a mutated (MT) consensus oligonucleotide and a wild-type (WT) consensus 
oligonucleotide (as a competitor for NFAT2 binding). ELISA data is representative of two biological 
experiments apart from the panel of GCB non-BCR cell lines which were run in a single experiment. 
Error bars indicate the standard deviation of duplicate wells.  
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3.2.4. DLBCL cell lines sensitive to chemical inhibition of the calcineurin-NFAT 
pathway by CsA 
 
After confirming the expression, activation and DNA-binding of NFAT in most DLBCL 
cell lines, their relative dependency on the calcineurin-NFAT pathway for survival was 
assessed using the chemical inhibitor CsA. DLBCL cell lines were treated with a range 
of concentrations of CsA (0µg/ml-30µg/ml) for 72 hours before cell viability was 
determined using the resazurin assay. Figure 18 shows the growth inhibitory effects of 
CsA in a panel of cell lines, where a dose-dependent reduction in cell viability was 
observed. Differences between the shapes of the kill curves indicate how individual cell 
lines responded to the inhibitory effects of CsA. In most cell lines the curve is sigmoidal, 
where lower doses had little effect on cell viability but higher doses caused the viability 
to reduce to zero. In RIVA cells however (figure 18a), higher doses did not entirely kill 
cells. In other cell lines the response to CsA was marginal at low concentrations, cells 
remaining viable until a specific dose of CsA which drastically initiated cell death, as 
shown in Farage, Toledo and Karpas 422 cells (figure 18f, l and m). 
Figure 19 shows the average IC50 values obtained from cell lines treated with a range of 
concentrations of CsA (0µg/ml-30µg/ml) for 72 hours. An IC50 value is the half maximal 
inhibitory concentration, indicating the concentration needed to inhibit a biological or 
chemical function by half, which in this study is cell viability. The viability of all cell 
lines was reduced in a dose-dependent manner (figure 18), indicating the requirement of 
the calcineurin-NFAT pathway for lymphoma cell survival. However, there was no 
apparent relationship between IC50 concentrations and particular DLBCL subgroups or 
BCR status. IC50 values varied between cell lines and when compared to NFAT protein 
expression and DNA binding assays, there was no correlation with inhibitor sensitivity. 
Cell line IC50 values are also shown in table 10, where cell line-specific CsA sensitivity 
is also classified according to respective IC50 values, where high sensitivity = <8μg/ml, 
medium sensitivity = 8μg/ml-13μg/ml and low sensitivity = >13μg/ml. 
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a) b) c) 
d) e) f) 
g) h) i) 
j) k) l) 
m) 
Figure 18. CsA causes a dose-dependent reduction in cell viability in DLBCL cell lines. A panel of 
ABC (a-d), GCB BCR (e-i) and GCB non-BCR (j-m) DLBCL cell lines were treated with a range of 
concentrations of CsA (0μg/ml-30μg/ml), including a vehicle control (0.25% DMSO). Cells were 
incubated for 72 hours before cell viability was recorded using the resazurin assay. Data is 
representative of one experiment from three biological repeat experiments where error bars indicate the 
standard deviation of triplicate wells. 
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Table 10 summarises NFAT2 activity based on ELISA data (figure 17c) and 
corresponding Western blots (figure 17a), where high activity = NFAT2 activation 
>100%, medium activity = 30-100% and low activity = <30% of the Jurkat + PHA 
positive control. The classification of NFAT1 activation is based on the presence of the 
lower band in figure 17a, which indicates the dephosphorylated active form of NFAT1. 
 
 
Figure 19. DLBCL cell lines sensitive to chemical inhibition of the calcineurin-NFAT pathway by 
CsA The panel of DLBCL cell lines were treated with a range of concentrations of CsA (0μg/ml-
30µg/ml, including a vehicle control (0.25% DMSO) and were incubated for 72 hours before viable 
cells were measured using the resazurin assay. Dose-response curves were plotted for each cell line and 
the IC50 concentration recorded. The average IC50 concentration across three independent experiments 
was determined and plotted. Data is representative of three biological repeat experiments, error bars 
indicate the standard error of the mean.  
Table 10. Summary of NFAT expression, activation and sensitivity to CsA. Table classifying 
DLBCL cell lines into categories of NFAT1 and NFAT2 activity, including sensitivity to CsA. The 
degree of NFAT2 activity is based on ELISA data and corresponding Western blots, where high activity 
= NFAT2 activation >100%, medium activity = 30-100% and low activity = <30% of Jurkat + PHA 
positive control. The degree of NFAT1 activation is based on the presence of the lower band, which 
indicates the dephosphorylated active form of NFAT1. CsA sensitivity is classified according to 
respective IC50 values, where high sensitivity = <8μg/ml, medium sensitivity = 8μg/ml-13μg/ml and 
low sensitivity = >13μg/ml. 
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3.2.5. Cyclosporin A (CsA) inhibits nuclear translocation and activation of 
NFAT2  
 
NFAT activation has been  shown to be calcineurin-dependent in cell lines derived from 
DLBCL and T-ALL, where treatment with CsA or FK506 suppressed NFAT activation 
(Pham et al., 2005; Medyouf et al., 2007). Confirmation of CsA-induced NFAT inhibition 
can be demonstrated effectively by determining its effect on the subcellular localisation 
and phosphorylation status of NFAT. The ABC DLBCL cell lines U2932 and HLY-1 and 
the GCB cell line WSU-NHL were chosen for analysis due to previous data confirming 
their medium-high sensitivity to CsA treatment and their medium-high expression of 
NFAT family members when compared to other DLBCL cell lines. Of note, these three 
cell lines were used for many subsequent experiments, including the gene expression 
microarray, as described in chapter 5. 
Cells were treated with CsA using their respective IC50 concentrations for 2 and 6 hours 
before nuclear-cytoplasmic extracts were made and Western blot analysis performed. 
Timepoints were selected based on previous experiments performed by past-members of 
the Bacon laboratory. As shown in figure 20, in the DMSO controls, NFAT1 and NFAT2 
were at higher levels in the nucleus compared to the cytoplasm and detection of the lower 
band in these samples indicates they were in their dephosphorylated (activated) state. 
When treated with CsA, a shift from the nucleus to the cytoplasm is observed, occurring 
in a time-dependent manner. CsA also caused an increase in the intensity of upper bands 
within each cluster and a slight decrease in the dephosphorylated splice variants which is 
indicative of the rephosphorylation of the remaining NFAT proteins in the nucleus. 
To confirm the inhibitory effects of CsA using a different assay technique, nuclear 
samples from figure 20b were used for analysis in an NFAT2 DNA binding ELISA 
(figure 20c). The relative NFAT activity between U2932, HLY-1 and WSU-NHL cell 
lines was similar to previous experimental findings (figure 17a and c) and DNA binding 
activity was substantially reduced upon CsA treatment in all three cell lines. These data 
confirm that at these doses CsA effectively inhibits NFAT from translocating to the 
nucleus and binding to DNA, and therefore would be expected to prevent the induction 
of NFAT-specific target genes.   
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c) 
a) b) 
Figure 20. The calcineurin inhibitor CsA inhibits NFAT2 activation and DNA binding a) Two 
ABC DLBCL cell lines (U2932 and HLY-1) and one GCB DLBCL cell line (WSU-NHL) were 
treated with their IC50 concentration of CsA (8.6μg/ml, 7.4μg/ml and 10.4μg/ml respectively for 2 
hours and 6 hours before preparation of nuclear and cytoplasmic extracts. A vehicle control sample 
(0.01% DMSO) was also included. The effect of CsA on NFAT2 activity was analysed by Western 
blot analysis, including α-tubulin as a cytoplasmic loading control and PARP as a nuclear loading 
control. Data is representative of four individual experiments b) the effect of CsA on NFAT2 DNA 
binding activity was measured by an NFAT2 ELISA using nuclear extract samples from the 6 hour 
CsA timepoint (b). PHA-treated Jurkat nuclear extract was included as a positive control for NFAT2 
activation. To monitor the specificity of the assay, samples were run alongside a mutated (MT) 
consensus oligonucleotide and a wild-type (WT) consensus oligonucleotide (as a competitor for 
NFAT2 binding). ELISA data is representative of one experiment, where error bars indicate the 
standard deviation between duplicate wells.  
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3.2.6. Cells treated with CsA undergo cell cycle arrest and apoptosis 
 
To explore the mechanisms behind the reduction in cell viability observed upon treatment 
of DLBCL cells with CsA, the Propidium Iodide (PI) assay for cell cycle analysis was 
performed. WSU-NHL, U2932 and HLY-1 cells were treated with their respective IC50 
concentration and double their IC50 concentration of CsA for 24 hours before PI staining 
and analysis of cell cycle phase distribution by FACs. Previous proliferation assays 
(appendix figure 1) confirmed that a 24 hour incubation of cells with CsA was an ideal 
timepoint for PI experimental analysis. Treatment with CsA IC50 and 2xIC50 
concentrations killed approximately 20-40% of cells after 24 hours, allowing enough time 
for CsA to exert its cytostatic or cytotoxic effects while leaving sufficient remaining live 
cells for PI analysis (appendix figure 1).     
Figure 21a and b shows the percentage of cells in the G1/G0, S, G2/M and Sub-G1 stages 
of the cell cycle following CsA treatment. An increase of cells in the G1/G0 growth phase 
was observed in both WSU-NHL and U2932 cell lines upon CsA treatment (although 
slightly more so in U2932). This indicates a cytostatic effect of CsA, where cells are 
prevented from progressing further through the cell cycle. CsA also caused a dose-
dependent reduction in S phase and the G2/M phase. Moreover, CsA also had a cytotoxic 
effect on cells, as indicated by the accumulation of cells in the sub-G1 phase, which was 
particularly prevalent in WSU-NHL cells treated with 2x their IC50 concentration. 
Although HLY-1 cells were included in this experiment, unfortunately the nature of the 
PBS washes required for this assay repeatedly caused loss of the HLY-1 pellet, which is 
frequently very loose and scattered in this particular cell line and therefore PI analysis for 
this cell line was not possible.   
To assess whether cells undergo CsA-induced apoptosis, the effects of CsA on the 
cleavage of PARP was analysed by Western blot (figure 21c and d). PARP is a nuclear 
116KDa stress response protein involved in the detection and repair of DNA damage. 
Proteolytic cleavage of PARP into 85KDa and 24KDa fragments by caspases is an early 
indicator of apoptosis and can be detected by Western blot using an antibody directed 
against the PARP holoenzyme (114KDa) and its cleaved forms. Figure 21c and d show a 
dose-dependent induction of cleaved PARP (lower 85KDa band) in all three cell lines 
when compared to the DMSO control, which only expressed very low levels of uncleaved 
PARP protein. By 48 hours incubation with CsA (figure 21d), the apoptotic effect is 
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particularly apparent in WSU-NHL cells treated with 2xIC50 CsA, demonstrating strong 
expression of cleaved PARP, in addition to near complete loss of expression of the PARP 
holoenzyme itself. Moreover, expression of the cytoplasmic control protein α-tubulin is 
also lost in this sample, indicating that the apoptotic effects of CsA are also beginning to 
cause degradation of key cellular proteins.    
In summary, the data in figure 21 indicates that CsA uses a combination of cytostatic and 
cytotoxic mechanisms to reduce the viability of DLBCL cell lines. 
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Figure 21. Cells treated with CsA undergo cell cycle arrest and apoptosis. DLBCL cell lines were 
treated with their respective CsA IC50 concentration and double their IC50 concentration alongside a 
vehicle control (0.02% DMSO). For WSU-NHL (a); 1xIC50 = 20.8μg/ml and 2xIC50 = 41.6μg/ml. For 
U2932 (b); 1xIC50 = 8.6μg/ml and 2xIC50 = 17.2μg/ml. Cells were incubated for 24 or 48 hours before 
being stained with PI and the cell cycle phase distribution recorded by FACs analysis. The x-axis 
represents the G1/G0, S, G2/M and Sub-G1 stages of the cell cycle, while the y-axis indicates the 
percentage of cells in each phase. Data is representative of two independently performed experiments, 
where error bars indicate the standard error of the mean. c-d) Whole cell extracts of cells treated with 
CsA (as described above, including HLY-1 1xIC50 = 11.5μg/ml and 2xIC50 = 23μg/ml) were probed 
for PARP and analysed using Western blot analysis. Cleavage of PARP (lower band) was used as an 
indicator for CsA-induced apoptosis and α-tubulin was used as a loading control. Western blot data is 
representative of a single experiment.  
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3.2.7. The calcineurin inhibitor FK506 kills DLBCL cell lines in a dose-
dependent manor by inhibiting NFAT activation 
 
To further support this data indicating that DLBCL cell lines rely on the calcineurin-
NFAT signalling pathway for survival, it was important to test this model using another 
inhibitor of the pathway. FK506 (tacrolimus) is another highly effective 
immunosuppressant drug which also targets calcineurin activity. Originally sourced from 
the soil bacterium Streptomyces tsukubaensis, FK506 is a chemically distinct microbial 
product to CsA, exerting its effect by binding to the immunophillin FKBP12 (FK506 
binding protein 12) to form a complex which binds to calcineurin and prevents its 
phosphatase activity (Barik, 2006; Sieber, 2009 ).   
As shown in figure 22a and b, HLY-1 and RIVA cells were treated with increasing 
concentrations of FK506 (0-100µM) before the survival of cells was assessed by the 
resazurin assay. FK506 exerted a dose-dependent effect on the viability both cell lines, 
completely killing cells at the maximal dose, therefore allowing calculation of IC50 
concentrations. HLY-1 cells were more sensitive to FK506 compared to RIVA cells, with 
an IC50 of 25.3µM compared to 48.3µM in RIVA cells. These data confirmed that 
DLBCL cell lines are also sensitive to inhibition of the NFAT-calcineurin pathway using 
FK506.  
The effects of inhibiting the calcineurin NFAT pathway on NFAT protein expression 
were subsequently determined using nuclear extracts of HLY-1 cells treated with 30µg/ml 
of FK506 or 10µg/ml CsA for 1 hour or 4 hours (figure 22c). The effect of FK506 on the 
subcellular localisation and phosphorylation status of NFAT was identical to that of CsA 
treatment, shifting predominantly nuclear NFAT2 (in untreated samples) to the 
cytoplasm. FK506 also caused an increase in the intensity of upper bands within each 
cluster and a slight decrease in the dephosphorylated splice variants which demonstrates 
rephosphorylation of remaining NFATs in the nucleus. Both FK506 and CsA had a small 
effect on NFAT4, causing less to be expressed in the nucleus. This was most noticeable 
after 4 hours of CsA treatment.    
To confirm specificity, the effects of FK506 and CsA treatment on expression of members 
of the NF-κB pathway were analysed by Western blot (figure 22d). FK506 and CsA had 
no effect on the expression of most canonical members of the NF-κB pathway, including 
p65, phospho S536 p65 (P-p65) or p50 (including its precursor p105). These inhibitors 
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did however seem to cause slight elevation of c-Rel levels after 4 hours treatment, 
suggesting that they may have some secondary effects on pathways other than the 
calcineurin-NFAT pathway. Despite this, CsA and FK506 had no effect on the non-
canonical markers of the NF-κB pathway, including RelB and p52 (including its precursor 
p100).  
These data confirmed the calcineurin-NFAT pathway to be of key importance for the 
survival of DLBCL cell lines and validated FK506 as an alternative mechanism for 
effectively inhibiting the expression and activation of NFAT in DLBCL cell lines.   
 
 
 
 
PhD Thesis  Holly White 
 
105 
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Figure 22. The calcineurin inhibitor FK506 kills DLBCL cell lines in a dose dependent manor by 
inhibiting NFAT activation a-b) The ABC DLBCL cell lines HLY-1 and RIVA were treated with a 
range of concentrations of FK506 (0μM-100μM) for 72 hours before recording cell viability using the 
resazurin assay. Data is representative of three biological replicates where error bars indicate the 
standard error of the mean. c-d) HLY-1 cells were treated with 10μg/ml CsA or 30μM FK506 for 1 hour 
and 4 hours before preparation of nuclear and cytoplasmic extracts. A vehicle control sample (1% 
DMSO) was also included. The effect of CsA and FK506 on NFAT family members (c) and NF-κB (d) 
was analysed by Western blot analysis. Simple indicators of NF-κB pathway activation were used to 
assess the mode of NF-κB activation, where activation of the non-canonical NF-κB pathway is indicated 
by the presence of p100 cleavage to the active p52 subunit and the presence of the RelB unit. α-tubulin 
was used as a cytoplasmic loading control and PARP as a nuclear loading control. Data is representative 
of a single experiment.  
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3.2.8. DLBCL cell lines have variable sensitivity to the NFAT pathway inhibitor 
INCA-6, which was found to be non-specific 
 
Targeting calcineurin as a means of deciphering DLBCL dependency on NFAT is not 
ideal because calcineurin itself regulates signalling proteins other than NFAT (Macian, 
2005). As an alternative compound therefore, the inhibitor of NFAT-Calcineurin 
Association-6 (INCA-1) was investigated. INCA-6 is a highly selective compound that 
interferes with the interaction between calcineurin and NFAT by binding to  calcineurin’s 
discrete binding site on NFAT, rather than inhibiting the enzymatic activity of calcineurin 
like other NFAT inhibitors (Roehrl et al., 2004). Importantly, INCA-6 provides a 
potential practical advantage over CsA and FK506 by inhibiting NFAT 
dephosphorylation without altering calcineurin phosphatase activity, preventing 
dephosphorylation of other substrates (Roehrl et al., 2004; Kang et al., 2005) 
To investigate the dependency of cell lines on the NFAT pathway for survival, a large 
panel of DLBCL cell lines were treated with a range of concentrations of INCA-6 (0µM-
40µM) before average IC50 values for each cell line were calculated and plotted in figure 
23a. INCA-6 sensitivity was variable among the panel, with no apparent relationship 
between average IC50 concentration and NFAT protein expression, activation or DNA 
binding seen earlier (figure 17a and c). There was also no correlation between DLBCL 
subgroups or their respective BCR status. Despite this, all cell lines were killed in a dose-
dependent manor (data not shown), further supporting previous data illustrating the 
requirement for NFAT signalling in lymphoma cell survival.   
Cell line IC50 values for INCA-6 are shown in figure 23b, where cell line-specific INCA-
6 sensitivity is also classified according to respective IC50 values, where high sensitivity 
= <15μM, medium sensitivity = 15-20μM and low sensitivity = >20μM. Reassuringly, 
the relative sensitivity of cell lines to INCA-6 broadly matched CsA data (figure 19 and 
table 10), which can be compared in figure 23b. SUDHL-6 and OCI-Ly18 cells for 
example, were highly sensitive to both INCA-6 and CsA, whereas Karpas-422 and 
SUDHL-4 were among the least sensitive. These data initially provided confidence that 
both inhibitors were targeting the same pathway. 
When considering INCA-6 as a potential inhibitor for use in gene expression microarray 
analysis, it was important to confirm its effect on NFAT protein expression. WSU-NHL 
cells were treated with 12µM INCA-6 or 10µg/ml CsA for 2 hours or 6 hours before the 
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effects on NFAT expression were determined by Western blot analysis (figure 23c). 
While CsA worked as predicted, the INCA-6 compound had an unusual effect on NFAT 
and other cellular proteins. After 2 hours treatment, both NFAT1 and NFAT2 were 
completely absent from the nucleus, however by 6 hours cytoplasmic NFAT was also 
undetectable. Additionally, INCA-6 treatment affected PARP cleavage, where detection 
of the lower 85KDa band indicated cells were undergoing rapid apoptosis. Loss of the 
114KDa holoenzyme after 6 hours treatment also suggested INCA-6-induced degradation 
of PARP. The fact that INCA-6 induced rapid cleavage of PARP by just 2 hours suggested 
that INCA-6 may be having broader effects in the cell, perhaps targeting the proteasomal 
degradation of proteins by activating caspases. 
These observations suggested that INCA-6 was not functioning as desired and was likely 
having off-target effects. To test this hypothesis, the effects of INCA-6 on NF-κB 
subunits were assessed (figure 23d and e). Similar to NFAT, the NF-κB pathway 
members IκBα, p100/p52, c-Rel, RelB and P-p65 all seemed to become degraded upon 
incubation for 6 hours with INCA-6. Of note, in these experiments there is also some 
effect of CsA treatment on NF-κB. After 6 hours treatment for example, CsA appears to 
cause a reduction in p100 and P-p65, including a very slight reduction in c-Rel expression. 
A potential explanation for this is included in section 3.3.2. Overall, however, these 
analyses confirmed that INCA-6 was targeting signalling pathways other than NFAT and 
was not suitable for further use in this study.   
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3.2.9. 11R-VIVIT and MCV-1 peptides have no effect on DLBCL cell viability 
 
Although CsA and FK506 have revolutionised transplant therapy, their use is associated 
with a number of side effects, which are likely due to off target effects (Kiani et al., 2000; 
Rezzani, 2004). An alternative to small molecule inhibition of targets is the development 
of peptide sequences which are designed to selectively bind to complementary sites on 
d) 
Figure 23 (Continued from previous page). DLBCL cell lines have variable sensitivity to the 
NFAT pathway inhibitor INCA-6, which was found to be non-specific. a) A panel of DLBCL 
cell lines were treated with a range of concentrations of INCA-6 (0μM-40µM), including an 
untreated vehicle control sample (0.25% DMSO) and were incubated for 72 hours before viable 
cells were measured using the resazurin assay. DLBCL subgroups are colour coded, where purple = 
ABC DLBCL, orange = GCB BCR DLBCL and blue = GCB non-BCR DLBCL. Dose-response 
curves were plotted for each cell line and the IC50 concentration recorded. The average IC50 
concentration across three independent experiments was determined and plotted in (a). Data is 
representative of three biological repeat experiments, where error bars indicate the standard error of 
the mean b) Table showing respective INCA-6 IC50 concentrations for DLBCL cell lines and their  
relative sensitivity to INCA-6 (high sensitivity = <15μM, medium sensitivity = 15-20μM and low 
sensitivity = >20μM. The relative sensitivities of cells to CsA are provided as a comparison. c) 
WSU-NHL cells were treated with 10μg/ml calcineurin inhibitor CsA or 12μM NFAT inhibitor 
INCA-6 , including a vehicle control sample (0.1% DMSO) for 2 hours or 6 hours before nuclear 
and cytoplasmic extracts were prepared. The effect of CsA and INCA-6 on NFAT family members 
(c) and NF-κB (d-e) was analysed by Western blot analysis. Simple indicators of NF-κB pathway 
activation were used to assess the mode of NF-κB activation, where activation of the non-canonical 
NF-κB pathway is indicated by the presence of p100 cleavage to the active p52 subunit and the 
presence of the RelB unit. α-tubulin was used as a cytoplasmic loading control and PARP as a 
nuclear loading control. Data is representative of a single experiment in this cell line, however the 
experiment was also performed in the U2932 cell line, where the same effect was observed (data not 
shown).  
e) 
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protein targets. As described previously, the VIVIT peptide has a high affinity Pro-Val-
Ile-Val-Ile-Thr motif and has been valued for its enhanced selectivity when compared to 
CsA (Aramburu et al., 1998; Aramburu et al., 1999). VIVIT interferes with the interaction 
between calcineurin and NFAT, by binding to NFAT’s docking site on calcineurin, 
blocking NFAT dephosphorylation and nuclear translocation (Aramburu et al., 1999). By 
effectively competing with NFAT proteins for calcineurin binding, VIVIT prevents all 
downstream NFAT signalling.  
In 2004, Noguchi and colleagues synthesised a cell-permeable version of the VIVIT 
peptide which was used successfully in prolonging graft survival after islet cell 
transplantation in mice (Noguchi, 2004). Cell permeable VIVIT also proved to be a less 
toxic drug than calcineurin inhibitors, such as FK506 (Noguchi, 2004). As an alternative 
approach to inhibition of NFAT activity, the effects of the VIVIT peptide on cell viability 
were analysed using the resazurin assay. As shown in figure 24a-b, RIVA and HLY-1 
cells were unresponsive to treatment with a range of concentrations of VIVIT (0µM-
20µM), even at high doses. VIVIT peptide was subsequently tested using a range of 
conditions, including changing the medium type (from Gibco RPMI to Sigma RPMI), the 
percentage foetal calf serum and by testing concentrations of VIVIT up to 100µM (data 
not shown). However cells remained insensitive.  
In recent years a second generation VIVIT peptide has become commercially available 
for use in research laboratories. MCV-1 is a bipartite NFAT inhibitor that targets two 
separate calcineurin docking motifs, making it more potent than the 11R-VIVIT (Yu et 
al., 2012). Moreover. MCV-1 is reported to prevent NFAT activation at nanomolar 
potencies, independent of calcineurin activity and without impairing NF-κB activity (Yu 
et al., 2012). Following the lack of effect of VIVIT on DLBCL proliferation, the 
sensitivity of a large panel of cell lines to MCV-1 was analysed using concentrations 
ranging from 0µM-50µM (figure 24c-h), however cell viability was unaffected in all six 
cell lines. These data indicated that peptide-based inhibition of NFAT did not have the 
same growth inhibitory effect as small molecule inhibition. However, in these 
experiments I lacked a positive control and was not able to tell if the peptide was getting 
into cells. 
The experiments described in figure 24 were performed very early on in the PhD, before 
biochemical experiments showing the effects of other NFAT inhibitors on NFAT 
subcellular localisation (such as those in figure 23) were performed. By this stage, a 
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suitable inhibitor of NFAT (CsA) had already been chosen for use in a gene expression 
microarray. Although it would have been interested to confirm the effects of the VIVIT 
peptides on NFAT biochemically, I decided not revisit the peptides at this later stage of 
my studies, but to instead make the best use of my time using CsA. 
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3.3.Discussion 
 
3.3.1. Expression and activation of NFAT in DLBCL cell lines 
 
A significant part of this chapter involved a comprehensive analysis of the expression and 
activation of NFAT family members in a large panel of DLBCL cell lines. As expected, 
the lymphocyte-specific NFAT family members NFAT1, NFAT2 and NFAT4 were 
expressed at high levels in some cell lines. Analysis showed that expression of particular 
family members were fairly heterogeneous across the panel, with some cell lines 
demonstrating strikingly higher levels of expression than others, suggesting that NFAT 
plays an important role in these cell lines. Analysis of NFAT activation was also 
investigated with the presence of the lower dephosphorylated bands indicating that NFAT 
was in its activated state, combined with the expression of NFAT in the nucleus of 
DLBCL cells. Moreover, NFAT2 DNA-binding ELISA data correlated well with protein 
expression analysis, providing further evidence that NFAT2 is transcriptionally active in 
most DLBCL cell lines.  
These data supported the findings of Marafioti et al (2005), where NFAT2 was detected 
in the nucleus of routine DLBCL biopsy samples, suggesting ongoing activation of the 
NFAT pathway (Marafioti et al., 2005). Results were also consistent with the 
constitutively active NFAT2 identified in the nucleus of DLBCL cell lines in studies 
demonstrating a role for NFAT in maintaining lymphoma cell survival (Pham et al., 2005; 
Pham et al., 2010).  
It was interesting to observe expression of active and inactive NFAT3 in DLBCL cells. 
NFAT3 is known to have roles in the neuronal system and has recently been implicated 
in PTEN-regulated intestinal differentiation and non-small cell lung cancer (Zhao X, 
2010; Wang et al., 2011; Ulrich et al., 2012). However, a role for NFAT3 in immune 
cells has not been reported and could be an interesting area to explore in the future  
Figure 24. 11R-VIVIT and MCV-1 peptides have no effect on DLBCL cell viability. a-b) 
DLBCL cell lines RIVA and HLY-1 were treated with increasing concentrations of the VIVIT-11R 
peptide (0-20μM), including a vehicle (water) control sample. Cells were incubated for 72 hours 
before cell viability was measured using the resazurin assay. Data is representative of three biological 
repeat experiments where error bars indicate the standard error of the mean. c-h) A panel of DLBCL 
cell lines were treated with a range of concentrations of the VIVIT MCV-1 peptide (0-50μM), 
including a vehicle control sample (0.25% DMSO). Cells were incubated for 72 hours before cell 
viability was measured using the resazurin assay. Data is representative of one experiment, where 
each concentration was plated out in a single well.  
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When considering the positive feedback loop between NFAT2 and MYC described by 
Pham et al (2005), the expression of MYC relative to its transcriptional regulator NFAT2 
and other NFAT family members was analysed (Pham et al., 2010). Expression was 
heterogeneous between cell lines but did not correlate with NFAT expression. Moreover, 
despite the cell lines SUDHL-6 and OCI-Ly18 having MYC translocations, their 
expression of MYC was not significantly different to other cell lines. Although 
researchers at the MD Anderson Cancer Centre USA have shown convincing data 
correlating NFAT2 expression with MYC in SUDHL-4 and OCI-Ly10 cells, much of 
their research utilises DLBCL cells established in-house (Pham et al., 2010). Given the 
heterogeneity of the disease and representative cell lines, the use of alternative cell lines 
may be the reason that we do not see similar correlations in our system. Moreover, 
differences in the culture technique and culture medium over time can lead to changes in 
the underlying genetics of validated cell lines (such as in SUDHL-4), which can results 
in variation in cell behaviour.  
Given that NFAT is a key signalling pathway downstream of the BCR, it was 
hypothesised that cell lines with chronic active BCR signalling (ABC DLBCLs) and GCB 
BCR DLBCLs would harbour high expression of NFAT when compared to other cell 
lines. NFAT2 expression was generally higher in ABC and GCB BCR cell lines, 
suggesting that the NFAT pathway was of importance in these subgroups. Interestingly, 
it has been reported that BCR signals only increase the transcription of the NFAT2 gene, 
but not that of the NFAT1 and NFAT4 genes (Muhammad et al., 2014; Rudolf et al., 
2014). Indeed, the degree of NFAT1 and NFAT4 expression were similar between ABC, 
GCB BCR and GCB non-BCR cell lines, however NFAT2 expression and transcriptional 
activity in GCB non-BCR cell lines compared to BCR-dependent cell lines was 
noticeably lower. Conversely, some cell lines, such as OCI-Ly19, Pfeiffer and Karpas 
422, demonstrated low-medium expression and DNA binding of NFAT2, suggesting that 
NFAT in these lymphomas could be regulated by mechanisms other than the BCR.   
There is little information available regarding the upstream events that control NFAT 
activation in cancer cells. In addition to the BCR or TCR, NFAT is positioned 
downstream of a number of receptor initiated pathways, including RTK and GPCR 
receptors, which may explain the NFAT expression observed in GCB non-BCR cell lines 
(Pan et al., 2013). An interesting experiment, which would underpin more precisely the 
interaction between the BCR and NFAT in DLBCL cell lines, would be to treat cells with 
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inhibitors of various components of the BCR, such as the SYK inhibitor R406 or Ibrutinib 
which targets Bruton’s tyrosine kinase (BTK) to assess the effects on NFAT expression.  
Another consideration for future studies is whether calcineurin-modulation of NFAT is 
the only mechanism for NFAT activation in DLBCL. Upregulation of the expression of 
NFAT1 and NFAT5, for example, has been demonstrated in a calcineurin-independent 
manner in mammary tumour cells and was associated with the assembly of the α6β4 
integrin and promotion of carcinoma invasion (Jauliac et al., 2002). Additionally, NFAT 
activation in vivo has been proposed to occur via phosphorylation-induced protein 
stabilisation in the absence of Ca2+ activity (Kuroda et al., 2008). Mikishiba et al (2008) 
found that Ca2+ oscillation-independent osteoclastogenesis was insensitive to inhibition 
of calcineurin with FK506, with NFAT2 activity being unaffected (Kuroda et al., 2008). 
Cot, a serine threonine kinase was reported to phosphorylate NFAT2 in osteoblast cells, 
increasing its protein stability and resistance to degradation, thereby upregulating its total 
levels while also inducing calcineurin-independent activation of NFAT2 (Kuroda et al., 
2008; Kuroda et al., 2012). These reports provide evidence that NFAT expression is 
mediated by mechanisms other than calcium or calcineurin modulation in some systems, 
highlighting potential areas of future research.  
3.3.2. Inhibition of the calcineurin/NFAT pathway 
 
Another key aim at the beginning of the study was to investigate the effects of NFAT 
inhibition on DLBCL cell viability and to find a suitable, reliable inhibitor for use in gene 
expression microarray analysis. In addition to their huge success in the field of transplant 
therapy, CsA and FK506 are also practical tools for investigating the NFAT signalling 
pathway in vitro. CsA treatment caused a dose-dependent reduction in cell viability, 
confirming that the calcineurin-NFAT pathway is critical for lymphoma cell survival. It 
was hypothesised that CsA treatment may prevent the transcription and translation of 
survival/growth factors regulated by NFAT, BLyS, CD40 and MYC (Pham et al., 2005; 
Fu et al., 2006; Pham et al., 2010). To date, very few NFAT target genes have been 
reported in the context of B-cell lymphoma, highlighting a key area of unexplored 
investigation.   
The sensitivities of DLBCL cells to CsA were fairly similar, as indicated by their IC50 
concentrations which ranged from 3.6-15.6µg/ml. These were very comparable to 
concentrations reported in the literature. For example, in a study investigating the 
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sensitivity of 37 melanoma cell lines to CsA, the IC50 concentrations ranged from 3-
13µg/ml (Perotti et al., 2012). Moreover, the differences between the shapes of CsA kill 
curves also showed that the effect of CsA was different between cell lines, perhaps due 
to differences in the mechanisms of regulation by NFAT. However, as discussed 
previously, no relationship between IC50 value and NFAT protein expression was 
identified. HLY-1 cells for example, expressed the highest levels of active NFAT1 and 
NFAT2 (including NFAT2 transcriptional activity) and were one of the most sensitive 
cell lines to CsA. In comparison, OCI-Ly18 was also highly sensitive to CsA; however 
this cell line demonstrated virtually undetectable NFAT2 protein expression and DNA 
binding. Although this suggests that CsA sensitivity is independent of NFAT protein 
expression, it is important to consider that even small quantities of NFAT expressed in 
cells could be critical for their survival. Moreover, cell lines with low level expression of 
NFAT2 may in fact have a greater dependency on the expression of other NFAT isoforms. 
OCI-Ly18, for example, may depend on NFAT3, which was expressed at very high levels 
in this cell line. Considering that CsA targets multiple NFAT family members, the relative 
dependencies of cell lines on specific NFAT isoforms cannot be determined by this 
approach, which was recognised early on in the study to be a potential limitation.  
Mouse studies have demonstrated that FK506 and CsA are highly specific inhibitors of 
NFAT-mediated signalling (Graef et al., 2001). Furthermore, the phenotype of NFAT3 
and NFAT4 double knockout mice is almost identical to that of the embryos of mothers 
treated with CsA during embryonic development (Graef et al., 2001). However, inhibiting 
the activation of calcineurin also prevents the dephosphorylation of target proteins other 
than NFAT. Calcineurin, for example, also modulates other signalling pathways, such as 
the RAS-MAP kinase cascade and the TGF-β/Smad pathway (Manninen et al., 2000; 
Gooch et al., 2004). Other targets include the pro-inflammatory molecules NF-κB, Elk-1 
and AP-1, the InsP3R, ryanodine and NMDA receptors, as well as enzymes such as PKA, 
NO synthase and the MEF2C and MEF2D transcription factors (Blumenthal et al., 1986; 
Liu et al., 1991; Dawson et al., 1993; Cameron et al., 1995; Tong G, 1995; Wu et al., 
2001; Lynch et al., 2005; Medyouf et al., 2007; Vafadari et al., 2013).  
Of particular relevance to DLBCL is the reported off-target effects of CsA on the NF-κB 
pathway, whereby CsA has been shown to inhibit NF-κB activation by approximately 
50% in three specific positions of the NF-κB cascade in peripheral human T cells 
(González-Guerrero et al., 2013; Vafadari et al., 2013). Mechanistically, calcineurin has 
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been demonstrated to bind to and inactivate the cytoplasmic inhibitor of κB (IκB) (which 
usually keeps NF-κB proteins inactive in the cytoplasm), leading to activation and nuclear 
translocation of NF-κB (Biswas et al., 2003). Moreover, an interesting mechanism of 
CsA-induced activation of NF-κB was proposed by Palkowitsch et al (2011) where 
calcineurin was found to dephosphorylate BCL10 downstream of TCR-CD28 
engagement (Palkowitsch et al., 2011). BCL10 dephosphorylation is a central step for the 
formation of the CBM complex which in turn causes the activation of NF-κB 
(Frischbutter et al., 2011). To date, CsA-mediated NF-κB activation has only been 
demonstrated in T cells, but given that the CBM complex is essential for the survival of 
ABC DLBCL cell lines downstream of BCR signalling, it would be interesting to 
investigate whether CsA has a similar effect (Ngo et al., 2006).  
To investigate as these reported alternate effects in our system, the effects of FK506 and 
CsA on the activity of the NF-κB pathway were analysed. As described previously, the 
NF-κB pathway is a key pathway critical for lymphoma cell survival and is known to 
cross-talk with many other signalling pathways. The levels of some markers of NF-κB 
activation remained constant with FK506 and CsA treatment, however CsA caused some 
reduction of expression of other markers, such as p100, P-p65 and c-Rel after 6 hours 
treatment. These particular effects support data in the literature which show CsA to have 
an effect on NF-κB. It cannot therefore be confirmed that CsA is a specific inhibitor of 
NFAT in DLBCL. Moreover, the timescales of treatment used in this study were very 
short. Indirect effects on NF-κB and other pathways may become more apparent at the 
same timescale as the viability phenotype. It cannot therefore be guaranteed that there 
aren’t any effects on NFAT that in turn affect NF-κB at later timepoints, such as 24 and 
48 hours.   
During these early stages of the study, one of the principle aims was to choose appropriate 
model cells for use in a gene expression microarray with the aim of discovering novel 
NFAT target genes important for lymphoma cell survival. The key criteria for this were 
to find cell lines which expressed detectable levels of active NFAT and were dependent 
on the calcineurin-NFAT pathway for their survival based on their sensitivity to CsA. 
With the gene expression microarray in mind, two cell lines from the ABC DLBCL 
subgroup were chosen, which would be compared to gene expression changes in one GCB 
DLBCL cell line. HLY-1, U2932 (ABC) and WSU-NHL (GCB) cells were found to meet 
the above criteria and so were used for further experimental analysis. 
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The off-target effects seen with INCA-6 have not yet been reported in the literature. 
Presently, INCA-6 has only been used in a handful of studies in the literature, most of 
which have investigated the effects of NFAT inhibition on various proteins and mRNAs 
of interest (Shiratori et al., 2010; Prasad et al., 2011; Bretz et al., 2013; Faralli et al., 
2015; Savage et al., 2015). These studies did not investigate the direct effects of INCA-6 
on the expression of NFAT family members themselves. Biochemical experiments in 
these publications used similar concentrations of INCA-6 (5-20µM) to those in this study 
(12µM) but off-target effects were not reported. Deciphering the precise mechanism of 
action of INCA-6 would have been an interesting area to explore. However, my goal was 
to investigate the role of NFAT in DLBCL, for which it was decided that the use of CsA 
was suitable.  
In summary, this chapter confirmed the differential expression, activation and 
transcriptional activity of NFAT family members in a comprehensive panel of DLBCL 
cell lines. The use of chemical inhibition of calcineurin-NFAT signalling demonstrated 
this pathway to be critical for lymphoma cell survival, where analysis of IC50 
concentrations further demonstrated heterogeneity between cell lines. Although CsA and 
FK506 some specificity, attempts were made to inhibit NFAT more directly by use of the 
INCA-6 compound and two potent VIVIT peptides. Inhibition using these agents was 
ineffective due to off-target effects by INCA-6 and possibly issues of peptide cell 
permeability. After testing the majority of small molecule and peptide inhibitors 
commercially available, CsA was chosen for further experimental analysis. For example, 
its effects on cell viability were investigated in greater detail, where it was found to exert 
both cytostatic and cytotoxic effects on DLBCL cell lines. The decision to use CsA for 
the remainder of this study introduced a number of potential limitations. As described 
previously, NFAT is not the only calcineurin target and CsA has reported off-target 
effects. To specifically understand the role of NFAT in DLBCL, these factors would 
require consideration in future experiments, as described in chapter 5. Furthermore, CsA 
is a pan inhibitor of all calcineurin-regulated NFAT isoforms, therefore the function of 
specific NFAT family members cannot be determined using CsA, but rather would 
require siRNA or shRNA-mediated knockdown of individual proteins. 
Overall, these data provided a useful insight into in vitro models of NFAT in DLBCL, 
allowing me to strategically decide on the ABC DLBCL cell lines HLY-1 and U2932 and 
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the GCB DLBCL cell line WSU-NHL as appropriate cell lines for use in a gene 
expression array.   
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Chapter 4. 
Exploration of cooperativity between the 
NFAT and NF-κB signalling pathways 
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4. Exploration of cooperativity between the NFAT and NF-κB signalling 
pathways 
 
4.1. Introduction 
 
4.1.1. Evidence for cooperativity between NFAT and NF-κB  
 
The structural similarities between NFAT and NF-κB suggest they are evolutionarily 
derived from common ancestors, sharing similar modes of induction and structure of their 
DNA binding domain (de Lumley et al., 2004). Recent evidence demonstrates the 
coordinate regulation of lymphocyte survival factors by NFAT and NF-κB, suggesting 
that the pathways may function together to promote lymphomagenesis (Pham et al., 2005; 
Fu et al., 2006; Pham et al., 2010).  
Evidence for the cooperative interaction of NFAT and NF-κB was first identified in 
activated T cells, where transcriptional induction of the IFN-γ promoter was enhanced by 
the simultaneous binding of NFAT proteins with the p50 and p65 NF-κB subunits (Sica 
et al., 1997). Moreover, Li-Weber et al (2004) showed synergistic activation of 
interleukin-4 gene transcription by NFAT and NF-κB in T cells via two overlapping 
binding sequences for NF-κB and NFAT (Li-Weber et al., 2004). Studies prior to this had 
proposed that NF-κB and NFAT competed for binding to specific DNA sites, where NF-
κB could antagonise NFAT and inhibit NFAT-mediated transcriptional at this site 
(Casolaro et al., 1995). However, Li-Weber et al (2004) demonstrated that combined p65 
and NFAT signalling actually enhanced the expression of IL-4, suggesting that NFAT 
and NF-κB function in a cooperative manner (Li-Weber et al., 2004).  
The precise NF-κB subunits and NFAT family members that can function cooperatively 
in different systems are still in early stages of investigation. It is well known that the NF-
κB subunits p65 and c-Rel are highly involved in the activation of T cells following TCR-
engagement. However, the mechanisms through which TCR engagement drives p65 and 
c-Rel activation are not fully understood (Köntgen et al., 1995; Grumont et al., 2004; 
Hatchi et al., 2014). While p65 rapidly translocates to the nucleus, c-Rel activation 
requires calcineurin and NFAT amplification (Tan et al., 1992; Grumont et al., 2004). A 
recent study found that the ubiquitin E3-ligase TRIM13 is a key enhancer of NF-κB 
activation in T cells, where diminished expression of TRIM13 reduced activation of p65, 
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c-Rel and NFAT (Hatchi et al., 2014). Furthermore, another study in CD4+ T cells 
confirmed cooperative functions of NFAT1 and p65 (Jash et al., 2012). In the study, 
NFAT1 induced an active chromatin configuration for the assembly of transcriptional 
coactivators at the IL-9 promoter, whereas binding of the p65 NF-κB subunit caused 
transactivation of the promoter (Jash et al., 2012). Finally, in a study investigating 
signalling defects in NF-κB p50-/- c-Rel-/- CD8+ T cells an unexpected role for these NF-
κB subunits were identified, where the expression p50 and c-Rel was crucial for proximal 
TCR signalling and for the activation of NFAT (Bronk et al., 2014).  
It appears that the interaction between NFAT and NF-κB may differ between various 
cellular contexts. For example, the molecular mechanisms underlying the marked 
differences in regulation of the transcriptional co-activator BOB.1/OBF.1 between B cells 
and T cells was recently investigated (Mueller et al., 2013). Unlike B cells, where 
BOB.1/OBF.1 is constitutively expressed throughout B-cell development, BOB.1/OBF.1 
expression is inducible in T cells by PMA/Ionomycin or antigen receptor engagement 
(Schubart et al., 1996; Zwilling et al., 1997; Sauter P, 1997 ). In addition to an array of 
genetic and biochemical analysis, Mueller et al (2003) found that in silico analysis of the 
BOB.1/OBF.1 promoter identified previously unknown combined NF-κB and NFAT 
target sites in T cells (Mueller et al., 2013). Deletion of NFAT or NF-κB impaired 
expression of BOB.1/OBF.1 and its transcriptional recruiter Oct2 and was predicted to 
participate in T-cell mediated immunodeficiency (Mueller et al., 2013).   
Cooperative roles of NFAT and NF-κB are not limited to cells of the immune system. For 
example, the p65 subunit of NF-κB coimmunoprecipitates with NFAT in cardiomyocytes 
and this interaction maps to the RHD of p65 (Liu et al., 2012). Moreover, parallel 
activation of NFAT and NF-κB was found to be required for expression of COX-2 in 
bronchial epithelial cell lines exposed to carcinogenic nickel compounds (Cai, 2011). 
Overall, these studies provide compelling evidence for combined NFAT and NF-κB 
signalling in various cellular contexts. 
As described previously, both the NFAT and NF-κB pathways are individually important 
for the pathogenesis of DLBCL and a small number of genes in lymphocytes have been 
shown to be regulated by NFAT and NF-κB in combination (figure 25) (Pham et al., 
2005; Fu et al., 2006; Pham et al., 2010). We hypothesised that the NFAT and NF-κB 
pathways functionally intersect to co-ordinately promote lymphoma development and 
maintenance. To address whether the NFAT and NF-κB pathways co-ordinately promote 
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lymphoma development and maintenance, I aimed to investigate whether simultaneous 
depletion of the NFAT and NF-κB pathways caused additive or synergistic effects on the 
viability of DLBCL cell lines. Moreover, I aimed to better understand the expression, 
activation and dependency of DLBCL cells on NF-κB with the intention of picking model 
cell lines for use in a gene expression microarray analysis. 
 
Figure 25. The NF-κB and NFAT signalling pathways may function in synergy to coordinate the 
regulation of genes known to promote B-cell survival.  
 
4.2. Results 
 
4.2.1. DLBCL cell lines have heterogeneous expression and activation of NF-κB 
family members and are sensitive to chemical inhibition of the NF-κB 
pathway by TPCA-1 
 
To gain a general understanding of the expression and activation of NF-κB family 
members in DLBCL and to help determine appropriate cell lines models for use in gene 
expression array analysis, NF-κB family members and their respective activation status 
were analysed by Western blot in a comprehensive panel of ABC and GCB DLBCL cell 
lines. The total expression of individual NF-κB family members from samples prepared 
as whole cell extracts was heterogeneous across the panel (figure 26). DLBCL lines of 
both the ABC and GCB subgroup expressed almost all NF-κB subunits at relatively high 
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comparative levels; however some cell lines had markedly high or low expression of 
specific subunits.  Some NF-κB family members, such as p65 and c-Rel for example, 
were expressed at relatively high levels by all cell lines, whereas the expression of p50 
and p52 (and their inactive precursors) were extremely heterogeneous.  
Indicators of NF-κB pathway activation were used to assess the mode of NF-κB activation 
in DLBCL cell lines. Activation of the NF-κB pathway occurs via phosphorylation of 
IκBα at serine 32 and serine 36 followed by proteasome-mediated degradation that results 
in the release of subunits and their translocation to the nucleus (Finco et al., 1994; 
Brockman et al., 1995; Traenckner et al., 1995; Chen et al., 1996). While expression of 
the inhibitor of NF-κB subunits (IκBα) was at similar levels in all cell lines, the expression 
of P-IκBα was highly variable, indicating that the general activation of NF-κB family 
members was heterogeneous between cell lines. Although an indicator of NF-κB 
activation, the absolute levels of P-IκBα expression are hard to measure due to its rapid 
turnover by proteasomal degradation.  
Activation of the canonical NF-κB pathway, represented by phosphorylation of p65 (P-
p65) at serine 536 was observed at strikingly high levels in HLY-1 cells. The canonical 
pathway was also active in other DLBCL cells, such as OCI-Ly3 and Farage; however 
their apparent faint P-p65 expression is likely due to the low exposure of this particular 
Western blot.  Activation of the non-canonical NF-κB pathway is indicated by the 
presence of p100 cleavage to the active p52 subunit and the expression of the RelB 
subunit. There was generally no significant correlation between the expression of either 
the canonical or noncanonical pathways in cell lines, indicating that both pathways could 
be important for most lymphoma cells. Interestingly however, Farage cells expressed 
non-canonical pathway components at high levels, whereas OCI-Ly18, OCI-Ly19 and 
Karpas 422 cells had very low expression of p52, p100 and RelB. Finally, the inactive 
precursor p105 and its active cleavage product p50 were expressed in almost all cell lines, 
but were not expressed at all by Karpas 422 cells.  
To further investigate the expression and activation of NF-κB family members in DLBCL 
cell lines, Western blot analysis of cytoplasmic and nuclear protein extracts allowed a 
comparative analysis of subcellular location and activation status of NF-κB between cell 
lines (figure 27a). This analysis correlated well with the whole cell extracts, with for 
example, SUDHL-4, OCI-Ly18, OCI-Ly19 and Karpas-422 cells lacking expression of 
the non-canonical pathway subunit p52. Apart from SUDHL-4, these particular cell lines 
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also expressed low levels of RelB, indicating inactivity of the non-canonical signalling 
pathway. Similar to the whole cell extracts, p65 was expressed in the cytoplasm of most 
cell lines, although detection of nuclear p65 was significantly more varied. Again, despite 
NF-κB being a hallmark of ABC DLBCL, the expression and nuclear activation of family 
members in GCB cell lines was comparable to ABC cell lines, suggesting that NF-κB 
signalling could be important for all subgroups of DLBCL.  
Overall these data gave a general insight into the relative expression and activation of 
NF-κB in a large panel of cell lines. Although expression was heterogeneous between cell 
lines, these data allowed cell lines to be identified as being particularly high or low in NF-
κB which could have been useful for selection of cell lines for microarray analysis using 
an NF-κB inhibitor. Farage cells for example demonstrated high expression of almost all 
family members, whereas Karpas 422 had distinctly low expression of most NF-κB 
subunits.    
The IKK2 inhibitor IV (TPCA-1) is a potent small molecule inhibitor of IKK2 and 
therefore inhibits the canonical NF-κB pathway (Podolin et al., 2005). When compared 
to other commonly used NF-κB inhibitors such as BAY 11-7082, TPCA-1 has shown to 
be potent and very selective in inhibiting the canonical NF-κB pathway (Rauert-
Wunderlich et al., 2013). Figure 27b shows the average IC50 values obtained from cell 
lines treated with a range of concentrations of TPCA-1 (0µM-40µM) for 72 hours. All 
cell lines were killed in a dose-dependent manor, indicating the requirement of the NF-
κB pathway for lymphoma cell survival. However, there was no apparent relationship 
between IC50 concentrations and particular DLBCL subgroups. IC50 values were highly 
varied between cell lines and when compared to NF-κB protein expression, there was no 
correlation with inhibitor sensitivity. Cell line IC50 values are shown in the table in figure 
27c, where cell line-specific TPCA-1 sensitivity is also classified according to respective 
IC50 values, where high sensitivity = <3μM, medium sensitivity = 3μM-6μM and low 
sensitivity = >6μM.  
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Figure 26. DLBCL cell lines have heterogeneous expression and activation of NF-κB family 
members. Whole cell extracts were taken from a panel of ABC and GCB DLBCL cell lines, 
including one T-ALL cell line and the expression of NF-κB family members were analysed by 
Western blot. Indicators of NF-κB pathway activation were used to assess the mode of NF-κB 
activation, where activation of the non-canonical NF-κB pathway is indicated by the presence of 
p100 cleavage to the active p52 subunit and the presence of RelB expression. Cell lines are 
categorised into their respective DLBCL subgroups where ABC = activated B-cell, GCB = 
germinal centre B-cell, BCR = B cell receptor. α-tubulin was included as a loading control. Data 
is from one experiment.  
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c) 
d) 
PhD Thesis  Holly White 
 
127 
 
 
4.2.2. Combined inhibition of the NFAT and NF-κB pathways using CsA and 
TPCA-1 has variable effects in DLBCL cell lines  
 
The effects of simultaneous inhibition of NFAT and NF-κB signalling on cell viability 
was tested using increasing concentrations of CsA and the IKK2 inhibitor TPCA-1 (figure 
28). In these experiments I aimed to assess whether the drug combination was synergistic, 
where the addition of two drugs have a greater effect than one drug alone. Combined 
inhibition of both pathways had variable effects across the panel of cell lines, as shown 
in figure 29. Cell lines such as U2932 (figure 29e) exhibited very little additional effect 
of dual treatment when compared to inhibition of a single pathway alone, whereas the 
viability of RIVA cells (figure 29b) was reduced with both inhibitors, perhaps indicating 
a slight additive effect of the two drugs. In some cell lines, combined treatment merely 
reflected the sensitivity of inhibition of one pathway alone, for example addition of the 
drug combination to OCI-Ly3 (figure 29d) did not alter the dose-response curves of cells 
treated with TPCA-1 alone. Similarly, OCI-Ly18 treatment with both drugs had no effect 
on cell viability compared to single agent CsA treatment (figure 29j). Interestingly, the 
GCB DLBCL cell lines WSU-NHL (figure 29h) and SUDHL-4 (figure 29f) displayed 
dramatic cell death when treated with specific concentrations of both drugs compared to 
single agent treatments. 
Figure 27 (Continued from previous page). DLBCL cell lines have heterogeneous expression and 
activation of NF-κB family members and are sensitive to chemical inhibition of the NF-κB pathway by 
TPCA-1 a) Nuclear-cytoplasmic preparations were used to analyse comparative subcellular localisation and 
activation of NF-κB family members in a panel of ABC and GCB DLBCL cell lines by Western blot. α-
tubulin was included as a cytoplasmic loading control and PARP was included as a nuclear loading control. 
Data is from one experiment. b) The panel of DLBCL cell lines were treated with a range of concentrations 
of TPCA-1 (0μM-40µM), including an untreated vehicle control sample (0.25% DMSO) and were incubated 
for 72 hours before viable cells were measured using the resazurin assay. Dose-response curves were plotted 
for each cell line and the IC50 concentration recorded. The average IC50 concentration across three 
independent experiments was determined and plotted in (b). Data is representative of three biological repeat 
experiments, where error bars indicate the standard error of the mean. c) Table showing the degree of NF-κB 
activity based on nuclear protein levels, respective IC50 concentrations for DLBCL cell lines and their relative 
sensitivity to TPCA-1 (high sensitivity = IC50 <3μM, medium sensitivity = 3-6μM, low sensitivity >6μM. 
DLBCL subgroups are colour coded, where purple = ABC DLBCL, orange = GCB BCR DLBCL and blue = 
GCB non-BCR DLBCL.  
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This effect was most apparent in the Jurkat T-cell line (figure 29o), which was included 
in the study due to previous reports showing calcineurin/NFAT and NF-κB dependencies 
in T-ALL (Medyouf et al., 2007; dos Santos et al., 2010). This was an interesting 
observation given that sustained calcineurin activation and highly active NF-κB 
signalling (via constitutively active NOTCH1) are known features of T-ALL (Medyouf 
et al., 2007; Vilimas et al., 2007; Gachet et al., 2013). To test for similar effects in another 
T-ALL cell line, the experiment was also performed in MOLT-4 cells, (figure 29p); 
however CsA/TPCA-1 cooperativity was not observed.  
Overall, these data suggest that although there may be some cooperative effects of 
combined inhibition of the NFAT and NF-κB pathways in some cell lines, these effects 
were not striking in most cell lines. To validate the effects observed, it was decided to 
quantify results by calculation of the combination index using the CalcuSyn analysis 
software, as described below.  
 
Figure 28. Combined chemical inhibition of the NFAT and NF-κB signalling pathways. The 
calcineurin/NFAT inhibitor CsA prevents the nuclear translocation of NFATs by inhibiting calcineurin 
activation. Inhibition of calcineurin’s phosphatase activity prevents the dephosphorylation of substrates 
downstream of calcineurin, including NFAT, therefore preventing the transcription of multiple genes. 
The IKK2 inhibitor TPCA-1 inhibits canonical NF-κB signalling by inhibiting IKK2 activity. Image 
adapted from figure 25. 
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Figure 29 (Continued from previous two pages). Combined inhibition of the NFAT and NF-κB 
pathways using CsA and TPCA-1 has variable effects in DLBCL cell lines. a) A panel of DLBCL 
cell lines were treated with five concentrations of the calcineurin inhibitor CsA and the IKK2 inhibitor 
TPCA-1 (a), both alone and in combination and incubated for 72 hours before addition of resazurin and 
the viability of cells recorded. Cell lines represent four ABC DLBCL (b-d), nine GCB DLBCL (f-m) 
and two T-ALL cell lines (o-p). Data shown are representative of 3 separate experiments where error 
bars indicate the standard error of the mean. 
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4.2.3. CalcuSyn analysis of combined inhibition of the NFAT and NF-κB 
pathways suggests some synergistic effects between CsA and TPCA-1 
 
To more rigorously investigate the potential synergistic effects seen in WSU-NHL cells 
treated with CsA and TPCA-1, the calcineurin/NFAT and NF-κB inhibitors were used 
alone at 0.25x, 0.5x, 1x, 2x and 4x their respective IC50 concentration and at equipotent 
concentrations at the ratios in combination, as shown in figure 30a. Figure 30b shows the 
dose-response curve for WSU-NHL cells, which is of similar shape to previous 
experiments using non-fixed ratios, where at least two pairs of inhibitor combinations 
were more growth inhibitory than either compound alone  (figure 29h).  
The most noticeable effect on cell viability was observed at an IC50 fraction of 1 (1x the 
IC50 concentration for each drug). To assess whether this effect was statistically 
significant the CalcuSyn software for dose-effect analysis was used. CalcuSyn provides 
the software for calculating the median-drug effect analysis for quantifying synergism or 
antagonism, as originally described by Chou and Talalay (Chou TC, 1984). The median-
effect equation for dose-effect relationship was designed by Chou-Talalay in 1983 and is 
based on a mathematical analysis of hundreds of enzyme kinetic models, where it 
correlates the drug dose with the effect (Chou, 1974; Chou TC, 1984). Following 
calculation of the median effect, Chou’s method for analysis uses a combination index 
(CI) equation which calculates whether a drug combination has an additive effect (Chou 
TC, 1984). Chou and Talalay proposed the designation of an additive effect being based 
on a CI greater than 1, where synergism is defined as more than an expected additive 
effect (CI less than 0.9) and antagonism as a less than expected additive effect, as shown 
in the table in figure 30c (Chou TC, 1984).  
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Viability data for WSU-NHL data was analysed by median effect analysis to investigate 
whether the growth inhibitory actions of drug combinations represented a synergistic 
effect. With a combination index of 0.67 (figure 30a and c), only one drug combination 
(1xIC50) was classified as being synergistic when combined at the IC50 concentration 
compared with CsA and TPCA-1 treatment alone. The remaining drug combination doses 
were classified as either nearly additive or antagonistic.    
4.3.4. Biochemical experiments suggest TPCA-1 is an ineffective inhibitor of NF-κB 
activation 
 
Despite a lack of synergistic effects on cell viability, I considered it possible that NFAT 
and NF-κB may still co-ordinately regulate joint target genes that are important in 
lymphoma. Using RNA from cells depleted with NFAT and NF-κB components I aimed 
to use gene expression microarray analysis to investigate genes whose expression patterns 
a) 
c) b) 
Fraction of IC50 value CsA TPCA-1 Combination Index
0.25 2.6μg/ml 0.9μM 1.31
0.5 5.2μg/ml 1.8μM 1.24
1 10.4μg/ml 3.6μM 0.67
2 20.8μg/ml 7.2μM 0.91
4 41.6μg/ml 14.4μM 1.86
Figure 30. CalcuSyn analysis of combined inhibition of the NFAT and NF-κB pathways suggests 
some synergistic effects between CsA and TPCA-1. The DLBCL cell line WSU-NHL was treated 
with five fixed-ratio concentrations of the calcineurin inhibitor CsA and the IKK2 inhibitor TPCA-1, 
both alone and in combination (a). Fixed ratio concentrations are based on cell-line specific fractions 
of CsA or TPCA-1 IC50 values (as determined previously), where a fraction of 0.25=0.25xIC50, 0.5 
=0.5xIC50, 1=1xIC50 concentration, 2=2xIC50 and 4=4xIC50. Cells were incubated for 72 hours 
before addition of resazurin and the viability of cells recorded. The effects of chemical inhibition are 
shown in (b). CalcuSyn software was used to determine combination index scores for each fixed ratio 
concentration (a) which were compared CalcuSyn combination index scores indicative of drug synergy 
(c). Data shown is representative of one individual experiment where error bars indicate the standard 
deviation between triplicate wells. 
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indicate coordinate regulation. NFAT and NF-κB may for example, separately regulate 
genes whose coinciding depletion creates a synthetic lethal phenotype resulting from loss 
of in-built redundancy. To confirm the inhibitory effects of TPCA-1, WSU-NHL cells 
were treated with their respective IC50 concentration (3.5μM) of TPCA1 for 2 hours or 
6 hours (figure 31).   
As shown in figure 31a, simple indicators of NF-κB pathway activation were used to 
assess the effects of TPCA-1. Figure 31a shows that activation of the canonical pathway 
(determined by the nuclear expression of subunits such as p65 and c-Rel) was somewhat 
reduced at 2 hours and 6 hours. P-p65 (serine 536) was also inhibited upon treatment with 
TPCA-1. Effective inhibition of IKK2 may also cause an accumulation of IκBα; however 
this was not observed and may be due to its rapid turnover. The reduction in p52 
expression by TPCA-1 (observed at both timepoints and in both cytoplasmic and nuclear 
extracts) may be due to off target or secondary effects of the treatment.  
Promisingly, TPCA-1 did not have major off target effects on NFAT activation (figure 
31b), although there does seem to be a small effect on NFAT1 at 6 hours. Interestingly, 
despite a mild effect on NF-κB, TPCA-1 clearly induced apoptosis, represented by 
expression of the cleaved form of PARP. This experiment was also performed in an 
additional cell line (U2932), where TPCA-1 also had no effect on NF-κB activity (data 
not shown).   
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a) b) 
Figure 31. Biochemical experiments suggest TPCA-1 is an ineffective inhibitor of NF-κB 
activation. WSU-NHL cells were treated with 3.5μM IKK2 inhibitor TPCA-1, including a vehicle 
control (0.01% DMSO) for 2 hours or 6 hours before nuclear and cytoplasmic extracts were prepared. 
The untreated and DMSO controls used in this data were the same as those presented in a previous 
chapter (chapter 3, figure 23d). The effect of TPCA-1 on NF-κB (a) and NFAT (b) were analysed by 
Western blot analysis. Simple indicators of NF-κB pathway activation were used to assess the mode of 
NF-κB activation, where activation of the non-canonical NF-κB pathway is indicated by the presence 
of p100 cleavage to the active p52 subunit and the presence of the RelB unit. α-tubulin was used as a 
cytoplasmic loading control and PARP as a nuclear loading control. Data is representative of a single 
experiment in this cell line, however the experiment was also performed in the U2932 cell line, where 
the same effect was observed (data not shown).  
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3.1.1. TPCA-1 inhibits DNA binding activity of the NF-κB subunit p65 
 
Here, I used a more sensitive assay to investigate whether TPCA-1 did indeed target NF-
κB. U2932 cells were treated with TPCA-1 and the effects on the two main canonical NF-
κB subunits p65 and c-Rel were analysed by ELISA. Reassuringly, p65 DNA binding 
activity was reduced upon treatment with TPCA-1, showing that this inhibitor was indeed 
exerting its desired effect by targeting NF-κB (figure 32). An interesting result here was 
the differential effects of TPCA-1 on p65 and c-Rel activity. Unlike p65, IKK2 inhibition 
by TPCA-1 had insignificant effects on c-Rel activity, suggesting that the effects of 
TPCA-1 may be subunit-specific. Of note, the effect of CsA treatment on p65 and c-Rel 
DNA binding activity was also investigated using this assay, however the data was 
inconclusive. It can therefore not be ruled out that CsA functions through the use of the 
NF-κB pathway in DLBCL cells.  
 
 
3.2.Discussion 
 
One of the main aims of the study was to investigate the contribution of different pathway 
components and transcription factor subunits to lymphoma cell growth and survival. 
During the MRes portion of this study I attempted to use siRNA knockdown of individual 
a) b) 
** 
Figure 32. TPCA-1 inhibits DNA binding activity of the NF-κB subunit p65. The DLBCL cell line 
U2932 was treated with its IC50 concentration of TPCA-1 (3.1μM) for 2 hours before extraction of 
nuclear protein. The DNA binding activities of the NF-κB subunits p65 and c-Rel were analysed using 
an NF-κB ELISA. Raji cell nuclear extracts were included as a positive control for NF-κB activation. 
To monitor the specificity of the assay, samples were run alongside a mutated (MT) consensus 
oligonucleotide and a wild-type (WT) consensus oligonucleotide (as a competitor for NF-κB binding). 
p65 ELISA data is representative of four biological experiments (a). c-Rel data represents three 
biological experiments, however the WT and MT samples represent one experiment (b). Error bars 
indicate the standard deviation of duplicate wells. P-values: p65 = 0.005, cRel = 0.20 (insignificant). 
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NFAT and NF-κB subunits to help understand the relative contribution and combinatorial 
interactions of these different transcription factors to disease. Unfortunately, due to 
difficulties achieving effective knockdown of proteins in DLBCL cells this approach was 
not considered feasible.  
3.2.1. Combined inhibition of the NFAT and NF-κB pathways 
 
Instead, I investigated whether simultaneous depletion of the pathways caused additive 
or synergistic effects on DLBCL cells by combined treatment with the calcineurin/NFAT 
inhibitor CsA and the IKK2 inhibitor TPCA-1. In hindsight the experimental design of 
these experiments was slightly flawed with respect to the choice of drug doses. The ranges 
of concentrations chosen were based on the sensitivity of a small selection of cell lines 
(RIVA and HLY-1) treated with these agents in preliminary experiments. The middle 
dose (concentration 3) was established by the average IC50 concentration from cells used 
in early experiments, whereas the upper and lower concentrations chosen aimed to cover 
as best possible the broad effects on different cell lines. Using non-fixed doses were a 
major limitation to these experiments, making it difficult to make comparisons between 
cell line sensitivities and cooperative effects. Although I was not able to extrapolate 
statistical interpretation of these results, the data was still useful since it showed no 
striking inhibition of cell viability when the NF-κB and calcineurin/NFAT pathways were 
simultaneously inhibited. 
To investigate cooperativity in a more rigorous way, the experiment was performed using 
fixed ratio drug doses. CalcuSyn software was used to calculate the combination index as 
a measure of synergism between respective doses of CsA and TPCA-1. Based on Chou 
and Talalay’s statistical measure for drug interactions, CsA and TPCA-1 showed 
maximum synergy when cells were dosed with 1x their IC50 value, effectively having a 
lethal effect on the viability of WSU-NHL cells at these concentrations. Although a 
fraction of 0.5xIC50 concentration was suggestive of having a ‘nearly additive’ effect of 
combining the chemical inhibitors, most other drug doses did not indicate significant 
cooperative effects. Some dose combinations were classified as being antagonistic, 
however the reasons for this are not understood.   
Although synergistic effects were observed in the WSU-NHL cell line tested, for a drug 
combination to be considered exciting and of potential use in the clinic the combination 
index values are usually required to be strongly synergistic. An example of this was 
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demonstrated by Haagensen et al (2012) where the combined treatment of colorectal cell 
lines with specific MEK and PI3K inhibitors resulted in marked synergy at all fixed IC50 
ratio concentrations, where combination index values were almost all less than 0.6 
(Haagensen et al., 2012). Nonetheless, reports of synergy between pathways to a lesser 
degree are also important biological findings and can aid our understanding of 
interactions between signalling pathways. For example, a study reporting cooperative 
signalling through STAT3 and NF-κB used CalcuSyn analysis to shown cooperative 
effects between a Janus Kinase (JAK) inhibitor and the IKK2 inhibitor MLN120B (Lam 
et al., 2008). The combination index values for some cell lines were in the same category 
for synergy as those in this study, where synergy was also only observed at specific doses 
(Lam et al., 2008). Ideally, the CalcuSyn method of experimental setup and data analysis 
would have been repeated in all cell lines, however it was clear from the previous data 
that there were no strikingly obvious cooperative effects between CsA and TPCA-1. 
Moreover, these experiments were not intended to assess the precise drug interaction 
mechanisms or clinical relevance of these inhibitors. It was therefore decided that the 
generation of repeat negative data was not time well spent and it would be best to focus 
on other aspects of the project.  
Although we did not observe significant additive or synergistic effects in cells treated 
with CsA and TPCA-1, it was possible that NFAT and NF-κB may still coordinate joint 
target genes which are important in lymphoma and so I considered using CsA and TPCA-
1 together in a gene expression microarray. This could determine the key genes which 
function as nodes of integration between these pathways and which are required for 
lymphoma growth and survival. Ultimately I hoped to evaluate the potential of the 
proteins encoded by these gene targets to be exploited as future drug targets. 
3.2.2. Inhibition of NF-κB  
 
One of the major challenges for this part of the study was finding a selective and reliable 
NF-κB inhibitor. Previously, I observed no effect on cell viability or NF-κB activity by 
the selective IKK2 inhibitor PS-1145 which was likely due to its extremely poor solubility 
(http://www.kinase-screen.mrc.ac.uk/kinase-inhibitors, 2015). Additionally, the 
biochemical effects of the IKK inhibitor BAY 11-7082 were investigated (data not 
shown), however no biochemical effects on NF-κB were observed. Interestingly, studies 
on multiple myeloma cells have comparatively tested NF-κB inhibition using the IKK2 
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inhibitor TPCA-1 and BAY 11-7082, where BAY 11-7082 was found to induce cell death 
independently from inhibition of activation of NF-κB (Rauert-Wunderlich et al., 2013). 
In fact, BAY 11-7082 was recently reported to not inhibit the IKKs at all, but rather 
targets upstream components of the ubiquitin system by inactivating the E2-conjugating 
enzymes Ubc (ubiquitin conjugating) 13 and UbcH7 and the E3 ligase LUBAC (linear 
ubiquitin assembly complex), therefore preventing formation of polyubiquitin chains 
(Strickson et al., 2013). Due to the poorly selective and off-target effects of BAY 11-
7082, this compound was disregarded from the study (Rauert-Wunderlich et al., 2013; 
Strickson et al., 2013). 
Biochemical analysis of NF-κB activation in cells treated with TPCA-1 showed inhibitory 
effects on NF-κB and the inhibitor also clearly affected the apoptotic machinery of the 
cell, as indicated by the expression of cleaved PARP. An effect on NF-κB activity would 
be expected during the period of incubation tested and the concentrations used were 
similar to published studies (Rauert-Wunderlich et al., 2013). Treatment of multiple 
myeloma cells with 5µM TPCA-1 for 1 hour for example, has been shown to largely 
block TNFα-induced phosphorylation and degradation of IκBα, while having no effect on 
expression of non-canonical markers such as p52 (Rauert-Wunderlich et al., 2013).  
Importantly, during this period of the study a report emerged in the literature 
demonstrating TPCA-1 to be a dual inhibitor of the NF-κB and STAT3 pathways (Nan et 
al., 2014). STAT3 has been reported to be constitutively activated in ABC DLBCL, where 
inactivation of STAT3 inhibited proliferation and initiated apoptosis (Ding et al., 2008). 
In fact, biological interplay between the NF-κB and STAT3 pathways was also 
established by the Staudt laboratory, where a gene expression signature of IL-6 and IL-
10 signalling through STAT3 was found in ABC DLBCLs, reflecting NF-κB activity 
(Lam et al., 2008). Moreover, inhibition of STAT3 using a JAK inhibitor synergised with 
an inhibitor of NF-κB signalling (Lam et al., 2008). These studies suggest that the STAT3 
and NF-κB pathways may be exploited for the treatments of ABC DLBCL. However, not 
only does inhibition of STAT3 increase the off target effects of TPCA-1, it also makes it 
very difficult to compare the response between DLBCL subgroups with different degrees 
of STAT3 dependency.  
With this in mind it was decided that microarray analysis with this inhibitor would no 
longer be pursued. In fact, during this stage of the study it became apparent that without 
a reliable and specific inhibitor of NF-κB, the output of a gene expression microarray 
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may be composed of many off-target effects. It was decided that further investment and 
time spent validating an effective NF-κB inhibitor was not the primary focus of the project 
and consequently the strategy and experimental approach for the microarray was 
reformed. Instead, I aimed to use single agent treatment with CsA to discover novel 
NFAT target genes which could then be cross-referenced with known, already 
documented NF-κB target genes, as described in chapter 5. Please note that this decision 
was also made before the data in figure 32 (which confirmed that TPCA-1 was having an 
effect in a more sensitive assay than Western Blots) was obtained.   
Regardless of this decision, the comprehensive analysis of NF-κB expression and 
activation in DLBCL cells produced some interesting data. Despite constitutively active 
NF-κB being associated with the ABC subgroup, high levels of NF-κB expression were 
also observed in GCB cell lines indicating that NF-κB activity and function may not be 
restricted to the ABC group. These results were in keeping with studies in the literature, 
where engagement of both the classical and alternative NF-κB pathways in DLBCL 
tumour samples were observed in 61% of ABC DLBCL tumour samples and a smaller 
fraction (30%) of GCB DLBCL (Compagno et al., 2009). Moreover, heterogeneous 
expression of p52 (as a marker for noncanonical NF-κB activity) was detected in DLBCL 
cell lines of both ABC and GCB subgroups by Compagno et al (2009) (Compagno et al., 
2009). Overall, the heterogeneity of NF-κB expression and activation observed between 
DLBCL cell lines probably reflects the different mechanisms of pathway activation used 
by these cells. Future studies would benefit from comprehensively analysing the 
expression, activation and sensitivity of cell lines to NF-κB inhibition with the underlying 
genetic abnormalities of cell lines. For example, it would be interesting to correlate cell 
line NF-κB activity or sensitivity to TPCA-1 with presence of CARD11, CD79B or 
MYD88 mutations.  
3.2.3. Cooperative effects between NFAT and NF-κB 
 
There are a number of explanations as to why we did not see cooperative effects when 
inhibiting the NFAT and NF-κB pathways. First, it is possible that both transcription 
factors bind to the same gene promoters, co-regulating their expression. Chemical 
depletion of a gene which has already been depleted by either CsA or TPCA-1 treatment 
alone may not cause additional effects on cell viability. There is evidence for a group of 
κB-like DNA binding motifs of which both transcription factors bind, such as the CD28-
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responsive element of the IL2 promoter (Maggirwar et al., 1997; Zhou et al., 2002b). 
However, the structural basis of synergy of NFATs with other transcription factors 
remains an area that is largely unexplored. 
Although there is currently no experimental evidence for the formation of NFAT/NF-κB 
heterodimers, cooperative binding of NFAT with other transcription factors is frequently 
observed in various systems (Chen et al., 1998). In 2005, Pham et al were the first 
researchers to demonstrate a cooperative interaction between NF-κB and NFAT family 
members in B-cell lymphoma (Pham et al., 2005). They demonstrated that NFAT2 and 
c-Rel proteins interact with each other at the CD154 (CD40 ligand) promoter by binding 
simultaneously to two sites; the distal CD154 κB site and the proximal NFAT site (Pham 
et al., 2005). Pham et al further suggested that the promoter DNA may ‘loop or bend to 
form an enhanceosome-like complex that synergistically regulates CD154 gene 
expression’ (Pham et al., 2005). This phenomenon has been reported at the promoter of 
IFN-β, where an ordered recruitment of chromatin modifying and transcription factors 
generated an enhanceosome complex (Agalioti et al., 2000). 
In contrast to these findings, a recent study argued that NFAT and NF-κB do not interact 
or collaborate when they bind to DNA (Muhammad et al., 2014). Muhammad et al (2014) 
showed that the NF-κB subunits p50 and c-Rel controlled the induction of the NFAT2/αA 
short isoform in BCR-induced splenic B cells (Muhammad et al., 2014). Ablation of c-
Rel or p50 led to a suppressive effect on NFAT2, which consequently (due to inhibition 
of the positive autoregulatory loop) caused the loss of induction of the short NFAT2/αA 
isoform (Muhammad et al., 2014). Researchers identified two NFAT/NF-κB binding sites 
in the P1 region of the inducible NFATC1 promoter which results in a persistent induction 
of NFAT2/αA by BCR signals (Serfling et al., 2004; Muhammad et al., 2014).  
Since NFAT2/αA is known to play a key role in the proliferation and survival of 
lymphocytes, it is possible that this isoform is a potential novel target in malignancies 
with dysregulated NF-κB or NFAT signalling. Although the study by Muhammad et al 
(2014) does not fit with the reported evidence for synergy by means of coordinate 
regulation of NF-κB and NFAT target genes, these data provided further evidence for a 
close connection between NFAT2 and NF-κB induction in peripheral B-lymphocytes.  
In their publication, Muhammad et al (2014) are critical of the study showing coordinate 
regulation of CD154 by NFAT and NF-κB by Pham et al (2005). They argue that their 
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use of conventional EMSAs and co-precipitation of NFAT2 by an antibody specific for 
c-Rel only suggest interplay between NFAT2 and NF-κB (Muhammad et al., 2014). 
Muhammad et al highlight that use of overexpression of NFAT and NF-κB by Pham et 
al does not allow consideration of possible interactions in normal physiological 
conditions (Muhammad et al., 2014). Also to be questioned is whether the protein-protein 
interactions described by Pham et al (2005) actually affect their DNA binding activity 
and subsequent regulation of genes (Pham et al., 2005; Muhammad et al., 2014).     
In summary, the results in this chapter suggest that simultaneous depletion of the NFAT 
and NF-κB pathways using CsA and TPCA-1 does not have substantial additive or 
synergistic effects on cell viability. Additionally, I experienced difficulty finding an 
effective, specific NF-κB inhibitor for gene expression microarray analysis. These data 
consequently prompted me to investigate cooperativity and combined target genes by 
alternative methods. Finally, analysis of NF-κB expression and activation in a 
comprehensive panel of DLBCL cell lines produced interesting data, some of which may 
be useful sources of reference for the lab in the future. Based on the data described in this 
chapter, it was decided that I would proceed with a gene expression microarray using CsA 
alone.  
 
 
 
 
 
 
 
 
 
 
Chapter 5. 
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Gene expression microarray analysis to 
investigate calcineurin/NFAT target 
genes 
 
 
 
 
 
 
 
 
 
 
4. Gene expression microarray analysis to investigate calcineurin/NFAT 
target genes 
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4.1. Introduction 
 
The role of the NFAT transcription factor family is well studied in T cells and in immune 
activation, however, less is known about NFAT function in B cells, especially in the 
malignant setting. Activation and overexpression of NFAT has been implicated in an 
array of cancers, including haematopoietic malignancies such as DLBCL (Marafioti et 
al., 2005; Pham et al., 2005; Fu et al., 2006; Pham et al., 2010). Of the few NFAT target 
genes reported in lymphoma, most are involved in lymphocyte survival (such as CD40L 
and BLyS) and proliferation (such as c-Myc), indicating that some NFAT family 
members are oncogenic and could be targets for therapeutic intervention (Pham et al., 
2005; Fu et al., 2006; Pham et al., 2010).    
Prior to this study, a comprehensive analysis of the transcriptional targets of NFAT in 
DLBCL had not been investigated, highlighting an area of unexplored research. In this 
study, I aimed to identify primary NFAT target genes by gene expression microarray 
analysis using the Illumina Human HT-12v4 Expression BeadChip array, as described in 
chapter 2, section 2.5. Two ABC DLBCL cell lines (HLY-1 and U2932) and one GCB 
DLBCL cell line (WSU-NHL) were chosen as appropriate cell lines based on data in 
chapter 3. To investigate changes in gene expression affected by calcineurin/NFAT 
inhibition, cells were treated with their respective IC50 concentration of CsA for two 
timepoints (2 and 6 hours) in 4 independent biological repeat experiments. These samples, 
used for the microarray were those showing effective drug treatment from previous 
experiments (figure 20). In addition to identifying potential NFAT gene targets, I aimed 
to analyse potential differences between NFAT-mediated gene regulation between ABC 
and GCB DLBCL cell lines.    
 
 
 
 
4.2. Results 
 
4.2.1. Normalisation and Quality Control  
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Data from the gene expression microarray was analysed by Dr Simon Cockell from the 
Bioinformatics Support Unit, Newcastle University. Firstly, of the 47,231 probes on the 
microarray, 24,493 probes passed the detection P-value threshold (0.01) on at least one 
array, allowing 51.9% of the total number of probes to be taken forward for analysis.  
Next, to achieve sample- and probe-level filtering, analysis included a series of quality 
control steps. The data from all 48 samples in the array were first transformed to log2 
space via a variance stabilising transformation, as described by Lin et al (2008) (Lin et 
al., 2008). Using the robust spline normalisation algorithm that was designed for Bead-
array data, the data was normalised, as shown in the box plot in appendix figure 2 (Du et 
al., 2008).  
Subsequently, samples underwent principal component analysis (PCA), which is a 
dimension reduction technique that allows the multivariate data to be projected and 
visualised on a two-dimensional plot (figure 33). This statistical procedure converts a set 
of observations that are possibly correlated, into a set of values of linearly uncorrelated 
variables called principal components. The first principal component accounts for as 
much variability in the data as possible (x-axis), whereas the second component (y-axis) 
has the highest possible variance that is statistically independent of the first component 
(Rencher, 2003).  
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Here, the spacial arrangement of the samples reflects their overall similarities or 
dissimilarities in the array. Samples were colour coded by the experimental groups they 
fell into, allowing identification of samples that responded similarly to others in their 
cohort as well as samples that were outliers. Using the first two principal components 
(PC1 and PC2), the PCA scatterplot in figure 33 shows three clusters of samples, which 
individually represent each of the three cell lines used in the array. Three samples were 
noticeably separate from the three groupings in the dataset and were recorded as outliers. 
Although the presence of outliers implies underlying experimental or biological 
problems, their occurrence in datasets this large are expected. Sample outliers included a 
sample from HLY-1 cells (6hr CsA, experimental repeat 3/4, chip 3/4), WSU-NHL cells 
(6hr CsA, experimental repeat 3/4, chip 1/4) and WSU-NHL cells (2hr CsA, experimental 
repeat 4/4, chip 1/4). Although all three outliers were treated with CsA, there was no 
uniform association with a particular experimental repeat or microarray chip. However, 
Figure 33. Principle component analysis for gene expression microarray data. A scatterplot of the 
microarray data along the two first two principle components. Clusters of samples represent samples which 
responded similarly to others in the cohort and are labelled as either HLY-1, U2932 or WSU-NHL cells. 
Three outlier samples were identified. The colour-coded key to the right of the figure indicates individual 
samples and their respective treatment conditions.  
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to remove erroneous data, these samples and their partners were excluded from further 
analysis of the microarray.   
4.2.2. Overview of statistically significant genes differentially expressed in 
DLBCL cells treated with CsA 
 
Table 11 shows an overview of the number of genes with statistical significance (adjusted 
P-value <0.05), after multiple testing correction (using Benjamini-Hochberg FDR 
correction), that were either upregulated or downregulated by treatment with CsA 
(Benjamini, 1995). A 1.3 fold-change (FC) cut-off was used here and throughout the rest 
of the study.  
The number of differentially expressed genes listed overall is surprisingly low, especially 
in the GCB DLBCL cell line WSU-NHL. In fact, initial analysis of the data set as a whole, 
revealed a high number of genes which were differentially expressed with a fold-change 
greater than 1.3, but with insignificant adjusted P-values (data not shown). There are a 
number of possible reasons for this, such as the short duration of calcineurin/NFAT 
inhibition or a lack of sensitivity of the array when detecting changes to low abundance 
mRNA. Increasing the incubation period of cells treated with CsA would likely have 
revealed more differentially expressed genes. However, my aim was to identify primary 
NFAT target genes, rather than genes which may have been up- or downregulated as a 
secondary response to calcineurin/NFAT inhibition. 
Table 11 shows a time-dependent increase in genes differentially expressed in U2932 and 
HLY-1 cell lines. Generally, after two hours, there were more genes downregulated by 
CsA compared to upregulated. However, by 6 hours of calcineurin/NFAT inhibition, there 
were generally more genes upregulated by CsA treatment, indicating that these genes 
(which NFAT may normally downregulate) were slower to respond to chemical inhibition 
of this pathway.  
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Surprisingly, there were no statistically significant genes identified in WSU-NHL cells at 
the 2 hour timepoint and only 4 genes were revealed by unpaired analysis after 6 hours 
CsA treatment (table 11, c). It is possible that WSU-NHL cells may have a slower acting 
response to inhibition of calcineurin/NFAT signalling. It would be of interest in the future 
to perform microarray analysis on these cells with a longer incubation of CsA. On the 
other hand, it is possible that calcineurin/NFAT signalling regulates fewer target genes in 
a) 
b) 
c) 
Timepoint Expression Genes Total Genes Total
Downregulated 7 2
Upregulated 2 0
Downregulated 25 133
Upregulated 98 214
U2932 Unpaired Paired
2hr
6hr
9 2
123 347
Timepoint Expression Genes Total Genes Total
Downregulated 12 28
Upregulated 2 8
Downregulated 17 52
Upregulated 12 101
2hr 14 36
6hr 29 153
HLY-1 Unpaired Paired
Timepoint Expression Genes Total Genes Total
Downregulated 0 0
Upregulated 0 0
Downregulated 1 0
Upregulated 3 0
6hr 4 0
WSU-NHL Unpaired Paired
2hr 0 0
Table 11. Overview of statistically significant genes differentially expressed in DLBCL cells treated 
with CsA. Data indicates the number of statistically significant gene probes (adjusted P-value <0.05) 
differentially expressed upon treatment with CsA for 2hrs and 6hrs in the ABC DLBCL cell lines U2932 
(a), HLY-1 (b) and the GCB DLBCL cell line WSU-NHL (c). Data includes genes identified from both 
unpaired and paired data analysis. Orange indicates genes downregulated by CsA, whereas blue indicates 
genes upregulated by CsA. Data includes occasional probes marked as N/A. 
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this GCB cell line compared to the two ABC cell lines. This hypothesis is explored in 
subsequent sections of this chapter.   
4.2.3. Differences between unpaired and paired data analysis 
 
During initial analysis of the array, both unpaired and paired methods of analysis were 
used. In summary, unpaired data analysis is applied to two independent groups e.g. 
vehicle control samples versus CsA-treated samples. It compares the mean of the entire 
set of vehicle control samples to the mean of the entire set of CsA-treated samples. This 
type of analysis assumes that the data is from a normal distribution and that the standard 
deviation is approximately the same in both groups. Paired data analysis on the other 
hand, is derived from study subjects, or samples, which have been subjected to two 
separate measurements. In this case, pairs were based on samples prepared in each of the 
four repeat experiments, where paired data analysis compared individual vehicle control 
samples with their specific CsA-treated partner. 
Interestingly, the number of genes identified was highly dependent on the way in which 
the data was analysed. For example, one of the most striking differences between paired 
and unpaired analysis was in the HLY-1 6 hour timepoint, where paired analysis produced 
153 differentially expressed genes compared to only 29 genes by unpaired analysis (table 
11, b).  
As described in the methods section (chapter 2, section 2.5), the 48 RNA samples sent for 
microarray analysis were randomised prior to shipping. Samples were then hybridised 
across four chips, containing twelve samples per chip. Although each of the four 
experimental repeats could have fitted nicely on one chip, it was decided that 
randomisation of samples was a more suitable method. The aim was to avoid chip-to-chip 
variability, which could ultimately skew an entire experimental repeat. Should one repeat 
experiment be different from the rest, the mean of an entire set of vehicle controls, for 
example, could be skewed, having a negative impact on unpaired data analysis. 
Randomisation of samples, however, meant that it was very unlikely that sample pairs, 
from specific experimental repeats, were on the same chip.  
After analysing the data using unpaired analysis, and obtaining a very low number of 
differentially expressed genes, it seemed possible that paired analysis may be more useful. 
Although this was true for all samples in some cell lines, such as HLY-1 (table 11b), this 
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did not appear true for other cell lines. This may be due to the fact that randomisation of 
samples may still be affected by differences between the readings of particular chips, 
upon which a particular sample partner may be hybridised. 
To gain a better insight into which type of analysis was best for this study, genes from the 
two methods of analysis were compared between treatment time points for U2932 and 
HLY-1 cells. Due to the absence of genes identified in the analysis of WSU-NHL, this 
cell line was not included. As shown by the Venn diagrams in figure 34 and figure 35, in 
HLY-1 cells, paired analysis produced many more genes of interest when compared to 
unpaired analysis. This was apparent at both time points, where only a fairly small number 
of genes were shared between the two methods of analysis.   
In contrast, in U2932 cells, at the 2 hour timepoint, unpaired data analysis produced more 
statistically significant genes than paired analysis, as shown in figure 36. In fact, after two 
hours CsA, only one gene (CCL4L2) was significant by paired analysis (figure 37). 
CCL4L2 was also identified by unpaired analysis, which included 6 additional genes. By 
6 hours CsA treatment however, far more genes were produced by paired analysis in 
U2932 compared to unpaired analysis. Although 99 genes at the 6 hour timepoint were 
common between the two methods of analysis, considerably more genes (186) were 
generated by paired analysis alone (figure 37).  
Overall, there were clear differences in the genes generated by paired versus unpaired 
analysis, where analysis in some cell lines and samples produced a much larger dataset 
of significantly up- or downregulated genes. Due to the overall lack of overlapping genes, 
it was not clear which analysis type was best. It was therefore decided that the data 
generated from both methods of analysis would be considered for experimental 
confirmation and validation of the array. 
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Figure 34. Paired data analysis produced more statistically significant genes that unpaired analysis in 
HLY-1 cells treated with CsA for 2hrs. The Venn diagram compares statistically significant, differentially 
expressed genes (adjusted P-value <0.05) analysed by unpaired (blue) or paired (orange) in HLY-1 cells 
treated with CsA for 2hrs. Data excludes gene probes marked as N/A. 
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Figure 35. Paired data analysis produced more statistically significant genes that unpaired analysis in 
HLY-1 cells treated with CsA for 6hrs. The Venn diagram compares statistically significant, differentially 
expressed genes (adjusted P-value <0.05) analysed by unpaired (blue) or paired (orange) in HLY-1 cells 
treated with CsA for 6hrs. Data excludes gene probes marked as N/A.  
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Figure 36. Unpaired data analysis produced more statistically significant genes that unpaired 
analysis in U2932 cells treated with CsA for 2hrs. The Venn diagram compares statistically 
significant, differentially expressed genes (adjusted P-value <0.05) analysed by unpaired (blue) or 
paired (orange) in U2932 cells treated with CsA for 2hrs. Data excludes gene probes marked as N/A. 
4 genes 99 genes 186 genes  
Figure 37. Paired data analysis produced more statistically significant genes that unpaired 
analysis in U2932 cells treated with CsA for 6hrs. The Venn diagram compares statistically 
significant, differentially expressed genes (adjusted P-value <0.05) analysed by unpaired (blue) or 
paired (orange) in U2932 cells treated with CsA for 6hrs. Data excludes gene probes marked as N/A. 
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4.2.4. Heat-map analysis of genes differentially expressed in HLY-1 and U2932 
cells treated with CsA 
 
As discussed previously, analysis of the array produced far more significantly relevant 
genes in the two ABC DLBCL cell lines U2932 and HLY-1, compared to the GCB cell 
line WSU-NHL. The heat-map in figure 38 shows the relative differential expression of 
these genes in the two ABC cell lines at both time points by paired analysis. Although 
there were some similarities between cell lines, this data indicates many differences 
between calcineurin/NFAT-regulated expression of certain genes. The Filamin A 
Interacting Protein 1-like gene (FILIP1L), for example, was significantly downregulated 
in HLY-1 cells after both 2 and 6 hours treatment with CsA, but not in U2932 cells. For 
many other genes, such as IL-10 and PCK2, expression was up- or downregulated at just 
one timepoint, indicating that NFAT may regulate these genes very transiently.  
Figure 39, on the other hand, shows the relative differential expression of genes in ABC 
cell lines analysed by unpaired data analysis. Some genes, such as PKC2, demonstrated 
similar differential expression to paired analysis. However, other genes, such as EGR2 
and EGR3 (which were significantly downregulated by CsA in some samples analysed 
by paired analysis) were not identified as significant by unpaired analysis. Similar to 
paired analysis however, most genes were significantly upregulated or downregulated at 
just one timepoint for each cell line. Exceptions to this however, were demonstrated in 
U2932 cells, were CCL3L1, CCL4L1, CCL4L2 and SLA were downregulated at both 
timepoints in U2932 cells.  
Moreover, both heat maps highlight the striking number of genes upregulated by CsA in 
U2932 cells, suggesting that NFAT may have a key role in suppressing the expression of 
these genes.      
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Figure 38 (Continued from previous 7 pages). Heat-map analysis of genes differentially expressed 
in HLY-1 and U2932 cells treated with CsA (paired analysis). The heat-map compares the 
statistically significant genes (adjusted P-value <0.05) which were differentially expressed in HLY-1 
and U2932 cells treated with CsA for 2 and 6 hours. Red indicates genes which were downregulated by 
CsA, whereas green indicates genes that were upregulated by CsA. The intensity of the colour signifies 
the degree to which genes were differentially expressed where a deeper colour represents a greater 
extent of differential expression. Genes are listed in alphabetical order. Data excludes gene probes 
marked as N/A. For genes where there were more than one probe, the average FC was used. 
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Figure 39 (Continued from previous 2 pages). Heat-map analysis of genes differentially expressed 
in HLY-1 and U2932 cells treated with CsA (unpaired analysis). The heat-map compares the 
statistically significant genes (adjusted P-value <0.05) which were differentially expressed in HLY-1 
and U2932 cells treated with CsA for 2 and 6 hours. Red indicates genes which were downregulated by 
CsA, whereas green indicates genes that were upregulated by CsA. The intensity of the colour signifies 
the degree to which genes were differentially expressed where a deeper colour represents a greater 
extent of differential expression. Genes are listed in alphabetical order. Data excludes gene probes 
marked as N/A. For genes where there were more than one probe, the average FC was used. 
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4.2.5. Inhibition of calcineurin/NFAT signalling in ABC and GCB DLBCL cell 
lines results in upregulation or downregulation of common target genes  
 
The heat-map in figure 40 shows the differential expression of genes commonly up- or 
downregulated by CsA in more than one DLBCL cell line. Genes in the heat-map were 
included based on their shared differential expression in at least two cell lines, regardless 
of their timepoint. The data as a whole gives a good representation of the broad shared 
directionality of response to CsA treatment of genes across cell lines. Of the 21 genes 
downregulated by CsA in U2932 cells, all but one of these genes were also downregulated 
by HLY-1 cells. Interestingly, the gene encoding follistatin (FST) was upregulated in 
HLY-1 cells, suggesting that NFAT may occasionally regulate the same genes differently 
between cell lines. For some genes, such as CCL4L2 and CCL4L1, the deep red colour 
in HLY-1 (2hr) and U2932 (2hr and 6hr) samples indicates a high level of downregulation 
upon CsA treatment, which is common in both HLY-1 and U2932 cell lines. In addition, 
EGR2 and NFAT2 (NFATC1) are downregulated in HLY-1 (2hr and 6hr) and U2932 
(6hr). In contrast, some genes, such as DDIT3 and TSC22D3 were commonly upregulated 
by both ABC DLBCL cell lines, but only at later timepoints.  
Interestingly, inhibition of the calcineurin/NFAT pathway caused significant 
downregulation of TNFα in all four ABC conditions, when both paired and unpaired data 
analysis was considered. The fact that TNFα also represents the fourth most 
downregulated gene overall suggests that this cytokine may be an important gene 
regulated by calcineurin/NFAT in these ABC DLBCL cell lines. Furthermore, of the very 
few significant genes differentially expressed in WSU-NHL cells, three out of four of 
these were shared with a least one ABC DLBCL cell line, particularly U2932 cells. Again, 
the regulation of gene expression induced by CsA treatment was comparable between all 
cell lines, suggesting similar modes of regulation by calcineurin/NFAT signalling between 
all three cell lines.  
The Venn diagrams in figures 41-44 indicate the overlapping genes affected by CsA in 
DLBCL cell lines. While unpaired analysis highlights the chemokines CCL4L1 and 
CCL4L2 as overlapping target genes (figure 41), only CCL4L2 was shared by paired 
analysis (figure 42). After 6 hours treatment, statistically significant genes were identified 
in all three cell lines by unpaired analysis, including WSU-NHL cells (figure 43). While 
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genes such as NFAT2 (NFATC1) were common between U2932 and HLY-1 cells, the 
only overlapping gene between all three cell lines was the gene encoding the small 
nucleolar RNA SNORD96A. Paired analysis of the 6 hour timepoint did not reveal any 
genes of significance in WSU-NHL (figure 44), however, U2932 and HLY-1 cells 
demonstrated 25 overlapping genes, including NFAT2 (NFATC1), early growth response 
2 (EGR2), the nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitors 
epsilon (NFKBIE) and alpha (NFKBIA) and tumour necrosis factor alpha (TNFα). 
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Figure 40. Heat-map analysis of genes differentially expressed in HLY-1, U2932 and WSU-NHL 
cells treated with CsA (combined paired and unpaired analysis). The heat-map compares the 
statistically significant genes (adjusted P-value <0.05) which were differentially expressed in HLY-1, 
U2932 and WSU-NHL cells treated with CsA for 2 and 6 hours. Genes in the heat-map were included 
based on their shared differential expression between at least two cell lines, regardless of timepoint. 
Red indicates genes which were downregulated by CsA, whereas green indicates genes that were 
upregulated by CsA. The intensity of the colour signifies the degree to which genes were differentially 
expressed where a deeper colour represents a greater extent of differential expression. Genes are ordered 
by their average logFC across all timepoints. Data excludes gene probes marked as N/A. 
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EVI2A 
GFI1 
IL10 
NUAK2 
PAX9 
PDCD1 
PRF1 
RIN2 
SOCS3 
TNFSF14 
ZNFX1 
CCL4L1 
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GCSAM 
PRRG4 
SLA 
TNF 
Figure 41. HLY-1 and U2932 cells share two genes that were significantly upregulated or 
downregulated when treated with CsA for 2hrs. The Venn diagram compares statistically significant, 
differentially expressed genes (adjusted P-value <0.05) between HLY-1 (blue) and U2932 (orange) cells 
treated with CsA for 2hrs (unpaired analysis). Data excludes gene probes marked as N/A. 
CCL4L2 30 genes 
Figure 42. HLY-1 and U2932 cells share one gene that was significantly upregulated or downregulated 
when treated with CsA for 2hrs. The Venn diagram compares statistically significant, differentially 
expressed genes (adjusted P-value <0.05) between HLY-1 (blue) and U2932 (orange) cells treated with CsA 
for 2hrs (paired analysis). Data excludes gene probes marked as N/A. 
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NFATC1 
HSPA5 
UPF3B 
SNORD96A 105 genes 
23 genes 
Figure 43. HLY-1, U2932 and WSU-NHL cells share one gene that was significantly upregulated 
or downregulated when treated with CsA for 6hrs. The Venn diagram compares statistically 
significant, differentially expressed genes (adjusted P-value <0.05) between HLY-1 (blue), U2932 
(orange) and WSU-NHL (green) cells treated with CsA for 6hrs (unpaired analysis). Data excludes gene 
probes marked as N/A. 
121 genes 
AMY1A 
CD83 
DDIT3 
DHCR7 
DNLZ 
EGR2 
FANCG 
FST 
IDI1 
LDLR 
MAP3K8 
MSMO1 
MZB1 
NFATC1 
NFKBIA 
NFKBID 
NFKBIE 
NLRP7 
SNORD96A 
SQLE 
SRF 
TCERG1 
TNF 
TSC22D3 
ZYX 
285 genes 
Figure 44. HLY-1 and U2932 cells share 25 genes that were significantly upregulated or downregulated 
when treated with CsA for 6hrs. The Venn diagram compares statistically significant, differentially 
expressed genes (adjusted P-value <0.05) between HLY-1 (blue) and U2932 (orange) cells treated with CsA 
for 6hrs (paired analysis). Data excludes gene probes marked as N/A. 
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4.2.6. Statistically significant genes differentially expressed in DLBCL cell lines 
treated with CsA 
 
The following tables (tables 12-20) provide the details of all the statistically significant 
genes (adjusted P-value <0.05) differentially expressed in each cell line and timepoint. 
Genes are ranked by logFC, where genes highlighted in orange indicate genes 
downregulated by CsA whereas data in blue represents genes upregulated by CsA. 
Adjusted P-values are also included. For a more comprehensive description of the top 150 
differentially expressed genes for each treatment condition, please refer to appendix 
tables 1-9. For bubble diagrams ranking genes by adjusted P-value, please locate 
appendix figures 3-19.   
 
 
 
 
 
 
 
 
U2932 2hr (unpaired data analysis) 
Number symbol name logFC adjusted P value
1 TNF tumor necrosis factor -1.894 0.004706188
2 NA NA -1.843 3.07E-05
3 CCL4L1 chemokine (C-C motif) l igand 4-like 1 -1.778 1.59E-05
4 CCL4L2 chemokine (C-C motif) l igand 4-like 2 -1.690 6.47E-05
5 SLA Src-like-adaptor -0.879 4.14E-05
6 CCL3L1 chemokine (C-C motif) l igand 3-like 1 -0.804 0.004706188
7 PRRG4 proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane) -0.626 0.022147325
2 GCSAM germinal center-associated, signaling and motility 0.564 0.027467991
1 NA NA 0.578 0.022147325
Table 12. Statistically significant genes differentially expressed in U2932 cells treated with CsA 
for 2hrs (unpaired data analysis). Columns indicate the gene symbols, names, log fold-change 
(logFC) and P values for statistically significant genes (adjusted P-value <0.05) differentially expressed 
upon treatment with CsA. Data in orange indicates genes downregulated by CsA and data in blue 
indicates genes upregulated by CsA. Gene numbers represent genes ordered by logFC, where 1 indicates 
the gene with the greatest logFC. Data includes gene probes marked as N/A. 
U2932 2hr (paired data analysis) 
Number symbol name logFC adjusted p value
2 CCL4L2 chemokine (C-C motif) ligand 4-like 2 -1.690 0.009380052
1 NA NA -1.843 0.021429372
Table 13. Statistically significant genes differentially expressed in U2932 cells treated with CsA 
for 2hrs (paired data analysis). Columns indicate the gene symbols, names, log fold-change (logFC) 
and P values for statistically significant genes (adjusted P-value <0.05) differentially expressed upon 
treatment with CsA. Data in orange indicates genes downregulated by CsA. Gene numbers represent 
genes ordered by logFC, where 1 indicates the gene with the greatest logFC. Data includes gene probes 
marked as N/A. 
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U2932 6hr (unpaired data 
analysis) 
Number symbol name logFC adjusted P value
1 NA NA -2.460 3.22E-08
2 CCL4L1 chemokine (C-C motif) l igand 4-like 1 -2.209 3.22E-08
3 CCL4L2 chemokine (C-C motif) l igand 4-like 2 -2.147 2.96E-07
4 RILPL2 Rab interacting lysosomal protein-like 2 -1.072 0.00261022
5 NA NA -1.048 0.000295978
6 SLA Src-like-adaptor -0.928 7.22E-06
7 SLA Src-like-adaptor -0.922 0.000917712
8 NA NA -0.853 0.014970312
9 LOC285628 uncharacterized LOC285628 -0.780 0.008035991
10 NFATC1 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 -0.728 0.001868128
11 ZBTB32 zinc finger and BTB domain containing 32 -0.698 0.029049451
12 WDR1 WD repeat domain 1 -0.650 0.02630768
13 KIF26B kinesin family member 26B -0.638 0.029049451
14 CCL3L1 chemokine (C-C motif) l igand 3-like 1 -0.570 0.041515298
15 PDDC1 Parkinson disease 7 domain containing 1 -0.557 0.029049451
16 BSPRY B-box and SPRY domain containing -0.554 0.007613104
17 NA NA -0.551 0.02407641
18 UPF3B UPF3 regulator of nonsense transcripts homolog B (yeast) -0.550 0.003270619
19 CLDN14 claudin 14 -0.549 0.021746963
20 CA2 carbonic anhydrase II -0.547 0.002162172
21 UPF3B UPF3 regulator of nonsense transcripts homolog B (yeast) -0.516 0.003673103
22 CSTF3 cleavage stimulation factor, 3' pre-RNA, subunit 3, 77kDa -0.501 0.02630768
23 CD58 CD58 molecule -0.445 0.00532788
24 LOC730101 uncharacterized LOC730101 -0.431 0.017416102
25 CLECL1 C-type lectin-like 1 -0.424 0.021963104
98 ZBTB8A zinc finger and BTB domain containing 8A 0.382 0.02146968
97 SOX7 SRY (sex determining region Y)-box 7 0.391 0.013375629
96 NA NA 0.402 0.030102889
95 ALKBH8 alkB, alkylation repair homolog 8 (E. coli) 0.420 0.031423395
94 RAB24 RAB24, member RAS oncogene family 0.423 0.016228488
93 NA NA 0.446 0.020574108
92 TMED5 transmembrane emp24 protein transport domain containing 5 0.455 0.02972874
91 EIF2S2 eukaryotic translation initiation factor 2, subunit 2 beta, 38kDa 0.458 0.019950904
90 UGGT1 UDP-glucose glycoprotein glucosyltransferase 1 0.458 0.017416102
89 UGGT1 UDP-glucose glycoprotein glucosyltransferase 1 0.459 0.038104893
88 DNAJC12 DnaJ (Hsp40) homolog, subfamily C, member 12 0.463 0.042674281
87 PSMA8 proteasome (prosome, macropain) subunit, alpha type, 8 0.476 0.039280693
86 SRPRB signal recognition particle receptor, B subunit 0.481 0.028675312
85 RGS16 regulator of G-protein signaling 16 0.482 0.012504995
84 FAM120C family with sequence similarity 120C 0.482 0.02018112
83 PROSER1 proline and serine rich 1 0.484 0.02630768
82 OSTCP2 oligosaccharyltransferase complex subunit pseudogene 2 0.502 0.005774258
81 PGM3 phosphoglucomutase 3 0.509 0.042674281
80 UGDH UDP-glucose 6-dehydrogenase 0.510 0.008748128
79 SEC23B Sec23 homolog B (S. cerevisiae) 0.515 0.01915417
78 SEL1L sel-1 suppressor of l in-12-like (C. elegans) 0.532 0.008748128
77 YARS tyrosyl-tRNA synthetase 0.535 0.014009867
76 BET1 Bet1 golgi vesicular membrane trafficking protein 0.539 0.042522949
75 STT3A STT3A, subunit of the oligosaccharyltransferase complex (catalytic) 0.547 0.000830742
74 LMAN1 lectin, mannose-binding, 1 0.568 0.044160822
73 DEPTOR DEP domain containing MTOR-interacting protein 0.569 0.002814085
72 SELK selenoprotein K 0.572 0.00532788
71 FAM129A family with sequence similarity 129, member A 0.579 0.014777277
70 GDPD5 glycerophosphodiester phosphodiesterase domain containing 5 0.582 0.012479994
69 NA NA 0.588 0.016283125
68 PDIA3P1 protein disulfide isomerase family A, member 3 pseudogene 1 0.591 0.048405193
67 SH2B3 SH2B adaptor protein 3 0.591 0.009016194
66 RELL1 RELT-like 1 0.594 0.019470183
65 SLC30A7 solute carrier family 30 (zinc transporter), member 7 0.596 0.042687224
64 SNORD96A small nucleolar RNA, C/D box 96A 0.598 0.002250795
63 GOT1 glutamic-oxaloacetic transaminase 1, soluble 0.601 0.027193809
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U2932 6hr (unpaired data analysis) continued. 
62 FAM84B family with sequence similarity 84, member B 0.602 0.005567665
61 DNAJC10 DnaJ (Hsp40) homolog, subfamily C, member 10 0.607 0.005139158
60 CREB3L2 cAMP responsive element binding protein 3-like 2 0.614 0.019321075
59 CDRT4 CMT1A duplicated region transcript 4 0.615 0.025168611
58 PPAPDC1B phosphatidic acid phosphatase type 2 domain containing 1B 0.637 0.008748128
57 DNAJC3 DnaJ (Hsp40) homolog, subfamily C, member 3 0.641 0.002309772
56 NA NA 0.645 0.042674281
55 TMEM39A transmembrane protein 39A 0.651 0.001095584
54 NA NA 0.652 0.019470183
53 FICD FIC domain containing 0.665 0.001287642
52 SLC10A7 solute carrier family 10, member 7 0.678 0.000617907
51 GARS glycyl-tRNA synthetase 0.685 0.000946563
50 SARS seryl-tRNA synthetase 0.694 0.008748128
49 PDIA4 protein disulfide isomerase family A, member 4 0.695 0.000917712
48 EDEM2 ER degradation enhancer, mannosidase alpha-like 2 0.697 0.005634219
47 ARFGAP3 ADP-ribosylation factor GTPase activating protein 3 0.701 0.005847348
46 ASNS asparagine synthetase (glutamine-hydrolyzing) 0.702 0.038698093
45 MTHFD2
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, 
methenyltetrahydrofolate cyclohydrolase 0.704 3.57E-05
44 HERPUD1
homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like 
domain member 1 0.710 0.020085983
43 SSR1 signal sequence receptor, alpha 0.711 2.08E-05
42 WIPI1 WD repeat domain, phosphoinositide interacting 1 0.715 0.001378825
41 RIMS3 regulating synaptic membrane exocytosis 3 0.722 0.037391237
40 SSR2 signal sequence receptor, beta (translocon-associated protein beta) 0.732 0.014777277
39 TARS threonyl-tRNA synthetase 0.739 0.020574108
38 TIMM44 translocase of inner mitochondrial membrane 44 homolog (yeast) 0.748 0.025406677
37 PARM1 prostate androgen-regulated mucin-like protein 1 0.754 0.003467139
36 EDEM1 ER degradation enhancer, mannosidase alpha-like 1 0.760 0.002250795
35 GNL3 guanine nucleotide binding protein-like 3 (nucleolar) 0.765 0.00026869
34 SLC1A5 solute carrier family 1 (neutral amino acid transporter), member 5 0.777 0.016832394
33 ERLEC1 endoplasmic reticulum lectin 1 0.781 0.000455295
32 MANF mesencephalic astrocyte-derived neurotrophic factor 0.786 0.005774258
31 PCK2 phosphoenolpyruvate carboxykinase 2 (mitochondrial) 0.798 0.015847846
30 HSPA5 heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) 0.799 0.009146536
29 SDF2L1 stromal cell-derived factor 2-like 1 0.808 0.001785335
28 NFE2L1 nuclear factor, erythroid 2-like 1 0.809 0.00131707
27 CHAC1 ChaC, cation transport regulator homolog 1 (E. coli) 0.809 0.042674281
26 DEPTOR DEP domain containing MTOR-interacting protein 0.821 0.000946563
25 CARS cysteinyl-tRNA synthetase 0.823 0.002543534
24 MTHFD1L methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like 0.831 0.000150423
23 CTH cystathionase (cystathionine gamma-lyase) 0.843 0.000156392
22 NA NA 0.855 0.006675448
21 FKBP14 FK506 binding protein 14, 22 kDa 0.857 0.007429306
20 LAT2 linker for activation of T cells family, member 2 0.857 0.009146536
19 PSPH phosphoserine phosphatase 0.879 0.000496868
18 SLC6A9 solute carrier family 6 (neurotransmitter transporter, glycine), member 9 0.883 0.029840227
17 HAX1 HCLS1 associated protein X-1 0.890 0.005139158
16 TMED10 transmembrane emp24-like trafficking protein 10 (yeast) 0.895 0.020193903
15 HYOU1 hypoxia up-regulated 1 0.917 0.039280693
14 VIMP VCP-interacting membrane protein 0.951 0.000648233
13 SEC24D SEC24 family member D 0.976 0.019470183
12 CTH cystathionase (cystathionine gamma-lyase) 1.011 0.000138647
11 ATF4 activating transcription factor 4 1.099 0.025168611
10 CARS cysteinyl-tRNA synthetase 1.132 0.0009649
9 TSC22D3 TSC22 domain family, member 3 1.166 0.006554991
8 DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 1.180 0.000914516
7 GPT2 glutamic pyruvate transaminase (alanine aminotransferase) 2 1.236 0.005223122
6 NA NA 1.322 0.000374446
5 PSAT1 phosphoserine aminotransferase 1 1.421 2.02E-06
4 DDIT3 DNA-damage-inducible transcript 3 1.474 0.00026869
3 CTH cystathionase (cystathionine gamma-lyase) 1.494 0.000295978
2 TSC22D3 TSC22 domain family, member 3 1.555 0.001880118
1 PCK2 phosphoenolpyruvate carboxykinase 2 (mitochondrial) 1.589 3.98E-05
Table 14 (Continued from previous page). Statistically significant genes differentially expressed 
in U2932 cells treated with CsA for 6hrs (unpaired data analysis). Columns indicate the gene 
symbols, names, log fold-change (logFC) and P values for statistically significant genes (adjusted P-
value <0.05) differentially expressed upon treatment with CsA. Data in orange indicates genes 
downregulated by CsA and data in blue indicates genes upregulated by CsA. Gene numbers represent 
genes ordered by logFC, where 1 indicates the gene with the greatest logFC. Data includes gene probes 
marked as N/A. 
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U2932 6hr (paired data analysis) 
Number symbol name logFC adjusted P value
1 NA NA -2.46024 1.33E-05
2 CCL4L1 chemokine (C-C motif) l igand 4-like 1 -2.20902 6.82E-06
3 CCL4L2 chemokine (C-C motif) l igand 4-like 2 -2.14727 1.33E-05
4 CCL3L3 chemokine (C-C motif) l igand 3-like 3 -1.25032 0.002786341
5 RILPL2 Rab interacting lysosomal protein-like 2 -1.07234 0.000896008
6 BATF basic leucine zipper transcription factor, ATF-like -1.06888 0.003367153
7 TNF tumor necrosis factor -1.05313 0.001776479
8 LRRC32 leucine rich repeat containing 32 -1.04826 0.006574593
9 NA NA -1.04768 0.00094904
10 SLA Src-like-adaptor -0.92831 0.000604875
11 SLA Src-like-adaptor -0.92184 0.002592167
12 NFKBIE NA -0.85271 0.001776479
13 CCL3 chemokine (C-C motif) l igand 3 -0.83513 0.003828764
14 ZYX zyxin -0.81341 0.005497236
15 MAP3K8 mitogen-activated protein kinase kinase kinase 8 -0.8095 0.003074677
16 NFKBIE nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon -0.79267 0.00387355
17 LOC285628 uncharacterized LOC285628 -0.77988 0.002093238
18 EGR3 early growth response 3 -0.77058 0.010619499
19 FKBP4 FK506 binding protein 4, 59kDa -0.74933 0.01188207
20 NFATC1 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 -0.72798 0.003828764
21 EGR2 early growth response 2 -0.69989 0.003128221
22 ZBTB32 zinc finger and BTB domain containing 32 -0.69805 0.00668888
23 TPM4 tropomyosin 4 -0.69701 0.012554762
24 SCO2 SCO2 cytochrome c oxidase assembly protein -0.69144 0.003817548
25 SRF serum response factor (c-fos serum response element-binding transcription factor) -0.67605 0.03266934
26 NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha -0.66561 0.00387355
27 RBM14 RNA binding motif protein 14 -0.65338 0.047771027
28 WDR1 WD repeat domain 1 -0.64984 0.005591198
29 HILPDA hypoxia inducible l ipid droplet-associated -0.64401 0.019056907
30 MIR155HG MIR155 host gene (non-protein coding) -0.6405 0.012554762
31 KIF26B kinesin family member 26B -0.63771 0.013911572
32 CCL3L1 chemokine (C-C motif) l igand 3-like 1 -0.62826 0.012233686
33 HES6 hes family bHLH transcription factor 6 -0.62456 0.017557919
34 RHPN2 rhophilin, Rho GTPase binding protein 2 -0.61989 0.006574593
35 IKZF1 IKAROS family zinc finger 1 (Ikaros) -0.60894 0.03523105
36 EXO1 exonuclease 1 -0.59242 0.006697883
37 FANCG Fanconi anemia, complementation group G -0.59064 0.034405111
38 FST follistatin -0.58891 0.010773303
39 BCL2L11 BCL2-like 11 (apoptosis facil itator) -0.58747 0.007775984
40 DNLZ DNL-type zinc finger -0.58674 0.01065754
41 PTGES2 prostaglandin E synthase 2 -0.58079 0.012233686
42 CCL3L1 chemokine (C-C motif) l igand 3-like 1 -0.57041 0.013953787
43 AGAP3 ArfGAP with GTPase domain, ankyrin repeat and PH domain 3 -0.56774 0.016756454
44 LIMA1 LIM domain and actin binding 1 -0.56619 0.033309286
45 SLC25A19 solute carrier family 25 (mitochondrial thiamine pyrophosphate carrier), member 19 -0.5593 0.025511885
46 BRK1 BRICK1, SCAR/WAVE actin-nucleating complex subunit -0.55848 0.02373166
47 PDDC1 Parkinson disease 7 domain containing 1 -0.55658 0.028336008
48 LOC730101 uncharacterized LOC730101 -0.55523 0.044623686
49 NFKBID nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, delta -0.55507 0.023834561
50 AMY1B amylase, alpha 1B (salivary) -0.55434 0.032733413
51 BSPRY B-box and SPRY domain containing -0.55405 0.010619499
52 NA NA -0.55134 0.011174268
53 PSME3 proteasome (prosome, macropain) activator subunit 3 (PA28 gamma; Ki) -0.55042 0.033845817
54 UPF3B UPF3 regulator of nonsense transcripts homolog B (yeast) -0.55038 0.021191687
55 BCL2L11 BCL2-like 11 (apoptosis facil itator) -0.54896 0.034721721
56 CLDN14 claudin 14 -0.54857 0.018968968
57 CA2 carbonic anhydrase II -0.54714 0.015294926
58 CCL3L1 chemokine (C-C motif) l igand 3-like 1 -0.54626 0.019031456
59 UBQLN4 ubiquilin 4 -0.54508 0.028336008
60 FAM65B family with sequence similarity 65, member B -0.53952 0.017557919
61 NA NA -0.53507 0.015280539
62 DHRS11 dehydrogenase/reductase (SDR family) member 11 -0.53497 0.013902319
63 TNFRSF1B tumor necrosis factor receptor superfamily, member 1B -0.53226 0.020831682
64 SAP30L SAP30-like -0.52613 0.013911572
65 DMAP1 DNA methyltransferase 1 associated protein 1 -0.52449 0.027958367
66 C9orf37 chromosome 9 open reading frame 37 -0.51835 0.047771027
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67 UPF3B UPF3 regulator of nonsense transcripts homolog B (yeast) -0.51632 0.012233686
68 NCOA1 nuclear receptor coactivator 1 -0.51273 0.015136811
69 LRRC20 leucine rich repeat containing 20 -0.50287 0.025910053
70 TUBA4A tubulin, alpha 4a -0.50287 0.031226285
71 CSTF3 cleavage stimulation factor, 3' pre-RNA, subunit 3, 77kDa -0.50076 0.03523105
72 PPOX protoporphyrinogen oxidase -0.49994 0.049360192
73 PMS2P4 postmeiotic segregation increased 2 pseudogene 4 -0.49971 0.049762703
74 POLA2 polymerase (DNA directed), alpha 2, accessory subunit -0.49952 0.025481384
75 ZAK sterile alpha motif and leucine zipper containing kinase AZK -0.49906 0.034721721
76 AMD1 adenosylmethionine decarboxylase 1 -0.49646 0.028336008
77 GPR137B G protein-coupled receptor 137B -0.49415 0.030661525
78 ZDHHC16 zinc finger, DHHC-type containing 16 -0.49275 0.033845817
79 NA NA -0.49153 0.028336008
80 HSPH1 heat shock 105kDa/110kDa protein 1 -0.49083 0.042792531
81 LPCAT3 lysophosphatidylcholine acyltransferase 3 -0.48911 0.014865142
82 PRPSAP1 phosphoribosyl pyrophosphate synthetase-associated protein 1 -0.4873 0.025511885
84 FAM136A family with sequence similarity 136, member A -0.48713 0.030649683
84 AMY1A amylase, alpha 1A (salivary) -0.48298 0.025474092
85 NA NA -0.47945 0.029010307
86 C16orf59 chromosome 16 open reading frame 59 -0.47764 0.034213914
87 DNAJA4 DnaJ (Hsp40) homolog, subfamily A, member 4 -0.47396 0.025511885
88 CAPRIN1 cell cycle associated protein 1 -0.47322 0.015717724
89 FANCL Fanconi anemia, complementation group L -0.47182 0.027958367
90 NA NA -0.46857 0.028336008
91 WWP1 WW domain containing E3 ubiquitin protein l igase 1 -0.46331 0.025666446
92 FAM133B family with sequence similarity 133, member B -0.46242 0.043284223
93 TRIOBP TRIO and F-actin binding protein -0.46034 0.02546761
94 COCH cochlin -0.45903 0.019775018
95 SDCBP syndecan binding protein (syntenin) -0.45804 0.049471046
96 CD24 CD24 molecule -0.45444 0.033309286
97 CSRP2 cysteine and glycine-rich protein 2 -0.45405 0.03523105
98 ELL3 elongation factor RNA polymerase II-l ike 3 -0.45191 0.033465045
99 ADAP2 ArfGAP with dual PH domains 2 -0.45133 0.04508246
100 IER3 immediate early response 3 -0.44735 0.04702118
101 ACTG1 actin, gamma 1 -0.44715 0.034721721
102 PRRG4 proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane) -0.44499 0.023834561
103 CD58 CD58 molecule -0.4445 0.022825104
104 NA NA -0.43586 0.036634046
105 BID BH3 interacting domain death agonist -0.43561 0.029010307
106 METTL13 methyltransferase like 13 -0.43511 0.042701416
107 SNX8 sorting nexin 8 -0.43508 0.0490733
108 LOC730101 uncharacterized LOC730101 -0.43149 0.026678785
109 NICN1 nicolin 1 -0.43102 0.039106595
110 CA2 carbonic anhydrase II -0.43101 0.043284223
111 C22orf39 chromosome 22 open reading frame 39 -0.42995 0.025511885
112 RRP7A ribosomal RNA processing 7 homolog A (S. cerevisiae) -0.42923 0.025814373
113 TYMP thymidine phosphorylase -0.42622 0.027495256
114 SNHG9 small nucleolar RNA host gene 9 (non-protein coding) -0.42589 0.032733413
115 NA NA -0.42561 0.048626688
116 C3orf70 chromosome 3 open reading frame 70 -0.42477 0.034213914
117 CLECL1 C-type lectin-like 1 -0.42387 0.041084607
118 PAM peptidylglycine alpha-amidating monooxygenase -0.42331 0.04021813
119 SUV420H1 suppressor of variegation 4-20 homolog 1 (Drosophila) -0.42299 0.028336008
120 NA NA -0.42189 0.039106595
121 DDTL D-dopachrome tautomerase-like -0.42088 0.027330137
122 CD83 CD83 molecule -0.40965 0.030649683
123 RPL29 ribosomal protein L29 -0.40906 0.048176288
124 RTCB RNA 2',3'-cyclic phosphate and 5'-OH ligase -0.40847 0.033975099
125 MCM10 minichromosome maintenance complex component 10 -0.4074 0.044623686
126 CD40 CD40 molecule, TNF receptor superfamily member 5 -0.40711 0.033153297
127 NA NA -0.40615 0.043961805
128 MPDU1 mannose-P-dolichol util ization defect 1 -0.4032 0.042792531
129 ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 -0.40242 0.036257109
130 WDR77 WD repeat domain 77 -0.40174 0.042792531
131 DUSP3 dual specificity phosphatase 3 -0.39127 0.044623686
132 LAMP2 lysosomal-associated membrane protein 2 -0.389 0.048791169
133 ACOT7 acyl-CoA thioesterase 7 -0.38534 0.048976659
214 SQLE squalene epoxidase 0.388121 0.044623686
U2932 6hr (paired data analysis) continued. 
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U2932 6hr (paired data analysis) continued. 
213 SLC30A5 solute carrier family 30 (zinc transporter), member 5 0.388688 0.0490733
212 PDIA5 protein disulfide isomerase family A, member 5 0.390472 0.049471046
211 NA NA 0.401922 0.039450906
210 SPCS3 signal peptidase complex subunit 3 homolog (S. cerevisiae) 0.413122 0.030728263
209 MMAB methylmalonic aciduria (cobalamin deficiency) cblB type 0.413447 0.048976659
208 NA NA 0.415339 0.038977112
207 SERPINA9 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 9 0.415554 0.039450906
206 MYO9A myosin IXA 0.419136 0.030649683
205 MAP1LC3B microtubule-associated protein 1 l ight chain 3 beta 0.419286 0.029010307
204 ALKBH8 alkB, alkylation repair homolog 8 (E. coli) 0.419918 0.033309286
203 GPR89C G protein-coupled receptor 89C 0.422361 0.028720756
202 UFM1 ubiquitin-fold modifier 1 0.422801 0.033309286
201 RAB24 RAB24, member RAS oncogene family 0.423 0.034347383
200 MGAT2 mannosyl (alpha-1,6-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase 0.426105 0.030638931
199 DERL1 derlin 1 0.428954 0.049471046
198 CHD2 chromodomain helicase DNA binding protein 2 0.430628 0.033455517
197 RNY1 RNA, Ro-associated Y1 0.431955 0.026678785
196 PAG1 phosphoprotein associated with glycosphingolipid microdomains 1 0.432002 0.034721721
195 ETV5 ets variant 5 0.432065 0.046852995
194 TVP23B trans-golgi network vesicle protein 23 homolog B (S. cerevisiae) 0.437154 0.034213914
193 NFX1 nuclear transcription factor, X-box binding 1 0.438249 0.024495532
192 AKAP13 A kinase (PRKA) anchor protein 13 0.439217 0.048354392
191 FAM3C family with sequence similarity 3, member C 0.43974 0.032605173
190 TCERG1 transcription elongation regulator 1 0.4429 0.042792531
189 DERL2 derlin 2 0.442967 0.043961805
188 NLRP7 NLR family, pyrin domain containing 7 0.444564 0.034133939
187 YPEL5 yippee-like 5 (Drosophila) 0.450595 0.044583427
186 GPR89B G protein-coupled receptor 89B 0.451525 0.047283383
185 NA NA 0.452246 0.038058521
184 HM13 histocompatibil ity (minor) 13 0.4546 0.034213914
183 TMED5 transmembrane emp24 protein transport domain containing 5 0.455088 0.023447568
182 ITGAL
integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; 
alpha polypeptide) 0.455887 0.028336008
181 SLC7A6OS solute carrier family 7, member 6 opposite strand 0.456045 0.028336008
180 CLCN6 chloride channel, voltage-sensitive 6 0.456884 0.034721721
179 EIF2S2 eukaryotic translation initiation factor 2, subunit 2 beta, 38kDa 0.457538 0.032871745
178 UGGT1 UDP-glucose glycoprotein glucosyltransferase 1 0.457557 0.02266537
177 SLC38A1 solute carrier family 38, member 1 0.457868 0.042792531
176 UGGT1 UDP-glucose glycoprotein glucosyltransferase 1 0.459498 0.025977079
175 RNA5S9 RNA, 5S ribosomal 9 0.460687 0.033309286
174 TMEM41B transmembrane protein 41B 0.462287 0.025061667
173 CLPTM1L CLPTM1-like 0.462569 0.029010307
172 PSMA8 proteasome (prosome, macropain) subunit, alpha type, 8 0.476483 0.034213914
171 NA NA 0.477219 0.025814373
170 DNAJB11 DnaJ (Hsp40) homolog, subfamily B, member 11 0.477984 0.015280539
169 HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase 0.48004 0.044130385
168 SRPRB signal recognition particle receptor, B subunit 0.480555 0.017387647
167 NLRP7 NLR family, pyrin domain containing 7 0.48076 0.042792531
166 DHCR7 7-dehydrocholesterol reductase 0.480833 0.039106595
165 UBR4 ubiquitin protein l igase E3 component n-recognin 4 0.481429 0.04508246
164 XBP1 X-box binding protein 1 0.481721 0.021191687
163 RGS16 regulator of G-protein signaling 16 0.481775 0.025511885
162 FAM120C family with sequence similarity 120C 0.48244 0.033465045
161 NSG1 neuron specific gene family member 1 0.482556 0.017557919
160 GOLGA3 golgin A3 0.484963 0.022364513
159 SC5D sterol-C5-desaturase 0.488852 0.033309286
158 NA NA 0.496974 0.021478771
157 OSTCP2 oligosaccharyltransferase complex subunit pseudogene 2 0.501738 0.021390993
156 NA NA 0.502565 0.033309286
155 NA NA 0.502647 0.016543045
154 SLC7A1 solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 0.505211 0.018140838
153 OSTCP1 oligosaccharyltransferase complex subunit pseudogene 1 0.505459 0.026038902
152 GPR18 G protein-coupled receptor 18 0.507866 0.022364513
151 C7orf55 chromosome 7 open reading frame 55 0.508592 0.049471046
150 PGM3 phosphoglucomutase 3 0.509376 0.012554762
149 UGDH UDP-glucose 6-dehydrogenase 0.509528 0.021564143
148 SNX29 sorting nexin 29 0.512102 0.030649683
147 SEC23B Sec23 homolog B (S. cerevisiae) 0.515351 0.025511885
146 MSMO1 methylsterol monooxygenase 1 0.515463 0.027495256
145 ASNS asparagine synthetase (glutamine-hydrolyzing) 0.518677 0.020915874
144 PREB prolactin regulatory element binding 0.521182 0.039450906
143 ZCCHC8 zinc finger, CCHC domain containing 8 0.524404 0.034721721
142 CRELD2 cysteine-rich with EGF-like domains 2 0.525689 0.022364513
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U2932 6hr (paired data analysis) continued. 
141 FKBP2 FK506 binding protein 2, 13kDa 0.52575 0.044487281
140 SEL1L sel-1 suppressor of l in-12-like (C. elegans) 0.531553 0.044623686
139 SYTL1 synaptotagmin-like 1 0.532337 0.048982213
138 YARS tyrosyl-tRNA synthetase 0.535436 0.01794073
137 NLRP11 NLR family, pyrin domain containing 11 0.535728 0.025851479
136 LIPG lipase, endothelial 0.536419 0.009673828
135 BET1 Bet1 golgi vesicular membrane trafficking protein 0.538502 0.010619499
134 OSTC oligosaccharyltransferase complex subunit (non-catalytic) 0.544451 0.01741491
133 NA NA 0.547035 0.037220693
132 STT3A STT3A, subunit of the oligosaccharyltransferase complex (catalytic) 0.547063 0.008900982
131 DBNDD2 dysbindin (dystrobrevin binding protein 1) domain containing 2 0.549538 0.011932323
130 HAX1 HCLS1 associated protein X-1 0.555553 0.033845817
129 NA NA 0.55761 0.028720756
128 WARS tryptophanyl-tRNA synthetase 0.558349 0.027495256
127 SLC35B1 solute carrier family 35, member B1 0.558828 0.041372422
126 SGK1 serum/glucocorticoid regulated kinase 1 0.562749 0.013903108
125 FCAR Fc fragment of IgA, receptor for 0.563287 0.037220693
124 XPOT exportin, tRNA 0.564617 0.013903108
123 NA NA 0.565596 0.020831682
122 PDIA3P1 protein disulfide isomerase family A, member 3 pseudogene 1 0.567463 0.016285318
121 LMAN1 lectin, mannose-binding, 1 0.568062 0.014865142
120 DEPTOR DEP domain containing MTOR-interacting protein 0.568601 0.01714672
119 SELK selenoprotein K 0.571773 0.007585682
118 ARMCX3 armadillo repeat containing, X-linked 3 0.573453 0.008148856
117 ZNF791 zinc finger protein 791 0.573947 0.030649683
116 NA NA 0.576418 0.028336008
115 FAM129A family with sequence similarity 129, member A 0.578746 0.029010307
114 DNASE2 deoxyribonuclease II, lysosomal 0.578976 0.033309286
113 NA NA 0.5799 0.030649683
112 TXNIP thioredoxin interacting protein 0.580446 0.032172513
111 GDPD5 glycerophosphodiester phosphodiesterase domain containing 5 0.581546 0.027380708
110 NA NA 0.583244 0.015594172
109 SEC61A1 Sec61 alpha 1 subunit (S. cerevisiae) 0.583573 0.015280539
108 MARS methionyl-tRNA synthetase 0.586618 0.012233686
107 NA NA 0.588101 0.015717724
106 MSMO1 methylsterol monooxygenase 1 0.5902 0.010619499
105 PDIA3P1 protein disulfide isomerase family A, member 3 pseudogene 1 0.590922 0.01188207
104 SH2B3 SH2B adaptor protein 3 0.591453 0.033309286
103 TXNDC5 thioredoxin domain containing 5 (endoplasmic reticulum) 0.591672 0.042792531
102 SLC3A2 solute carrier family 3 (amino acid transporter heavy chain), member 2 0.59267 0.025851479
101 RELL1 RELT-like 1 0.593991 0.030661525
100 SLC30A7 solute carrier family 30 (zinc transporter), member 7 0.596284 0.011489243
99 DMTF1 cyclin D binding myb-like transcription factor 1 0.597786 0.017557919
98 SNORD96A small nucleolar RNA, C/D box 96A 0.598306 0.012233686
97 GOT1 glutamic-oxaloacetic transaminase 1, soluble 0.60132 0.006697883
96 FAM84B family with sequence similarity 84, member B 0.601527 0.025511885
95 IDI1 isopentenyl-diphosphate delta isomerase 1 0.60203 0.008675143
94 VIMP VCP-interacting membrane protein 0.605458 0.012554762
93 DNAJC10 DnaJ (Hsp40) homolog, subfamily C, member 10 0.607169 0.00668888
92 MTHFD2
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, 
methenyltetrahydrofolate cyclohydrolase 0.610772 0.005591198
91 SLC3A2 solute carrier family 3 (amino acid transporter heavy chain), member 2 0.61197 0.007585682
90 FNDC3A fibronectin type III domain containing 3A 0.612733 0.023358994
89 HERPUD1
homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain 
member 1 0.612898 0.010619499
88 CREB3L2 cAMP responsive element binding protein 3-like 2 0.613561 0.008643368
87 LDLR low density l ipoprotein receptor 0.614751 0.020831682
86 CDRT4 CMT1A duplicated region transcript 4 0.615341 0.013903108
85 PGM3 phosphoglucomutase 3 0.631624 0.008675143
84 SHROOM4 shroom family member 4 0.63568 0.033309286
83 PPAPDC1B phosphatidic acid phosphatase type 2 domain containing 1B 0.636697 0.007585682
82 NA NA 0.639376 0.004633017
81 DNAJC3 DnaJ (Hsp40) homolog, subfamily C, member 3 0.640713 0.005591198
80 SLC33A1 solute carrier family 33 (acetyl-CoA transporter), member 1 0.643859 0.010773303
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U2932 6hr (paired data analysis) continued. 
79 NA NA 0.644729 0.022330056
78 HRK harakiri, BCL2 interacting protein 0.645622 0.02179235
77 TMEM39A transmembrane protein 39A 0.651069 0.006697883
76 NA NA 0.651657 0.029010307
75 NA NA 0.654071 0.034744431
74 NA NA 0.65414 0.044936215
73 FICD FIC domain containing 0.665024 0.009890445
72 CHRNA5 cholinergic receptor, nicotinic, alpha 5 (neuronal) 0.672513 0.025910053
71 C19orf10 chromosome 19 open reading frame 10 0.672907 0.023601336
70 SLC10A7 solute carrier family 10, member 7 0.678197 0.0036323
69 GARS glycyl-tRNA synthetase 0.685334 0.007585682
68 NA NA 0.688143 0.005180881
67 SARS seryl-tRNA synthetase 0.694314 0.015594172
66 PDIA4 protein disulfide isomerase family A, member 4 0.69504 0.005951128
65 EDEM2 ER degradation enhancer, mannosidase alpha-like 2 0.697402 0.003033585
64 TM6SF1 transmembrane 6 superfamily member 1 0.698383 0.007107279
63 ARFGAP3 ADP-ribosylation factor GTPase activating protein 3 0.700789 0.012554762
62 ASNS asparagine synthetase (glutamine-hydrolyzing) 0.702349 0.017387647
61 MTHFD2
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, 
methenyltetrahydrofolate cyclohydrolase 0.703636 0.006697883
60 SESN2 sestrin 2 0.709595 0.009449765
59 HERPUD1
homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain 
member 1 0.7098 0.005591198
58 SSR1 signal sequence receptor, alpha 0.710991 0.003038622
57 CDK2AP2 cyclin-dependent kinase 2 associated protein 2 0.711359 0.02373166
56 WIPI1 WD repeat domain, phosphoinositide interacting 1 0.715121 0.011174268
55 RIMS3 regulating synaptic membrane exocytosis 3 0.722443 0.005951128
54 NA NA 0.726949 0.048976659
53 WARS tryptophanyl-tRNA synthetase 0.729405 0.01188377
52 SSR2 signal sequence receptor, beta (translocon-associated protein beta) 0.732358 0.005194784
51 TARS threonyl-tRNA synthetase 0.738811 0.007133845
50 LOC100190986uncharacterized LOC100190986 0.744321 0.005591198
49 TIMM44 translocase of inner mitochondrial membrane 44 homolog (yeast) 0.748022 0.02179235
48 PARM1 prostate androgen-regulated mucin-like protein 1 0.753679 0.005497236
47 MZB1 marginal zone B and B1 cell-specific protein 0.757892 0.029125291
46 EDEM1 ER degradation enhancer, mannosidase alpha-like 1 0.759675 0.005964065
45 GNL3 guanine nucleotide binding protein-like 3 (nucleolar) 0.765224 0.002657337
44 SLC1A5 solute carrier family 1 (neutral amino acid transporter), member 5 0.776662 0.006574593
43 ERLEC1 endoplasmic reticulum lectin 1 0.780985 0.004815008
42 RGS1 regulator of G-protein signaling 1 0.785255 0.00387355
41 MANF mesencephalic astrocyte-derived neurotrophic factor 0.785629 0.003128221
40 PCK2 phosphoenolpyruvate carboxykinase 2 (mitochondrial) 0.798453 0.003033585
39 HSPA5 heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) 0.798953 0.007693883
38 SDF2L1 stromal cell-derived factor 2-like 1 0.808028 0.00316128
37 NFE2L1 nuclear factor, erythroid 2-like 1 0.808684 0.006574593
36 CHAC1 ChaC, cation transport regulator homolog 1 (E. coli) 0.809486 0.003128221
35 EGR1 early growth response 1 0.80959 0.01065754
34 DEPTOR DEP domain containing MTOR-interacting protein 0.821001 0.002093238
33 CARS cysteinyl-tRNA synthetase 0.822985 0.01065754
32 MTHFD1L methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like 0.830947 0.00387355
31 CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 0.833289 0.008271467
30 CTH cystathionase (cystathionine gamma-lyase) 0.843326 0.00387355
29 NA NA 0.854598 0.003033585
28 FKBP14 FK506 binding protein 14, 22 kDa 0.85657 0.00316128
27 LAT2 linker for activation of T cells family, member 2 0.85687 0.005497236
26 ULBP1 UL16 binding protein 1 0.864554 0.007775984
25 PSPH phosphoserine phosphatase 0.878546 0.003033585
24 SLC6A9 solute carrier family 6 (neurotransmitter transporter, glycine), member 9 0.88289 0.00668888
23 HAX1 HCLS1 associated protein X-1 0.889668 0.005497236
22 TMED10 transmembrane emp24-like trafficking protein 10 (yeast) 0.8946 0.006697883
21 INHBE inhibin, beta E 0.912903 0.010699661
20 HYOU1 hypoxia up-regulated 1 0.916951 0.014865142
19 VIMP VCP-interacting membrane protein 0.951048 0.003033585
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18 SLC3A2 solute carrier family 3 (amino acid transporter heavy chain), member 2 0.971069 0.005497236
17 SEC24D SEC24 family member D 0.975646 0.003259562
16 ADM2 adrenomedullin 2 1.00892 0.010619499
15 CTH cystathionase (cystathionine gamma-lyase) 1.010549 0.002802261
14 HYOU1 hypoxia up-regulated 1 1.02276 0.012759015
13 CEBPB CCAAT/enhancer binding protein (C/EBP), beta 1.079577 0.005591198
12 ATF4 activating transcription factor 4 1.098727 0.000612591
11 CARS cysteinyl-tRNA synthetase 1.132496 0.00316128
10 TSC22D3 TSC22 domain family, member 3 1.166124 0.001794099
9 DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 1.180008 0.000164111
8 TRIB3 tribbles pseudokinase 3 1.218832 0.001861368
7 GPT2 glutamic pyruvate transaminase (alanine aminotransferase) 2 1.235849 0.000593454
6 NA NA 1.322123 0.000551401
5 PSAT1 phosphoserine aminotransferase 1 1.421133 0.000168502
4 DDIT3 DNA-damage-inducible transcript 3 1.474143 0.00017867
3 CTH cystathionase (cystathionine gamma-lyase) 1.493669 0.000168502
2 TSC22D3 TSC22 domain family, member 3 1.554707 0.000551401
1 PCK2 phosphoenolpyruvate carboxykinase 2 (mitochondrial) 1.588798 0.000168502
U2932 6hr (paired data analysis) continued. 
Table 15 (Continued from previous five pages). Statistically significant genes differentially 
expressed in U2932 cells treated with CsA for 6hrs (paired data analysis). Columns indicate the 
gene symbols, names, log fold-change (logFC) and P values for statistically significant genes (adjusted 
P-value <0.05) differentially expressed upon treatment with CsA. Data in orange indicates genes 
downregulated by CsA and data in blue indicates genes upregulated by CsA. Gene numbers represent 
genes ordered by logFC, where 1 indicates the gene with the greatest logFC. Data includes gene probes 
marked as N/A. 
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HLY-1 2hr (unpaired data analysis) 
Number symbol name logFC Adjusted p value
1 NA NA -1.55229 0.000490704
2 CCL4L2 chemokine (C-C motif) l igand 4-like 2 -1.54347 0.000440057
3 CCL4L1 chemokine (C-C motif) l igand 4-like 1 -1.35926 0.000785135
4 PDCD1 programmed cell death 1 -0.90421 0.001522435
5 RIN2 Ras and Rab interactor 2 -0.8322 0.005003284
6 PAX9 paired box 9 -0.80567 2.00E-06
7 IL10 interleukin 10 -0.73247 0.009463346
8 TNFSF14 tumor necrosis factor (l igand) superfamily, member 14 -0.67338 3.64E-05
9 PRF1 perforin 1 (pore forming protein) -0.62594 0.007775043
10 ZNFX1 zinc finger, NFX1-type containing 1 -0.61761 0.015667893
11 GFI1 growth factor independent 1 transcription repressor -0.61137 0.014837415
12 EVI2A ecotropic viral integration site 2A -0.43986 0.000785135
2 SOCS3 suppressor of cytokine signaling 3 0.612697 0.050001082
1 NUAK2 NUAK family, SNF1-like kinase, 2 0.643851 3.64E-05
Table 16. Statistically significant genes differentially expressed in HLY-1 cells treated with CsA 
for 2hrs (unpaired data analysis). Columns indicate the gene symbols, names, log fold-change 
(logFC) and P values for statistically significant genes (adjusted P-value <0.05) differentially expressed 
upon treatment with CsA. Data in orange indicates genes downregulated by CsA and data in blue 
indicates genes upregulated by CsA. Gene numbers represent genes ordered by logFC, where 1 indicates 
the gene with the greatest logFC. Data includes gene probes marked as N/A. 
Number symbol name logFC adjusted p-value
1 NA NA -1.552 0.000945959
2 CCL4L2 chemokine (C-C motif) l igand 4-like 2 -1.543 0.000819302
3 CCL4L1 chemokine (C-C motif) l igand 4-like 1 -1.359 0.000945959
4 EGR2 early growth response 2 -1.219 0.000401285
5 CCL3L3 chemokine (C-C motif) l igand 3-like 3 -1.181 0.000583142
6 CCL3L1 chemokine (C-C motif) l igand 3-like 1 -1.016 0.005002719
7 CCL3L1 chemokine (C-C motif) l igand 3-like 1 -1.015 0.005993273
8 CCL3 chemokine (C-C motif) l igand 3 -0.988 0.003429333
9 CD69 CD69 molecule -0.950 0.009742034
10 EGR3 early growth response 3 -0.946 0.013790183
11 PDCD1 programmed cell death 1 -0.904 0.009422215
12 HSPE1 heat shock 10kDa protein 1 -0.864 0.003429333
13 EVI2A ecotropic viral integration site 2A -0.811 0.00730127
14 PAX9 paired box 9 -0.806 0.003429333
15 RAB11FIP1 RAB11 family interacting protein 1 (class I) -0.757 0.005002719
16 TNS3 tensin 3 -0.750 0.025770314
17 IL10 interleukin 10 -0.732 0.025770314
18 TNFAIP6 tumor necrosis factor, alpha-induced protein 6 -0.711 0.005002719
19 NFATC1 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 -0.682 0.011092949
20 TNF tumor necrosis factor -0.676 0.010843149
21 EVI2A ecotropic viral integration site 2A -0.654 0.042443215
22 NA NA -0.631 0.025770314
23 PTPN7 protein tyrosine phosphatase, non-receptor type 7 -0.622 0.035362512
24 ZNFX1 zinc finger, NFX1-type containing 1 -0.618 0.027488853
25 GFI1 growth factor independent 1 transcription repressor -0.611 0.027488853
26 CLEC17A C-type lectin domain family 17, member A -0.588 0.02282443
27 FILIP1L filamin A interacting protein 1-like -0.582 0.025770314
28 CCL3L1 chemokine (C-C motif) l igand 3-like 1 -0.566 0.03667148
8 KLHL42 kelch-like family member 42 0.517 0.036539906
7 DCAF5 DDB1 and CUL4 associated factor 5 0.522 0.03667148
6 ID3 inhibitor of DNA binding 3, dominant negative helix-loop-helix protein 0.556 0.025770314
5 SOCS3 suppressor of cytokine signaling 3 0.613 0.037807413
4 NUAK2 NUAK family, SNF1-like kinase, 2 0.644 0.03667148
3 RGS12 regulator of G-protein signaling 12 0.664 0.041870692
2 TXNIP thioredoxin interacting protein 0.726 0.025770314
1 NA NA 0.754 0.035399725
HLY-1 2hr (paired data analysis) 
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Table 17 (Continued from previous page). Statistically significant genes differentially expressed 
in HLY-1 cells treated with CsA for 2hrs (paired data analysis). Columns indicate the gene symbols, 
names, log fold-change (logFC) and P values for statistically significant genes (adjusted P-value <0.05) 
differentially expressed upon treatment with CsA. Data in orange indicates genes downregulated by 
CsA and data in blue indicates genes upregulated by CsA. Gene numbers represent genes ordered by 
logFC, where 1 indicates the gene with the greatest logFC. Data includes gene probes marked as N/A. 
HLY-1 6hr (unpaired data analysis) 
Number symbol name logFC adjusted P value
1 NUP43 nucleoporin 43kDa -0.870 0.036621561
2 DHRS3 dehydrogenase/reductase (SDR family) member 3 -0.823 0.006479651
3 SSR3 signal sequence receptor, gamma (translocon-associated protein gamma) -0.805 0.026607204
4 LBH limb bud and heart development -0.789 0.011755439
5 NFATC1 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 -0.728 0.030097875
6 HLF hepatic leukemia factor -0.719 0.000301597
7 GBP1 guanylate binding protein 1, interferon-inducible -0.676 0.009842981
8 CRY1 cryptochrome circadian clock 1 -0.672 0.009531744
9 EHD4 EH-domain containing 4 -0.651 0.036621561
10 CD36 CD36 molecule (thrombospondin receptor) -0.612 0.005841722
11 NAMPT nicotinamide phosphoribosyltransferase -0.606 0.030097875
12 HNRNPH1 heterogeneous nuclear ribonucleoprotein H1 (H) -0.584 0.005841722
13 GNG10 guanine nucleotide binding protein (G protein), gamma 10 -0.558 0.040294347
14 NA NA -0.545 0.021162023
15 C1orf186 chromosome 1 open reading frame 186 -0.544 0.011755439
16 LEF1 lymphoid enhancer-binding factor 1 -0.541 0.037655527
17 GBP2 guanylate binding protein 2, interferon-inducible -0.492 0.011755439
12 NA NA 0.418 0.030097875
11 SCN2A sodium channel, voltage-gated, type II, alpha subunit 0.481 0.006479651
10 GUSBP11 glucuronidase, beta pseudogene 11 0.579 0.026607204
9 NA NA 0.588 0.005841722
8 NA NA 0.658 0.043990101
7 SNORD96A small nucleolar RNA, C/D box 96A 0.693 0.008859118
6 SCART1 scavenger receptor protein family member 0.699 0.009531744
5 RALGPS2 Ral GEF with PH domain and SH3 binding motif 2 0.765 0.045460261
4 NA NA 0.789 0.036621561
3 DDX17 DEAD (Asp-Glu-Ala-Asp) box helicase 17 0.801 0.047802366
2 RALGPS2 Ral GEF with PH domain and SH3 binding motif 2 0.910 0.005841722
1 SFN stratifin 1.188 0.005841722
Table 18. Statistically significant genes differentially expressed in HLY-1 cells treated with CsA 
for 6hrs (unpaired data analysis). Columns indicate the gene symbols, names, log fold-change 
(logFC) and P values for statistically significant genes (adjusted P-value <0.05) differentially expressed 
upon treatment with CsA. Data in orange indicates genes downregulated by CsA and data in blue 
indicates genes upregulated by CsA. Genes numbers represent genes ordered by logFC, where 1 
indicates the gene with the greatest logFC. Data includes gene probes marked as N/A. 
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HLY-1 6hr (paired data analysis) 
Number symbol name logFC adjusted P value
1 TNF tumor necrosis factor -1.123 0.007625712
2 MAP3K8 mitogen-activated protein kinase kinase kinase 8 -1.023 0.006507769
3 NA NA -0.906 0.027633349
4 JUN jun proto-oncogene -0.879 0.007625712
5
NFKBIE
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, 
epsilon
-0.873 0.020173855
6 NUP43 nucleoporin 43kDa -0.870 0.035812526
7 SSR3 signal sequence receptor, gamma (translocon-associated protein gamma) -0.805 0.017309688
8 EGR2 early growth response 2 -0.797 0.035812526
9 LBH limb bud and heart development -0.789 0.018836051
10 SRF serum response factor (c-fos serum response element-binding transcription factor) -0.778 0.018836051
11 RFWD3 ring finger and WD repeat domain 3 -0.736 0.043530578
12 FILIP1L filamin A interacting protein 1-like -0.728 0.019217247
13 NFATC1 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 -0.728 0.020173855
14 NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha -0.727 0.027633349
15 PRPS1 phosphoribosyl pyrophosphate synthetase 1 -0.723 0.020173855
16 IGF2R insulin-like growth factor 2 receptor -0.723 0.035812526
17 HLF hepatic leukemia factor -0.719 0.022685527
18 CD1C CD1c molecule -0.715 0.027633349
19 ATP6V1F ATPase, H+ transporting, lysosomal 14kDa, V1 subunit F -0.709 0.027633349
20 FANCG Fanconi anemia, complementation group G -0.700 0.033798353
21 NA NA -0.680 0.027633349
22 GBP1 guanylate binding protein 1, interferon-inducible -0.676 0.036227514
23 CIRH1A cirrhosis, autosomal recessive 1A (cirhin) -0.670 0.036784658
24 NA NA -0.668 0.031901152
25 NOL12 nucleolar protein 12 -0.666 0.029689317
26 CD83 CD83 molecule -0.661 0.027633349
27 TRMT2B tRNA methyltransferase 2 homolog B (S. cerevisiae) -0.656 0.027633349
28 CD83 CD83 molecule -0.655 0.029689317
29 EHD4 EH-domain containing 4 -0.651 0.031843488
30 PTGER4 prostaglandin E receptor 4 (subtype EP4) -0.649 0.028928287
31 AMY1A amylase, alpha 1A (salivary) -0.645 0.037951338
32 DDX23 DEAD (Asp-Glu-Ala-Asp) box polypeptide 23 -0.640 0.031843488
33 PPP2R4 protein phosphatase 2A activator, regulatory subunit 4 -0.638 0.046021356
34 NFKBID nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, delta -0.633 0.036920475
35 FCF1 FCF1 rRNA-processing protein -0.633 0.03348353
36 SGK223 homolog of rat pragma of Rnd2 -0.632 0.035812526
37 LTA lymphotoxin alpha -0.631 0.035812526
38 AGMAT agmatine ureohydrolase (agmatinase) -0.629 0.045294349
39 ZYX zyxin -0.618 0.037951338
40 DYRK1A dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A -0.614 0.03333404
41 CD36 CD36 molecule (thrombospondin receptor) -0.612 0.032717701
42 NAMPT nicotinamide phosphoribosyltransferase -0.606 0.03333404
43 SLX1A SLX1 structure-specific endonuclease subunit homolog A (S. cerevisiae) -0.605 0.035812526
44 MB21D1 Mab-21 domain containing 1 -0.599 0.035812526
45 NFKBIZ nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta -0.594 0.037951338
46 MCRS1 microspherule protein 1 -0.589 0.036920475
47 NA NA -0.585 0.042392229
48 POLR2L polymerase (RNA) II (DNA directed) polypeptide L, 7.6kDa -0.564 0.047803903
49 GNG10 guanine nucleotide binding protein (G protein), gamma 10 -0.558 0.043958881
50 DNLZ DNL-type zinc finger -0.553 0.046091687
51 FBXL20 F-box and leucine-rich repeat protein 20 -0.550 0.046091687
52 GCLC glutamate-cysteine ligase, catalytic subunit -0.546 0.047317135
101 WASF2 WAS protein family, member 2 0.563 0.042392229
100 HSD17B7P2 hydroxysteroid (17-beta) dehydrogenase 7 pseudogene 2 0.563 0.047803903
99 UBA1 ubiquitin-like modifier activating enzyme 1 0.575 0.046021356
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HLY-1 6hr (paired data analysis) continued. 
98 FAM98B family with sequence similarity 98, member B 0.576 0.047652546
97 GUSBP11 glucuronidase, beta pseudogene 11 0.579 0.036227514
96 VPREB3 pre-B lymphocyte 3 0.582 0.046021356
95 SMA5 glucuronidase, beta pseudogene 0.582 0.042417263
94 NEMF nuclear export mediator factor 0.584 0.039488201
93 NA NA 0.588 0.036607731
92 FAF1 Fas (TNFRSF6) associated factor 1 0.597 0.036920475
91 ORAI2 ORAI calcium release-activated calcium modulator 2 0.597 0.033658626
90 HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) 0.600 0.035812526
89 MVK mevalonate kinase 0.604 0.035812526
88 NA NA 0.609 0.042411387
87 NA NA 0.610 0.035812526
86 SNORD3A small nucleolar RNA, C/D box 3A 0.614 0.03333404
85 IDH1 isocitrate dehydrogenase 1 (NADP+), soluble 0.615 0.032717701
84 GUSBP2 glucuronidase, beta pseudogene 2 0.616 0.03333404
83 HNRNPA3 heterogeneous nuclear ribonucleoprotein A3 0.619 0.037951338
82 MZB1 marginal zone B and B1 cell-specific protein 0.623 0.032717701
81 GOLIM4 golgi integral membrane protein 4 0.626 0.03348353
80 USF2 upstream transcription factor 2, c-fos interacting 0.626 0.03312661
79 TCERG1 transcription elongation regulator 1 0.629 0.036068649
78 GINM1 glycoprotein integral membrane 1 0.629 0.030624744
77 TAF5L
TAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor, 
65kDa 0.632 0.032717701
76 VOPP1 vesicular, overexpressed in cancer, prosurvival protein 1 0.633 0.035369597
75 SORL1 sortil in-related receptor, L(DLR class) A repeats containing 0.637 0.038557508
74 NA NA 0.639 0.032717701
73 ST6GALNAC4
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide 
alpha-2,6-sialyltransferase 4 0.639 0.031843488
72 SNORA12 small nucleolar RNA, H/ACA box 12 0.640 0.032717701
71 NA NA 0.649 0.03348353
70 GUSBP2 glucuronidase, beta pseudogene 2 0.650 0.031993965
69 NA NA 0.653 0.027633349
68 CD79A CD79a molecule, immunoglobulin-associated alpha 0.656 0.03333404
67 NA NA 0.658 0.027633349
66 NA NA 0.658 0.029689317
65 NA NA 0.658 0.029689317
64 ITGB7 integrin, beta 7 0.658 0.028656323
63 TAF1 TAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 250kDa 0.660 0.038557508
62 SQLE squalene epoxidase 0.660 0.029857453
61 KRI1 KRI1 homolog (S. cerevisiae) 0.666 0.027633349
60 LCMT1 leucine carboxyl methyltransferase 1 0.666 0.039645885
59 RN7SK RNA, 7SK small nuclear 0.669 0.031843488
58 CDK5RAP3 CDK5 regulatory subunit associated protein 3 0.671 0.027028101
57 FAM102A family with sequence similarity 102, member A 0.673 0.039920214
56 SDF4 stromal cell  derived factor 4 0.678 0.036227514
55 SNORD96A small nucleolar RNA, C/D box 96A 0.693 0.021634582
54 NA NA 0.693 0.036920475
53 ADAP1 ArfGAP with dual PH domains 1 0.696 0.029689317
52 SCART1 scavenger receptor protein family member 0.699 0.027633349
51 NA NA 0.701 0.033658626
50 RBM39 RNA binding motif protein 39 0.704 0.020173855
49 RBM38 RNA binding motif protein 38 0.710 0.020173855
48 NA NA 0.717 0.031391766
47 SNORD56 small nucleolar RNA, C/D box 56 0.719 0.032717701
46 DDIT3 DNA-damage-inducible transcript 3 0.720 0.039645885
45 NLRP7 NLR family, pyrin domain containing 7 0.725 0.027028101
44 IDI1 isopentenyl-diphosphate delta isomerase 1 0.725 0.042417263
43 PPM1K protein phosphatase, Mg2+/Mn2+ dependent, 1K 0.726 0.035812526
42 NA NA 0.730 0.032717701
41 RAB5C RAB5C, member RAS oncogene family 0.737 0.027633349
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HLY-1 6hr (paired data analysis) continued. 
40 SNHG4 small nucleolar RNA host gene 4 (non-protein coding) 0.742 0.01907066
39 PLEKHA2
pleckstrin homology domain containing, family A (phosphoinositide binding 
specific) member 2 0.742 0.020173855
38 ANP32AP1 acidic (leucine-rich) nuclear phosphoprotein 32 family, member A pseudogene 1 0.743 0.033658626
37 DHCR7 7-dehydrocholesterol reductase 0.744 0.027028101
36 MSMO1 methylsterol monooxygenase 1 0.748 0.018836051
35 LSP1 lymphocyte-specific protein 1 0.753 0.026873039
34 POU2F2 POU class 2 homeobox 2 0.753 0.020173855
33 FST follistatin 0.757 0.027633349
32 TSC22D3 TSC22 domain family, member 3 0.761 0.027028101
31 RALGPS2 Ral GEF with PH domain and SH3 binding motif 2 0.765 0.018020406
30 NLRP7 NLR family, pyrin domain containing 7 0.765 0.020173855
29 NA NA 0.770 0.027633349
28 PRKCSH protein kinase C substrate 80K-H 0.774 0.017885243
27 DHCR7 7-dehydrocholesterol reductase 0.774 0.020173855
26 NA NA 0.776 0.018020406
25 NA NA 0.789 0.017309688
24 TMEM159 transmembrane protein 159 0.789 0.018836051
23 DDX17 DEAD (Asp-Glu-Ala-Asp) box helicase 17 0.801 0.020173855
22 MEF2BNB-MEF2B MEF2BNB-MEF2B readthrough 0.808 0.027633349
21 NA NA 0.815 0.013238241
20 UBE2E1 ubiquitin-conjugating enzyme E2E 1 0.827 0.010967044
19 LDLR low density l ipoprotein receptor 0.836 0.04535726
18 KPNA6 karyopherin alpha 6 (importin alpha 7) 0.850 0.010119927
17 AP1S1 adaptor-related protein complex 1, sigma 1 subunit 0.851 0.010119927
16 FADS1 fatty acid desaturase 1 0.862 0.027063976
15 DDX17 DEAD (Asp-Glu-Ala-Asp) box helicase 17 0.896 0.010119927
14 FBXW7 F-box and WD repeat domain containing 7, E3 ubiquitin protein l igase 0.910 0.007625712
13 RALGPS2 Ral GEF with PH domain and SH3 binding motif 2 0.910 0.007625712
12 NA NA 0.912 0.028928287
11 CCDC71 coiled-coil domain containing 71 0.921 0.007625712
10 AP1S1 adaptor-related protein complex 1, sigma 1 subunit 0.924 0.007625712
9 KIAA1524 KIAA1524 0.924 0.010119927
8 MSMO1 methylsterol monooxygenase 1 0.952 0.006507769
7 COPG2 coatomer protein complex, subunit gamma 2 0.973 0.005970127
6 TSC22D3 TSC22 domain family, member 3 1.006 0.005413247
5 SFN stratifin 1.188 0.0036354
4 PPP3R1 protein phosphatase 3, regulatory subunit B, alpha 1.197 0.005970127
3 ROCK1 Rho-associated, coiled-coil containing protein kinase 1 1.306 0.000925619
2 CTSZ cathepsin Z 1.918 5.74E-05
1 NA NA 3.068 0.000228568
Table 19 (Continued from previous two pages). Statistically significant genes differentially 
expressed in HLY-1 cells treated with CsA for 6hrs (paired data analysis). Columns indicate the 
gene symbols, names, log fold-change (logFC) and P values for statistically significant genes (adjusted 
P-value <0.05) differentially expressed upon treatment with CsA. Data in orange indicates genes 
downregulated by CsA and data in blue indicates genes upregulated by CsA. Gene numbers represent 
genes ordered by logFC, where 1 indicates the gene with the greatest logFC. Data includes gene probes 
marked as N/A. 
WSU-NHL 6hr (unpaired data analysis) 
Number symbol name logFC adjusted P value
1 UPF3B UPF3 regulator of nonsense transcripts homolog B (yeast) -0.678 0.021156406
3 SNORD96A small nucleolar RNA, C/D box 96A 0.731 0.021156406
2 DNAJB11 DnaJ (Hsp40) homolog, subfamily B, member 11 0.826 0.023488487
1 HSPA5 heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) 1.063 0.021156406
Table 20. Statistically significant genes differentially expressed in WSU-NHL cells treated with 
CsA for 6hrs (unpaired data analysis). Columns indicate the gene symbols, names, log fold-change 
(logFC) and P values for statistically significant genes (adjusted P-value <0.05) differentially expressed 
upon treatment with CsA. Data in orange indicates genes downregulated by CsA and data in blue 
indicates genes upregulated by CsA. Gene numbers represent genes ordered by logFC, where 1 indicates 
the gene with the greatest logFC. Data includes gene probes marked as N/A. 
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4.2.7. Confirmation of array data target genes using qRT-PCR 
 
To confirm the CsA-induced effects on gene expression observed in the microarray and 
to help decide whether paired or unpaired data analysis was most representative of the 
array, qRT-PCR analysis was conducted using the RNA array samples. Seven statistically 
significant, differentially expressed genes of interest were chosen for analysis, as 
described below. To further validate the findings of the microarray, the experiment was 
repeated in HLY-1 cells.  
Moreover, to gain an understanding of the regulation of potential NFAT target genes in 
DLBCL, the effects of CsA treatment on an expanded panel of DLBCL cell lines was 
investigated. First, to confirm CsA-induced inhibition of NFAT2 in the panel, the 
subcellular localisation of NFAT2 was assessed by Western blot. As shown in figure 45, 
in the DMSO controls, NFAT2 was expressed at higher levels in the nucleus compared 
to the cytoplasm. When treated with CsA, a shift from the nucleus to the cytoplasm is 
observed in all cell lines. Moreover, CsA also caused an increase in the intensity of upper 
bands within each cluster and a decrease in the dephosphorylated (active) splice variants 
which is indicative of the rephosphorylation of the remaining NFAT2 protein in the 
nucleus.     
 
 
Figure 45. NFAT2 is inhibited by CsA in a panel of DLBCL cell lines. A panel of DLBCL cell lines 
were treated with their respective IC50 concentrations of CsA (HLY-1 7.4μg/ml, RIVA 13.5μg/ml, OCI-
Ly3 10.6μg/ml, SUDHL-4 15.6μg/ml, Farage 11.8μg/ml, SUDHL-6 3.6μg/ml and Karpas 422 14.9μg/ml) 
for 2 hours before nuclear extracts were taken and the expression of NFAT2 analysed by Western blot. . A 
vehicle control sample (0.01% DMSO) was also included. Nuclear-cytoplasmic preparations illustrate the 
comparative subcellular localisation and activation of family members. Data is from one experiment.   
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4.2.7.1.Differential regulation of NFAT2 by calcineurin/NFAT signalling in 
DLBCL cell lines 
 
As described in earlier sections of the study, NFAT2 is a calcium-responsive member of 
the NFAT family of transcription factors. Activated by stimulation of the BCR, 
constitutive expression and activation of NFAT2 has been demonstrated in patient 
samples and cell lines representative of DLBCL (Marafioti et al., 2005; Pham et al., 2005; 
Fu et al., 2006; Pham et al., 2010). Moreover, NFAT2 isoforms have demonstrated 
oncogenic characteristics in certain cell types, where autoregulation of the short 
NFAT2/Aα isoform is thought to play a key role (Chuvpilo et al., 2002; Asagiri et al., 
2005; Serfling et al., 2006a; Hock et al., 2013).  
 
Considering the known autoregulation of NFAT2 by other NFAT family members, it was 
anticipated that NFAT2 expression would be downregulated in the array and would 
therefore be suitable as a good positive control gene for confirmation of array findings by 
qRT-PCR analysis. Indeed, differential expression of NFAT2 was recurrently in the top 
20 genes downregulated by CsA (tables 14-15 and 17-19) and NFAT2 was among the top 
15 genes with the lowest adjusted P-value. Data in figure 46b-d demonstrates that CsA 
significantly downregulated the expression of NFAT2 in U2932 and HLY-1 cells after 6 
hours incubation in the microarray, but no effect was observed in the GCB DLBCL cell 
line WSU-NHL. qRT-PCR analysis recapitulated these findings, demonstrating a time-
dependent reduction of NFAT2 in the ABC lines but having little to no effect in WSU-
NHL cells (figure 46b-d). Although not striking, NFAT2 was downregulated in HLY-1 
cells treated with CsA for 2 hours, as indicated by paired, but not paired analysis. This 
suggests that paired analysis was slightly more representative of the array than unpaired 
analysis for this particular gene. 
 
Despite NFAT2 being an excellent positive-control gene, the degree to which its 
expression was inhibited by CsA was less than expected, particularly across the cell line 
panel, as shown in figure 46e. This may be explained by the fact that ablation of 
calcineurin activity results in the inhibition of all calcium-responsive NFAT isoforms. 
The effects observed on one single family member (such as NFAT2) therefore, may not 
be substantial and may depend on which NFAT isoforms are expressed in particular cell 
lines and the extent to which a cell line utilised the NFAT2 autoregulatory mechanism. 
Moreover, autoregulation of NFAT2 has only been reported for the short NFAT2/Aα 
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isoform, however these experiments used a primer specific for all NFAT2 isoforms 
(Chuvpilo et al., 2002; Hock et al., 2013) . It is therefore possible that downregulation of 
the short NFAT2/Aα isoform may have been masked by the expression of other NFAT2 
isoforms. Overall however, an interesting observation was that CsA-induced 
downregulation of NFAT2 was only observed in ABC DLBCL cell lines (apart from OCI-
Ly3), whereas there was no apparent effect in all five GCB DLBCL cell lines tested. 
These data suggest that autoregulation of NFAT2 may be DLBCL subgroup-specific.  
 
 
 
Figure 46. Differential regulation of NFAT2 by calcineurin/NFAT signalling in DLBCL cell lines. 
a) Table showing the microarray log FC expression of NFAT2 in cell lines treated with CsA for 2hrs or 
6hrs, including respective adjusted p-values from unpaired and paired data analysis. Adjusted P-values 
highlighted in red are indicative of statistical significance (adjusted P-value <0.05). b-d) The ABC 
DLBCL cell lines U2932 and HLY-1 (b and d) and the GCB DLBCL cell line WSU-NHL (c) were 
treated with their respective IC50 concentrations of CsA (U2932 8.6μg/ml, HLY-1 7.4μg/ml and WSU-
NHL10.4μg/ml) for 2 hours and 6 hours before the effects of treatment on NFAT2 mRNA expression 
were analysed by qRT-PCR (using RNA from gene expression microarray samples). Data is 
representative of four independent experiments where error bars indicate the standard error of the mean. 
P-values for qRT-PCR; U2932 2hr: 0.22 (insignificant) 6hr: 0.004, WSU-NHL 2hr: 0.390 
(insignificant) 6hr: 0.148 (insignificant), HLY-1 2hr: <0.000 6hr: 0.005. 
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4.2.7.2. CsA has no effect on MYC and BCL6 mRNA expression 
 
To confirm the accuracy of the array, the expression of the transcription factors BCL6 
and MYC (which were unaffected by CsA treatment in the array analysis), were analysed 
by qRT-PCR using RNA samples used in the microarray. The log expression fold-change 
(logFC) for BCL6 probes in the data set for all three cell lines ranged from -0.13 to 0.29 
and for MYC ranged from -0.36-0.3 (based on data from multiple MYC and BCL6 
probes), indicating no change or only very little change in gene expression upon CsA 
treatment. Data in figure 47 demonstrates no effect of CsA on BCL6 expression in all 
three cell lines tested. Similarly, CsA treatment had little to no effect on the expression 
of MYC (figure 48). These data show that probe intensity and differential expression of 
genes were accurately reflected by qRT-PCR analysis, therefore providing confidence for 
the specificity and validity of the microarray.   
Figure 46 (Continued from previous page). Differential regulation of NFAT2 by 
calcineurin/NFAT signalling in DLBCL cell lines. e) A panel of DLBCL cell lines were treated with 
their respective IC50 concentrations of CsA (HLY-1 7.4μg/ml, RIVA 13.5μg/ml, OCI-Ly3 10.6μg/ml, 
SUDHL-4 15.6μg/ml, Farage 11.8μg/ml, SUDHL-6 3.6μg/ml and Karpas 422 14.9μg/ml) for 2 hours 
before the effects on NFAT2 mRNA expression were analysed by qRT-PCR. Lighter shaded bars 
indicate ABC DLBCL cell lines (HLY-1, RIVA and OCI-Ly3) whereas darker shaded bars represent 
GCB DLBCL cell lines (SUDHL-4, Farage, SUDHL-6 and Karpas 422). Data for b-e were normalised 
to the house-keeping gene GAPDH. Data for e is representative of three independent experiments where 
error bars indicate the standard error of the mean. P-values for qRT-PCR; HLY-1: 0.092 (insignificant), 
RIVA: 0.022, OCI-Ly3: 0.088 (insignificant), SUDHL-4: 0.389 (insignificant), Farage: 0.444 
(insignificant), SUDHL-6: 0.173 (insignificant), Karpas 422: 0.517 (insignificant).  
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a)  
c) 
Figure 47. CsA has no effect on BCL6 mRNA expression. a-c) The ABC DLBCL cell lines U2932 
and HLY-1 (a-b) and the GCB DLBCL cell line WSU-NHL (c) were treated with their respective IC50 
concentrations of CsA (U2932 8.6μg/ml, HLY-1 7.4μg/ml and WSU-NHL10.4μg/ml) for 2 hours and 
6 hours before the effects of treatment on BCL6 mRNA expression were analysed by qRT-PCR (using 
RNA from gene expression microarray samples). Data is representative of four independent 
experiments where error bars indicate the standard error of the mean. 
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4.2.7.3. Differential regulation of CCL4L2 by calcineurin/NFAT signalling in 
DLBCL cell lines 
 
Given the key function of NFAT in the immune system, it was not surprising to see the 
downregulation of a number of cytokines upon CsA treatment. Cytokines are a family of 
small secreted proteins which play a key role in inflammation and immunoregulation. 
Chemokines are a subgroup of the cytokine family, mostly known for their recruitment 
of leukocytes to sites of inflammation, infection or injury (Howard et al., 2004). 
Dysregulated expression of chemokines and their receptors has been shown to influence 
the proliferative and invasive properties of cancer cells. In breast cancer for example, 
chemokines are reported to mediate tumour metastasis and are being considered as 
targetable molecules for cancer treatment (Muller et al., 2001; Mukaida et al., 2014). 
Chemokine (C-C motif) ligand 4-like 2 (CCL4L2) is a gene encoding a chemokine known 
to induce chemotaxis of cells expressing the chemokine receptors CCR5 or CCR1 
(Howard et al., 2004). There are limited reports on CCL4L2, but it differs by only a single 
amino acid from the more characterised gene encoding CCL4, a major chemotactic and 
proinflammatory factor produced by macrophages (Irving et al., 1990; Howard et al., 
2004). Moreover, CCL4L2 has an identical exonic sequence to the CCL4L1 chemokine 
 
b
) 
 
b) 
Figure 48. CsA has no effect on MYC mRNA expression. a-c) The ABC DLBCL cell lines U2932 
and HLY-1 (a-b) and the GCB DLBCL cell line WSU-NHL (c) were treated with their respective IC50 
concentrations of CsA (U2932 8.6μg/ml, HLY-1 7.4μg/ml and WSU-NHL10.4μg/ml) for 2 hours and 
6 hours before the effects of treatment on MYC mRNA expression were analysed by qRT-PCR (using 
RNA from gene expression microarray samples). Data is representative of four independent 
experiments where error bars indicate the standard error of the mean. 
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(which was also significantly downregulated in the array), even though these genes 
produce different patterns of mRNA expression (Colobran et al., 2010).  
CCL4L2 was chosen to confirm the array findings due to its presence in the top 5 
statistically significant genes downregulated by CsA treatment in the two ABC DLBCL 
cell lines U2932 and HLY-1, as shown in figure 49a and tables 12-15 and 16-17. 
Moreover, CCL4L2 was among the top 15 statistically significant genes differentially 
expressed in these cell lines. Figure 49b-d illustrates downregulation of CCL4L2 by CsA 
in all three cell lines by qRT-PCR analysis, where expression was almost completely 
abolished by 6 hours treatment, particularly in U2932 (b) and HLY-1 (d) cell lines. For 
U2932 cell lines in particular, these data were consistent with the time-dependent logFC 
reduction in CCL4L2 gene expression, which was significant in both paired and unpaired 
analysis for both timepoints. Data from the microarray demonstrated no effect of CsA on 
CCL4L2 expression in WSU-NHL cells (figure 40), however qRT-PCR analysis showed 
significant depletion of expression. The Ct values obtained for CCL4L2 during qRT-PCR 
analysis of WSU-NHL cells were higher than those from HLY1 and U2932 cells, 
suggesting a lower abundance mRNA (not shown). It is possible that the gene expression 
microarray was not sensitive enough to detect changes in CCL4L2 expression in WSU-
NHL RNA samples, unlike the qRT-PCR analysis.  
To further validate data generated in the gene expression microarray and to more 
comprehensively understand calcineurin/NFAT-mediated expression of CCL4L2 in 
DLBCL, the expression of CCL4L2 was analysed in a larger panel of cell lines treated 
with CsA for 2 hours. qRT-PCR analysis demonstrated downregulation of CCL4L2 in 
almost all cell lines, however the effects were more prominent in DLBCL cell lines of the 
ABC subgroup (figure 49e). CsA had little effect on CCL4L2 expression in SUDHL-4 
cells and appeared to increase expression in SUDHL-6 cells, but there was significant 
variability between experiments in this cell line, as indicated by the large error bars.  
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Figure 49. Differential regulation of CCL4L2 by calcineurin/NFAT signalling in DLBCL cell 
lines. a) Table showing the microarray log FC expression of CCL4L2 in cell lines treated with CsA for 
2hrs or 6hrs, including respective adjusted p-values from unpaired and paired data analysis. Adjusted 
P-values highlighted in red are indicative of statistical significance (adjusted P-value <0.05). b-d) The 
ABC DLBCL cell lines U2932 and HLY-1 (b and d) and the GCB DLBCL cell line WSU-NHL (c) 
were treated with their respective IC50 concentrations of CsA (U2932 8.6μg/ml, HLY-1 7.4μg/ml and 
WSU-NHL10.4μg/ml) for 2 hours and 6 hours before the effects of treatment on CCL4L2 mRNA 
expression were analysed by qRT-PCR (using RNA from gene expression microarray samples). Data 
is representative of four independent experiments where error bars indicate the standard error of the 
mean. P-values for qRT-PCR; U2932 2hr: 0.001 6hr: <0.000, WSU-NHL 2hr: 0.001 6hr: <0.000, HLY-
1 2hr: 0.006 6hr: <0.000. 
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4.2.7.4.Differential regulation of TNFα by calcineurin/NFAT signalling in 
DLBCL cell lines 
 
Tumour necrosis factor alpha (TNFα) is a cytokine that plays a pivotal role in the immune 
response and inflammation, however it is also involved with many other cellular 
processes such as proliferation, differentiation and apoptosis (Locksley et al., 2001). 
Although TNFα displays a plethora of functions in the cell, it is mostly associated with 
regulation of the proinflammatory response, where it behaves as a ligand for TNF receptor 
activation and subsequent activation of downstream pathways such as NF-κB. Despite 
being critical for normal immune function, dysregulation of TNFα activity has been 
implicated in conditions such as cancer, autoimmune disorders, Alzheimer’s disease, 
diabetes and osteoporosis (Chen et al., 2002; Kollias et al., 2002; Kodama et al., 2005).  
The table in figure 50a shows a significant downregulation of TNFα upon CsA treatment 
in U2932 and HLY-1 cell lines at both the 2 hour and 6 hour timepoints, whereas there 
was no effect in WSU-NHL cells. TNFα was in fact ranked the number one gene 
differentially expressed by calcineurin/NFAT inhibition in HLY-1 6 hour paired analysis 
and U2932 2 hour unpaired data analysis (table 19 and 12). In addition, TNFα was among 
Figure 49 (Continued from previous page). Differential regulation of CCL4L2 by 
calcineurin/NFAT signalling in DLBCL cell lines. e) A panel of DLBCL cell lines were treated with 
their respective IC50 concentrations of CsA (HLY-1 7.4μg/ml, RIVA 13.5μg/ml, OCI-Ly3 10.6μg/ml, 
SUDHL-4 15.6μg/ml, Farage 11.8μg/ml, SUDHL-6 3.6μg/ml and Karpas 422 14.9μg/ml) for 2 hours 
before the effects on CCL4L2 mRNA expression were analysed by qRT-PCR. Lighter shaded bars 
indicate ABC DLBCL cell lines (HLY-1, RIVA and OCI-Ly3) whereas darker shaded bars represent 
GCB DLBCL cell lines (SUDHL-4, Farage, SUDHL-6 and Karpas 422). Data for b-e were normalised 
to the house-keeping gene GAPDH. Data for e is representative of three independent experiments where 
error bars indicate the standard error of the mean. P-values for qRT-PCR; HLY-1: 0.008, RIVA: 0.002, 
OCI-Ly3: 0.034, SUDHL-4: 0.481 (insignificant), Farage: 0.068 (insignificant), SUDHL-6: 0.154 
(insignificant), Karpas 422: 0.427 (insignificant).  
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the top most statistically significant genes downregulated according to P-value, further 
supporting this gene as a candidate for array confirmation by qRT-PCR analysis.  
qRT-PCR analysis correlated with these findings (figure 50b-d), showing the greatest 
reduction of TNFα after 2 hours treatment in U2932, followed by a slight increase in 
expression after 6 hours. Also in accordance with the array, a time-dependent depletion 
of TNFα was observed in HLY-1 cells, whereas TNFα expression in WSU-NHL cells did 
not change. Moreover, apart from U2932 cells treated with CsA for 2 hours, paired 
analysis seemed to reflect qRT-PCR analysis more consistently than unpaired analysis 
for this particular gene. 
Apart from OCI-Ly3 cells, CsA-induced reduction in TNFα expression was largely 
correlated with the ABC subgroup of DLBCL, as shown in figure 50e. Interestingly, OCI-
Ly3 was the only ABC DLBCL found to express low levels of NFAT2 protein (chapter 
3, figure 15). TNFα expression in the GCB cell lines however did not appear to 
significantly change by CsA treatment, suggesting that TNFα may specifically be 
regulated by calcineurin/NFAT in ABC DLBCL cells. Although the large error bars for 
SUDHL-4 and SUDHL-6 indicate inconsistency between experiments, it is possible that 
this was due to the inability of qRT-PCR analysis to detect changes in expression of 
TNFα, which was apparent by the high Ct values recorded for these two cell lines (not 
shown).  
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Figure 50. Differential regulation of TNFα by calcineurin/NFAT signalling in DLBCL cell lines. 
a) Table showing the microarray log FC expression of TNFα in cell lines treated with CsA for 2hrs or 
6hrs, including respective adjusted p-values from unpaired and paired data analysis. Adjusted P-values 
highlighted in red are indicative of statistical significance (adjusted P-value <0.05). b-d) The ABC 
DLBCL cell lines U2932 and HLY-1 (b and d) and the GCB DLBCL cell line WSU-NHL (c) were 
treated with their respective IC50 concentrations of CsA (U2932 8.6μg/ml, HLY-1 7.4μg/ml and WSU-
NHL10.4μg/ml) for 2 hours and 6 hours before the effects of treatment on TNFα mRNA expression 
were analysed by qRT-PCR (using RNA from gene expression microarray samples). Data is 
representative of four independent experiments where error bars indicate the standard error of the mean. 
P-values for qRT-PCR; U2932 2hr: <0.000 6hr: 0.010, WSU-NHL 2hr: 0.008 6hr: 0.579 (insignificant), 
HLY-1 2hr: 0.001 6hr: 0.000. 
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4.2.7.5.Differential regulation of NFKBIE by calcineurin/NFAT signalling in 
DLBCL cell lines 
 
The protein encoded by the Nuclear Factor of Kappa Light Polypeptide Gene Enhancer 
in B cells Inhibitor Epsilon (NFKBIE) gene is a member of the IκB family of NF-κB 
inhibitory proteins. Along with other IκB proteins, IκBε binds to NF-κB subunits, 
masking their nuclear localisation sequence, keeping them sequestered in an inactive state 
in the cytoplasm. Phosphorylation of IκB proteins by IKK targets them for 
polyubiquitination and degradation by the 26S proteasome, activating NF-κB and 
allowing their translocation to the nucleus. Unlike IκBα, there is considerably less 
information regarding the specific role of IκBε. There is however evidence showing that 
IκBε functions differently to other IκB proteins (Whiteside et al., 1997). First, IκBε is 
fairly inefficient at inhibiting the transcription of genes regulated by p50/p65 
heterodimers, mostly functioning to sequester p65 and/or c-Rel homodimer in the 
cytoplasm (Whiteside et al., 1997). Moreover, IκBε does not contain a PEST-like 
sequence (responsible for inhibition of DNA-binding), suggesting that IκBε may regulate 
the transient activation of a distinct subset of genes (Ernst et al., 1995; Whiteside et al., 
1997). Additionally, in their report studying the temporal control and selective gene 
activation of IκB proteins, Hoffman and Baltimore (2002) describe IκBα to be responsible 
Figure 50 (Continued from previous page). Differential regulation of TNFα by calcineurin/NFAT 
signalling in DLBCL cell lines. e) A panel of DLBCL cell lines were treated with their respective IC50 
concentrations of CsA (HLY-1 7.4μg/ml, RIVA 13.5μg/ml, OCI-Ly3 10.6μg/ml, SUDHL-4 15.6μg/ml, 
Farage 11.8μg/ml, SUDHL-6 3.6μg/ml and Karpas 422 14.9μg/ml) for 2 hours before the effects on 
TNFα mRNA expression were analysed by qRT-PCR. Lighter shaded bars indicate ABC DLBCL cell 
lines (HLY-1, RIVA and OCI-Ly3) whereas darker shaded bars represent GCB DLBCL cell lines 
(SUDHL-4, Farage, SUDHL-6 and Karpas 422). Data for b-e were normalised to the house-keeping 
gene GAPDH. Data for e is representative of three independent experiments where error bars indicate 
the standard error of the mean. P-values for qRT-PCR; HLY-1: 0.083, RIVA: <0.000, OCI-Ly3: 0.026, 
SUDHL-4: 0.004, Farage: 0.041, SUDHL-6: 0.799 (insignificant), Karpas 422: 0.036.  
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for a fast turn-off of the NF-κB response, whereas IκBβ and IκBε control the oscillations 
of NF-κB in and out of the nucleus, stabilising NF-κB activity during longer periods of 
stimulation (Hoffmann et al., 2002).   
 
Interestingly, elevated expression of IκBε has been linked to oncogenesis in a number of 
malignancies, including ovarian, prostate and breast cancer (Qin et al., 2010; Péant et al., 
2011; Hsu et al., 2012). Moreover, in regard to blood malignancies, inactivating 
mutations of the NFKBIE gene have been identified in early haematopoietic cells and B 
cells of CLL patients, potentially contributing to the pathogenesis of CLL (Damm et al., 
2014).      
 
IκBε expression was downregulated in the ABC DLBCL cell lines upon treatment with 
CsA, particularly after 6 hours of treatment where data was statistically significant by 
paired data analysis (figure 51a). Interestingly, IκBε was not the only IκB encoding gene 
differentially expressed in the microarray. In fact, IκBα (NFKBIA) and IκBδ (NFKBID) 
were significantly downregulated by CsA in HLY-1 and U2932 cells after 6 hours 
treatment and IκBζ (NFKBIZ) was downregulated in HLY-1 cells. These data suggest 
that the calcineurin/NFAT pathway may be associated with the transcriptional regulation 
of IκB proteins.  
   
NFKBIE was chosen for qRT-PCR analysis due to it being the fifth most differentially 
expressed gene in HLY-1 cells (table 19) and the fourteenth most differentially expressed 
gene in U2932 after 6 hours CsA treatment (table 15). Moreover, the adjusted P-values 
for NFKBIE were among the 15 lowest in some samples. As shown in figure 51b and d, 
the expression of NFKBIE was reduced in a time-dependent manner in U2932 cells at 
both 2 hour and 6 hour timepoints and was downregulated in HLY-1 cells by 6 hours. 
Calcineurin/NFAT inhibition in WSU-NHL cells (figure 51c) had little to no effect on 
NFKBIE expression, which was in line with the microarray results. Overall, unpaired 
analysis did not appear to identify significant downregulation of NFKBIE in any samples, 
despite the obvious reduction observed by qRT-PCR analysis, suggesting that in this case 
paired analysis was more suitable. 
 
When the experiment was repeated in a larger panel of cell lines, the effect of CsA on 
NFKBIE was highly variable and there were no obvious trends between DLBCL 
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subgroups (figure 51e). The presence of the large error bar on CsA-treated RIVA cells 
was due to inconsistency between each of the four repeat experiments, perhaps due to 
experimental error or maybe indicating NFKBIE to be highly sensitive to any fluctuations 
of CsA-treatment around the 2 hour timepoint.  
 
 
 
 
 
Figure 51. Differential regulation of NFKBIE by calcineurin/NFAT signalling in DLBCL cell 
lines. a) Table showing the microarray log FC expression of NFKBIE in cell lines treated with CsA for 
2hrs or 6hrs, including respective adjusted p-values from unpaired and paired data analysis. Adjusted 
P-values highlighted in red are indicative of statistical significance (adjusted P-value <0.05). b-d) The 
ABC DLBCL cell lines U2932 and HLY-1 (b and d) and the GCB DLBCL cell line WSU-NHL (c) 
were treated with their respective IC50 concentrations of CsA (U2932 8.6μg/ml, HLY-1 7.4μg/ml and 
WSU-NHL10.4μg/ml) for 2 hours and 6 hours before the effects of treatment on NFKBIE mRNA 
expression were analysed by qRT-PCR (using RNA from gene expression microarray samples). Data 
is representative of four independent experiments where error bars indicate the standard error of the 
mean. P-values for qRT-PCR; U2932 2hr: 0.046 6hr: 0.006, WSU-NHL 2hr: 0.453 6hr: 0.082, HLY-1 
2hr: 0.172 6hr: 0.006. 
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4.2.7.6.Differential regulation of EGR2 by calcineurin/NFAT signalling in 
DLBCL cell lines 
 
Early Growth Response 2 (EGR2) is a member of the zinc finger family of transcription 
factors induced by many mitotic signals on cells such as fibroblasts, and T and B-
lymphocytes (Gómez-Martín et al., 2010). The family is comprised of four members 
(EGR1, EGR2, EGR3 and EGR4), which have a key role in modulating the immune 
response, such as activating lymphocytes and monitoring central and peripheral tolerance. 
EGR1 is the family member most well-researched, its expression directly depending on 
antigen receptor signalling through the BCR and activation of PKC (Gómez-Martín et al., 
2010). Functioning as a positive regulatory factor for effector functions in T and B cells, 
EGR1 is known to interact with NFAT to modulate the transcription of IL-2 and TNFα 
after stimulation of the TCR (Skerka, 1995; Gómez-Martín et al., 2010).  
 
In contrast to EGR1, EGR2 and EGR3 function as regulators involved in the induction of 
anergy and apoptosis (Gómez-Martín et al., 2010). Anergy is a state of immune 
unresponsiveness, induced when a cell’s antigen receptor is stimulated in the absence of 
a second signal from an antigen presenting cell. A form of immune tolerance, anergy is a 
e) 
Figure 51 (Continued from previous page). Differential regulation of NFKBIE by 
calcineurin/NFAT signalling in DLBCL cell lines. e) A panel of DLBCL cell lines were treated with 
their respective IC50 concentrations of CsA (HLY-1 7.4μg/ml, RIVA 13.5μg/ml, OCI-Ly3 10.6μg/ml, 
SUDHL-4 15.6μg/ml, Farage 11.8μg/ml, SUDHL-6 3.6μg/ml and Karpas 422 14.9μg/ml) for 2 hours 
before the effects on NFKBIE mRNA expression were analysed by qRT-PCR. Lighter shaded bars 
indicate ABC DLBCL cell lines (HLY-1, RIVA and OCI-Ly3) whereas darker shaded bars represent 
GCB DLBCL cell lines (SUDHL-4, Farage, SUDHL-6 and Karpas 422). Data for b-e were normalised 
to the house-keeping gene GAPDH. Data for e is representative of three independent experiments where 
error bars indicate the standard error of the mean. P-values for qRT-PCR; HLY-1 0.293 (insignificant), 
RIVA: 0.741 (insignificant), OCI-Ly3: 0.220 (insignificant), SUDHL-4: 0.384 (insignificant), Farage: 
0.068 (insignificant), SUDHL-6: 0.275 (insignificant), Karpas 422: 0.342 (insignificant).  
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useful mechanism used by normal lymphoid cells to avoid an undesirable immune 
response, such as to one’s own immune system. However, in the malignant setting 
lymphocyte anergy can be deleterious, acting as an immunosuppressive mechanism in the 
tumour microenvironment, driving immune escape.  
EGR2 was chosen as a candidate gene to confirm the array data due to its significant 
downregulation in U2932 (6 hours) and HLY-1 (2 hours and 6 hours) upon CsA treatment 
(figure 52a). EGR2 was in fact the fourth most downregulated gene in the 2 hour HLY-1 
CsA treatment and the eighth most downregulated gene in the 6 hour HLY-1 treatment, 
as shown in tables 17 and 19. Moreover, EGR2 had one of the most statistically significant 
adjusted P-values. The downregulation of EGR2 expression observed by paired data 
analysis was confirmed by qRT-PCR, showing that paired analysis recapitulated the 
microarray more accurately than unpaired analysis.  
 
The Ct values obtained for EGR2 during qRT-PCR analysis of WSU-NHL cells were 
higher than those from HLY1 and U2932 cells, suggesting a lower abundance mRNA 
(not shown). This could account for why an effect was observed by qRT-PCR in WSU-
NHL cells, suggesting that qRT-PCR analysis was more sensitive than the array, which 
may not have been able to detect changes in the lower levels of EGR2 expressed by WSU-
NHL. When expanded to a larger cell line panel, the effect of CsA on EGR2 expression 
was fairly heterogeneous, suggesting that EGR2 may be regulated to different degrees by 
calcineurin/NFAT in different DLBCL cells (figure 52e).  
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Figure 52. Differential regulation of EGR2 by calcineurin/NFAT signalling in DLBCL cell lines. 
a) Table showing the microarray log FC expression of EGR2 in cell lines treated with CsA for 2hrs or 
6hrs, including respective adjusted p-values from unpaired and paired data analysis. Adjusted P-values 
highlighted in red are indicative of statistical significance (adjusted P-value <0.05). b-d) The ABC 
DLBCL cell lines U2932 and HLY-1 (b and d) and the GCB DLBCL cell line WSU-NHL (c) were 
treated with their respective IC50 concentrations of CsA (U2932 8.6μg/ml, HLY-1 7.4μg/ml and WSU-
NHL10.4μg/ml) for 2 hours and 6 hours before the effects of treatment on EGR2 mRNA expression 
were analysed by qRT-PCR (using RNA from gene expression microarray samples). Data is 
representative of four independent experiments where error bars indicate the standard error of the mean. 
P-values for qRT-PCR; U2932 2hr: 0.001 6hr: 0.003, WSU-NHL 2hr: 0.001 6hr: 0.001, HLY-1 2hr: 
<0.000 6hr: <0.000.   
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4.2.7.7. Differential regulation of EGR3 by calcineurin/NFAT signalling in 
DLBCL cell lines 
 
Early Growth Response 3 (EGR3) is also a member of the zinc family of transcription 
factors described previously in section 5.2.7.6. EGR3 was also chosen for confirmation 
of the array data by qRT-PCR analysis due to its significant downregulation in HLY-1 
cells after 2 hours (figure 53a), where it was the tenth most downregulated gene by paired 
analysis (table 17) and among the top 15 genes with the lowest adjusted P-values. Indeed, 
qRT-PCR analysis confirmed reduced expression of EGR3 by CsA treatment in HLY-1 
cells and U2932 cells, suggesting that paired analysis was accurate. In line with the array 
data, there was no effect of calcineurin/NFAT inhibition on EGR3 in WSU-NHL cells. 
When the experiment was repeated in a large panel of cell lines, there was no trend 
between DLBCL subgroups. The error between experiments was generally high, as 
indicated by the large error bars, particularly in OCI-Ly3 and SUDHL-4 cells (figure 53e). 
Higher Ct values for EGR3 in these cell lines suggested a lower abundance mRNA (not 
shown), which appeared to correlate with the extent of the error, suggesting that EGR3 
was difficult to detect by qRT-PCR analysis. 
 
Figure 52 (Continued from previous page). Differential regulation of EGR2 by calcineurin/NFAT 
signalling in DLBCL cell lines. e) A panel of DLBCL cell lines were treated with their respective IC50 
concentrations of CsA (HLY-1 7.4μg/ml, RIVA 13.5μg/ml, OCI-Ly3 10.6μg/ml, SUDHL-4 15.6μg/ml, 
Farage 11.8μg/ml, SUDHL-6 3.6μg/ml and Karpas 422 14.9μg/ml) for 2 hours before the effects on 
EGR2 mRNA expression were analysed by qRT-PCR. Lighter shaded bars indicate ABC DLBCL cell 
lines (HLY-1, RIVA and OCI-Ly3) whereas darker shaded bars represent GCB DLBCL cell lines 
(SUDHL-4, Farage, SUDHL-6 and Karpas 422). Data for b-e were normalised to the house-keeping 
gene GAPDH. Data for e is representative of three independent experiments where error bars indicate 
the standard error of the mean. P-values for qRT-PCR; HLY-1: 0.002, RIVA: <0.000, OCI-Ly3: 0.017, 
SUDHL-4: 0.106 (insignificant), Farage: 0.070 (insignificant), SUDHL-6: 0.445 (insignificant), Karpas 
422: 0.547 (insignificant).  
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Figure 53. Differential regulation of EGR3 by calcineurin/NFAT signalling in DLBCL cell lines. 
a) Table showing the microarray log FC expression of EGR3 in cell lines treated with CsA for 2hrs or 
6hrs, including respective adjusted p-values from unpaired and paired data analysis. Adjusted P-values 
highlighted in red are indicative of statistical significance (adjusted P-value <0.05). b-d) The ABC 
DLBCL cell lines U2932 and HLY-1 (b and d) and the GCB DLBCL cell line WSU-NHL (c) were 
treated with their respective IC50 concentrations of CsA (U2932 8.6μg/ml, HLY-1 7.4μg/ml and WSU-
NHL10.4μg/ml) for 2 hours and 6 hours before the effects of treatment on EGR3 mRNA expression 
were analysed by qRT-PCR (using RNA from gene expression microarray samples). Data is 
representative of four independent experiments where error bars indicate the standard error of the mean. 
P-values for qRT-PCR; U2932 2hr: <0.000 6hr: <0.000, WSU-NHL 2hr: 0.541 (insignificant) 6hr: 
0.401 (insignificant), HLY-1 2hr: <0.000 6hr: 0.022. 
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4.2.7.8. Differential regulation of PDCD1 by calcineurin/NFAT signalling in 
DLBCL cell lines 
 
Programmed Cell Death 1 (PDCD1) (also commonly known to as PD1), is a cell surface 
immune check-point receptor. PDCD1 limits autoimmunity by reducing the activity of T 
cells in peripheral tissues during an inflammatory response (Rivoltini et al., 2005; Keir et 
al., 2008; Pardoll, 2012). During T-cell activation, engagement of the PDCD1 receptor 
causes inhibition of the kinases associated with T-cell activation (Bryan et al., 2015). The 
PDCD1 receptor is highly expressed on infiltrating TReg cells and is thought to upregulate 
their proliferation (Pardoll, 2012). PDCD1 therefore functions as a major immune escape 
mechanism, which, when engaged frequently or constitutively, creates a tumour 
microenvironment that effectively avoids the anti-tumour immune response (Bryan et al., 
2015). Malignancies such as DLBCL have been shown to adopt this mechanism in order 
to escape the anti-tumour activity of surrounding lymphocytes (Fanoni et al., 2011). 
PDCD1 ligands PD-L1 and PD-L2 have been found to be upregulated in various types of 
cancer, including DLBCL, where high levels of PD-L1 were associated with reduced 
overall survival (Rossille et al., 2014). Blockade of PDCD-1 ligand binding using 
monoclonal antibodies such as Pidilizumab are an attractive therapeutic strategy and 
Figure 53 (Continued from previous page). Differential regulation of EGR3 by calcineurin/NFAT 
signalling in DLBCL cell lines. e) A panel of DLBCL cell lines were treated with their respective IC50 
concentrations of CsA (HLY-1 7.4μg/ml, RIVA 13.5μg/ml, OCI-Ly3 10.6μg/ml, SUDHL-4 15.6μg/ml, 
Farage 11.8μg/ml, SUDHL-6 3.6μg/ml and Karpas 422 14.9μg/ml) for 2 hours before the effects on 
EGR3 mRNA expression were analysed by qRT-PCR. Lighter shaded bars indicate ABC DLBCL cell 
lines (HLY-1, RIVA and OCI-Ly3) whereas darker shaded bars represent GCB DLBCL cell lines 
(SUDHL-4, Farage, SUDHL-6 and Karpas 422). Data for b-e were normalised to the house-keeping 
gene GAPDH. Data for e is representative of three independent experiments where error bars indicate 
the standard error of the mean. P-values for qRT-PCR; HLY-1: 0.038, RIVA: <0.000, OCI-Ly3: 0.844 
(insignificant), SUDHL4: 0.932 (insignificant), Farage: 0.005, SUDHL6: 0.077 (insignificant), Karpas 
422: 0.593 (insignificant).  
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clinical trials are currently in place for a range of malignancies, including DLBCL (Bryan 
et al., 2014).  
 
Although it is interesting that PDCD1 may potentially be upregulated by 
calcineurin/NFAT in DLBCL tumour cells, it is the increased engagement of PDCD1 on 
surrounding immune cells (rather than the cancer cells themselves) that is associated with 
the immune evasion reported in the tumour microenvironment. Interestingly however, 
PDCD1 has been reported to be an NFAT target gene in T cells (Oestreich et al., 2008). 
Moreover, PDCD1 signalling has recently been shown to promote proliferation and 
survival in mouse models of melanoma (Kleffel et al., 2015). Treatment with CsA was 
shown to reduce the expression of PDCD1, with ChIP analysis revealing an association 
with NFAT2 binding and activation of PDCD1 during stimulation of primary CD8 T cells 
(Oestreich et al., 2008).       
 
HLY-1 cells were the only cell line sensitive to CsA-induced downregulation of PDCD1 
in the microarray. However, this was only statistically significant after 2 hours of 
treatment (figure 54a). qRT-PCR supported these findings, demonstrating around 50% 
reduction of PDCD1 expression. Interestingly, despite the array data indicating no 
significant effect in U2932 cells, qRT-PCR revealed CsA-induced downregulation of 
PDCD1 in U2932 cells. It is possible that this effect was undetectable in the array due to 
lower level mRNA expression of PDCD1 in U2932 compared to HLY1, as indicated by 
higher Ct values (not shown). Moreover, the Ct values for PDCD1 in WSU-NHL cells 
were even higher, suggesting very low abundant mRNA. PDCD1 was perhaps difficult 
for even the sensitivity of qRT-PCR analysis to detect, as suggested by the large error 
bars on figure 54c, where individual experiments produced highly variable expression 
data.  
 
The effects observed in HLY-1 cells were validated by repeating the experiment in this 
cell line, where data repeatedly showed around 50% reduction of PDCD1 upon CsA 
treatment (figure 54e), demonstrating consistency between experiments. Although the 
array data and subsequent qRT-PCR analysis was suggestive of an ABC DLBCL-specific 
effect of CsA on PDCD1 expression, no trend was observed when the experiment was 
expanded to a larger cell line panel (figure 54e), suggesting similar regulation of PDCD1 
by calcineurin/NFAT among DLBCL subtypes.  
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Figure 54. Differential regulation of PDCD1 by calcineurin/NFAT signalling in DLBCL cell lines. 
a) Table showing the microarray log FC expression of PDCD1 in cell lines treated with CsA for 2hrs or 
6hrs, including respective adjusted p-values from unpaired and paired data analysis. Adjusted P-values 
highlighted in red are indicative of statistical significance (adjusted P-value <0.05). b-d) The ABC 
DLBCL cell lines U2932 and HLY-1 (b and d) and the GCB DLBCL cell line WSU-NHL (c) were 
treated with their respective IC50 concentrations of CsA (U2932 8.6μg/ml, HLY-1 7.4μg/ml and WSU-
NHL10.4μg/ml) for 2 hours and 6 hours before the effects of treatment on PDCD1 mRNA expression 
were analysed by qRT-PCR (using RNA from gene expression microarray samples). Data is 
representative of four independent experiments where error bars indicate the standard error of the mean. 
P-values for qRT-PCR; U2932 2hr: 0.003 6hr: 0.001, WSU-NHL 2hr: 0.143 (insignificant) 6hr: 0.135 
(insignificant), HLY-1 2hr: 0.057 (insignificant) 6hr: 0.014. 
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4.2.8. Gene Set Enrichment Analysis 
 
To extract further information from the gene expression microarray, GSEA analysis was 
performed, as described in chapter 2, section 2.6. I aimed to utilise this powerful 
computational technique to determine whether a set of genes showed statistically 
significant differences between vehicle control and CsA-treated phenotypes. Considering 
that previous experiments confirming and validating the microarray suggested paired data 
analysis to be best, data derived from this method of analysis only was used for GSEA.   
The Broad Institute of Harvard and MIT’s molecular signatures database (MSigDB) was 
used for analysis (http://www.broadinstitute.org/gsea/index.jsp). Comprising 10,348 
gene sets, the MSigDB are divided into eight major collections, from which the C2 
curated gene set collection was chosen for this study 
(http://www.broadinstitute.org/gsea/index.jsp). This collection is composed of 4,725 
genes obtained from various sources such as online pathway databases, publications in 
PubMed and the knowledge of domain experts. Within the collection are five 
subcategories of gene sets, including chemical and genetic permutations, canonical 
pathways, and the BioCarta, KEGG (Kyoto Encyclopaedia of Gene and Genomes) and 
Figure 54 (Continued from previous page). Differential regulation of PDCD1 by 
calcineurin/NFAT signalling in DLBCL cell lines. e) A panel of DLBCL cell lines were treated with 
their respective IC50 concentrations of CsA (HLY-1 7.4μg/ml, RIVA 13.5μg/ml, OCI-Ly3 10.6μg/ml, 
SUDHL-4 15.6μg/ml, Farage 11.8μg/ml, SUDHL-6 3.6μg/ml and Karpas 422 14.9μg/ml) for 2 hours 
before the effects on PDCD1 mRNA expression were analysed by qRT-PCR. Lighter shaded bars 
indicate ABC DLBCL cell lines (HLY-1, RIVA and OCI-Ly3) whereas darker shaded bars represent 
GCB DLBCL cell lines (SUDHL-4, Farage, SUDHL-6 and Karpas 422). Data for b-e were normalised 
to the house-keeping gene GAPDH. Data for e is representative of three independent experiments where 
error bars indicate the standard error of the mean. P-values for qRT-PCR; HLY-1: 0.013, RIVA: 0.394 
(insignificant), OCI-Ly3: 0.596 (insignificant), SUDHL4: 0.370 (insignificant), SUDHL-6: 0.029. 
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Reactome gene sets. These gene sets were believed suitable for this study due to their 
broad coverage of a range of biological activities, including well known pathways (such 
as NFAT) important for cellular function.  
4.2.8.1. Enrichment of gene sets in DLBCL cell lines treated with CsA 
 
During GSEA, the genes that were differentially expressed in our two experimental 
conditions (CsA and vehicle) were identified and compared to gene sets recorded in the 
C2 MSigDB to identify classes of genes enriched or depleted in our datasets. Gene sets 
analysed were given an enrichment score (ES), which is the principal result of gene set 
enrichment analysis, representing the degree to which a gene set is overrepresented at the 
top or the bottom of a ranked list of genes. The ES is calculated by the GSEA programme, 
which walks down the ranked list of genes, increasing a running-sum statistic when a 
gene is in the gene set and decreasing it when it is not 
(http://www.broadinstitute.org/gsea/index.jsp). The extent of the increment depends on 
how correlated the gene is with a particular phenotype. When walking the list of genes, 
the ES is the point at which the maximum deviation from zero is reached.  Positive ES 
indicates enrichment of a gene set at the top of the ranked list of genes, whereas a negative 
ES value indicates gene set enrichment at the bottom of the ranked list 
(http://www.broadinstitute.org/gsea/index.jsp).  
Although PARP cleavage was observed after 6 hours CsA treatment (figure 20), 
suggesting that changes relevant to DLBCL survival were seen at this timepoint, GSEA 
for the 2 hour timepoint was used in this study to look for more immediate gene targets. 
Importantly however, GSEA was also performed for the 6 hour timepoint (data not 
shown), which gave very similar findings.   
Of the 4,725 gene sets in the C2 collection, 984 gene sets were filtered out by size 
preferences set (min = 15, max = 500 genes within a gene set), leaving 3,738 gene sets to 
be analysed. Two analysis reports were generated, one of which indicated the genes and 
gene sets enriched in the vehicle samples (but not in the CsA-treated samples) and the 
other report showing genes enriched in the CsA-treatment samples (but not in the vehicle 
samples). GSEA analysis of all three DLBCL cell lines treated with CsA for 2 hours 
produced a wealth of interesting data, as summarised in table 21.  
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The table also indicates the number of gene sets which had a False Discovery Rate (FDR) 
of less than 25% or less than 5%. The FDR is the estimated probability that a gene set 
represents a false positive finding. For example, an FDR of 25% indicates that the result 
is likely to be valid 3 out of 4 times. According to the Broad Institute GSEA user 
handbook, gene sets with an FDR less than 25% are those most likely to generate an 
interesting hypothesis and drive further research. However, if a small number of samples 
were used for GSEA, such as less than 7 samples for a phenotype (4 were used in this 
study), it is recommended to use a more stringent FDR cut-off, such as 5% 
(http://www.broadinstitute.org/gsea/index.jsp). Many of the gene sets generated in all 
three DLBCL cell lines had an FDR less than 25% and some cell lines, such as WSU-
NHL, showed a respectable number of gene sets with an FDR less than 5%.  
4.2.8.2. GSEA reveals enrichment of common gene sets between DLBCL cell lines 
treated with CsA 
 
The top 50 potentially interesting genes sets are listed in appendix tables 10-15, many of 
which are likely to be groups of genes that share common biological characteristics, 
biochemical pathways or modes of regulation. Due to time restrictions, thorough analysis 
of all gene sets was not possible. Instead, I found that some gene sets were of particular 
interest due to the fact that they were highly supportive of some of the genes and pathways 
identified in the array.  
These were best identified by investigating trends between the gene sets that arose 
between DLBCL cell lines. As shown in the Venn diagrams in figure 55 and 56, some 
cell lines shared common gene sets. Interestingly, many of the gene sets were associated 
with cancer, such as ‘Zhan, Multiple Myeloma, PR up’, ‘Pedersen, Metastasis, BY Erbb2 
Isoform 3’ and ‘Nikolsky Breast Cancer 16Q24 Amplicon’. Gene sets associated with 
proliferation and immune function were also evident, including ‘Benporath, Proliferation’ 
Vehicle CsA Vehicle CsA Vehicle CsA
Gene sets significant at FDR <25% 569 216 451 387 466 328
Gene sets significant at FDR <5% 61 1 8 32 104 24
HLY-1 U2932 WSU-NHL
Table 21. Summary of GSEA in DLBCL cell lines treated with CsA for 2 hours. The data in the 
table shows the number of gene sets enriched in vehicle vs. CsA samples and CsA vs. vehicle samples 
with a FDR (False Discovery Rate) less than 25% and 5%. Data is from paired analysis. 
PhD Thesis  Holly White 
 
208 
 
and ‘Seki, Inflammatory Response’. Moreover, in line with the large number of 
chemokines differentially expressed in the microarray, gene sets such as ‘Kegg 
chemokine signalling pathway’ arose as significant.  
 
 
 
 
There were 6 gene sets which overlapped between all three cell lines in the analysis of 
enrichment in CsA-treated samples compared to vehicle samples (figure 56). However, 
there were no overlapping gene sets between all three cell lines when considering 
enrichment in the vehicle compared to CsA-treated samples (figure 55). Overall, the cell 
lines showed both unique and shared CsA-sensitive gene sets suggesting both 
commonalities and differences in calcineurin/NFAT regulated genes in the three cell 
lines. 
 
Figure 55. GSEA reveals enrichment of common gene sets between DLBCL cell lines treated with 
CsA for 2hrs (enrichment in vehicle vs. CsA). The Venn diagram compares common gene sets that 
are enriched in vehicle control samples compared to CsA-treated samples. Gene sets are derived from 
the top 50 enriched gene sets (ordered by FDR) for each cell line, including U2932 (blue), HLY-1 
(orange) and WSU-NHL (green) DLBCL cells. Only overlapping gene sets are indicated on the 
diagram. Data is based on paired analysis. Gene sets highlighted in red are discussed in the following 
sections. 
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4.2.8.3. U2932 and HLY-1 cells demonstrate enrichment of gene sets associated 
with NFAT signalling  
 
Importantly, some very interesting gene sets were shared between the two ABC DLBCL 
cell lines U2932 and HLY-1 (figure 55). These included two gene sets associated with 
TCR/NFAT signalling, ‘PID NFAT TF Pathway’ and ‘PID TCR Calcium Pathway’. The 
enrichment plots for these gene sets are shown in figure 57. The top portion of the plot 
shows the running ES for the gene sets as the analysis walks down the ranked list. The 
score at the peak of the plot (the score furthest from zero) is the ES for the gene set.  
Figure 56. GSEA reveals enrichment of common gene sets between DLBCL cell lines treated with 
CsA for 2hrs (enrichment in CsA-treated samples vs. vehicle). The Venn diagram compares 
common gene sets that are enriched in vehicle control samples compared to CsA-treated samples. Gene 
sets are derived from the top 50 enriched gene sets (ordered by FDR) for each cell line, including U2932 
(blue), HLY-1 (orange) and WSU-NHL (green) DLBCL cells. Only overlapping gene sets are indicated 
on the diagram. Data is based on paired analysis.    
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The normalised enrichment scores (NES) is the main statistic for examining gene set 
enrichment results. The enrichment score is normalised, allowing GSEA to account for 
differences in gene set size and in correlations between gene sets and the expression 
dataset. The NES therefore allows comparisons to be made across gene sets. The NES for 
the ‘PID NFAT TF pathway’ gene set were 2.14 for U2932 cells with an FDR of 2.5% 
(figure 57a) and 2.15 for HLY-1 cells with an FDR of 0.6% (figure 57b). For the ‘PID 
TCR calcium pathway’ gene set, the ES for U2932 cells was 1.88 (FDR 10%) (figure 
57c) and 2.22 for HLY-1 cells (FDR 0.2%) (figure 57d). The distinct peaks at the 
beginning of the ranked lists in these graphs indicate that these gene sets are potentially 
interesting.   
The middle section of the plot shows where the members of the two NFAT-associated 
gene sets appear in the ranked list of genes. The bottom portion of the plot shows the 
value of the ranking metric as you move down the ranked list of genes, which measures 
a gene’s correlation with a phenotype. The ranking metric value goes from positive to 
negative as you move down the list, where a positive value indicates a correlation with 
the first phenotype e.g. the vehicle and a negative value indicates correlation with the 
second phenotype e.g. CsA treated samples (http://www.broadinstitute.org/gsea/index. 
jsp).  
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4.2.8.4. U2932 and HLY-1 cells demonstrate enrichment of gene sets associated 
with anergy 
 
Another gene set that was significantly enriched in both U2932 and HLY-1 cells treated 
with CsA for 2 hours was the ‘Safford T-Lymphocyte Anergy’, as shown in figures 55 
and 58. The NES for this gene set in U2932 cells was 2.08 (FDR 3%) and 2.20 in HLY-
1 cells (FDR 0.3%). Identification of this gene set was interesting due to the 
downregulation of anergy-associated genes in the array, such as EGR2 and EGR3, as 
described in sections 5.2.7.6 and 5.2.7.7.  
a) b) 
c) d) 
Figure 57. U2932 and HLY-1 cells demonstrate enrichment of gene sets associated with NFAT 
signalling. GSEA enrichment plots for U2932 (a and c) and HLY-1 cells (b and d) treated with CsA for 
2 hours, showing enrichment of two gene sets associated with NFAT signalling in vehicle samples 
compared to CsA-treated samples. Data is based on paired analysis. 
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4.2.8.5. HLY-1 cells demonstrate enrichment of gene sets associated with TNFα 
signalling 
 
Finally, although not shared between multiple cell lines, a gene set associated with TNFα 
was statistically significant. The ‘Phong, TNF Targets Up’ gene set had the 5th most 
significant FDR (0.2%), with an NES of 2.23 in HLY-1 cells treated with CsA for 2 hours. 
This gene set was also enriched in U2932 cells (NES 1.62), although its significance was 
much lower (FDR 14%). Overall however, GSEA was a useful tool for showing that 
TNFα signalling may be involved with the functions of the calcineurin/NFAT pathway in 
DLBCL (figure 59).  
 
 
a) b) 
Figure 58. U2932 and HLY-1 cells demonstrate enrichment of gene sets associated with anergy. 
GSEA enrichment plots for U2932 (a) and HLY-1 cells (b) treated with CsA for 2 hours, showing 
enrichment of two gene sets associated with anergy in vehicle samples compared to CsA-treated 
samples. Data is based on paired analysis. 
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4.3. Discussion  
 
4.3.1. Analysis of microarray data by qRT-PCR  
 
qRT-PCR analysis (using RNA from samples sent for microarray analysis) was a useful 
way of confirming the effects of CsA on the expression of seven selected genes. Overall, 
the expression fold-change recorded in the array was highly reproducible by qRT-PCR 
analysis, demonstrating time-dependent changes in gene expression and differences 
between particular cell lines. There was great consistency between most experiments, 
however the degree of error was fairly high in some genes/cell lines. Analysis of the 
differential expression of genes between cell lines identified some cell lines (especially 
WSU-NHL) which had higher Ct values for specific genes, suggesting low abundance 
mRNA. This may have been difficult to detect by qRT-PCR analysis, increasing inter-
experimental error. Often, the high error also correlated with data which did not reflect 
findings in the array, suggesting that the microarray may not have been sensitive enough 
to detect changes in the expression of some genes which were expressed at very low 
levels. Overall, these data provided sound evidence for the accuracy of the microarray. 
Although not shown, qRT-PCR analysis was also normalised to the TATA-binding 
protein (TBP) transcription factor, where results were consistent with data normalised to 
GAPDH.  
 
Figure 59. HLY-1 cells demonstrate enrichment of gene sets associated with TNFα signalling. 
GSEA enrichment plots for HLY-1 cells treated with CsA for 2 hours, showing enrichment of a gene 
associated with TNFα signalling in vehicle samples compared to CsA-treated samples. Data is based on 
paired analysis. 
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During initial analysis of the array, there were differences in the genes identified as 
significant between paired, compared to unpaired methods of analysis. While the general 
direction of differential expression of genes was the same when paired and unpaired 
analysis were combined, it was important to investigate which method of analysis best 
reflected biological functions in the array samples. For most genes analysed by qRT-PCR, 
paired data analysis from the microarray was most accurate, which led to my decision to 
use the data from paired data analysis for GSEA. However, for some genes, it was not 
entirely clear cut as to which type of analysis was most accurate. Therefore genes 
identified as significantly significant by unpaired analysis were not entirely disregarded.  
 
4.3.2. Investigation of the effects of CsA on potential calcineurin/NFAT target 
gene expression in an expanded panel of DLBCL cell lines 
 
An interesting observation in the microarray was the lack of effects on gene expression 
in WSU-NHL cells. Perhaps a longer incubation period of CsA was required for inhibition 
of calcineurin/NFAT signalling in these cells. qRT-PCR analysis investigated a potential 
trend between CsA-induced changes in gene expression between ABC and GCB DLBCL 
cell lines. While some genes, such as NFKBIE, EGR2, EGR3, and PDCD1 were regulated 
similarly by calcineurin/NFAT, other genes including TNFα, CCL4L2 and NFAT2 were 
mostly depleted by CsA in cell lines of the ABC DLBCL subgroup only. In the future it 
would be interesting to perform gene expression analysis on the entire panel of cell lines 
and to further analyse the effects of CsA on different pathways in ABC versus GCB cell 
lines, such as by using ingenuity pathway analysis.  
4.3.3. Summary of statistically significant genes differentially expressed by 
treatment with CsA 
4.3.3.1. Genes associated with cancer and lymphoma 
 
In addition to the functional subgroups of genes discussed below, a number of genes 
identified in the array analysis as regulated by CsA (in at least one cell line and at least 
one time point) were of interest due to their associations with lymphoma and cancer in 
general. The transcription factor paired-box 9 (PAX9) for example, was significantly 
downregulated in HLY-1 cells after 2 hours CsA treatment (unpaired analysis). Known 
for their role in early development, PAX family members have been found to be 
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frequently expressed and required for cell growth in malignancies such as breast cancer, 
lung cancer and lymphoma (Muratovska et al., 2003). 
 
Moreover, the type II transmembrane receptor CD69 was another top 10 gene 
downregulated in the microarray. Involved in lymphocyte activation, CD69 has been 
associated with haematological malignancies such as T-cell virus type-1 leukaemia’s and 
non-Hodgkin B-cell lymphomas (Ishikawa et al., 2013; Ishikawa, 1998). Moreover, 
upregulation of the suppressor of cytokine signalling-3 protein (SOCS3) by CsA 
(therefore normally downregulated by calcineurin/NFAT) was an interesting feature 
highlighted by the array due its known suppressive activity on pathways such as STAT3 
and NF-κB (Starr et al., 1997; Karlsen et al., 2004; Lam et al., 2008). SOCS family 
members have also demonstrated pivotal roles in inflammation and connections with 
cancer development (Inagaki-Ohara et al., 2013). Overexpression of SOCS3 has now 
been implicated in an array of lymphomas, including de novo follicular lymphoma, T-cell 
lymphomas, classical Hodgkin lymphomas and mantle cell lymphomas (Brender et al., 
2001; Brender et al., 2004; Baus et al., 2006; Krishnadasan et al., 2006; Molavi et al., 
2013). Another example of a cancer-associated gene upregulated by CsA treatment is the 
transcriptional regulator ID3 (inhibitor of DNA binding-3), which has recently been 
linked to oncogenesis of Burkitt’s lymphoma in which inactivating ID3 mutations 
promote TCF3-mediated expression of BCR components (Schmitz et al., 2014; Spender 
et al., 2014).  
 
Interestingly, CsA-induced downregulation of a number of genes encoding IκB proteins 
was apparent in the ABC DLBCL data analysis. Upregulation of these proteins by 
calcineurin/NFAT suggests that this signalling pathway in fact downregulates NF-κB 
signalling, which does not fit with the hypothesis that NFAT and NF-κB function by 
together promoting lymphomagenesis. However, expression of IκBζ, which is encoded 
by the NFKBIZ gene, has recently been shown to be upregulated in ABC DLBCL patient 
samples, but not GCB DLBCL samples or other NF-κB dependent malignancies such as 
multiple myeloma (Nogai et al., 2013). Moreover, IκBζ expression was essential for the 
survival of ABC DLBCL cell lines as well as for nuclear NF-κB activity (Nogai et al., 
2013). Fascinatingly, gene expression profiling showed that IκBζ controls many NF-κB 
target genes by interacting with the NF-κB subunits p50 and p52 (Nogai et al., 2013). 
Although IκBζ is a known NF-κB target gene itself, it is possible that other signalling 
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pathways, such as NFAT may also contribute to the elevated expression of IκBζ observed 
in some DLBCL. Unlike IκBα and IκBδ, IκBζ was significantly downregulated in just 
HLY-1 cells after 6 hours CsA treatment (paired analysis). Nevertheless, this is a 
potentially interesting result, which could be explored in greater depth in the future.    
4.3.3.2. Cytokines and genes associated with the tumour microenvironment 
 
A striking observation from the gene expression array was the significant downregulation 
of many cytokines. Due to the known involvement of NFAT in immune cell function this 
was perhaps not an unexpected result. The chemokines CCL4L1, CCL4L2, CCL3, 
CCL3L1 and CCL3L3 were frequently among the most statistically significant genes 
differentially expressed, however little is known about their function. Interestingly, a 
recent study reported high levels of secretion of CCL3 and CCL4 in the serum of patients 
with newly diagnosed DLBCL, where high CCL3 levels correlated with significantly 
shorter progression-free and overall survival (Takahashi et al., 2015). Furthermore, in 
vitro studies demonstrated high levels of CCL3 and CCL4 after BCR triggering in ABC, 
but not GCB DLBCL cells, suggesting that these chemokines may be useful biomarkers 
in ABC DLBCL (Takahashi et al., 2015).     
 
Lymphotoxin alpha (LTA) and Interleukin 10 (IL-10) are examples of other cytokines 
downregulated by calcineurin/NFAT inhibition, IL-10 functioning as a known enhancer 
of B-cell survival and proliferation (Itoh et al., 1995). Interestingly, high levels of 
circulating IL-10 have been reported in DLBCL patients, and IL-10 promotes the 
proliferation and survival of ABC DLBCL cell lines through an autocrine mechanism 
involving NF-κB and STAT3 (Lam et al., 2008). IL-10 has in fact been reported a novel 
therapeutic target in DLBCL by Béguelin et al (2015), who also identified amplifications 
of the IL-10 surface receptor in primary DLBCLs (Beguelin et al., 2015). Importantly, 
anti-IL-10-receptor therapy resulted in cell cycle arrest and induction of apoptosis in 
DLBCL cell lines (Beguelin et al., 2015).         
 
Furthermore, the proinflammatory cytokine Marginal Zone B and B1 Cell-Specific 
Protein (MZB1) was a gene significantly differentially expressed in the array. 
Interestingly, high expression of MZB1 has been predicted to cause adverse prognosis in 
CLL, follicular lymphoma and DLBCL (Herold, 2013). However, CsA caused an 
PhD Thesis  Holly White 
 
217 
 
upregulation of this gene in the array, suggesting that calcineurin/NFAT is not the 
underlying cause of the increased expression of this gene in these malignancies.  
 
4.3.4. GSEA 
 
It was encouraging to see the NFAT pathway among the most significant gene sets 
enriched in U2932 and HLY-1 vehicle control samples compared to CsA-treated samples. 
Data reassuringly pulled out genes and pathways previously associated with the 
biological function of NFAT signalling. Future analysis would ideally gain a greater 
insight into the genes which encompass the ‘PID NFAT TF Pathway’ and ‘PID TCR 
Calcium Pathway’ gene sets by using leading edge analysis.  
The leading edge subset in a gene set include the genes that appear in the ranked list at or 
before the point where the running sum reached its maximum deviation from zero 
(http://www.broadinstitute.org/gsea/index.jsp). Therefore, the leading edge-subset can be 
regarded as the core genes that account for the gene set’s enrichment signal. Analysis of 
genes that are commonly in the leading edge subsets are therefore more likely to be of 
interest and biological importance than a gene that is only in a small number of the 
leading-edge subsets. Appendix table 16 shows an example of the genes that form the 
leading edge analysis within the ‘PID NFAT TF Pathway’ gene set, which was enriched 
in U2932 cells treated with CsA for 2 hours. Interestingly, the core enrichment genes 
include EGR2 and EGR3, confirming that these genes have been associated with the 
biological activities of NFAT in already published data. Moreover, interferon regulatory 
factor 4 (IRF4) was also among the top ranked genes in this gene set. IRF4 is a 
transcription factor which plays a key role in lymphoid development, functioning to 
terminate the germinal centre transcriptional program, class switch recombination and 
plasma cell development (De Silva et al., 2012). Of note, IRF4 is highly expressed in 
ABC DLBCL, due to constitutive active NF-κB signalling, and is required for the survival 
of this subgroup of DLBCL (Lam et al., 2005; Yang et al., 2012). Moreover, IRF4 is 
known to synergise with NFAT to regulate combined target genes, further supporting a 
potential association between these proteins in DLBCL (Rengarajan et al., 2002)    
Analysis of the C2 curated collection of gene sets also demonstrated enrichment of gene 
sets associated with the anergic phenotype and TNFα signalling. In the future, it would 
be of great interest to explore some of the other collections of gene sets. For example, the 
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C3 motif collection contains gene sets based upon shared cis-regulatory motifs that are 
conserved across human, mouse, rat and dog genomes 
(http://www.broadinstitute.org/gsea/index. jsp). The catalogued motifs represent known, 
or likely regulatory elements in promoters and 3’UTRs, thus allowing identification of 
other transcription factors that might regulate genes in cooperation with NFAT, such as 
NF-κB (Xie et al., 2005).     
4.3.5. Gene Expression Microarray Summary 
 
Although analysis thus far has mainly been focused on early changes in gene expression 
to identify direct NFAT targets, some of the regulated genes described in this chapter 
were also identified as true targets of NFAT and NF-κB in EBV transformed 
lymphoblastoid cell lines. As explained in greater detail in Chapter 6, through access of 
previously published ChIP-sequencing data, binding of the NFAT and NF-κB 
transcription factors to the promoter regions of the TNFα gene in lymphoblastic cells 
were identified (appendix figure 20, provided by Professor Neil Perkins). Data was also 
generated for another potential NFAT target gene, PDCD-1 (not shown).  
In summary, the gene expression array provided an abundance of interesting data, with 
which many avenues could be explored. One of the most exciting results from the array 
was the potential regulation of the cytokine TNFα by NFAT, which is investigated in the 
next chapter.   
 
 
 
 
 
 
 
 
PhD Thesis  Holly White 
 
219 
 
 
Chapter 6. 
The role of TNFα in DLBCL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PhD Thesis  Holly White 
 
220 
 
5. The role of TNFα in DLBCL 
 
5.1. Introduction 
 
Gene expression microarray analysis revealed TNFα to be a gene significantly 
downregulated by CsA treatment in the ABC DLBCL cell lines HLY-1 and U2932, but 
not in the GCB DLBCL cell line WSU-NHL. Given that TNFα activates pathways 
involved in proliferation and cell death, this suggested TNFα could be a potential NFAT 
target gene responsible for the killing of cells treated with CsA. Moreover, TNFα has 
recently been associated with reduced overall survival and reduced progression-free 
survival in patients with DLBCL, suggesting that its role should be further explored 
(Nakayama et al., 2014a; Nakayama et al., 2014b).  
5.1.1. TNFα and TNFα receptors 
 
TNFα is a cytokine that is highly involved in immune regulation and inflammation, 
playing a key role in cell proliferation, differentiation, apoptosis, and lipid metabolism 
(Locksley et al., 2001). First coined as ‘Lymphotoxin’ by Dr Gale A Granger, TNF was 
first discovered to be a cytotoxic factor produced by lymphocytes and was later named 
‘TNF’ by Dr Lloyd J. Old who reported macrophages to be the predominant cell-type of 
the immune system to produce this cytokine (Granger GA, 1969; Carswell et al., 1975). 
The name tumour necrosis factor came from the discovery of TNF’s ability to kill the 
mouse fibrosarcoma cell line L-929 (Carswell et al., 1975). This interesting finding 
highlighted the potential involvement of TNF in anti-tumoural responses by the immune 
system, a theory which was first described by the physician William B. Coley (McCarthy, 
2006).  
Cloning of the cDNAs encoding Lymphotoxin and TNF in 1984 revealed the two proteins 
to be strikingly similar, also demonstrating significant functional homology in binding to 
the TNF receptor (Gray PW, 1984; Pennica D, 1984). These important discoveries led to 
the renaming of TNF to TNFα and Lymphotoxin to TNFβ (Aggarwal, 2003). Since these 
key discoveries, many other TNFR-related proteins have been identified to form a large 
TNF superfamily of 19 TNF ligands and 29 TNF receptors, which have been extensively 
reviewed (Smith et al., 1994; Ashkenazi et al., 1998; Idriss et al., 2000; Aggarwal, 2003).  
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TNFα is a 212 amino acid type II transmembrane protein (Kriegler et al., 1988). Forming 
a stable arrangement of homotrimers, TNFα integrates into the membrane; however 
proteolytic cleavage by the metalloprotease TNFα converting enzyme (TACE) allows a 
soluble TNF (sTNF) 51kDa trimeric complex to be secreted (Black et al., 1997). The 
membrane-bound (mTNFα) and secreted, soluble forms of TNFα (sTNFα) are both 
biologically active, sharing some functionality, however in vivo models have revealed 
distinct roles for mTNFα and sTNFα. sTNFα is required for acute and chronic 
inflammation, whereas mTNFα is involved in the development of lymphoid tissues and 
provides protection from bacterial infection, chronic inflammation and autoimmunity 
(Ruuls et al., 2001; Kollias et al., 2002; Saunders et al., 2004; Allenbach et al., 2008). 
The differential effects of each form of TNFα generally imply protective immune 
functions for mTNFα, since it lacks the harmful effects of sTNFα (Locksley et al., 2001; 
Richter et al., 2012).   
TNFα can bind to two receptors, either the TNFR1 (TNF receptor type 1) or TNFR2 (TNF 
receptor type 2) (Locksley et al., 2001). TNFR1 is expressed in most tissues and can be 
activated by both the membrane-bound and soluble forms of TNFα (Grell et al., 1995). 
TNFR2 on the other hand is distinctly found on immune cells and can only be activated 
by the membrane-bound form of TNFα (Grell et al., 1995; Faustman et al., 2010). While 
mTNFα-mediated signalling occurs in a juxtacrine manor, interacting in a cell-cell 
contact dependent fashion, sTNFα functions by both paracrine and systemic functions via 
TNFR1 (Grell et al., 1995; Richter et al., 2012).  
In most cells, TNFR1 is the key mediator of TNFα signalling and plays an important role 
in apoptosis, whereas in the lymphoid system TNFR2 appears to play a more significant 
role, particularly for any function related to T-cell survival (Wajant et al., 2002; Faustman 
et al., 2010). There have been reports of crosstalk between the pathways that these 
receptors activate (Pimentel-Muiños et al., 1999; Naudé et al., 2011). Receptor crosstalk 
depends on the signalling kinetics between the two receptors, or the extent of their 
expression, which may result in agonistic or antagonistic effects on each other’s 
signalling pathways (Naudé et al., 2011).  
Ligand binding to the TNFα receptor forms a trimeric complex of receptors, initiating a 
conformational change, causing the inhibitory protein SODD (silencer of death domains) 
to dissociate from the intracellular death domain component of the TNF receptor 
(Kriegler et al., 1988; Tang et al., 1996; Locksley et al., 2001). In turn, the adaptor protein 
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TRADD (TNF Receptor type 1 Associated Death Domain) is permitted access to death 
domain binding, forming a platform for downstream protein domain activation (Wajant 
et al., 2002) 
5.1.2. Signalling pathways initiated by TNFα 
 
TNFα exhibits a large range of bioactivities in the cell but is mostly considered to function 
as a regulator of the proinflammatory response. In the pathological context however, 
TNFα can behave as a double-edged sword by exerting dual functionality. An early 
example of this is TNFα’s role in liver regeneration after a partial hepatectomy (Yamada 
et al., 1997). TNFα was shown to play a key role in liver regeneration, where mouse 
models deficient in TNFR1 showed severe impairment of hepatocyte DNA synthesis 
(Yamada et al., 1997). In models of acute hepatotoxicity however, TNFα functions via 
TNFR1 by causing destruction of the liver (Yamada et al., 1997). The ability of TNFα to 
play such opposing roles is likely due to engagement of different pathways downstream 
of the TNF receptors. Once activated, TNFRs use distinct, but partially overlapping 
signalling pathways. TNFR1 strongly enhances NF-κB signalling, but also has the ability 
to initiate cell death pathways via its cytoplasmic death domain (Naudé et al., 2011; 
Richter et al., 2012). TNFR2 on the other hand activates cytoprotective functions through 
canonical and non-canonical NF-κB signalling (Rauert et al., 2010; Naudé et al., 2011)  
Two main signalling pathways are initiated by ligation of TNFα to its receptor, TNFR1, 
including the NF-κB pathway and the MAPK pathways. These transcriptional pathways 
are required for the expression of genes involved in cell growth, death, development and 
immune responses (Chen et al., 2002). The molecular mechanisms of TNFα signal 
transduction are highly complex and in recent years there has been a wealth of 
information published involving molecules and pathways associated with TNFα 
(Locksley et al., 2001; Aggarwal, 2003; Van Herreweghe et al., 2010). Activation of the 
NF-κB and MAPK pathways (such as JNK) mediates an array of processes including cell 
proliferation, survival and inflammatory responses and anti-apoptotic factors. Generally 
speaking however, TNFα-induced NF-κB signalling leads to a pro-inflammatory and anti-
apoptotic responses whereas JNK activation is largely pro-apoptotic (Wajant et al., 2002).  
In addition to induction of transcriptional pathways, the activation of death signalling 
pathways are also triggered by TNFα, where binding of TRADD to FADD (Fas-
Associated protein with Death Domain) leads to the recruitment of caspase-8 and the 
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cleavage of downstream caspases, ultimately leading to apoptosis (Wilson et al., 2009). 
When compared to other cell death inducing pathways, the induction of cell death by 
TNFα is fairly weak and is often masked by the anti-apoptotic influence from NF-κB 
(Wajant et al., 2002).  
5.1.3. Autocrine and paracrine signalling by TNFα 
 
Many cytokines, including TNFα, can function by both autocrine and paracrine 
mechanisms. Autocrine signalling is a form of cell signalling in which a cell secretes a 
chemical, hormone or proteins such as cytokines that bind to autocrine receptors on that 
same cell, initiating downstream effects in the cell. During an immune response, autocrine 
functions often amplify signalling or gene expression in a cellular response to a given 
pathogen. For example, TNFα is a well-known autocrine regulator of inflammatory 
signalling in a number of cellular processes (Wu et al., 1993; Blasi et al., 1994; Xaus et 
al., 2000; Coward et al., 2002; Kuno et al., 2005). TNFα and NF-κB form a positive 
autocrine feedback loop during the initiation of an allergic response in mast cells for 
example, where TNFα synthesised as a consequence of NF-κB activation is released into 
the extracellular environment to further augment the NF-κB response, leading to more 
TNFα production and so on (Coward et al., 2002). If TNFα signalling in DLBCL 
functions in an autocrine manner it would be interesting to unravel the precise pathways 
TNFα targets and to investigate the effects of TNFα inhibition. 
Paracrine signalling on the other hand, is a form of cell-cell communication where a cell 
produces a signal, such as a chemokine which then induces effects on surrounding cells, 
altering their behaviour. In the immune environment, paracrine signalling is critical for 
the amplification of an inflammatory response within a tissue or organ, involving a 
diverse variety of cell types (Caldwell et al., 2014).  
5.1.4. Dysregulation of TNFα 
 
Now known to be produced by many cells of the immune system (including lymphoid 
cells, mast cells, cardiac cells and fibroblasts) (Locksley et al., 2001), TNFα is a widely 
researched cytokine, due to its involvement in a vast array of diseases. Dysregulation of 
TNFα has been implicated in conditions such as cancer, autoimmune disorders, 
Alzheimer’s disease, diabetes, osteoporosis and many more (Chen et al., 2002; Kollias et 
al., 2002; Kodama et al., 2005). In normal, healthy, individuals, TNFα is released from 
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cells in a controlled fashion in response to various cytokines (such as IL-1) or by the 
presence of foreign substances (such as LPS or other bacterial products). In the disease 
setting however, TNFα production becomes dysregulated whereby excessive levels are 
produced. As a result, this creates a chronic state of inflammation in autoimmune 
disorders, while also having detrimental effects in cancer patients.  
5.1.5. Inhibition of TNFα 
 
Significant clinical improvements have been achieved by treating patients with 
autoimmune diseases such as rheumatoid arthritis with TNFα inhibitors (Taylor et al., 
2000). These have also been effective treatments for other conditions such as Crone’s 
disease and inflammatory bowel disease, effectively suppressing overactivity of the 
immune system and dampening down the inflammatory response (Taylor et al., 2000; 
Blam et al., 2001). Inhibition is achieved by using monoclonal anti-TNFα antibodies, 
such as Infliximab (Remicade®) (Knight DM1, 1993), Adalimumab (Humira®) 
(Kempeni, 1999), Golimumab (Simponi®) (D. Shealy, 2007), or with Certolizumab 
pegol (Cimzia®) (Nesbitt A1, 2007), a pegylated Fab fragment of a humanised TNFα 
monoclonal antibody.  
5.1.5.1. Infliximab 
 
The TNFα neutralising antibody Infliximab was used in this study to investigate the 
effects of TNFα inhibition on DLBCL cell viability. Infliximab (trade name Remicade®) 
is a chimeric human-murine IgG monoclonal antibody against TNFα. Produced in 
Chinese hamster ovary cells by recombinant DNA technology, Infliximab is administered 
by intravenous infusion in the clinic to treat autoimmune diseases such as rheumatoid 
arthritis, psoriasis, Crohn’s disease and ulcerative colitis. As shown in figure 60, the 
mechanism of action behind Infliximab’s immunosuppressant effects are by high affinity 
binding to the soluble and membrane-bound forms of the TNFα cytokine, preventing 
TNFα from binding to the TNF receptor, thereby inhibiting the activation of downstream 
pro-inflammatory pathways. 
5.1.5.2. Etanercept 
 
Also used for the treatment of autoimmune diseases such as rheumatoid arthritis and 
psoriatic arthritis, Etanercept (Enbrel®) is an alternative approach used in the clinic to 
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antagonise TNFα. Although naturally occurring antagonists of TNFα receptor activation 
come in the form of soluble TNFα receptors, which compete with cell surface TNFα 
receptors for TNFα ligand binding, their actions are not sufficient to block the elevated 
levels of TNFα found in inflammatory diseases (D. Aderka, 1992; Goffe et al., 2003). 
Comprised of a recombinant, dimeric fusion protein, Etanercept consists of the human 
75kDa TNFα receptor linked to the Fc portion of human IgG1 (Goffe et al., 2003), 
allowing it to mimic the activity of naturally occurring soluble TNFα receptors. 
Etanercept therefore competes with membrane-bound TNFα receptors for binding to the 
TNFα cytokine, as shown in figure 60 (K. Peppel, 1991). In fact, Etanercept binds 
receptor bound molecules of TNFα at 50-1000 times that of soluble forms of the TNFα 
receptor, which is owed to the dimeric structure of the fusion protein, enabling high 
affinity binding of Etanercept to two free TNFα molecules or two receptor-bound 
molecules of TNFα (K. Peppel, 1991; Mohler et al., 1993).  
 
Figure 60. Mechanism of TNFα inhibition using Infliximab or Etanercept. The TNFα neutralising 
antibody Infliximab binds with high affinity to the soluble and membrane-bound forms of TNFα, preventing 
TNFα from binding to the TNF receptor. Etanercept is a dimeric fusion protein which mimics the activity 
of soluble TNFα receptors, competing with membrane-bound receptors for the binding of TNFα, therefore 
inhibiting the activation of downstream pro-inflammatory pathways.  
 
5.1.6. Potential role for TNFα in DLBCL 
 
As described previously, TNFα has been identified as an NFAT target in a number of 
biological contexts and in recent years their relationship has been described as potentially 
oncogenic (Pedersen et al., 2009; Nakayama et al., 2014a; Nakayama et al., 2014b).  
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Recent studies have provided evidence supporting the addition of TNFα to the 
International Prognostic Index (IPI) to improve its predictive prognostic value for 
predicting the prognosis of patients with DLBCL (Nakayama et al., 2014a). An 
investigation by Nakayama et al (2014), for example, evaluated TNFα expression in 62 
lymphoma tissue samples from patients with not otherwise specified DLBCL (DLBCL, 
NOS), using immunostaining with an anti-TNFα antibody (Nakayama et al., 2014a). 
Tumour specimens could be divided into two groups; TNFα positive (38 cases, 61%) and 
TNFα negative (24 cases, 39%). They found that TNFα positivity correlated with poorer 
overall survival and progression free survival (OS P=0.0005 and PFS P=0.0330) when 
compared with TNFα negative samples (Nakayama et al., 2014a).  
Furthermore, in a second study by the same research group, a cohort of 60 DLBCL NOS 
tissue specimens were evaluated for expression of the TNFR1 and TNFR2 by 
immunohistochemical staining (Nakayama et al., 2014b). TNFR1 was expressed in 31 
cases (52%) and correlated with poorer overall survival (P=0.0006) when compared to 
TNFR1-negative tumours (29 cases, 48%) and was confirmed a significant prognostic 
factor for OS, independent of the IPI (Nakayama et al., 2014b). TNFR2 positive 
specimens were also predictive of a poorer OS, however this was not found to be 
statistically significant (Nakayama et al., 2014b). Their data suggests that expression of 
the TNFα cytokine is associated with expression of the TNFR1, where 87% of TNFα 
positive cases showed positive expression of the TNFR1 and these cases were correlated 
with a poorer OS compared with the TNFα negative, TNFR1 negative cases (Nakayama 
et al., 2014b). Moreover, a poorer prognosis for OS and progression-free survival, 
independent of the IPI was reported in 45% of TNFα positive, TNFR1 positive cases 
(Nakayama et al., 2014b). These clinical report findings further support that the inclusion 
of TNFα, (with the addition of TNFR1) to the IPI may be a logical step to improve the 
prognosis of patients with DLBCL NOS more accurately.  
Interestingly, previous studies by other research groups have shown that patients with 
ABC DLBCL display elevated serum levels of TNFα compared to patients with GCB 
DLBCL and other B-cell malignancies (Pedersen et al., 2005). These findings have also 
been confirmed from an in vitro perspective. For example, in a study investigating 
elevated levels of oncogenic miR-155 in DLBCL, increased miR-155 levels and 
diminished expression of its target SHIP-1 were found to be a result of autocrine 
stimulation by TNFα (Pedersen et al., 2009). Treatment of cells with Etanercept or 
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Infliximab was sufficient to reduce miR-155 levels and restore SHIP1 expression 
(Pedersen et al., 2009). Interestingly, an anti-TNFα regimen also caused a reduction in 
cell proliferation and a decrease in DLBCL tumour xenograft burden in response to 
Etanercept (Pedersen et al., 2009). These findings suggested that TNFα may be playing 
a key role in the survival of DLBCL cells and is indicative that anti-TNFα therapy may 
be a potential novel treatment for DLBCL.  
In summary, there is sufficient clinical evidence, as well as mechanistic evidence, that 
NFAT regulates TNFα expression, which may be oncogenic in some contexts, such as in 
DLBCL. Should TNFα be an important NFAT target gene in DLBCL, essential for cell 
survival and other pro-tumour functions, it is important to decipher the precise 
mechanisms involved. Following on from the microarray, I aimed to investigate whether 
DLBCL cell lines were producing high levels of TNFα and whether calcineurin/NFAT-
induced TNFα expression was driving the survival of DLBCL cells in an autocrine 
fashion, as shown in the model in figure 61. If TNFα were found to be a key cytokine 
required for DLBCL cell growth, I aimed to assess whether CsA-induced cell death could 
be rescued by the addition of exogenous TNFα. Should the calcineurin/NFAT-TNFα 
mechanism be effectively inhibited (and the viability of DLBCL cells reduced), this could 
reveal a potential treatment option for patients with DLBCL. Anti-TNFα treatments are 
already immediately accessible, so consequently their use as co-treatments with other 
therapeutic agents could be of potential benefit to patients in the near future.    
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Figure 61. Model for TNFα signalling in DLBCL. TNFα is potentially an NFAT target gene in DLBCL, 
where upregulation of TNFα production by DLBCL cells may stimulate survival pathways in an autocrine 
manner. Alternatively, TNFα production may function in a paracrine fashion, affecting cells in the tumour 
microenvironment.   
 
5.2. Results 
 
5.2.1. TNFα production by DLBCL cell lines is variable and in some cell lines is 
dependent on the calcineurin-NFAT signalling pathway 
 
To investigate whether DLBCL cell lines produce TNFα, either in soluble form or bound 
to soluble TNF receptors, cells were incubated for 2 days following the normal splitting 
procedure before their media supernatants were removed. The Quantikine TNFα assay 
was used to assess the quantity of TNFα produced from cells and to make a relative 
comparison of TNFα production between cell lines. Apart from when seeding cells, when 
harvesting supernatants cell counts were not performed to normalise TNFα expression in 
supernatants in relation to cell number per ml. Relative levels of TNFα produced are 
therefore only approximate.  
Figure 62a illustrates heterogeneous production of TNFα among the panel of cell lines, 
ranging from 25pg/mL to 150pg/mL. Some cell lines such as RIVA and U2932 released 
greater than six-fold the levels of TNFα when compared to HLY-1, OCI-Ly3 and 
SUDHL-4, with some cell lines producing TNFα at intermediate levels. 
 
a) b) 
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RIVA, U2932 and WSU-NHL cells were identified as high producers of TNFα in figure 
62a and were treated with CsA for 2 hours to analyse the effects of calcineurin/NFAT 
inhibition on TNFα production (figure 62b). Of note, compared to figure 62a, WSU-NHL 
cells appeared to produce considerably lower concentrations of TNFα when compared to 
RIVA and U2932. This was a consequence of diluting the samples by a dilution factor of 
4 with the aim of more accurately determining the effects of CsA treatment. CsA had a 
significant effect on TNFα production in the ABC DLBCL cell lines RIVA and U2932 
cells, reducing its production around 5-fold. However, in the GCB DLBCL cell line 
WSU-NHL, TNFα production was not reduced upon treatment with CsA.  
5.2.2. Infliximab and Etanercept are functioning appropriately by reducing the 
levels of TNFα-induced NF-κB activity 
 
To ensure that Infliximab and Etanercept were having their desired effect on TNFα and 
pathways downstream of TNFα, a positive control experiment was performed using an 
NF-κB luciferase reporter assay. It is well known that TNFα is a common initiator of the 
NF-κB pathway, and for this reason the NF-κB luciferase reporter assay was an 
appropriate choice of control experiment to ensure Infliximab and Etanercept were 
inhibiting the transcriptional activation of NF-κB.  
U2OS cells containing an NF-κB regulated promoter upstream of the firefly luciferase 
gene were treated with 10μg/ml TNFα (to induce NF-κB activity), followed immediately 
by treatment with 10μg/ml Infliximab or Etanercept. To make certain that any effects on 
NF-κB were due to inhibition of TNFα and not due to the addition of an antibody to cells, 
10μg/ml human IgG was also added to cells accordingly. Cells were subsequently 
incubated for 2 hours before being lysed and a luciferase assay performed.  
Figure 63 shows that the control human IgG had little to no effect on NF-κB activity when 
compared to the untreated -TNFα control. NF-κB activity was also similar in these 
Figure 62. TNFα production by DLBCL cell lines is variable and in some cell lines is dependent 
on the calcineurin-NFAT signalling pathway. a) DLBCL cells were incubated for 2 days 
(following splitting as normal) before media supernatants were removed for use in a TNFα ELISA. 
Data is representative of one experiment repeated three times, where error bars represent the 
standard deviation of duplicate wells. b) RIVA, U2932 and WSU-NHL cells were treated with their 
respective IC50 concentrations of CsA (RIVA = 13.5µg/ml, U2932 = 8.6µg/ml and WSU-NHL = 
10.4µg/ml) for 2 hours before removal of the media supernatants for use in the TNFα ELISA assay. 
Data is representative of two repeat experiments, where error bars indicate the standard error of the 
mean.   
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samples following the addition of TNFα, which (as expected) increased NF-κB activity 
substantially. Treatment of cells with Infliximab or Etanercept reduced NF-κB activity to 
levels comparable to the untreated –TNFα control. Addition of TNFα to samples treated 
with Infliximab and Etanercept demonstrated that the reduction of NF-κB activity was 
specifically by inhibition of TNFα and not due to off target effects of the anti-TNFα 
agents. This experiment was a useful tool to confirm that Infliximab, Etanercept and 
human IgG were functioning appropriately, allowing further experiments using these 
agents to be performed with confidence.   
 
5.2.3. TNFα produced by DLBCL cell lines is biologically active; however 
inhibition of TNFα signalling has no effect on p65 and c-Rel DNA binding 
activity 
 
NF-κB signalling plays a fundamental role in DLBCL and (as described previously) 
TNFα is a well-known activator of the NF-κB pathway. Therefore I investigated whether 
the TNFα produced by DLBCL cells was sufficient to induce NF-κB. Media supernatants 
Figure 63. Infliximab and Etanercept are functioning appropriately by reducing the levels of TNFα-
induced NF-κB activity. U2OS cells expressing the NF-κB gene regulatory region upstream of the firefly 
luciferase gene were treated with 10μg/ml TNFα, followed by immediate treatment with 10μg/ml of the 
TNFα neutralising antibody Infliximab, the TNFα antagonist Etanercept or a control human IgG, including 
a vehicle control (1% PBS + 0.05% FBS). Cells were incubated for 2 hours before being lysed and the 
luciferase reporter experiment performed. Data is representative of one experiment, where error bars 
indicate the standard deviation between triplicate wells.  
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from RIVA and HLY-1 cells were added to U2OS NF-κB luciferase reporter cells and 
the transcriptional activity of NF-κB analysed (figure 64a). As a positive control human 
TNFα was added to the cells, which demonstrated a substantial upregulation of NF-κB 
activity. Addition of RIVA cell medium (TNFα high) increased NF-κB activity almost 
two-fold and was statistically significant (P-value = 0.028) whereas addition of HLY-1 
medium (TNFα low) had no effect on NF-κB activity. Activation of NF-κB by TNFα in 
RIVA cells was specifically due to TNFα and not due to other components of cell 
medium, as confirmed by the addition of Etanercept, which reduced NF-κB activity to 
levels similar to untreated –TNFα samples. Overall, these data confirm that TNFα 
produced by some DLBCL cell lines is biologically functional.  
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I next aimed to assess whether inhibition of TNFα caused a downregulation of NF-κB 
DNA binding activity using ELISA assays specific for the p65 and c-Rel NF-κB family 
members. Treatment of U2932 cells with Infliximab and Etanercept had no significant 
effect on the DNA binding activity of either p65 or c-Rel compared to the vehicle control 
or human IgG (figure 64b and c). An explanation for this could be that the TNF that is 
produced by U2932 is not biologically active (as demonstrated in RIVA cells alone). 
Using U2932 cells for this particular experiment, rather than RIVA cells was indeed a 
limitation because we cannot be certain that the high levels of TNFα produced by U2932 
cells is biologically active. If there had been sufficient time to investigate this, and the 
TNFα in U2932s was proven active, the results in figure 64 would indicate that although 
TNFα produced by DLBCL cells is biologically active, it may not be required for the 
transcriptional activity of the p65 and c-Rel NF-κB family members in DLBCL.  
5.2.4. TNFα is an NFAT and NF-κB target gene 
 
Although TPCA-1 was not the broad NF-κB inhibitor that we wanted for gene expression 
microarray analysis, its inhibitory effects (proven by ELISA) were useful for 
investigating potential interactions between the NF-κB and NFAT pathways in regards to 
cell viability and expression of joint target genes. Considering TNFα is a known NF-κB 
target gene and my recent discovery of NFAT as a mediator of TNFα expression in 
DLBCL, it was decided to confirm that TNFα was an NF-κB target gene in DLBCL cells. 
U2932 and RIVA cells were treated with increasing concentrations of TPCA-1 (figures 
65a and b). Consistent with inhibition of IKK2, TPCA-1 caused a dose-dependent 
decrease in TNFα mRNA expression in both cell lines, confirming TNFα to be an NF-κB 
Figure 64. TNFα produced by DLBCL cell lines is biologically active; however inhibition of TNFα 
signalling has no effect on p65 and c-Rel DNA binding activity. a) The DLBCL cell lines RIVA and 
HLY-1 were incubated for 2 days (following splitting as normal) before media supernatants were 
removed. Media supernatants were immediately added to NF-κB luciferase reporter U2OS cells while 
10µg/ml human TNFα was added to appropriate wells as a positive control for NF-κB activity. To 
confirm observed effects on NF-κB activity was specifically due to TNFα production, 10µg/ml of the 
TNFα antagonist Etanercept was also added to cells accordingly. Cells were incubated for 2 hours or 6 
hours (showing very similar results) before NF-κB transcriptional activity was measured by a luciferase 
reporter assay. P-values: RIVA = 0.028, HLY-1 = insignificant. RIVA + Etanercept compared to RIVA 
P-value = 0.01. Data is representative of three individual biological repeat experiments performed in 
duplicate wells, where error bars represent the standard error of the mean. b-c) The DLBCL cell line 
U2932 was treated with 10μg/ml of the TNFα neutralising antibody Infliximab, the TNFα antagonist 
Etanercept or a control human IgG, including a vehicle control (1% PBS + 0.05% FBS). Cells were 
incubated for 2 hours before nuclear extraction and addition of nuclear samples to an NF-κB ELISA. 
To monitor the specificity of the assay, samples were run alongside a mutated (MT) consensus 
oligonucleotide and a wild-type (WT) consensus oligonucleotide (as a competitor for NF-κB binding). 
Data is representative of three independent biological repeat experiments (apart from the WT and MT 
controls (c) which represent one experiment), where error bars indicate the standard error of the mean.  
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target gene. Cells were also treated with increasing concentrations of CsA. Here, TNFα 
expression was considerably reduced even at concentrations representing 1/10th of the 
IC50 concentration. When treated simultaneously with CsA and TPCA-1, the expression 
of TNFα and TNFα production in RIVA and U2932 cells was downregulated slightly 
more than treatment of CsA treatment alone (figure 65b and d). However, this was not 
significant enough for the effects to be considered additive or synergistic and was not 
observed in other cell lines.  
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Figure 65. TNFα is a NFAT and NF-κB target gene. The DLBCL cells RIVA (a) and U2932 (b) 
were treated with increasing concentrations of CsA and TPCA-1, both alone and in combination for 
2 hours before RNA was extracted, followed by reverse transcription to cDNA and analysis of TNFα 
mRNA expression by qRT-PCR analysis. A vehicle control was also included (0.01% DMSO). 
Concentrations of drugs included 1xIC50, 0.25xIC50 and 0.1xIC50 concentrations respectively. For 
RIVA cells, concentrations for CsA were as follows; 1xIC50=13.5μg/ml, 0.25xIC50=3.375μg/ml, 
0.1xIC50=1.35μg/ml and for TPCA-1 included 1xIC50=4.2μM, 0.25xIC50=1.1μM and 
0.1xIC50=0.11μM. For U2932 cells, concentrations of CsA were as follows; 1xIC50=8.6μg/ml, 
0.25xIC50=2.15μg/ml, 0.1xIC50=0.86μg/ml and for TPCA-1 included 1xIC50=3.1μM, 
0.25xIC50=0.775μM and 0.1xIC50=0.31μM. Data is representative of three repeat experiments 
where error bars represent the standard error of the mean. The effect of combined TPCA-1 and CsA 
treatment on TNFα production in U2932 cells was analysed by a TNFα ELISA (c). Cells were treated 
with their respective CsA and TPCA-1 IC50 concentrations, both alone and in combination. A vehicle 
control was also included (0.01% DMSO). Data is representative of one individual experiment. * 
marks the degree of significance compared to the vehicle control, where *≤0.05, **≤0.01, ***≤0.001. 
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5.2.5. DLBCL cell lines are insensitive to the TNFα neutralising agent 
Infliximab and the TNFα antagonist Etanercept 
 
To investigate whether DLBCL cells rely on autocrine TNFα signalling for their survival, 
RIVA, U2932 and WSU-NHL cells were treated with a range of concentrations (0μg/ml-
30μg/ml) of the TNFα neutralising agent Infliximab or the TNFα antagonist Etanercept 
for 72 hours before cell viability was recorded using the resazurin assay (figure 66). 
Human IgG was used as a control antibody. Inhibition of TNFα receptor binding and 
inhibition of downstream pathways did not significantly affect the viability of cells, even 
at high concentrations, suggesting that cell lines were not dependent on TNFα signalling 
for their survival.  
It was next considered that perhaps the inhibition of simply one cytokine (TNFα) in these 
experiments may not have had an effect due to the multiple other growth factors and 
components in the cell medium supplemented with FBS. RIVA and U2932 cells were 
therefore stripped of serum factors by being cultured in either 10%, 5%, 1% or 0% FBS 
in addition to 20µg/ml Infliximab or human IgG for a timecourse of 24, 48 or 72 hours 
(figure 67). Reduction of serum concentrations did not have any effect on the viability of 
either cell line compared to the untreated or IgG control. The growth of cells plateaued 
out (U2932) or began to reduce (RIVA) after 48 hours of culture in 1% or 0% FBS, 
however this was not due to TNFα inhibition, but was rather due to deprivation of cells 
of essential nutrients in the FBS. This experiment was also performed using 20µg/ml 
Etanercept; however a similar lack of effect was observed (figure 68).  
Considering the inhibitory effects of TNFα neutralisation on DLBCL proliferation  
reported by Pedersen et al (2009) in OCI-Ly3 and Toledo cell lines, the anti-TNFα 
regimen was also conducted using these two cell lines (figure 69a and b). Interestingly, 
in my analysis, OCI-Ly3 and Toledo cells were identified as having minimal TNFα 
production, while also expressing very low levels of NFAT2, a potential regulator of 
TNFα (figure 61a. 65c and figure 15). For these reasons, HLY-1 cells (which also 
demonstrated low TNFα production, but with high NFAT2 expression) were run 
alongside OCI-Ly3 and Toledo treatment with Infliximab and Etanercept (figure 69c). 
Surprisingly, all three cell lines were unresponsive to 72 hours treatment with TNFα 
neutralising agents. 
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In a final effort to investigate a potential growth inhibitory effect of Infliximab and 
Etanercept, OCI-Ly3 and RIVA cells were treated for shorter incubation periods to 
confirm that potential effects were not being missed (figure 69d-e and g-h). After 24 and 
48 hours incubation, there was no significant effect on cell viability in OCI-Ly3 cells. A 
modest effect was observed in RIVA cells by 48 hours of treatment, however without 
repetition of this experiment, no solid conclusions can be drawn. Had there have been 
sufficient time for repetitions to be made, this effect may have become significant. 
To assess whether Infliximab and Etanercept had an effect on the early stages of 
apoptosis, the expression of PARP and its cleaved apoptotic fragment were analysed by 
Western blot (figure 69f and i). The presence of just the upper band indicated PARP was 
expressed in its uncleaved form, indicating that anti-TNFα treatment had no effect on the 
apoptotic cellular machinery. Finally, as an additional measure of cell viability to the 
resazurin assay, manual cell counting by trypan blue exclusion was performed, but no 
effect of the anti-TNFα treatment was seen (figure 69j-k). Of note, anti-TNFα treatments 
were only tested in cell lines with high TNFα production, where NFAT and NF-κB 
inhibitors affected both TNFα expression and viability.  
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a) b) 
c) d) 
e) f) 
Figure 66. DLBCL cell lines are insensitive to the TNFα neutralising agent Infliximab and the 
TNFα antagonist Etanercept. a-c) The DLBCL cell lines RIVA, U2932 and WSU-NHL were treated 
with a range of concentrations of the TNFα neutralising antibody Infliximab and a control human IgG 
(0μg/ml-30μg/ml), including a vehicle control (1% PBS + 0.05% FBS). d-f) RIVA, U2932s and WSU-
NHL were treated with a range of concentrations of the TNFα antagonist Etanercept (0μg/ml-30μg/ml), 
including a vehicle control (1% PBS + 0.05% FBS). Cells were incubated for 72 hours before cell 
viability was recorded using the resazurin assay. Data is representative of one experiment where error 
bars indicate the standard deviation of triplicate wells. 
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a) 
c) 
b) 
d) 
e) f) 
g) h) 
Figure 67. DLBCL cell lines deprived of serum factors are insensitive to the TNFα neutralising 
agent Infliximab. The DLBCL cell lines RIVA (a-d) and U2932 (e-h) were treated with 20μg/ml of 
the TNFα neutralising antibody Infliximab and a control human IgG, including a vehicle control (1% 
PBS + 0.05% FBS). Cells were cultured for 24, 48, 72 or 96 hours in a range of concentrations of FBS, 
including 10% (a and e), 5% (b and f), 1% (c and g) and 0% (d and h). Cell viability was then recorded 
using the resazurin assay. Data is representative of one experiment where error bars indicate the standard 
deviation of triplicate wells. 
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a) 
c) 
b) 
d) 
e) f) 
g) h) 
Figure 68. DLBCL cell lines deprived of serum factors are insensitive to the TNFα antagonist 
Etanercept. The DLBCL cell lines RIVA (a-d) and U2932 (e-h) were treated with 20μg/ml of the TNFα 
antagonist Etanercept, including a vehicle control (1% PBS + 0.05% FBS). Cells were cultured for 24, 
48, 72 or 96 hours in a range of concentrations of FBS, including 10% (a and e), 5% (b and f), 1% (c 
and g) and 0% (d and h). Cell viability was then recorded using the resazurin assay. Data is representative 
of one experiment where error bars indicate the standard deviation of triplicate wells. 
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a) b) 
d) e) 
g) h) 
c) 
f) 
i) 
j) k) 
RIVA Vehicle control 0.77 1.56
RIVA IgG 0.64 2
RIVA Infliximab 0.57 1.47
RIVA Etanercept 0.79 1.77
Cell density (x10
6
/ml)
TreatmentCell line
24 hours 48 hours
OCI-Ly3 Vehicle control 0.49 1.4
OCI-Ly3 IgG 0.65 0.96
OCI-Ly3 Infliximab 0.58 1.14
OCI-Ly3 Etanercept 0.37 1.13
Cell line Treatment
Cell density (x10
6
/ml)
24 hours 48 hours
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5.3.Discussion 
 
5.3.1. TNFα production by DLBCL cell lines 
 
The Quantikine TNFα ELISA was a useful tool for confirming that DLBCL cell lines 
produce TNFα. TNFα was largely heterogeneous among the panel and no apparent 
correlation was observed between TNFα production and particular DLBCL subgroups. 
Half of the ABC cell lines, for example displayed high TNFα production (RIVA and 
U2932) whereas the remaining ABC lines generated much lower TNFα concentrations 
(HLY-1 and OCI-Ly3). The degree of heterogeneity observed may be due to alternative 
mechanisms of TNFα modulation by NFAT or other transcription factors in these cells.  
If NFAT were a master regulator of TNFα induction in DLBCL it is possible that NFAT 
protein expression and activation in cell lines may correlate with the degree of TNFα 
produced. Analysis showed that although some cell lines expressed medium-high levels 
of NFAT1 and NFAT2 protein (chapter 3, figure 15 and 17a) in association with high 
production of TNFα (such as the four highest TNFα-producing cell lines RIVA, U2932, 
Farage and WSU-NHL), this correlation was not consistent among the cell line panel. 
HLY-1 for example, expressed substantially high levels of NFAT1 and NFAT2 protein, 
yet produced very little TNFα. SUDHL-4 on the other hand, also produced small 
quantities of TNFα, but expressed active NFAT1 and NFAT2 at considerably low levels.  
Comparing cell line TNFα production with data in the literature is difficult due to 
differences between cell types tested, incubation periods, culture conditions and 
experimental setup. Generally speaking however, the concentrations of TNFα produced 
Figure 69 (Continued from previous page). Viability and apoptosis of ‘Etanercept-sensitive’ 
DLBCL cell lines used in the literature are unaffected by anti-TNFα treatment. a-c) The DLBCL 
cell lines OCI-Ly3, Toledo and HLY-1 were treated with 10μg/ml of the TNFα neutralising antibody 
Infliximab, the TNFα antagonist Etanercept or a control human IgG, including a vehicle control (1% 
PBS + 0.05% FBS). Cell viability was recorded after 72 hours incubation. d-e and f-g) DLBCL cell 
lines OCI-Ly3 and RIVA were treated with 10μg/ml of Infliximab, Etanercept or control human IgG, 
including a vehicle control (1% PBS + 0.05% FBS). After 24 hours (d and g) or 48 hours (e and h) 
cell viability was recorded using the resazurin assay. Data is representative of one experiment where 
error bars indicate the standard deviation of triplicate wells. f and i) Western blot analysis for OCI-
Ly3 and RIVA cells treated with Infliximab, Etanercept or human IgG for 24 and 48 hours. The effect 
of 10μg/ml anti-TNFα treatment on apoptosis was analysed using an antibody specific for the PARP 
protein (116KDa) and its cleaved fragment (89KDa). Molecular weight marker lines to the right of 
the Western blot indicate the approximate location of antibody binding. α-tubulin was included as a 
loading control. Data is representative of one experiment. j-k) Trypan blue exclusion was used to 
investigate the effect of 10μg/ml anti-TNFα treatment on RIVA and OCI-Ly3 cell viability after 24 
and 48 hours. Data in tables indicates manual cell counts for each treatment. Data is representative of 
one experiment.      
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by DLBCL cell lines (ranging from 20-150pg/ml) were considered relatively high, 
especially compared to non-cancerous cell lines. Basal expression of monocytes for 
example is around 25-50pg/ml, which can increase more than 10-fold after LPS 
stimulation (Guha et al., 2001; Maus et al., 2001). Moreover, Ebert et al (2006) found 
that TNFα production in human intestinal intraepithelial lymphocytes remained below 
20pg/ml after 5 days culture (Ebert et al., 2006). Cells were found to keep their TNFα 
levels low by low cell uptake of TNFα and negative feedback inhibition of transcription 
(Ebert et al., 2006).  
TNFα production in DLBCL cells appears to be either comparable or in some cell lines 
produced at higher levels compared to other cancer cell lines, for example, HT-29 human 
colon adenocarcinoma cells incubated for 48 hours in serum-free media were shown to 
produce 40-50pg/ml of TNFα  (Scamuffa et al., 2008). Moreover, the IGROV-1 ovarian 
cell line was reported to produce approximately 30pg/ml after 48 hours incubation (Kulbe 
et al., 2012).  
The effects of CsA treatment on TNFα production in these cell lines showed great 
consistency with the array results and qRT-PCR validation of samples used in the array. 
As seen in the array, where CsA treatment in U2932 cells at 2 hours caused a significant 
downregulation of TNFα mRNA, the ELISA assay also detected a substantial reduction 
in TNFα production. Also in line with the array, CsA had no effect on TNFα expression 
or production in WSU-NHL cells, further validating data from a number of different assay 
procedures.  
Data shown in figure 62b also confirmed the DLBCL subtype-specific effects on TNFα 
observed between cell lines in the array and validation experiments. Inhibition of 
calcineurin/NFAT signalling had no effect on TNFα in the GCB cell line WSU-NHL 
compared to the two ABC cell lines RIVA and U2932, suggesting that calcineurin/NFAT 
may regulate the expression of TNFα differently in specific disease subsets. Data in the 
literature reports TNFα expression to be a significant prognostic factor for overall survival 
and progression free survival in addition to being an independent prognostic factor of the 
IPI (Nakayama et al., 2014a; Nakayama et al., 2014b). As of yet only one research group 
has published evidence for the differential distribution of TNFα expression between ABC 
and GCB DLBCL. Future experiments would aim to check the effects of TNFα 
expression with CsA treatment in more cell lines. Moreover, immunohistochemical 
analysis of TNFα expression in patient samples with ABC and GCB DLBCL would be a 
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very interesting avenue to explore given the heterogeneity of TNFα production between 
cell lines observed in this study. 
5.3.2. Inhibition of TNFα signalling using Infliximab and Etanercept 
 
The response of DLBCL cell lines to Infliximab and Etanercept was first tested using a 
broad range of concentrations, however even doses considered to be high did not have 
any additional effect on cell viability. The range of concentrations of Infliximab and 
Etanercept were similar to or exceeded those used in the literature and were therefore 
considered appropriate (Mitoma et al., 2005; Teimourian et al., 2015). In fact, in the 
publication described previously where the viability of non GC-cells was reduced upon 
Etanercept and Infliximab treatment, doses as low as 100ng/ml were used at an identical 
72 hour timepoint (Pedersen et al., 2009). 
Before ruling out the hypothesis that cell lines depended on TNFα for survival, a number 
of alterations were made to the experimental procedure to see whether a potential effect 
was being missed. Of note, this series of optimisation experiments were performed as 
single experiments because it was not considered important to repeatedly produce 
negative results. After experimenting with different concentration of drug, cells were 
stripped of serum factors to allow the effects of TNFα inhibition to be more identifiable, 
however this had no effect on cell viability. Moreover, shorter incubation periods did not 
capture early effects of Infliximab or Etanercept, which also demonstrated a lack of 
impact on PARP cleavage. Together, the sum total of these data provided no evidence 
that anti-TNFα treatment impacts the viability of DLBCL cells, suggesting that 
calcineurin/NFAT-induced TNFα production does not promote the survival of cells in an 
autocrine fashion. A useful experiment in this study was confirmation that Etanercept and 
Infliximab were functioning appropriately, however a limitation of this assay was the use 
of U2OS cells rather than DLBCL cells. In hindsight, it may have been useful to have a 
cell line known to be sensitive to TNFα inhibition, although this effectively performed 
using Toledo and OCI-Ly3 cells used by Pedersen et al (2009) (Pedersen et al., 2009). 
A surprising observation was the lack of effect of Infliximab and Etanercept on the 
viability of OCI-Ly3 and Toledo cells, which were intended to complement our 
experiments by behaving as positive control cell lines. In their paper demonstrating 
autocrine stimulation of ABC DLBCL cell lines by TNFα, treatment of cells with 
0.1µg/ml Etanercept caused significant antiproliferative effects compared to untreated 
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control cells (Pedersen et al., 2009). Pedersen reported similar results using Infliximab; 
although these data were not shown. Growth inhibitory effects were observed in OCI-
Ly3, OCI-Ly10 and Toledo cells but not SUDHL-4 or the BL cell line Daudi (Pedersen 
et al., 2009). Sensitivity was concluded as being ABC DLBCL specific. However, Toledo 
cells in their study were wrongly classified and are in fact of GCB origin (Singh et al., 
2010). Nevertheless, to be absolutely sure that Etanercept and Infliximab were functional 
and to confirm published data, OCI-Ly3 and Toledo cells were treated with the anti-TNFα 
agents, but no anti-proliferative effects were observed.  
There are a number of possible reasons that the effects reported by Pedersen et al (2009) 
were not repeated in our study. These include differences in cell culture, underlying 
genetic changes developed by passaging of continuous cell lines and dissimilarities in 
assay procedures. Pedersen for example, used a Beckman Coulter Counter for cell 
proliferation assays, whereas viability experiments in this study were performed using the 
resazurin assay, which measures the metabolic activity of cells. It is possible that the 
resazurin assay may not have been sensitive enough to detect subtle changes in cell 
viability, however trypan blue exclusion analysis also showed no effects. Future work 
may benefit from using colony forming assays to investigate whether Etanercept or 
Infliximab prevent the formation of a population of cells from one single cell.   
Pedersen et al (2009) undoubtedly presented evidence for a clear mechanism proving that 
Onco-miR-155 targets SHIP1 to promote TNFα-dependent growth of DLBCL cells 
through autocrine stimulation by TNFα (Pedersen et al., 2009). Their study even 
demonstrated a substantial decrease in tumour burden using xenograft models treated 
with Etanercept (Pedersen et al., 2009). Despite this, it could be argued that their data 
lacked detailed investigation into the underlying production of TNFα by cell lines. Having 
investigated TNFα production in a comprehensive panel of DLBCL in this PhD study, it 
was recognised that OCI-Ly3 and Toledo cells were among the lowest producers of TNFα 
(and NFAT2 expression). It is possible that the small quantity of TNFα released from 
these cells is critical for autocrine survival mechanisms; although our data demonstrated 
no difference between cell line sensitivity and TNFα production.  
5.3.3. TNFα and future work  
 
In the future it would be useful to silence TNFα in DLBCL cell lines by shRNA 
knockdown. This would be a beneficial method for understanding the precise role of 
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TNFα in DLBCL, enabling further experiments to be conducted. Importantly, to pinpoint 
exactly which NFAT isoform upregulates TNFα in DLBCL cells, future experiments 
could use shRNA knockdown of individual NFAT family members. Similarly, ChIP 
experiments could be used to confirm TNFα as an NFAT target gene, where analysis of 
which NFAT isoforms bind to the TNFα promoter could be determined. As mentioned 
previously, TNFα is already a known NFAT1 target gene in other cellular systems, such 
as NIH/3T3 fibroblasts, where NFAT1 was demonstrated to induce cell death through 
cooperation with the Ras/Raf/MEK/ERK pathway and up-regulation of TNFα (Robbs et 
al., 2013). Although NFAT1 was highly tumour suppressive in NIH/3T3 fibroblasts, 
regulation of TNFα in DLBCL may differ. A key question is whether regulation of TNFα 
by other NFAT isoforms may exert oncogenic roles in DLBCL. Ultimately, the relative 
balance of TNFα regulation by different NFAT isoforms may result in contrasting effects, 
some which may be tumour suppressive and others oncogenic.   
Cooperative effects between NFAT and NF-κB signalling in DLBCL remains to be fully 
investigated. In chapter 4, analysis of combined CsA and TPCA-1 treatment 
demonstrated variable effects on cell viability, where additive effects were observed in 
select cell lines. Although a valid approach for investigating synergy between NF-κB and 
NFAT signalling, this data did not capture potentially interesting coordinate regulation of 
specific genes which may be important for DLBCL survival. After the NF-κB target gene 
TNFα was identified as a potential calcineurin/NFAT target gene by gene expression 
microarray analysis I investigated whether TNFα is also an NF-κB target gene in DLBCL 
cells. First I tested the effects of TPCA-1 on NF-κB, where ELISA assays proved to be a 
useful, sensitive tool for analysis, effectively showing a considerable reduction in p65 
activity upon TPCA-1 treatment. Retrospectively, in previous TPCA-1 biochemical 
assays, where the conclusion was that TPCA-1 is an ineffective NF-κB inhibitor in 
DLBCL, additional assay techniques should have been used to confirm its effects. An 
interesting result was the differential effect of IKK2 inhibition on p65 and c-Rel activity. 
Although both subunits are highly involved in canonical NF-κB signalling, TPCA-1 
exerted very mild effects on c-Rel activity compared to p65, suggesting that IKK2 
inhibition may be subunit-specific. These data suggest that future investigation of NF-
κB/NFAT synergy may require inhibition of both of these subunits. Interestingly, 
functional redundancy between c-Rel and p65 have in fact been reported in the literature, 
where mice lacking combinations of different NF-κB proteins demonstrated different 
haematopoietic and immune functions (Grossmann et al., 1999). 
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TNFα was shown to be an NF-κB target gene by qRT-PCR analysis, however 
downregulation of TNFα mRNA expression by combined inhibition of NF-κB and NFAT 
was not significant enough for the effects to be considered additive or synergistic. 
Interestingly, through access of previously published ChIP-sequencing data, binding of 
the NFAT and NF-κB transcription factors to the promoter regions of the TNFα gene in 
lymphoblastic cells were identified (appendix figure 20, provided by Professor Neil 
Perkins). Transcription factor binding data was accessible through the ENCODE 
(Encyclopaedia of DNA Elements) consortium  
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32465, accessed 18.09.15; 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1010779, accessed 18.09.15). 
One study, which used ChIP-seq to investigate the genetic landscape of NF-κB binding, 
revealed strong peaks around the TNFα promoter regions and were particularly apparent 
for the RelA, RelB and c-Rel NF-κB subunits (Zhao et al., 2014). Appendix figure 20, 
also shows ChIP-seq data for NFAT2, which was obtained from a study analysing the 
cell-type-specific DNA-binding of the oestrogen receptor (Gertz et al., 2013). 
Importantly, both studies used EBV-transformed GM12878 lymphoblastic cells, allowing 
sensible comparisons to be made regarding the DNA binding of the NFAT and NF-κB 
transcription factors in lymphoma cells. Interestingly, the peaks also indicate binding of 
NFAT2 to the TNFα promoter, which occurred in similar areas to NF-κB. Additionally, 
strong NF-κB peaks were observed surrounding the LTB (TNFβ) gene, however this was 
not apparent for NFAT2.                
Overall, there is undoubtedly evidence, both in literature and from this study, supporting 
a role for TNFα in DLBCL. Anti-TNFα therapy for DLBCL is a feasible novel co-
treatment for DLBCL; however the function of TNFα and its precise mechanism action 
must first be better understood. Confirmation that TNFα is a direct target of NFAT 
remains to be elucidated and further investigation of cooperative regulation of TNFα 
between NFAT and NF-κB is required.  
 
 
Chapter 7. 
Discussion and Future Directions 
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6. Discussion and Future Directions 
 
6.1. Exploration of NFAT pathway activation and inhibition 
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In this study, the expression of two lymphoid-specific NFAT family members, NFAT1 
and NFAT2, were confirmed to be heterogeneously expressed in a large panel of DLBCL 
cell lines. In many cell lines, NFAT proteins were located in the nucleus in their activated 
state, which was also confirmed using an NFAT2 DNA-binding ELISA. These data were 
in line with studies in the literature, which showed expression of nuclear NFAT2 in 
DLBCL patient samples and cell lines (Marafioti et al., 2005; Pham et al., 2005). Similar 
to the heterogeneity of the disease, these data imply significant differences between 
DLBCL cell line expression and activation of NFAT.  
Due to difficulties experienced with the small molecule compound INCA-6 and the 
peptide inhibitors VIVIT and MCV-1, the calcineurin inhibitor CsA was chosen as the 
best possible option for use in the microarray. It was accepted that, by using CsA, it could 
not be certain that differentially expressed genes were direct NFAT target genes. Changes 
in gene expression for example, could potentially be a downstream effect of calcineurin 
inhibition. Although far from perfect, it was anticipated that true NFAT target genes could 
later be identified by means of ChIP analysis or knockdown of NFAT family members, 
as described below.  
This study demonstrated that CsA treatment reduced the viability of cells by inducing cell 
cycle arrest and apoptosis. Despite the use of CsA as an effective immunosuppressant in 
the clinic for the prevention of organ transplant rejections, its application for the treatment 
of cancer is unlikely (Kiani et al., 2000). In addition to its off target effects on other 
pathways (such as NF-κB) and its neuro- and nephrotoxicity, CsA is also a reported 
inhibitor of multidrug resistance protein 2 (MRP2) (Kiani et al., 2000; Rezzani, 2004; 
Hesselink et al., 2005; El-Sheikh et al., 2014). Similar to p-glycoprotein, which encodes 
the multidrug resistance protein 1 (MRP1), multidrug resistance proteins are derived from 
a superfamily of ATP-binding cassette (ABC) transporters that pump molecules out of 
cells (Gottesman et al., 1993; Borst et al., 2000). The presence of these transporters in 
tumour cells makes them key suspects for drug resistance in cancer treatment. CsA was 
demonstrated to interact with mycophenolic acid (MPA), (an immunosuppressant often 
used in combination with CsA as transplant therapy) by inhibiting MRP2, which targets 
MPA (Hesselink et al., 2005; El-Sheikh et al., 2014). CsA caused a reduction in cell 
exposure to MPA, which, should the same apply in cancer therapy, could prevent 
therapeutic agents from having their desired effect in the cell (Hesselink et al., 2005). 
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Reports such as this imply that CsA is probably best used as a tool for research purposes 
only, such as by aiding our understanding of NFAT function in DLBCL.   
There is demand for new, highly specific inhibitors of NFAT that are suitable for research 
purposes and are clinically applicable. To better understand the specific requirements and 
functions of specific NFAT family member isoforms, it is key that there be structural 
studies of the full-length phosphorylated and dephosphorylated proteins, to which 
inhibitors can subsequently be designed. Future efforts to inhibit NFAT may also be 
through upstream inhibition, such as by targeting components of the BCR. For this to be 
pursued however, a better understanding for the mechanisms by which NFAT is regulated 
in different diseases is required. Alternatively, NFAT may be inhibited by gaining a better 
understanding of its natural inhibitors. Activity of the NFAT export kinase GSK-3β, for 
example, is downregulated in some human solid tumours as a result of inhibition from 
hyperactivity of the PI3K/AKT pathway (Mancini et al., 2009). Consequently, this leads 
to constitutive activation of NFAT in the nucleus, which may perhaps be reversed by 
effective inhibition of PI3K or AKT (Mancini et al., 2009).     
6.2. Gene expression microarray analysis  
 
Characterisation of cell lines and sensitivities to CsA enabled selection of appropriate cell 
lines for gene expression microarray analysis. Despite producing a surprisingly low 
number of statistically significant genes, the microarray nonetheless generated a wealth 
information, highlighting potential NFAT target genes that may be important for 
lymphomagenesis. Analysis of some of the most significantly up- or downregulated genes 
from the array by qRT-PCR analysis validated the accuracy of the microarray. Given the 
differences observed between unpaired and paired analysis of the array data, these 
experiments were also a useful tool for proving that paired analysis was the best form of 
data analysis. 
The molecular pathways on which the ABC and GCB DLBCL subgroups depend for 
survival and growth are vastly different and thus they represent two different disease 
entities with severely different outcomes (Lenz et al., 2008c). It is therefore not surprising 
that distinct differences in transcriptional regulation are frequently observed between the 
subgroups. Initial analysis of the microarray suggested that the genes regulated by 
calcineurin/NFAT may be different between ABC and GCB cell lines. Subsequent 
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experiments treated a larger panel of DLBCL cell lines with CsA and found that indeed, 
specific genes, such as TNFα, were downregulated by CsA in mostly ABC cell lines only.  
To further explore differences between the modes of gene regulation by NFAT in 
different subgroups of DLBCL, a gene expression microarray using a broader panel of 
cell lines would be required. Moreover, additional microarray analysis could include 
samples which have been treated with CsA for a longer period of incubation. This would 
generate a greater selection of genes to analyse, therefore providing a more 
comprehensive analysis of the primary and secondary effects of NFAT transcriptional 
regulation. Longer inhibition of calcineurin/NFAT could also be of particular use for 
understanding the role of NFAT in WSU-NHL/GCB cells, where few genes were 
differentially expressed after 2 or 6 hours CsA incubation. Should NFAT regulate select 
genes in ABC vs. GCB DLBCLs, and genes identified are proven critical for the 
development and maintenance of lymphoma, this could have a huge impact on a more 
stratified approach to the future treatment of these diseases.  
6.3. Possible roles for the NFAT signalling pathway in DLBCL 
 
Considering the significant effects of CsA on cell viability shown in previous 
experiments, it was anticipated that genes differentially expressed in the microarray were 
likely to represent genes associated with cell death, survival or cell cycle regulation. 
Interestingly, for the vast majority of statistically significant genes, this was not the case. 
Future analysis would benefit from Ingenuity Pathway Analysis, which could identify 
genes whose expression patterns and ontology suggest a critical role in cell death or 
survival. Interestingly, the gene expression array did reveal a small number of potential 
NFAT target genes that have previously been associated with cancer or lymphoma. In the 
future, it would be of interest to follow up some of these genes, such as PAX9, CD69, 
SOCS3 and NFKBIZ.  
 
6.4. Induction of anergy 
 
GSEA was a helpful tool for confirming that some of genes in the microarray were 
associated with previously published gene sets. For example, a gene set associated with 
anergy was statistically significant in U2932 and HLY-1 cells, but not in WSU-NHL cells. 
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Indeed, the array demonstrated downregulation of EGR2 in these two ABC DLBCLs and 
EGR3 in HLY-1 cells, suggesting that NFAT transcription factors normally upregulate 
the genes encoding these proteins.  
EGR2 and EGR3 are well-documented regulators of the induction of anergy (Gómez-
Martín et al., 2010). In murine models for example, deficiency of EGR2 and ERG3 
transcription factors have been associated with a phenotype resistant to anergy (Gómez-
Martín et al., 2010). Moreover, their expression has been shown to be highly upregulated 
by using microarray analysis of anergic T-cell clones (Safford et al., 2005).  
In the past ten years, NFAT transcription factors have been repeatedly reported to have a 
central role in the control of tolerance mechanisms. Formation of NFAT1 homodimers, 
for example, have been identified as transcriptional complexes responsible for the 
expression of anergy-inducing genes in T cells, such as Grail and Caspase-3 (Noemi 
Soto-Nieves, 2009). NFAT1 has also recently been identified as a key mediator of the 
expression of anergy-associated genes in the context of cancer, where CD4+ T cells 
isolated from the draining lymph nodes of Nfat1-/- tumour-bearing mice lacked an anergic 
phenotype, which was observed in wild-type T cells (Abe et al., 2012). 
Interestingly, EGR family members are known to form stable heterodimers with NFAT 
and regulate the expression of proinflammatory cytokines, such as TNFα (Decker et al., 
2003). Interestingly, EGR2 and EGR3 have also been reported as NFAT target genes, 
suggesting that the interplay between these transcription factors could enhance an anergic 
phenotype (Rengarajan et al., 2000). In the context of lymphoma, a study has shown 
EGR1 and NFAT2 to cooperate in the regulation of early stages of T-cell lymphoma 
development, however this was not found true for EGR2 and EGR3 (Koltsova, 2007).  
Direct interaction with anergy-promoting proteins, and induction of anergy-inducing 
genes, could place NFAT as a key driver of immune unresponsiveness in the tumour 
microenvironment. NFAT may therefore assist evasion of immune destruction in 
lymphoma, thereby demonstrating the characteristics of one of Hanahan and Weinberg’s 
most recent hallmarks of cancer (Hanahan et al., 2011). Moreover, studies investigating 
the role of EGR2 and EGR3 in B-cell lymphomas are lacking and may be of great interest 
and therapeutic value.     
6.5. Cooperation with the NF-κB pathway  
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One of the aims of this study was to investigate cooperativity between the NFAT and NF-
κB signalling pathways in DLBCL. First, the effects of simultaneous inhibition of the two 
pathways using CsA and TPCA-1 were explored, although no strikingly obvious effects 
were observed. Considering the requirement of NF-κB and NFAT for the function of 
normal cells, this approach was not likely to ever translate to a clinical setting. It was 
possible however, that NFAT and NF-κB may still coordinate joint target genes which 
are important in lymphoma. For example, it was hypothesised NFAT and NF-κB may 
separately regulate genes whose simultaneous depletion creates a synthetic lethal 
phenotype, resulting from loss of in-built redundancy. Using a more specific approach 
therefore, the effects of CsA and TPCA-1 on TNFα mRNA expression were analysed. 
Inhibition of NF-κB confirmed TNFα to be an NF-κB target gene in DLBCL cells and 
when simultaneously treated with CsA, the expression of TNFα was downregulated 
slightly more than one treatment alone. However this was not significant enough for the 
effects to be considered additive or synergistic. Future work may investigate the effect of 
combined NFAT and NF-κB inhibition on other potential NFAT target genes that were 
generated from the microarray.  
Due to time restrictions, a comprehensive analysis of known, databased NF-κB target 
genes were not cross-referenced with genes identified in the gene expression microarray. 
Although this would be an interesting avenue to explore, ChIP-seq analysis using DLBCL 
cell lines would be a superior experimental choice, allowing confirmed NFAT target 
genes in DLBCL cells to be considered as joint NF-κB target genes. Co-regulated NFAT 
and NF-κB target genes may represent important nodes of integration between NFAT and 
NF-κB signalling, where sequential ChIP analysis would ultimately be used to confirm 
simultaneous promoter occupancy and siRNA knockdown could be used to determine if 
NFAT and NF-κB promoter binding is interdependent. As described previously, there 
appear to be contrasting opinions as to the interaction of NFAT and NF-κB when they 
bind to DNA. While publications in the past have suggested coordinate regulation of 
genes such as CD154, some researchers are critical of the experimental approach taken 
to reach these conclusions (Pham et al., 2005; Fu et al., 2006; Muhammad et al., 2014). 
Recently, evidence suggests that the connection between NF-κB and NFAT signalling in 
BCR-induced B cells is by induction of the NFAT2/αA short isoform by the p50 and c-
Rel NF-κB subunits (Muhammad et al., 2014). Although these two transcriptional 
pathways are individually important for DLBCL, the complexity with which they interact 
is likely to be very complex. 
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6.6. Tumour microenvironment  
 
After 125 years, Stephen Paget’s seed and soil hypothesis has finally been accepted, 
where relationships between cancer cells and the cells of the microenvironment are 
proving pivotal for the fate of the tumour (Paget, 1889). Recent evidence suggests that 
NFAT may be a key mediator in the creation of the tumour microenvironment and the 
potentiation of tumourigenesis (Mancini et al., 2009; Tripathi et al., 2013).  
The gene expression array highlighted an abundance of potential NFAT target genes 
which are known to play key roles in immunity and possibly the tumour 
microenvironment. For example, among the genes significantly downregulated by CsA, 
were the chemokines CCL4L1, CCL4L2, CCL3, CCL3L1 and CCL3L3, and the 
cytokines LTA and IL-10. Interestingly, LTA, also known as TNFβ, has been linked to 
cancer, while IL-10 is known to function as an enhancer of B-cell survival and 
proliferation (Itoh et al., 1995; Drutskaya et al., 2010). Little is known about the functions 
of many of the chemokines generated by microarray analysis, suggesting future avenues 
for this project to be directed.     
In addition to the induction of an array of inflammatory chemokines, NFAT family 
members appear to have a close relationship with macrophages. Upregulation of 
chemokines by NFAT in advanced breast cancer, for example, is known to stimulate 
macrophage infiltration and secretion of EGF and colony stimulating factor 1 (CSF1) 
(Muller et al., 2001). In turn, EGF activates NFAT signalling in a feedforward paracrine 
loop, which consequently induces further production of CSF1 (Wyckoff et al., 2004; 
Wang et al., 2012). Specifically, NFAT2 has recently been shown to initiate primary 
tumour formation by establishment of a tumour microenvironment (Tripathi et al., 2013). 
In addition to autonomous NFAT signalling, by upregulation of oncogenic proteins, 
Tripathi et al (2013) demonstrated that NFAT2 has non-cell autonomous effects on 
nearby cells (Tripathi et al., 2013).   
In this study, TNFα was identified as being one of the most significantly downregulated 
genes among ABC DLBCL cell lines and gene sets associated with TNFα signalling were 
identified by GSEA. Given the recently reported correlation between TNFα expression 
with worse overall survival and progression-free survival in some patients with DLBCL, 
I decided to investigate its role further. After demonstrating high levels of biologically 
active TNFα production in a select number of DLBCL cell lines, the sensitivity of cells 
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to inhibition of TNFα signalling were tested, as previously reported by Pedersen et al 
(2009) (Pedersen et al., 2009). Overall, Infliximab and Etanercept had no effect on the 
viability of DLBCL cells, suggesting that calcineurin/NFAT-induced TNFα production 
does not promote the survival of cells in an autocrine fashion.  
 
Figure 70. Proposed mechanism of action for NFAT in the tumour microenvironment. NFAT-
mediated TNFα production by DLBCL cells (purple) is released into the tumour microenvironment before 
binding to TNFα receptors on non-tumour cells, such as macrophages or stromal cells in a paracrine fashion 
(blue). In turn, non-tumour cells produce TNFα and growth factors that allow surrounding cells to thrive. 
TNFα released by non-tumour cells may subsequently activate TNFα responsive pathways in DLBCL cells.       
 
TNFα produced by DLBCL cells may however, be of functional relevance in a paracrine 
fashion, signalling to nearby cells in the tumour microenvironment. TNFα produced by 
DLBCL cells may stimulate signalling pathways of neighbouring non-tumour cells, such 
as macrophages, which in turn produce more TNFα and potentially increase the 
expression of growth factors. Growth factors produced by non-tumour cells may 
consequently activate signalling pathways in DLBCL cells. A similar phenomenon has 
been described in epithelial ovarian cancer, where TNFα produced by cancer cells was 
shown to sustain a tumour-promoting cytokine network in the microenvironment, which 
then promoted neovascularisation of tumour deposits in an autocrine and paracrine 
fashion (Kulbe et al., 2007). Moreover, paracrine signalling has been shown to be 
important for tumour growth in mouse models of colon cancer (Greten et al., 2004). For 
example, deletion of IKKβ in myeloid cells from colitis-associated mice inhibited tumour 
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growth and development by production of tumour-promoting paracrine factors, including 
TNFα (Greten et al., 2004). Release of TNFα from DLBCL cells may therefore create a 
pro-proliferative tumour microenvironment, a proposed model for which is shown in 
figure 70. 
In the future, this could be analysed by xenograft experiments where cells treated with or 
without TNFα neutralising agents could be injected into mouse models and the effects on 
nearby cells observed. Moreover, paracrine effects of TNFα could be investigated by 
trans-well assays, where the effects of TNFα (produced by DLBCL cell lines) on 
neighbouring cells could be evaluated, for example by analysing the effects on NF-κB 
target gene expression. 
6.7. Future work/directions for the project 
 
6.7.1. Knockdown of NFAT transcription factors 
 
There is currently little understanding of the specific genes that NFAT family members 
and their isoforms regulate. ChIP-seq would be a suitable assay technique for identifying 
specific NFAT family member target genes in DLBCL cell lines, which would ultimately 
aid our understanding for the differential functions described in the literature.  
Alternatively, shRNA knockdown of particular NFAT family members would have been 
a highly beneficial method for determining their function in cell line models of DLBCL. 
In fact, considerable time was spent during this study to achieve shRNA lentiviral 
knockdown of NFAT1 and NFAT2 by means of the PTRIPZ inducible system (Thermo-
Scientific). For this, plasmid DNA was prepared and co-transfected into 293T cells before 
extraction of virus. DLBCL cell lines were subsequently transduced by spinfection and 
induced by addition of doxycycline. Unfortunately, considerable difficulty was 
experienced in transducing the DLBCL cell lines when compare to cell line models of T-
cell lymphomas used in the laboratory. The expression of red fluorescent protein (RFP), 
detected by FACs analysis was used as a measure of percentage cells transduced and the 
DLBCL cell lines rarely demonstrated more than 5% transduction efficiency, as shown 
in appendix figure 21a. Using a potent non-silencing virus, the transduction of DLBCL 
cells were compared to two T-cell lines. After 72 hours of doxycycline induction, the T 
cells demonstrated transduction of over 80%. To decrease the chances of multiple 
integration of the shRNA into the DNA of cells, an ideal transduction efficiency of 30% 
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is usually required. With such ineffective transduction in the B cells, puromycin selection 
was challenging due to the high volume of death occurring in puromycin-sensitive cells. 
This was eventually overcome by considerably reducing the cell media volume, allowing 
healthy transduced cells to grow and eventually (after around three weeks of careful 
culture), become fully transduced. Interestingly, the difficulties of transducing these 
mature B cells have also been experienced by other well-known research groups, 
including the Louis Staudt laboratory (National Cancer Institute, USA), however the 
reasons for this are currently unknown.    
Although stable cell lines were generated and knockdown of NFAT2 protein was 
achieved, as indicated by Western blot analysis (appendix figure 21b-c), the degree of 
protein knockdown was highly variable between experiments. In addition, the expression 
of NFAT2 mRNA was also variable between experiments and was often only slightly 
downregulated (appendix figure 21d). Furthermore, qRT-PCR experiments were 
performed to investigate the effect of NFAT2 knockdown on genes differentially 
expressed in the microarray. However, as illustrated in appendix figure 21e, expression 
of potential NFAT target genes in DLBCL cells were highly sensitive to doxycycline 
treatment alone, making the data inaccurate and unreliable. Interestingly, a recent paper 
was published showing that doxycycline accumulates in DLBCL cells to high 
concentrations and affects multiple signalling pathways crucial for lymphomagenesis 
(Pulvino et al., 2015). For these reasons, and due to time restrictions, no further work 
regarding shRNA related studies were carried out. 
In the future, this project would highly benefit from knockdown studies, both to 
investigate the role of NFAT transcription factors, but also to analyse the effects of TNFα 
depletion. While NFAT dominant negative constructs are available for purchase, it would 
be more ideal to optimise a method for shRNA knockdown, which can be used to 
investigate various proteins of interest, including NFAT, TNFα, or even NF-κB subunits. 
There are a number of different options available, including use of the GIPZ system for 
shRNA knockdown, which although is non-inducible, is smaller in size and known to 
achieve a higher degree of transduction into cells (www.dharmacon.com, 2015).   
Alternatively, the CRISPR-Cas9 (clustered, regularly interspaced, short palindromic 
repeat-Cas9) system for gene knockdown is proving to revolutionise biomedical research 
and could be an advantageous technique for future work on this project. CRISPR/Cas is 
derived from a prokaryotic adaptive immune response, allowing organisms such as 
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bacteria and archaea to respond to and eliminate invading genetic material (Pyzocha et 
al., 2014). The CRISPR/Cas approach generates RNA-guided nucleases, such as Cas9, 
which can cut any desired location of the genome in a highly targeted manor (Sander et 
al., 2014).   
6.7.2. Translational studies using tissue microarray analysis (TMA) 
 
Finally, to gain insight into how this research project translates into the clinical setting, it 
would be interesting to obtain experimental data using DLBCL patient samples. A tissue 
microarray is in the process of being prepared within the lymphoma team, which will 
ultimately be used to analyse around 250 cases of de novo R-CHOP-treated DLBCL. It 
would be of great interest to stain for different NFAT family members and compare 
expression levels between different subgroups of patients with DLBCL.  
In addition, the TMA would also be of value for confirming the high level of TNFα 
expression observed by Nakayama et al (2014) in DLBCL-NOS patient samples 
(Nakayama et al., 2014a). Moreover, a particularly interesting analysis would involve 
probing for a selection of proteins associated with the tumour microenvironment, such as 
those revealed in the gene expression microarray. This would help gain an understanding 
of the nature of the tissue microenvironment surrounding different subgroups of 
lymphoma.   
6.8. Study Summary 
 
The data in this study has provided a strong foundation for future research regarding the 
role of the NFAT signalling pathway in DLBCL. Required for the survival of DLBCL 
cell lines, the calcineurin/NFAT pathway was demonstrated to regulate many genes 
associated with different aspects of cancer biology.  
Data obtained from the gene expression microarray may act as a platform for future 
projects to be performed within the lymphoma team. In time, a greater understanding for 
the functions of other genes identified will be established, which may yet have a 
significant impact on our mission to understanding this devastating disease. Should the 
NFAT target genes investigated be oncogenic, or DLBCL subgroup –specific, there is 
opportunity to move towards a more stratified treatment approach.   
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Overall, the potential involvement of NFAT in the regulation of TNFα and the tumour 
microenvironment was a key finding in this study and could be of great importance. 
Ultimately, any new therapy targeting NFAT will need to consider the cell-dependent and 
context-dependent functions of NFAT within the microenvironment. Furthermore, 
treatment strategies will also need to comprehend the contribution of specific NFAT 
isoforms in different types of cancer.   
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Appendix Figure 1. CsA causes a dose-dependent and time-dependent reduction in cell viability in 
DLBCL cell lines. The GCB DLBCL cell line WSU-NHL (a-c) and ABC DLBCL cell lines U2932 and 
HLY-1 (b-i) were treated with a range of concentrations of CsA (0μg/ml-30μg/ml), including a vehicle 
control (0.02% DMSO). Cells were incubated for 24, 48 and 72 hours before recording cell viability using 
the resazurin assay. Data is representative of one experiment where error bars indicate the standard 
deviation of triplicate wells. 
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U2932 2hr (unpaired data analysis) 
symbol name Family Information based on GeneCard (www.genecards.org)
TNF tumor necrosis factor
Cytokine
Encodes a multifunctional proinflammatory cytokine that belongs to the tumour necrosis 
factor superfamily. Mostly secreted by macrophages and is involved in cell proliferation, 
differentiation, apoptosis and many other cellular processes. Implicated in diseases such 
as cancer, autoimmune diseases and insulin resistance. 
NA NA N/A N/A
CCL4L1
chemokine (C-C motif) l igand 4-
like 1
Chemokine 
A chemokine that induces chemotaxis of cells expressing CCR5 or CCR1. One of several 
cytokine genes clustered on the q-arm of chromosome 17. This protein is similar to CCL4 
which inhibits HIV entry by binding to the cell receptor CCR5 (protective role against HIV). 
Diseases associated include HIV and psoriasis. 
CCL4L2
chemokine (C-C motif) l igand 4-
like 2
Chemokine 
A chemokine that induces chemotaxis of cells expressing CCR5 or CCR1. One of several 
cytokine genes clustered on the q-arm of chromosome 17. This protein is similar to CCL4 
which inhibits HIV entry by binding to the cell receptor CCR5 (protective role against HIV). 
Diseases associated include HIV and psoriasis. 
SLA Src-like-adaptor Adaptor protein 
Negatively regulates T cell receptor signalling and inhibits NFAT signalling. Involved in the 
positive selection and mitosis of T cells.
CCL3L1
chemokine (C-C motif) l igand 3-
like 1
Chemokine 
A chemokine that binds to chemokine receptors such as CCR5. 
PRRG4
proline rich Gla (G-
carboxyglutamic acid) 4 
(transmembrane) Transmembrane protein
No information found
GCSAM
germinal center-associated, 
signaling and motility No information found
Negatively regulates lymphocyte motility and is a regulator of B-cell receptor signalling via 
SYK kinase activation. The expression of this protein has been shown to be elevated in 
germinal centre B cells and is known to be induced by IL-4. 
NA NA N/A N/A
Appendix Table 1. Description of statistically significant genes differentially expressed in U2932 
cells treated with CsA for 2hrs (unpaired data analysis). Columns indicate the gene symbols, names, 
family and function for statistically significant genes (adjusted P-value <0.05) differentially expressed 
upon treatment with CsA. Data in orange indicates genes downregulated by CsA and data in blue 
indicates genes upregulated by CsA. Data includes genes marked as N/A. 
symbol name Family Information based on GeneCard (www.genecards.org)
NA NA N/A N/A
CCL4L2
chemokine (C-C motif) 
ligand 4-like 2
Chemokine 
A chemokine that induces chemotaxis of cells expressing CCR5 or CCR1. One of several cytokine 
genes clustered on the q-arm of chromosome 17. This protein is similar to CCL4 which inhibits 
HIV entry by binding to the cell receptor CCR5 (protective role against HIV). Diseases associated 
include HIV and psoriasis. 
U2932 2hr (paired data analysis) 
Appendix Table 2. Description of statistically significant genes differentially expressed in U2932 
cells treated with CsA for 2hrs (paired data analysis). Columns indicate the gene symbols, names, 
family and function for statistically significant genes (adjusted P-value <0.05) differentially expressed 
upon treatment with CsA. Data in orange indicates genes downregulated by CsA and data in blue 
indicates genes upregulated by CsA. Data includes genes marked as N/A.  
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symbol name Family Information based on GeneCard (www.genecards.org)
NA NA N/A N/A
CCL4L1
chemokine (C-C motif) 
ligand 4-like 1
Chemokine 
A chemokine that induces chemotaxis of cells expressing CCR5 or CCR1. One of several cytokine 
genes clustered on the q-arm of chromosome 17. This protein is similar to CCL4 which inhibits HIV 
entry by binding to the cell  receptor CCR5 (protective role against HIV). Diseases associated include 
HIV and psoriasis. 
CCL4L2
chemokine (C-C motif) 
ligand 4-like 2
Chemokine 
A chemokine that induces chemotaxis of cells expressing CCR5 or CCR1. One of several cytokine 
genes clustered on the q-arm of chromosome 17. This protein is similar to CCL4 which inhibits HIV 
entry by binding to the cell  receptor CCR5 (protective role against HIV). Diseases associated include 
HIV and psoriasis. 
RILPL2
Rab interacting 
lysosomal protein-like 2
Regulator of lysosome 
morphology Plays a role in cellular transport.
NA NA N/A N/A
SLA Src-like-adaptor
Adaptor protein 
Negatively regulates T cell  receptor signalling and inhibits NFAT signalling. Involved in the positive 
selection and mitosis of T cells.
SLA Src-like-adaptor
Adaptor protein 
Negatively regulates T cell  receptor signalling and inhibits NFAT signalling. Involved in the positive 
selection and mitosis of T cells.
NA NA N/A N/A
LOC285628 uncharacterized No information found No information found
NFATC1
nuclear factor of 
activated T-cells, 
cytoplasmic, calcineurin-
dependent 1
Transcription factor
DNA-binding transcription factor which plays a key role in inducible gene transcription during an 
immune response. Commonly known to induce the expression of genes such as IL-2 and IL-4 during T 
cell  activation but now known to be expressed in many cell  types. Recent studies suggest a role for this 
family of transcription factors in cancer. A central molecular target for the immunosuppresive drug 
CsA. 
ZBTB32
zinc finger and BTB 
domain containing 32
Transcriptional 
transactivator or 
repressor
May function as a transcriptional transactivator or repressor. Thought to have a repressive 
effect by preventing GATA3 from binding to DNA
WDR1 WD repeat domain 1 F-actin binding protein May induce the disassembley of actin filaments
KIF26B kinesin family member Kinesin family member Essential for kidney development. 
CCL3L1
chemokine (C-C motif) 
ligand 3-like 1
Chemokine A chemokine that binds to chemokine receptors such as CCR5. 
PDDC1
Parkinson disease 7 
domain containing 1 No information found No information found
BSPRY
B-box and SPRY domain 
containing Calcium transporter Involved in calcium transport
NA NA N/A N/A
UPF3B
UPF3 regulator of 
nonsense transcripts 
Component of a post-
splicing multiprotein 
Involved in nonsense mediated decay of mRNAs and mRNA nuclear export and surveillance
CLDN14 claudin 14 Claudin family member
Integral membrane protein and component of tight junction strands
CA2 carbonic anhydrase II Enzyme
A carbonic anhydrase which catalyses the reversible hydration of carbon dioxide
UPF3B
UPF3 regulator of 
nonsense transcripts 
Component of a post-
splicing multiprotein 
Involved in nonsense mediated decay of mRNAs and mRNA nuclear export and surveillance
CSTF3
cleavage stimulation 
factor, 3' pre-RNA, 
Cleavage stimulation 
factor
Involved in the polyadenylation and 3-end cleavage of pre-mRNAs
CD58 CD58 molecule Immunoglobulin protein
Encodes a ligand for the T lymphpcyte CD2 protein, functioning in adhesion and activation 
of T cells
LOC730101 uncharacterized RNA gene Affiliated with the IncRNA class of proteins 
CLECL1 C-type lectin-like 1
Type II transmembrane 
protein
Highly expressed on dendritic and B cells, may act as a T-cell costimulatory protein which 
enhances IL4 production
NA NA N/A N/A
BEND6 BEN domain containing 6 No information found Associated with Notch signalling pathways
ZBTB8A
zinc finger and BTB 
domain containing 8A Transcriptional regulator Could be associated with gastric cancer
SOX7
SRY (sex determining 
region Y)-box 7 Transcription factor
Important in embryonic development and determination of cell fate. May play a role in 
tumourigenesis 
NA NA N/A N/A
ALKBH8
alkB, alkylation repair 
homolog 8 (E. coli) Enzyme Involved in RNA binding and has tRNA methyltransferase activity
RAB24
RAB24, member RAS 
oncogene family Small GTPase
Member of the Rab subfamily of proteins that regulate intracellular protein trafficking
NA NA N/A N/A
TMED5
transmembrane emp24 
protein transport 
domain containing 5
Transmembrane transport 
protein
Associated with vesicular protein trafficking, GPCR and WNT signalling 
EIF2S2
eukaryotic translation 
initiation factor 2, 
subunit 2 beta, 38kDa No information found
Functions in the early stages of protein synthesis by forming a complex with GTP and 
initiator tRNA and binds to the 40S ribosomal subunit. 
UGGT1
UDP-glucose 
glycoprotein Enzyme
Soluble protein of the ER with a role in protein transport out of the ER
UGGT1
UDP-glucose 
glycoprotein Enzyme
Soluble protein of the ER with a role in protein transport out of the ER
U2932 6hr (unpaired data analysis) 
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DNAJC12
DnaJ (Hsp40) homolog, 
subfamily C, member 12 Chaperone protein Involved in protein folding 
PSMA8
proteasome (prosome, 
macropain) subunit, 
alpha type, 8 Proteasome component
Part of the spermatoproteosome found in the testis. Associated with degradation of 
histones but also linked to downstream signalling events of the B-cell receptor
SRPRB
signal recognition 
particle receptor, B 
Transmembrane GTPase Anchors alpha subunit and peripheral membrane GTPase to the ER membrane 
RGS16
regulator of G-protein 
signaling 16 G protein regulator
Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits
FAM120C
family with sequence 
similarity 120C Transmembrane protein 
Lies in a region where mutations and deletions are associated with disability and autism
PROSER1 proline and serine rich 1 No information found
A protein with serine and proline rich regions and may be associated with protein-protein 
interactions
OSTCP2
oligosaccharyltransferas
e complex subunit 
pseudogene 2 Pseudogene No information found
PGM3 phosphoglucomutase 3 Phosphohexose mutase Mediates glycogen formation 
UGDH
UDP-glucose 6-
dehydrogenase Enzyme
Involved in the biosynthesis of components of the extracellular matrix
SEC23B
Sec23 homolog B (S. 
cerevisiae) Vesicle trafficking protein Involved in vesicle budding from the ER
SEL1L
sel-1 suppressor of lin-
12-like (C. elegans) No information found
Associated with the retrotranslocation or dislocation of misfolded proteins from the ER 
lumen to the cytosol
YARS tyrosyl-tRNA synthetase Enzyme
Thought to be among one of the first proteins that appeared in evolution. Involved with 
catalysing the aminoacetylation of tRNA by their cognate amino acid
BET1
Bet1 golgi vesicular 
membrane trafficking 
Golgi-associated 
membrane protein Involved in vesicle transport from the ER to the Golgi complex
STT3A
STT3A, subunit of the 
oligosaccharyltransferas
e complex (catalytic)
Integral membrane 
protein
Encodes the catalytic subunit of the N-oligosaccharyltransferase complex 
LMAN1 lectin, mannose- Type I integral membrane A recyling protein located between the ER and the Golgi
DEPTOR
DEP domain containing 
MTOR-interacting Kinase inhibitor
Negative regulator of mTORC1 and mTORC2 (inhibits kinase activity) and associated with 
Akt signalling
SELK selenoprotein K Selenoprotein Signals translation termination
FAM129A
family with sequence 
similarity 129, member No information found
Regulates the phosphorylation of a number of proteins such as EIF2A
GDPD5
glycerophosphodiester 
phosphodiesterase 
domain containing 5 Enzyme Involved in glycerol metabolism
NA NA N/A N/A
PDIA3P1
protein disulfide 
isomerase family A, 
member 3 pseudogene 1 Pseudogene No information found
SH2B3 SH2B adaptor protein 3 SH2B adaptor protein
Negative regulator of cytokine signalling and plays a key role in haematopoesis
RELL1 RELT-like 1 No information found No information found
SLC30A7
solute carrier family 30 
(zinc transporter), Enzyme cofactor Involved in the transport of glucose and other sugars
SNORD96A
small nucleolar RNA, 
C/D box 96A
Small nucleolar RNA Plays a role in the processing of ribosomal RNA precursors.
GOT1
glutamic-oxaloacetic 
transaminase 1, soluble Enzyme Involved in amino acid metabolism
FAM84B
family with sequence 
similarity 84, member B No information found
Linked to gastroesophageal junction adenocarcimona and breast cancer
DNAJC10
DnaJ (Hsp40) homolog, 
subfamily C, member 10 Co-chaperone
ER co-chaperone involved in recogising and degrading misfolded proteins
CREB3L2
cAMP responsive 
element binding protein Transcription factor
Transcriptional activator which regulates the transcription of unfolded protein response 
target genes
CDRT4
CMT1A duplicated 
region transcript 4 No information found No information found
PPAPDC1B
phosphatidic acid 
phosphatase type 2 
domain containing 1B Enzyme May be a metastatic suppressor in hepatocellular carcinoma
DNAJC3
DnaJ (Hsp40) homolog, 
subfamily C, member 3 Chaperone protein Involved in the unfolded protein response during ER stress
NA NA N/A N/A
TMEM39A transmembrane protein Transmembrane protein No information found
NA NA N/A N/A
FICD FIC domain containing Enzyme
Mediates the addition of AMP to target proteins and known to Inactivate Rho GTPases
SLC10A7
solute carrier family 10, 
member 7 No information found No information found
GARS glycyl-tRNA synthetase Enzyme Aminoaceyl-tRNA that charges tRNAs with their amino acids
SARS seryl-tRNA synthetase Enzyme Catalyses the attachment of serine to tRNA (ser)
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PDIA4
protein disulfide 
isomerase family A, No information found No information found
EDEM2
ER degradation 
enhancer, mannosidase Enzyme Involved in degradation of misfolded proteins
ARFGAP3
ADP-ribosylation factor 
GTPase activating GTPase activating protein
Associates with the golgi apparatus and regulates the early secretory pathway of proteins
ASNS
asparagine synthetase 
(glutamine-hydrolyzing) Enzyme Involved in the synthesis of asparagine
MTHFD2
methylenetetrahydrofol
ate dehydrogenase 
(NADP+ dependent) 2, 
methenyltetrahydrofola
te cyclohydrolase Enzyme Functions in the mitochondria and is involved in metabolism
HERPUD1
homocysteine-
inducible, endoplasmic 
reticulum stress-
inducible, ubiquitin-like Enzyme Functions in the mitochondria and is involved in metabolism
SSR1
signal sequence 
receptor, alpha ER membrane receptor Associated with protein translocation across the ER membrane
WIPI1
WD repeat domain, 
phosphoinositide 
interacting 1 WD40 repeat protein
Regulates the assembly of multiprotein complexes and plays a role in autophagy
RIMS3
regulating synaptic 
membrane exocytosis 3 No information found Regulates synaptic membrane exocytosis
SSR2
signal sequence 
receptor, beta 
(translocon-associated Enzyme Associated  with protein translocation across the ER membrane
TARS threonyl-tRNA Enzyme Aminoaceyl-tRNA that charges tRNAs with their amino acids
TIMM44
translocase of inner 
mitochondrial 
membrane 44 homolog No information found
Translocation of proteins from the inner membrane to the mitochondrial matrix in an ATP-
dependent manner 
PARM1
prostate androgen-
regulated mucin-like No information found May regulate telomerase activity
EDEM1
ER degradation 
enhancer, mannosidase No information found Targets misfolded proteins for degradation
GNL3
guanine nucleotide 
binding protein-like 3 
(nucleolar) No information found
May interact with p53 and therefore be involved in tumourigenesis. Known to stabilise 
MDM2 by preventing its ubiquitination and degradation. Also thought to be important in 
stem cell proliferation and associated with ribosome biosynthesis
SLC1A5
solute carrier family 1 
(neutral amino acid 
transporter), member 5 Amino acid transporter Associated with metabolism
ERLEC1
endoplasmic reticulum 
lectin 1 ER protein
ER protein that functions in N-glycan recognition. Involved in ER-associated degradation 
and stress-response pathways. May promote metastatic cell survival 
MANF
mesencephalic astrocyte-
derived neurotrophic 
factor No information found
Reducing the expression of this gene has been shown to increase susceptibility to ER stress-
induced death and results in proliferation. 
PCK2
phosphoenolpyruvate 
carboxykinase 2 
(mitochondrial) Mitochondrial enzyme The main enzyme involved with gluconeogenesis in the liver
HSPA5
heat shock 70kDa 
protein 5 (glucose-
regulated protein, Heat shock family protein
Located in the ER this protein is involved in protein folding and assembly
SDF2L1
stromal cell-derived 
factor 2-like 1 No information found No information found
NFE2L1
nuclear factor, erythroid 
2-like 1 Transcription factor
Involved in globin gene expression in erythrocytes. Also associated with ERK signalling.
CHAC1
ChaC, cation transport 
regulator homolog 1 (E. 
coli) Enzyme
Role as a pro-apoptotic protein by mediating the pro-apoptotic effects of the ATF4-ATF3-
DDIT3/CHOP cascade. Also involved in NOTCH signalling 
DEPTOR
DEP domain containing 
MTOR-interacting Kinase inhibitor
Negative regulator of mTORC1 and mTORC2 (inhibits kinase activity) and associated with 
Akt signalling
CARS
cysteinyl-tRNA 
synthetase
Aminoacyl-tRNA 
synthetase 
Catalyses the aminoacylation of tRNAs with their cognate amino acid. Associated with lung, 
breast and ovarian cancers.
MTHFD1L
methylenetetrahydrofol
ate dehydrogenase 
(NADP+ dependent) 1- Enzyme De novo synthesis of purines and thymidylate. Involved in metabolism 
CTH
cystathionase 
(cystathionine gamma- Enzyme
Cytoplasmic enzyme involved in trans-sulfuration of methionine into cysteine. Role in 
metabolism.
NA NA N/A N/A
FKBP14
FK506 binding protein 
14, 22 kDa Enzyme
Peptidyl-prolyl cis-trans isomerase found in the lumen of the ER. May have a role in protein 
folding.
LAT2
linker for activation of T 
cells family, member 2 Adaptor protein 
Involved in signalling in mast cells and is associated with Williams's disease 
(developmental disorder). May be associated with BCR signalling 
PSPH phosphoserine Enzyme Phosphotransferase protein involved in L-serine formation
SLC6A9
solute carrier family 6 
(neurotransmitter 
transporter, glycine), 
member 9 No information found Involved in the transport of glucose and other sugars
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HAX1
HCLS1 associated 
protein X-1 No information found
Known to associate with a Src family member of kinases named haematopoetic cell-
specific Lyn substrate 1. Also interacts with the polycystic kidney disease gene . Known to 
promote cell survival and involved with intracellular calcium pools
TMED10
transmembrane emp24-
like trafficking protein Type I membrane protein Involved in vesicular protein trafficking 
HYOU1 hypoxia up-regulated 1 Heat shock family protein
Protein folding and secretion in the ER. Associated with increasing apoptosis and has been 
linked to increased invasiveness in breast tumours
VIMP
VCP-interacting 
membrane protein
Selenoprotein
May regulate cytokine production and the inflammatory response. Involved in the degradation of 
misfolded ER proteins. 
SEC24D SEC24 family member D No information found Involved in vesicle trafficking 
CTH
cystathionase 
(cystathionine gamma- Enzyme
Cytoplasmic enzyme involved in trans-sulfuration of methionine into cysteine. Role in 
metabolism.
ATF4
activating transcription 
factor 4 Transcription factor
Belongs to a family of DNA binding proteins which include AP-1, cAMP-response element binding 
proteins (CREB) and CREB-like proteins. Presence of leucine-zipper elements allow this protein to 
interact with other proteins. Associated with glucose homeostatisis in osteoblasts and the induction 
of asparagine synthetase in response to ER stress. Also regulates proteins associated with the 
circadian clock. 
CARS
cysteinyl-tRNA 
synthetase
Aminoacyl-tRNA 
synthetase 
Catalyses the aminoacylation of tRNAs with their cognate amino acid. Associated with lung, 
breast and ovarian cancers.
TSC22D3
TSC22 domain family, 
member 3 Transcriptional regulator
Stimulated by glucocorticoids and IL10. Plays a role in the anti-inflammatory response and 
immunosuppressive activities
DNAJB9
DnaJ (Hsp40) homolog, 
subfamily B, member 9 J protein family member 
Regulated ATPase activity of 70kDa heat shock proteins. Induced by ER stress and plays a 
role protecting cells from apoptosis 
GPT2
glutamic pyruvate 
transaminase (alanine 
aminotransferase) 2 Enzyme
Encodes a mitochondrial alanine transaminase. Involved in metabolism. Upregulated by 
ATF4  under metabolic stress in hepatocyte cells 
NA NA N/A N/A
PSAT1
phosphoserine 
aminotransferase 1 Enzyme Aminotransferase Involved in metabolism 
DDIT3
DNA-damage-inducible 
transcript 3 Transcription factor
CCAAT/enhancer-binding protein (C/EBP) family of transcription factors involved in the ER 
stress response. Known to induce cell cycle arrest and apoptosis in response to ER stress
CTH
cystathionase 
(cystathionine gamma- Enzyme
Cytoplasmic enzyme involved in trans-sulfuration of methionine into cysteine. Role in 
metabolism.
TSC22D3
TSC22 domain family, 
member 3 Transcriptional regulator
Stimulated by glucocorticoids and IL10. Plays a role in the anti-inflammatory response and 
immunosuppressive activities
PCK2
phosphoenolpyruvate 
carboxykinase 2 
(mitochondrial) Mitochondrial enzyme The main enzyme involved with gluconeogenesis in the liver
Appendix Table 3 (Continued from previous three pages). Description of statistically significant 
genes differentially expressed in U2932 cells treated with CsA for 6hrs (unpaired data analysis). 
Columns indicate the gene symbols, names, family and function for statistically significant genes 
(adjusted P-value <0.05) differentially expressed upon treatment with CsA. Data in orange indicates 
genes downregulated by CsA and data in blue indicates genes upregulated by CsA. Data includes genes 
marked as N/A. 
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symbol name Family Information based on GeneCard (www.genecards.org)
NA NA NA NA
CCL4L1 chemokine (C-C motif) l igand 4-like 1
Chemokine 
A chemokine that induces chemotaxis of cells 
expressing CCR5 or CCR1. One of several cytokine genes 
clustered on the q-arm of chromosome 17. This protein 
is similar to CCL4 which inhibits HIV entry by binding to 
the cell  receptor CCR5 (protective role against HIV). 
Diseases associated include HIV and psoriasis. 
CCL4L2 chemokine (C-C motif) l igand 4-like 2
Chemokine 
A chemokine that induces chemotaxis of cells 
expressing CCR5 or CCR1. One of several cytokine genes 
clustered on the q-arm of chromosome 17. This protein 
is similar to CCL4 which inhibits HIV entry by binding to 
the cell  receptor CCR5 (protective role against HIV). 
Diseases associated include HIV and psoriasis. 
CCL3L3 chemokine (C-C motif) l igand 3-like 3
Chemokine 
A chemokine that binds to chemokine receptors such as 
CCR5. 
RILPL2 Rab interacting lysosomal protein-like 2
Regulator of lysosome 
morphology Plays a role in cellular transport.
BATF basic leucine zipper transcription factor, ATF-like Transcription factor
An AP-1 family transcription factor which dimerises 
with members of the Jun family
TNF tumor necrosis factor
Cytokine
Encodes a multifunctional proinflammatory cytokine 
that belongs to the tumour necrosis factor superfamily. 
Mostly secreted by macrophages and is involved in cell  
proliferation, differentiation, apoptosis and many other 
cellular processes. Implicated in diseases such as 
cancer, autoimmune diseases and insulin resistance. 
LRRC32 leucine rich repeat containing 32 Type I membrane protein No information found
NA NA NA NA
SLA Src-like-adaptor
Adaptor protein 
Negatively regulates T cell  receptor signalling and 
inhibits NFAT signalling. Involved in the positive 
selection and mitosis of T cells.
SLA Src-like-adaptor
Adaptor protein 
Negatively regulates T cell  receptor signalling and 
inhibits NFAT signalling. Involved in the positive 
selection and mitosis of T cells.
NFKBIE nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon
IkB protein which inhibits 
nuclear localisation and 
activation of NF-κB alongside 
IκBa and IκBb 
The protein encoded by this gene binds to components 
of NF-kappa-B, trapping the complex in the cytoplasm 
and preventing it from activating genes in the nucleus. 
Phosphorylation of the encoded protein targets it for 
desruction by the ubiquitin pathway, which activates NF-
kappa-B by making it available to translocate to the 
nucleus
CCL3 chemokine (C-C motif) l igand 3
Chemokine 
A small inducible cytokine also known as macrophage 
inflammatory protein 1 alpha which plays a role in 
inflammatory responses by binding to the receptor 
CCR1, CCR4 and CCR5.
ZYX zyxin Zinc-binding phosphoprotein
Concentrates at focal adhesions and along the actin 
cytoskeleton 
MAP3K8 mitogen-activated protein kinase kinase kinase 8
Serine/threonine kinase
Encodes a serine/threonine kinase which localises to 
the cytoplasm and can activate both the MAP kinase and 
JNK kinase pathways. Known to activate NF-κB via 
activation of I kappa B kinases. Also reported to 
promote the production of TNF-alpha and IL-2 during 
lymphocyte activation. 
NFKBIE nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon
IkB protein which inhibits 
nuclear localisation and 
activation of NF-κB alongside 
IκBa and IκBb 
The protein encoded by this gene binds to components 
of NF-kappa-B, trapping the complex in the cytoplasm 
and preventing it from activating genes in the nucleus. 
Phosphorylation of the encoded protein targets it for 
desruction by the ubiquitin pathway, which activates NF-
kappa-B by making it available to translocate to the 
nucleus
LOC285628 uncharacterized LOC285628 No information found No information found
EGR3 early growth response 3 Transcription factor
Encodes a transcription factor from the three tandem 
C2H2-type zinc finger family.
FKBP4 FK506 binding protein 4, 59kDa Immunophilin Plays a role in protein trafficking
NFATC1 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1
Transcription factor
DNA-binding transcription factor which plays a key role 
in inducible gene transcription during an immune 
response. Commonly known to induce the expression of 
genes such as IL-2 and IL-4 during T cell  activation but 
now known to be expressed in many cell  types. Recent 
studies suggest a role for this family of transcription 
factors in cancer. A central molecular target for the 
immunosuppresive drug CsA. 
EGR2 early growth response 2
Transcription factor
Encodes a transcription factor from the three tandem 
C2H2-type zinc finger family.
ZBTB32 zinc finger and BTB domain containing 32
Transcriptional 
transactivator or repressor
May function as a transcriptional transactivator or 
repressor. Thought to have a repressive effect by 
preventing GATA3 from binding to DNA
TPM4 tropomyosin 4 Actin binding protein Important for muscle structure and function
SCO2 SCO2 cytochrome c oxidase assembly protein
Enzyme
Maintains proton gradient across the inner 
mitrochondrial membrane 
SRF serum response factor (c-fos serum response element-binding transcription factor) Ubiquitous nuclear protein Involved in proilferation and differentiation
NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha
IkB protein which inhibits 
nuclear localisation and 
activation of NF-κB alongside 
IκBa and IκBb 
The protein encoded by this gene binds to components 
of NF-kappa-B, trapping the complex in the cytoplasm 
and preventing it from activating genes in the nucleus. 
Phosphorylation of the encoded protein targets it for 
desruction by the ubiquitin pathway, which activates NF-
kappa-B by making it available to translocate to the 
nucleus
RBM14 RNA binding motif protein 14 Nuclear coactivator Nuclear coactivator and RNA splicing modulator
WDR1 WD repeat domain 1 F-actin binding protein May induce the disassembley of actin fi laments
HILPDA hypoxia inducible l ipid droplet-associated No information found
Involved in growth and proliferation. Known to 
stimulate some cytokines
MIR155HG MIR155 host gene (non-protein coding) Micro RNA No information found
KIF26B kinesin family member 26B Kinesin family member Essential for kidney development. 
PhD Thesis  Holly White 
 
268 
 
 
 
 
CCL3L1 chemokine (C-C motif) l igand 3-like 1
Chemokine 
A chemokine that binds to chemokine receptors such as 
CCR5. 
HES6 hes family bHLH transcription factor 6 Transcriptional repressor Regulates cell  differentiation
RHPN2 rhophilin, Rho GTPase binding protein 2 GTPase binding protein Involved in organisation of the actin cytoskeleton
IKZF1 IKAROS family zinc finger 1 (Ikaros) Transcription factor Regulator of lymphocyte differentiation
EXO1 exonuclease 1 Enzyme Require for SHM and CSR
FANCG Fanconi anemia, complementation group G No information found Involved in DNA repair
FST follistatin Gonadal protein Inhibits foll icle stimulating hormone release
BCL2L11 BCL2-like 11 (apoptosis facil itator) BCL-2 family member Acts as an apoptotic activator 
DNLZ DNL-type zinc finger No information found No information found
PTGES2 prostaglandin E synthase 2 Enzyme
Catalyzes the conversion of prostaglandin H2 to 
prostaglandin E2
CCL3L1 chemokine (C-C motif) l igand 3-like 1
Chemokine 
A chemokine that binds to chemokine receptors such as 
CCR5. 
AGAP3 ArfGAP with GTPase domain, ankyrin repeat and PH domain 3 No information found Involved in endocytosis
LIMA1 LIM domain and actin binding 1
Cytoskeleton-associated 
protein Inhibits actin fi lament polymerisation
SLC25A19 solute carrier family 25 (mitochondrial thiamine pyrophosphate carrier), member 19 Solute carrier protein Solute carrier protein in the mitochondria
BRK1 BRICK1, SCAR/WAVE actin-nucleating complex subunit No information found Regulates the actin cytoskeleton
PDDC1 Parkinson disease 7 domain containing 1 No information found No information found
LOC730101 uncharacterized LOC730101 RNA gene Affil iated with the IncRNA class of proteins 
NFKBID nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, delta
IkB protein which inhibits 
nuclear localisation and 
activation of NF-κB alongside 
IκBa and IκBb 
The protein encoded by this gene binds to components 
of NF-kappa-B, trapping the complex in the cytoplasm 
and preventing it from activating genes in the nucleus. 
Phosphorylation of the encoded protein targets it for 
desruction by the ubiquitin pathway, which activates NF-
kappa-B by making it available to translocate to the 
nucleus
AMY1B amylase, alpha 1B (salivary) Enzyme Produced by the salvary gland
BSPRY B-box and SPRY domain containing Calcium transporter Involved in calcium transport
NA NA NA NA
PSME3 proteasome (prosome, macropain) activator subunit 3 (PA28 gamma; Ki) Proteasome component Subunit of the proteasome
UPF3B UPF3 regulator of nonsense transcripts homolog B (yeast)
Component of a post-splicing 
multiprotein complex
Involved in nonsense mediated decay of mRNAs and 
mRNA nuclear export and surveillance
BCL2L11 BCL2-like 11 (apoptosis facil itator) BCL-2 family member Acts as an apoptotic activator 
CLDN14 claudin 14 Claudin family member
Integral membrane protein and component of tight 
junction strands
CA2 carbonic anhydrase II Enzyme
A carbonic anhydrase which catalyses the reversible 
hydration of carbon dioxide
CCL3L1 chemokine (C-C motif) l igand 3-like 1
Chemokine 
A chemokine that binds to chemokine receptors such as 
CCR5. 
UBQLN4 ubiquilin 4 Nuclear hormone receptor
Acts as a transcriptional coactivator for steroid 
hormones 
FAM65B family with sequence similarity 65, member B No information found Involved in proteasomal protein degradation
NA NA NA NA
DHRS11 dehydrogenase/reductase (SDR family) member 11 Enzyme No information found
TNFRSF1B tumor necrosis factor receptor superfamily, member 1B
TNF-receptor superfamily 
member Mediates the recruitment of anti-apoptotic proteins
SAP30L SAP30-like No information found Involved in the recruitment of HDACs to the nucleus
DMAP1 DNA methyltransferase 1 associated protein 1 Transcriptional regulator
Transcriptional activator and repressor. Interacts with 
HDACs
C9orf37 chromosome 9 open reading frame 37 No information found No information found
UPF3B UPF3 regulator of nonsense transcripts homolog B (yeast)
Component of a post-splicing 
multiprotein complex
Involved in nonsense mediated decay of mRNAs and 
mRNA nuclear export and surveillance
NCOA1 nuclear receptor coactivator 1 Transcriptional coactivator Transcriptional coactivator for steroid hormones
LRRC20 leucine rich repeat containing 20 No information found No information found
TUBA4A tubulin, alpha 4a Tubulin Member of the tubulin family of microtubles
CSTF3 cleavage stimulation factor, 3' pre-RNA, subunit 3, 77kDa Cleavage stimulation factor
Involved in the polyadenylation and 3-end cleavage of 
pre-mRNAs
PPOX protoporphyrinogen oxidase Enzyme 
Catalyzes the 6-electron oxidation of 
protoporphyrinogen-IX to form protoporphyrin-IX.
PMS2P4 postmeiotic segregation increased 2 pseudogene 4 Pseudogene No information found
POLA2 polymerase (DNA directed), alpha 2, accessory subunit Polymerase subunit Involved in the cell  cycle
NA NA NA NA
NA NA NA NA
NA NA NA NA
FICD FIC domain containing Enzyme
Mediates the addition of AMP to target proteins and 
known to Inactivate Rho GTPases
CHRNA5 cholinergic receptor, nicotinic, alpha 5 (neuronal) Ligand-gated ion channel
Nicotinic receptor subunit. Mediates fast signals at 
synapses.
C19orf10 chromosome 19 open reading frame 10 No information found No information found
SLC10A7 solute carrier family 10, member 7 No information found No information found
GARS glycyl-tRNA synthetase Enzyme
Aminoaceyl-tRNA that charges tRNAs with their amino 
acids
NA NA NA NA
SARS seryl-tRNA synthetase Enzyme Catalyses the attachment of serine to tRNA (ser)
PDIA4 protein disulfide isomerase family A, member 4 No information found No information found
EDEM2 ER degradation enhancer, mannosidase alpha-like 2 No information found Involved in glycoprotein degradation
TM6SF1 transmembrane 6 superfamily member 1 Transmembrane protein No information found
ARFGAP3 ADP-ribosylation factor GTPase activating protein 3 GTPase activating protein
Associates with the golgi apparatus and regulates the 
early secretory pathway of proteins
ASNS asparagine synthetase (glutamine-hydrolyzing) Enzyme Involved in the synthesis of asparagine
MTHFD2 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolaseEnzyme Functions in the mitochondria 
SESN2 sestrin 2 PA2 related protein Regulation of growth and survival
HERPUD1 homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1 Enzyme
Functions in the mitochondria and is involved in 
metabolism
SSR1 signal sequence receptor, alpha Membrane receptor Binds calcium to the ER membrane
CDK2AP2 cyclin-dependent kinase 2 associated protein 2
Cyclin -dependent kinase 
associated protein Diseases associated include oral cancer
WIPI1 WD repeat domain, phosphoinositide interacting 1 WD40 repeat protein
Regulates the assembly of multiprotein complexes and 
plays a role in autophagy
RIMS3 regulating synaptic membrane exocytosis 3 No information found Regulates synaptic membrane exocytosis
NA NA NA NA
WARS tryptophanyl-tRNA synthetase Enzyme tRNA synthetase 
SSR2 signal sequence receptor, beta (translocon-associated protein beta) Enzyme
Associated  with protein translocation across the ER 
membrane
TARS threonyl-tRNA synthetase Enzyme
Aminoaceyl-tRNA that charges tRNAs with their amino 
acids
LOC100190986 uncharacterized LOC100190986 No information found No information found
TIMM44 translocase of inner mitochondrial membrane 44 homolog (yeast) No information found
Translocation of proteins from the inner membrane to 
the mitochondrial matrix in an ATP-dependent manner 
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PARM1 prostate androgen-regulated mucin-like protein 1 No information found May regulate telomerase activity
MZB1 marginal zone B and B1 cell-specific protein
EDEM1 ER degradation enhancer, mannosidase alpha-like 1 No information found Targets misfolded proteins for degradation
GNL3 guanine nucleotide binding protein-like 3 (nucleolar) No information found
May interact with p53 and be linked to stem cell 
proliferation and tumourigenesis
SLC1A5 solute carrier family 1 (neutral amino acid transporter), member 5 Amino acid transporter Associated with metabolism
ERLEC1 endoplasmic reticulum lectin 1 No information found
Degradation of the ER and a regulator of cell  stress-
response pathways 
RGS1 regulator of G-protein signaling 1
Regulator of G-protein 
signalling
Inhibitis transduction of signals by increasing the 
GTPase activity of G-protein alpha subunits, causing 
them to turn into their inactive GDP-bound form. May 
also be involved in regulation of B-cell  activation and 
proliferation.
MANF mesencephalic astrocyte-derived neurotrophic factor No information found
Reducing the expression of this gene has been shown to 
increase susceptibil ity to ER stress-induced death and 
results in proliferation. 
PCK2 phosphoenolpyruvate carboxykinase 2 (mitochondrial) Mitochondrial enzyme
Catalyses the conversion of oxaloacetate to 
phosphoenolpyruvate in the presence of GTP
HSPA5 heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) Heat shock family protein
Located in the ER this protein is involved in protein 
folding and assembly
SDF2L1 stromal cell-derived factor 2-like 1 No information found No information found
NFE2L1 nuclear factor, erythroid 2-like 1 Transcription factor
Involved in globin gene expression in erythrocytes. Also 
associated with ERK signalling.
CHAC1 ChaC, cation transport regulator homolog 1 (E. coli) Enzyme
Pro-apoptotic component of the unfolded protein 
response pathway
EGR1 early growth response 1 Early growth response protein Transcriptional regulator involved in anergy
DEPTOR DEP domain containing MTOR-interacting protein No information found
Negative regulator of the mTORC1 and mTORC2 
signalling pathways
CARS cysteinyl-tRNA synthetase Aminoacyl-tRNA synthetase 
Catalyses the aminoacylation of tRNAs with their 
cognate amino acid. Associated with lung, breast and 
ovarian cancers.
MTHFD1L methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like Enzyme De novo synthesis of purines 
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1)
Cyclin dependent kinase 
inhibitor
Regulator of cell  cycle checkpoint at G1. Controlled by 
p53.
CTH cystathionase (cystathionine gamma-lyase) Enzyme Catalyses the final step in the trans-sulfuration process
NA NA NA NA
FKBP14 FK506 binding protein 14, 22 kDa
Peptidyl-prolyl cis-trans 
isomerase
Found in the lumen of the ER, this protein may 
accelerate protein folding 
LAT2 linker for activation of T cells family, member 2 Adaptor protein 
Involved in signalling in mast cells and is associated 
with Will iams's disease (developmental disorder). May 
be associated with BCR signalling 
ULBP1 UL16 binding protein 1 No information found
Involved in class 1 MHC mediated antigen processing 
and presentation
PSPH phosphoserine phosphatase Enzyme
Phosphotransferase protein involved in L-serine 
formation
SLC6A9 solute carrier family 6 (neurotransmitter transporter, glycine), member 9 No information found Involved in the transport of glucose and other sugars
HAX1 HCLS1 associated protein X-1 No information found
Known to associate with a Src family member of kinases 
named haematopoetic cell-specific Lyn substrate 1. Also 
interacts with the polycystic kidney disease gene . 
Known to promote cell  survival and involved with 
intracellular calcium pools
TMED10 transmembrane emp24-like trafficking protein 10 (yeast) Type I membrane protein Involved in vesicular protein trafficking 
INHBE inhibin, beta E Inhibin Pancreatic cell  growth and many other diverse roles
HYOU1 hypoxia up-regulated 1 Heat shock family protein
Protein folding and secretion in the ER. Associated with 
increasing apoptosis and has been linked to increased 
invasiveness in breast tumours
VIMP VCP-interacting membrane protein
Selenoprotein
May regulate cytokine production and the inflammatory 
response. Involved in the degradation of misfolded ER 
proteins. 
SLC3A2 solute carrier family 3 (amino acid transporter heavy chain), member 2
Cell surface transmembrane 
protein
Required for the function of l ight chain amino-acid 
transporters
SEC24D SEC24 family member D Phosphotransferase L-serine formation
ADM2 adrenomedullin 2 No information found No information found
CTH cystathionase (cystathionine gamma-lyase) Enzyme Catalyses the final step in the trans-sulfuration process
HYOU1 hypoxia up-regulated 1 Heat shock family protein
Protein folding and secretion in the ER. Associated with 
increasing apoptosis and has been linked to increased 
invasiveness in breast tumours
CEBPB CCAAT/enhancer binding protein (C/EBP), beta Transcription factor Involed in immune function
ATF4 activating transcription factor 4 Transcription factor
Belongs to a family of DNA binding proteins which 
include AP-1, cAMP-response element binding proteins 
(CREB) and CREB-like proteins. Presence of leucine-
zipper elements allow this protein to interact with other 
proteins. Associated with glucose homeostatisis in 
osteoblasts and the induction of asparagine synthetase 
in response to ER stress. Also regulates proteins 
associated with the circadian clock. 
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CARS cysteinyl-tRNA synthetase
Class I aminoacyl-tRNA 
synthetase Associated with lung, ovarian and breast cancers
TSC22D3 TSC22 domain family, member 3 Transcriptional regulator Known to inhibit NF-kappa B DNA binding activity
DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 Regulator of ATPase activity
Regulates ATPase activity in heat shock proteins and 
plays a role in protecting stressed cells from apoptosis
TRIB3 tribbles pseudokinase 3 Kinase
Induced by NF-κB, but is also a negative regulator of NF-
κB by interacting with p65.  
GPT2 glutamic pyruvate transaminase (alanine aminotransferase) 2 Enzyme 
Roles in amino acid metabolism. Upregulated by ATF4 
under metabolic stress in hepatocyte cell l ines 
NA NA NA NA
PSAT1 phosphoserine aminotransferase 1 Enzyme Encodes a protein associated with metabolism
DDIT3 DNA-damage-inducible transcript 3
Transcription factor
This gene encodes a member of the C/EBP family of 
transcription factors. The protein functions as a 
dominant negative inhibitor. This multifunctional 
transcription factor is involved in the ER stress 
response and plays a wide role in cell stresses and 
induces cell cycle arrest and apoptosis in response to 
ER stress. Negatively regulates expression of BCL2, ATF4-
dependent transcriptional activation of asparagine 
synthetase and other genes. Inhibits Wnt signalling and 
plays a role in the inflammatory response through the 
induction of caspase 11. 
CTH cystathionase (cystathionine gamma-lyase) Enzyme
Involved in the trans-sulphuration pathway from 
methionine to cysteine
TSC22D3 TSC22 domain family, member 3 Transcriptional regulator Known to inhibit NF-kappa B DNA binding activity
PCK2 phosphoenolpyruvate carboxykinase 2 (mitochondrial) Enzyme Encodes a mitochondrial enzyme 
Appendix Table 4 (Continued from previous 3 pages). Description of statistically significant genes 
differentially expressed in U2932 cells treated with CsA for 6hrs (paired data analysis). Columns 
indicate the gene symbols, names, family and function for statistically significant genes (adjusted P-
value <0.05) differentially expressed upon treatment with CsA. Data in orange indicates genes 
downregulated by CsA and data in blue indicates genes upregulated by CsA. Data includes genes 
marked as N/A 
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HLY-1 2hr (unpaired data analysis) 
 
 
symbol name Family Information based on GeneCard (www.genecards.org)
NA NA N/A N/A
CCL4L2 chemokine (C-C motif) l igand 4-like 2 Chemokine 
A chemokine that induces chemotaxis of cells expressing CCR5 or CCR1. One 
of several cytokine genes clustered on the q-arm of chromosome 17. This 
protein is similar to CCL4 which inhibits HIV entry by binding to the cell  
receptor CCR5 (protective role against HIV). Diseases associated include HIV 
and psoriasis. 
CCL4L1 chemokine (C-C motif) l igand 4-like 1 Chemokine 
A chemokine that induces chemotaxis of cells expressing CCR5 or CCR1. One 
of several cytokine genes clustered on the q-arm of chromosome 17. This 
protein is similar to CCL4 which inhibits HIV entry by binding to the cell  
receptor CCR5 (protective role against HIV). Diseases associated include HIV 
and psoriasis. 
PDCD1 programmed cell  death 1
Immune checkpoint 
receptor expressed by 
activated T cells
This gene encodes a cell  surface membrane protein of the immunoglobulin 
superfamily. It is expressed in pro-B-cells and is thought to play a role in 
their differentiation and the immune response. Diseases associated with 
PDCD1 include indolent b cell  lymphoma and nodular lymphocyte 
predominant hodgkin lymphoma 
RIN2
Ras and Rab interactor 2 Small GTPase
Involved in membrane trafficking in the early endocytic pathway. The protein 
encoded by the RIN2 gene binds the GTP-bound form of the RAB5 protein and 
functions as a guanine exchange factor for RAB5.  Found as a tetramer in the 
cytoplasm RIN2 does not. Mutations in this gene cause macrocephaly 
alopecia cutis laxa and scoliosis (MACS) syndrome (an elastic tissue 
disorder) as well as the related connective tissue disorder, RIN2 syndrome. 
PAX9
paired box 9 Transcription factor
Encodes a member of the paired box (PAX) family of transcription factors. 
PAX family members are important regulators in early development. Critical 
role in cancer growth. 
IL10
interleukin 10 Cytokine
Role in immune regulation and inflammation. Known to enhance B-
cell survival
TNFSF14
tumor necrosis factor (l igand) superfamily, member 14 Member of the TNF ligand 
superfamily 
May function as a costimulatory factor for the activation of lymphoid cells. 
Has been shown to stimulate T cell  proliferation and trigger the apoptosis of 
malignant cells.
PRF1
perforin 1 (pore forming protein)
Transmembrane 
tubule protein Forms part of the transmembrane tubule
ZNFX1 zinc finger, NFX1-type containing 1 No information found No information found
GFI1
growth factor independent 1 transcription repressor
Transcriptional 
repressor Encodes a nuclear zinc finger protein that plays a role in oncogenesis
EVI2A
ecotropic viral integration site 2A
Gene encoding a viral 
integration site. 
Thought to complex with itself or other proteins within the cell  membrane, 
perhaps functioning as a cell-surface receptor.
SOCS3
suppressor of cytokine signaling 3
Negative regulator of 
cytokine signalling
Member of the STAT induced STAT inhibitors. Induced by IL10 and 
can inhibit JAK kinase
NUAK2
NUAK family, SNF1-like kinase, 2
Stress-activated kinase 
involved in tolerance to 
glucose starvation
A stress-activated kinase involved in tolerance to glucose stravation and 
cytoskeletal signalling. Expression is induced by TNF-alpha via NF-κB. Also 
protects cells from Fas-mediated apoptosis and is required for increased 
motility and invasiveness in fas-mediated tumour cells.
Appendix Table 5. Description of statistically significant genes differentially expressed in HLY-1 
cells treated with CsA for 2hrs (unpaired data analysis). Columns indicate the gene symbols, names, 
family and function for statistically significant genes (adjusted P-value <0.05) differentially expressed 
upon treatment with CsA. Data in orange indicates genes downregulated by CsA and data in blue 
indicates genes upregulated by CsA. Data includes genes marked as N/A. 
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HLY-1 2hr (paired data analysis) 
symbol name Family Information based on GeneCard (www.genecards.org)
NA NA N/A N/A
CCL4L2
chemokine (C-C motif) ligand 4-
like 2
Chemokine 
A chemokine that induces chemotaxis of cells expressing CCR5 or CCR1. One of several 
cytokine genes clustered on the q-arm of chromosome 17. This protein is similar to CCL4 
which inhibits HIV entry by binding to the cell receptor CCR5 (protective role against 
HIV). Diseases associated include HIV and psoriasis. 
CCL4L1
chemokine (C-C motif) ligand 4-
like 1
Chemokine 
A chemokine that induces chemotaxis of cells expressing CCR5 or CCR1. One of several 
cytokine genes clustered on the q-arm of chromosome 17. This protein is similar to CCL4 
which inhibits HIV entry by binding to the cell receptor CCR5 (protective role against 
HIV). Diseases associated include HIV and psoriasis. 
EGR2 early growth response 2
Transcription factor
Encodes a transcription factor from the three tandem C2H2-type zinc finger family. Early 
growth response gene induced by mitogenic stimulation and is involved in muscle 
development, lymphocyte development and many other cellular processes.
CCL3L3
chemokine (C-C motif) ligand 3-
like 3
Chemokine A chemokine that binds to chemokine receptors such as CCR5. 
CCL3L1
chemokine (C-C motif) ligand 3-
like 1
Chemokine A chemokine that binds to chemokine receptors such as CCR5. 
CCL3L1
chemokine (C-C motif) ligand 3-
like 1
Chemokine A chemokine that binds to chemokine receptors such as CCR5. 
CCL3 chemokine (C-C motif) ligand 3
Chemokine 
A small inducible cytokine also known as macrophage inflammatory protein 1 alpha 
which plays a role in inflammatory responses by binding to the receptor CCR1, CCR4 and 
CCR5.
CD69 CD69 molecule
Type II transmembrane receptor
Encodes a member of the calcium-dependent lectin superfamily of type II 
transmembrane receptors. Expression is induced during activation of T lymphocytes and 
may play a role in lymphocyte proliferation.
EGR3 early growth response 3
Transcription factor Encodes a transcription factor from the three tandem C2H2-type zinc finger family.
PDCD1 programmed cell death 1
Immune checkpoint receptor 
expressed by activated T cells
This gene encodes a cell surface membrane protein of the immunoglobulin superfamily. 
It is expressed in pro-B-cells and is thought to play a role in their differentiation and the 
immune response. Diseases associated with PDCD1 include indolent b cell lymphoma 
and nodular lymphocyte predominant hodgkin lymphoma 
HSPE1 heat shock 10kDa protein 1
Heat shock protein
Encodes a major heat shock protein which functions as a chaperonin. Binds to other 
heat shock proteins to enhance ATP-dependent protein folding
EVI2A ecotropic viral integration site 2A
Gene encoding a viral 
integration site. 
Thought to complex with itself or other proteins within the cell membrane, perhaps 
functioning as a cell-surface receptor.
PAX9 paired box 9
B cell specific transcription 
factor
Encodes a member of the paired box (PAX) family of transcription factors. PAX family 
members are important regulators in early development. Altered expression of these 
genes are thought to contribute to neoplastic transformation. Expressed at early (but 
not late) stages of B-cell differentiation.  Dysregulation of this gene is known to 
contribute to the pathogenesis of large-cell lymphomas.
RAB11FIP1
RAB11 family interacting protein 1 
(class I)
Vesicle recycling protein
Plays a role in Rab-11 mediated recycling of vesicles and may be involved in endocytic 
sorting and trafficking of proteins such as epidermal growth factor receptor (EGFR)
TNS3 tensin 3
Actin remodelling
May play a role in the remodelling of actin and the dissociation of the integrin-tensin-
actin complex 
IL10 interleukin 10
Cytokine
Encodes a cytokine which is primarily produced by monocytes and to a lesser extent by 
lymphocytes. IL10 functions in immunoregulation and inflammation and downregulates 
the expression of Th1 cytokines, MHC class II Ags and costimulatory molecules on 
macrophages. This cytokine is also known to enhance B cell survival, proliferation and 
antibody production and is also known to inhibit NF-κB production. Also involved in the 
regulation of the JAK-STAT signalling pathway.
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TNFAIP6
tumor necrosis factor, alpha-
induced protein 6
Hyaluronan-binding secretory protein
A secretory protein which contains a hyaluronan-binding domain and is known to be 
involved in extracellular matrix stability and cell migration. Induced by proinflammatory 
cytokines such as TNF-alpha and interleukin-1. Important in the protease network 
associated with inflammation. Enhanced levels of TNFAIP6 have been found in the 
synovial fluid of patients with osteoarthritis and rheumatoid arthritis. Some evidence of 
involvement in cell-cell and cell-matrix interactions during inflammation and 
tumourigenesis. 
NFATC1
nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-
dependent 1
Transcription factor
DNA-binding transcription factor which plays a key role in inducible gene transcription 
during an immune response. Commonly known to induce the expression of genes such 
as IL-2 and IL-4 during T cell activation but now known to be expressed in many cell 
types. Recent studies suggest a role for this family of transcription factors in cancer. A 
central molecular target for the immunosuppresive drug CsA. 
TNF tumor necrosis factor
Cytokine
Encodes a multifunctional proinflammatory cytokine that belongs to the tumour necrosis 
factor superfamily. Mostly secreted by macrophages and is involved in cell proliferation, 
differentiation, apoptosis and many other cellular processes. Implicated in diseases 
such as cancer, autoimmune diseases and insulin resistance. 
EVI2A ecotropic viral integration site 2A
Gene encoding a viral 
integration site
Thought to complex with itself or other proteins within the cell membrane, perhaps 
functioning as a cell-surface receptor.
NA NA N/A N/A
PTPN7
protein tyrosine phosphatase, non-
receptor type 7
Protein tyrosine phosphatase 
A member of the protein tyrosine phosphatase (PTP) family which are known to regulate 
cell growth, differentiation and the cell cycle. Also implicated in oncogenesis. PTPN7 is 
mostly expressed in haematopoietic cells and is an early response gene in activated T 
and B lymphocytes
ZNFX1 zinc finger, NFX1-type containing 1
No information found No information found
GFI1
growth factor independent 1 
transcription repressor
Transcriptional repressor
A zinc finger protein that functions as a transcriptional repressor in haematopoiesis and 
oncgenesis. Functions as a complex to control histone modifications that lead to 
silencing of specific target gene promoters. Mutations in this gene cause autosomal 
dominant congenital neutropenia and dominant nonimmune chronic idiopathic 
neutropenia, which predispose patients to leukaemia. Reported to regulate TLR 
reponses such as by antagonising RELA.
CLEC17A
C-type lectin domain family 17, 
member A
Cell surface receptor
A cell surface receptor which may play a role in carbohydrate-mediated communication 
between cells in the germinal centre. Known to bind glycans such as mannose and 
fucose residues.
FILIP1L filamin A interacting protein 1-like
Regulator of endothelial 
antiapoptotic activity
Regulates antiangiogenic activity on endothelial cells and when overexpressed, leads to 
inhibition of proliferation, migration and apoptosis. Also demonstrated to inhibit 
melanoma growth when expressed in tumour-associated vasculature.
CCL3L1
chemokine (C-C motif) ligand 3-
like 1
Cytokine
Encodes a cytokine which binds to chemokine receptors such as CCR5. Known to be 
involved in chemotaxis of monocytes and lymphocytes
KLHL42 kelch-like family member 42
BCR E3 ubiquitin-protein ligase 
complex adaptor
Encodes an adaptor for a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex 
required for mitotic progression and cytokinesis. Also involved in microtubule dynamics 
during mitosis.
DCAF5
DDB1 and CUL4 associated factor 
5
Substrate receptor
May  function as a substrate receptor for a CLU4-DDB1 E3 ubiquitin-protein ligase 
complex
ID3
inhibitor of DNA binding 3, 
dominant negative helix-loop-helix 
protein Transcriptional regulator
Encodes a transcriptional regulator (lacking a basic DNA binding domain) which 
negatively regulates the basic helix-loop-helix transcription factors by inhibiting their 
transcriptional activity. Involved in many cellular processes such as proliferation, 
growth, senescence, apoptosis, differentiation and neoplastic transformation. Also 
involved in myogenesis and regulation of the circadian clock.
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SOCS3 suppressor of cytokine signaling 3
Suppressor of cytokine signalling 
Encodes a member of the STAT-induced STAT inhibitor, known as the suppressor of 
cytokine signalling family which are cytokine-inducible negative regulators of cytokine 
signalling. The expression of SOCS3 is induced by IL6, IL10 and interferon gamma.  
NUAK2 NUAK family, SNF1-like kinase, 2
Stress-activated kinase 
involved in tolerance to 
glucose starvation
A stress-activated kinase involved in tolerance to glucose stravation and cytoskeletal 
signalling. Expression is induced by TNF-alpha via NF-κB. Also protects cells from Fas-
mediated apoptosis and is required for increased motility and invasiveness in fas-
mediated tumour cells.
RGS12 regulator of G-protein signaling 12
GTPase-activating protein
Functions as a guanosine triphosphatase (GTPase) -activating protein and a 
transcriptional repressor. May play a role in tumourigenesis.
TXNIP thioredoxin interacting protein
Mediator of oxidative stress
May function as a mediator of oxidative stress by inhibiting the activity of thioredoxin. 
Also plays a role as a transcriptional repressor by acting as a molecular bridge between 
trascription factors and corepressor complexes. Also known to suppress tumour cell 
growth. 
NA NA N/A N/A
Appendix Table 6 (continued from previous two pages). Description of statistically significant 
genes differentially expressed in HLY-1 cells treated with CsA for 2hrs (paired data analysis). 
Columns indicate the gene symbols, names, family and function for statistically significant genes 
(adjusted P-value <0.05) differentially expressed upon treatment with CsA. Data in orange indicates 
genes downregulated by CsA and data in blue indicates genes upregulated by CsA. Data includes genes 
marked as N/A. 
symbol name Family Information based on GeneCard (www.genecards.org)
NUP43
nucleoporin 43kDa
Nuclear pore complex 
transporter
Encodes a protein involved in the bidirectional transport of macromolecules between 
the cytoplasm and the nucleus through nuclear pore complexes embedded in the 
nuclear envelope. NUP43 is part of a subcomplex which composes a nuclear pore 
complex. 
DHRS3
dehydrogenase/reductase (SDR 
family) member 3
Short-chain 
dehydrogenases/reductase
Catalyses the oxidation/reduction of a wide range of substrates such as retinoids and 
steroids
SSR3
signal sequence receptor, gamma 
(translocon-associated protein 
gamma)
Signal-sequence receptor
Encodes a gamma subunit of a signal sequence receptor which forms a glycosylated 
endoplasmic reticulum (ER) membrane receptor which aids the translocation of 
proteins across the ER membrane.  
LBH limb bud and heart development
Transcriptional 
regulator/cofactor
Diseases associated are rheumatoid arthritus and celiacs disease
NFATC1
nuclear factor of activated T-
cells, cytoplasmic, calcineurin-
dependent 1
Transcription factor
DNA-binding transcription factor which plays a key role in inducible gene 
transcription during an immune response. Commonly known to induce the expression 
of genes such as IL-2 and IL-4 during T cell activation but now known to be expressed 
in many cell types. Recent studies suggest a role for this family of transcription factors 
in cancer. A central molecular target for the immunosuppresive drug CsA. 
HLF
hepatic leukemia factor Transcription factor
Encodes a member of the proline and acidic-rich (PAR) protein family, a subset of the 
bZIP transcription factors. HLF forms homo- or heterodimers with other PAR family 
members and activates transcription. Chromosomal translocations fusing portions of 
this gene with the E2A gene are known to cause a subset of childhood B-lineage acute 
lymphoid leukaemias. 
HLY-1 6hr (unpaired data analysis) 
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GBP1
guanylate binding protein 1, 
interferon-inducible Guanylate binding protein
Induced by interferon, this guanylate binding protein binds guanine nucleotides such 
as GMP, GDP and GTP.
CRY1 cryptochrome circadian clock 1
Protein involved in regulating 
the circadian clock
This gene encodes a flavin adenine dinucleotide-binding protein that is a key 
component of the circadian core oscil lator complex, which regulates the circadian 
clock. Polymorphisms in this gene have been associated with altered sleep patterns. 
Diseases associated include sleep disorders and anxiety disorder.
EHD4
EH-domain containing 4
Endocytic trafficking protein
Associated with endocytosis and Trk receptor signalling mediated by the MAPK 
pathway. Also associated with hepatocellular carcinoma.  
CD36
CD36 molecule (thrombospondin 
receptor) Glycoprotein
A major glycoprotein on the surface of platelets which acts as a receptor for 
thrombospondin. 
NAMPT
nicotinamide 
phosphoribosyltransferase
Nicotinic acid 
phosphoribosyltransferase 
(NAPRTase)
Catalyses the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate 
to yield nicotinamide mononucleotide. Involved in metabolism, the stress-response 
and aging. 
HNRNPH1
heterogeneous nuclear 
ribonucleoprotein H1 (H) Heterogeneous nuclear 
ribonucleoprotein (hnRNP)
RNA binding protein that complex with heterogeneous nuclear RNA. Associated with 
pre-mRNA processing and other functions related to mRNA metabolism and transport.
GNG10
guanine nucleotide binding 
protein (G protein), gamma 10 Heterotrimeric G protein
Encodes a heterotrimeric G protein activates PLA2 and Gbetagamma coupled to M1 
receptors
NA NA N/A N/A
C1orf186
chromosome 1 open reading 
frame 186 No information found No information found
LEF1
lymphoid enhancer-binding 
factor 1
Transcription factor
Encodes a transcription factor which shares homology with the high mobility group 
protein-1. Binds to a key site in the T-cell  receptor-alpha enhancer. Also involved in the 
Wnt signalling pathway and has been linked to various cancers including prostate 
cancer.
GBP2
guanylate binding protein 2, 
interferon-inducible
GTPase
Encodes a guanine-binding protein which includes interferon-induced proteins that 
can bind gaunine nucleotides such as GMP, GDP and GTP. May play a role as a marker 
of squamous cell  carcinomas
NA NA N/A N/A
SCN2A
sodium channel, voltage-gated, 
type II, alpha subunit Voltage-gated sodium channel Encodes one member of the sodium channel alpha subunit gene family.
GUSBP11
glucuronidase, beta pseudogene 
11
Pseudogene
Pseudogene similar to glucuronidase beta and immunoglobulin lambda-like 
polypeptide 1
NA NA N/A N/A
NA NA N/A N/A
SNORD96A small nucleolar RNA, C/D box 96A Small nucleolar RNA Plays a role in the processing of ribosomal RNA precursors.
SCART1
scavenger receptor protein family 
member
Type I transmembrane 
molecule Scavenger receptor cysteine-rich type I transmembrane molecule.
RALGPS2
Ral GEF with PH domain and SH3 
binding motif 2
Guanine nucleotide exchange 
factor
A guanine nucleotide exchange factor for the small GTPase RALA. May be involved in 
cytoskeletal organisation and the stimulation of transcription in a Ras-independent 
way. Diseases associated are tonsil l itus and Alzheimers disease
NA NA N/A N/A
DDX17
DEAD (Asp-Glu-Ala-Asp) box 
helicase 17
RNA helicase
DEAD box proteins are characterised by the conserved motif Asp-Glu-Ala-Asp and their 
role as RNA helicases allows them to aid initiation of translation and assembly of 
ribosomes and splicesosome. Some family members are thought to have a role in 
cellular growth and division.  
RALGPS2
Ral GEF with PH domain and SH3 
binding motif 2
Guanine nucleotide exchange 
factor
Guanine nucleotide exchange factor for the small GTPase RALA. May be involved in 
transcription. 
SFN stratifin
Adaptor protein
Adaptor protein implicated in the regulation of a large spectrum of both general and 
specialised signalling pathways. Binds to a large number of partners and usually 
results in the modulation of activity of the binding partner. Involved in stimulation of 
the AkT/mTOR pathway and may activate p53 via MDM2 regulation. Diseases 
associated include phlebotomus fever and bladder squamous cell  carcinoma
Appendix Table 7 (Continued from previous page). Description of statistically significant genes 
differentially expressed in HLY-1 cells treated with CsA for 6hrs (unpaired data analysis). 
Columns indicate the gene symbols, names, family and function for statistically significant genes 
(adjusted P-value <0.05) differentially expressed upon treatment with CsA. Data in orange indicates 
genes downregulated by CsA and data in blue indicates genes upregulated by CsA. Data includes genes 
marked as N/A. 
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symbol name Family Information based on GeneCard (www.genecards.org)
TNF tumor necrosis factor
Cytokine
Encodes a multifunctional proinflammatory cytokine that belongs to the 
tumour necrosis factor superfamily. Mostly secreted by macrophages and is 
involved in cell  proliferation, differentiation, apoptosis and many other 
cellular processes. Implicated in diseases such as cancer, autoimmune 
diseases and insulin resistance. 
MAP3K8
mitogen-activated protein 
kinase kinase kinase 8 Serine/threonine kinase
Encodes a serine/threonine kinase which localises to the cytoplasm and can 
activate both the MAP kinase and JNK kinase pathways. Known to activate NF-
κB via activation of I kappa B kinases. Also reported to promote the 
production of TNF-alpha and IL-2 during lymphocyte activation. 
NA NA N/A N/A
JUN jun proto-oncogene Transcription factor
Known as the transforming gene of avian sarcoma virus 17. Encodes a 
tramscription factor which binds DNA and regulates gene transcription. 
Associated with PI3K and MAPK signalling pathways and involved in cell  cycle 
progression and anti-apoptosis.
NFKBIE
nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells inhibitor, epsilon
IkB protein which inhibits 
nuclear localisation and 
activation of NF-κB alongside 
IκBa and IκBb 
The protein encoded by this gene binds to components of NF-kappa-B, 
trapping the complex in the cytoplasm and preventing it from activating 
genes in the nucleus. Phosphorylation of the encoded protein targets it for 
desruction by the ubiquitin pathway, which activates NF-kappa-B by making 
it available to translocate to the nucleus
NUP43 nucleoporin 43kDa
Nuclear pore complex 
transporter
Encodes a protein involved in the bidirectional transport of macromolecules 
between the cytoplasm and the nucleus through nuclear pore complexes 
embedded in the nuclear envelope. NUP43 is part of a subcomplex which 
composes a nuclear pore complex. 
SSR3
signal sequence receptor, 
gamma (translocon-
associated protein gamma)
Signal-sequence receptor
Encodes a gamma subunit of a signal sequence receptor which forms a 
glycosylated endoplasmic reticulum (ER) membrane receptor which aids the 
translocation of proteins across the ER membrane.  
EGR2 early growth response 2
Transcription factor
Encodes a transcription factor from the three tandem C2H2-type zinc finger 
family.
LBH
limb bud and heart 
development
Transcriptional 
regulator/cofactor
Diseases associated are rheumatoid arthritus and celiacs disease. LBH 
encodes a nuclear protein which possesses a transcriptional activator 
function in tissue culture cells. Expressed during limb and heart 
development in the embryo.
SRF
serum response factor (c-fos 
serum response element-
binding transcription factor)
Transcription factor
Encodes a nuclear protein that stimulates cell  proliferation and 
differentiation and is a member of the MCM1, Agamous, Deficiens and SRF 
(MADS) box family of transcription factors.  Binds to the serum response 
element in the promoter region of target genes and regulates many immediate 
to early genes. Examples of genes regulated include c-fos, therefore having 
involvement in the cell  cycle, apoptosis and many other processes. SRF is also 
a downstream target for many pathways such as the MAPK pathway. 
RFWD3
ring finger and WD repeat 
domain 3
E3 ubiquitin l igase 
Mediates the ubiquitination of p53/TP53 in the late response to DNA damage 
and acts as a positive regulator of p53/TP53 stability by regulating the G1/A 
DNA damage checkpoint. 
FILIP1L
filamin A interacting protein 
1-like
Regulator of endothelial 
antiapoptotic activity
Regulates antiangiogenic activity on endothelial cells and when 
overexpressed, leads to inhibition of proliferation, migration and apoptosis. 
Also demonstrated to inhibit melanoma growth when expressed in tumour-
associated vasculature.
NFATC1
nuclear factor of activated T-
cells, cytoplasmic, 
calcineurin-dependent 1
Transcription factor
DNA-binding transcription factor which plays a key role in inducible gene 
transcription during an immune response. Commonly known to induce the 
expression of genes such as IL-2 and IL-4 during T cell  activation but now 
known to be expressed in many cell  types. Recent studies suggest a role for 
this family of transcription factors in cancer. A central molecular target for 
the immunosuppresive drug CsA. 
NFKBIA
nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells inhibitor, alpha
IkB protein which inhibits 
nuclear localisation and 
activation of NF-κB alongside 
IκBa and IκBb 
The protein encoded by this gene binds to components of NF-kappa-B, 
trapping the complex in the cytoplasm and preventing it from activating 
genes in the nucleus. Phosphorylation of the encoded protein targets it for 
desruction by the ubiquitin pathway, which activates NF-kappa-B by making 
it available to translocate to the nucleus
PRPS1
phosphoribosyl 
pyrophosphate synthetase 1
Enzyme
Catalyses the phosphoribosylation of ribose 5-phosphate to 5-
phosphoribosyl-1-pyrophosphate, which is required for metabolism and 
synthesis of nucleotides.
IGF2R
insulin-like growth factor 2 
receptor
Receptor
Encodes a receptor for insulin-like growth factor 2 and mannose 6-phosphate, 
functioning in intracellular trafficking of lysosomal enzymes and the 
activation of transforming growth factor.
HLF hepatic leukemia factor
Transcription factor
Encodes a member of the proline and acidic-rich (PAR) protein family, a 
subset of the bZIP transcription factors. HLF forms homo- or heterodimers 
with other PAR family members and activates transcription. Chromosomal 
translocations fusing portions of this gene with the E2A gene are known to 
cause a subset of childhood B-lineage acute lymphoid leukaemias. 
CD1C CD1c molecule
Transmembrane glycoprotein, 
similar to the MHC proteins and 
involved in antigen 
presentation
This gene encodes a member of the CD1 family of CD1 family of 
transmembrane glycoproteins, structurally related to the MHC proteins and 
form heterodimers with beta-2-microglobulin. The CD1 proteins mediate the 
presentation of antigens to T cells. 
ATP6V1F
ATPase, H+ transporting, 
lysosomal 14kDa, V1 subunit 
Vacuolar ATPase
Encodes a vacuolar ATPase which mediates acidification of eukaryotic 
intracellular organelles. 
FANCG
Fanconi anemia, 
complementation group G
DNA repair protein
May function in post replication repair or during cell  cycle checkpoints. Also 
thought to be a tumour suppressor gene.
HLY-1 6hr (paired data analysis) 
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NA NA N/A N/A
GBP1
guanylate binding protein 1, 
interferon-inducible Guanylate binding protein
Induced by interferon, this guanylate binding protein binds guanine 
nucleotides such as GMP, GDP and GTP.
CIRH1A
cirrhosis, autosomal 
recessive 1A (cirhin)
Transcriptional regulator Positive regulator of HIVEP1 which locates to viral promoters such as HIV-1. 
NA NA N/A N/A
NOL12 nucleolar protein 12 No information found No information found
CD83 CD83 molecule
Type I transmembrane molecule
Encodes a single-pass type I membrane protein and may be involved in 
antigen presentation.
TRMT2B
tRNA methyltransferase 2 
homolog B (S. cerevisiae)
tRNA methyltransferase 
Plays a role in tRNA maturation
CD83 CD83 molecule
Type I transmembrane molecule
Encodes a single-pass type I membrane protein and may be involved in 
antigen presentation.
EHD4 EH-domain containing 4
Endocytic trafficking protein
Associated with endocytosis and Trk receptor signalling mediated by the 
MAPK pathway. Also associated with hepatocellular carcinoma.  
PTGER4
prostaglandin E receptor 4 
(subtype EP4)
G-protein coupled receptor
Encodes a G-protein coupled receptor for prostaglandin E2 (PGE2) and has 
been shown to mediate PGE2 induced expression of early growth response 1. 
AMY1A amylase, alpha 1A (salivary)
Amylase
Encodes the secretory protein amylase which plays an important role in 
catalysing the first steps of digestion of dietary starch and glycogen.
DDX23
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 23
RNA helicase
DEAD box proteins are characterised by the conserved motif Asp-Glu-Ala-Asp 
and their role as RNA helicases allows them to aid initiation of translation 
and assembly of ribosomes and splicesosome. Some family members are 
thought to have a role in cellular growth and division.  
PPP2R4
protein phosphatase 2A 
activator, regulatory subunit 
Serine/threonine kinase
Encodes a serine/threonine kinase which is implicated in the negative control 
of cell  growth and division. 
NFKBID
nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells inhibitor, delta
IkB protein which inhibits 
nuclear localisation and 
activation of NF-κB alongside 
IκBa and IκBb 
The protein encoded by this gene binds to components of NF-kappa-B, 
trapping the complex in the cytoplasm and preventing it from activating 
genes in the nucleus. Phosphorylation of the encoded protein targets it for 
desruction by the ubiquitin pathway, which activates NF-kappa-B by making 
it available to translocate to the nucleus
FCF1
FCF1 rRNA-processing 
protein
rRNA processing protein
Plays an essential role in pre-rRNA processing and 40S ribosomal subunit 
assembly
SGK223 homolog of rat pragma of Tyrosine kinase Encodes a tyrosine kinase protein which in rats binds to Rho GTPase 2
LTA lymphotoxin alpha
Cytokine
Encodes a cytokine which is a member of the TNF family. Produced by 
lymphocytes, LTA is highly inducible and plays a role in inflammation, 
immune stimulation and apoptosis. Genetic mutations of this gene are 
associated with increased susceptibil ity of non-Hodgkin's lymphoma.
AGMAT
agmatine ureohydrolase 
(agmatinase)
Hydrolase enzyme
Involved in metabolism 
SOCS3
Supressor of cytokine 
signalling-3 
Zinc-binding phosphoprotein
This protein concentrates at focal adhesions (actin-rich structures that allow 
cells to adhere to the extracellular matrix) and along the actin cytoskeleton. 
The function of ZYX may be to interact with SH3 domains to aid initiation of 
downstream siganalling pathways. Thought to act as a messenger in 
signalling pathways that mediate adhesion-related genes.
DYRK1A
dual-specificity tyrosine-(Y)-
phosphorylation regulated 
kinase 1A
Kinase
Encodes a member of the dual-specifity tyrosine phosphorylation-regulated 
kinase (DYRK) family. Catalyses its autophosphorylation on serine/threonine 
and tyrosine residues and plays a key role in regulating cell  proliferation in 
signalling pathways such as NFAT. Homolog of the Drosophila mnb 
(minibrain) gene and rat Dyrk gene and is localised in the Down syndrome 
region of chromosome 21.  Also an important target for learning defects 
associated in Down syndrome. 
CD36
CD36 molecule 
(thrombospondin receptor)
Glycoprotein
A major glycoprotein on the surface of platelets which acts as a receptor for 
thrombospondin. 
NAMPT
nicotinamide 
phosphoribosyltransferase
Cytokine/adipokine
Encodes a protein which catalyses the condensation of nicrotinamide with 5-
phosphoribosyl-1-pyrophosphate to yield an intermedate in the biosynthesis 
of NAD (nicotinamide mononucleotide). Plays a role in regulation of the 
circadian clock. 
SLX1A
SLX1 structure-specific 
endonuclease subunit 
homolog A (S. cerevisiae)
Endonuclease subunit
Encodes the catalytic subunit for the SLX-SLX4 structure-specific endonuclease 
which plays a role in the repair and recombination of secondary DNA 
structures
MB21D1 Mab-21 domain containing 1
Nucleotidyltransferase
Catalyses the formation of cyclic GMP-AMP from ATP and GTP. A key cytosolic 
DNA sensor with antiviral activity.
NFKBIZ
nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells inhibitor, zeta
IkB protein which inhibits 
nuclear localisation and 
activation of NF-κB alongside 
IκBa and IκBb 
The protein encoded by this gene binds to components of NF-kappa-B, 
trapping the complex in the cytoplasm and preventing it from activating 
genes in the nucleus. Phosphorylation of the encoded protein targets it for 
desruction by the ubiquitin pathway, which activates NF-kappa-B by making 
it available to translocate to the nucleus
MCRS1 microspherule protein 1
Component of the chromatin 
remodeling complex
Regulatory component of the INO80 complex which is involved in 
transcriptional regulation and DNA replication. Associated with pigmented 
basal cell  carcinoma.
NA NA N/A N/A
POLR2L
polymerase (RNA) II (DNA 
directed) polypeptide L, 
RNA polymerase II subunit
Encodes a subunit for RNA polymerase II which is responsible for the 
synthesis of mRNA
GNG10
guanine nucleotide binding 
protein (G protein), gamma 
GTPase Heterotrimeric G protein involved in PI3K-Akt and Ras signalling pathways
DNLZ DNL-type zinc finger Co-chaperone protein May function as a co-chaperone for HSPA9/mortalin.
FBXL20
F-box and leucine-rich repeat 
protein 20 Ubiquitin l igase
Substrate-recognition component of the SCF-type E3 ubiquitin l igase complex 
with a role in neural transmission.
GCLC
glutamate-cysteine ligase, 
catalytic subunit Glutamate-cysteine ligase Functions as the first rate-limiting enzyme of glutathione synthesis.
WASF2
WAS protein family, member 
2
Linker of receptor kinases and 
actin
Encodes a member of the Wiskott-Aldrich syndrome protein family and 
functions by l inking receptor kinases and actin to aid changes in cell  shape, 
motil ity and function.
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HSD17B7P2
hydroxysteroid (17-beta) 
dehydrogenase 7 pseudogene Pseudogene Involved in metabolism 
UBA1
ubiquitin-like modifier 
activating enzyme 1
Activator of ubiquitin
Catalyses the first step in ubiquitin conjugation to mark proteins for 
degradation. 
FAM98B
family with sequence 
similarity 98, member B No information found No information found
GUSBP11
glucuronidase, beta 
pseudogene 11
Pseudogene
Pseudogene similar to glucuronidase beta and immunoglobulin lambda-like 
polypeptide 1
VPREB3 pre-B lymphocyte 3
Related to the immunoglobin 
supergene family
Associates with membrane Ig-mu heavy chains during pre-B cell  receptor 
biosynthesis.
SMA5
glucuronidase, beta 
pseudogene Pseudogene
Related pathways are involved in protein processing in the endoplasmic 
reticulum
NEMF
nuclear export mediator 
factor
Component of the ribosome 
quality control complex Part of a ribosome-associated complex that regulates ubiquitination.
NA NA N/A N/A
FAF1 Fas (TNFRSF6) associated Initiator of apoptosis Interacts with Fas antigen and initiate apoptosis. 
ORAI2
ORAI calcium release-
activated calcium modulator ER calcium sensor CRAC-like channel subunit which mediates calcium influx from the ER
HMGCS1
3-hydroxy-3-methylglutaryl-
CoA synthase 1 (soluble) Enzyme Regulation of cholesterol biosythesis
MVK mevalonate kinase Kinase
Encodes a peroxisomal enzyme mevalonate kinase which is involved in 
metabolism. 
NA NA N/A N/A
NA NA N/A N/A
SNORD3A small nucleolar RNA, C/D box Small nucleolar RNA Plays a role in the processing of ribosomal RNA precursors.
IDH1
isocitrate dehydrogenase 1 
(NADP+), soluble Isocitrate dehydrogenase
Functions by catalysing the oxidative decarboxylation of isocitrate to 2-
oxoglutarate. 
GUSBP2 glucuronidase, beta Pseudogene No information found
HNRNPA3
heterogeneous nuclear 
ribonucleoprotein A3 Cytoplasmic trafficking protein
Functions in the cytoplasmic trafficking of RNA and is involved in gene 
expression pathways and the spliceosome.
MZB1
marginal zone B and B1 cell-
specific protein Cytokine
Diversifies peripheral B-cell  functons by regulating Calcium stores, antibody 
secretion and integrin activation.  Functions as a proinflammatory cytokine 
associated with chronic inflammation.  
GOLIM4
golgi integral membrane 
protein 4 Type II Golgi-resident protein
Functions in endosome to Golgi trafficking by mediating protein transport 
along the late endosome-bypass pathway 
USF2
upstream transcription 
factor 2, c-fos interacting Transcription factor
Encodes a member of the basic helix-loop-helix leucine zipper family. 
Functions as a trancription factor and is associated with the transcriptional 
targets of AP1 family members
TCERG1
transcription elongation 
regulator 1 Transcription factor Regulates transcriptional elongation and pre-RNA splicing.
GINM1 glycoprotein integral Integral membrane protein No information found
TAF5L
TAF5-like RNA polymerase II, 
p300/CBP-associated factor 
(PCAF)-associated factor, 
Component of the PCAF histone 
acetylase complex
Required for myognic transcription and differentiation.
VOPP1
vesicular, overexpressed in 
cancer, prosurvival protein 1 Regulator of NF-κB 
Increases the transcriptional activity of NFKB1 by facil itating its nuclear 
translocation, DNA-binding and associated apoptotic response when 
overexpressed.
SORL1
sortil in-related receptor, 
L(DLR class) A repeats Endocytic endocytic receptor Involved in the uptake of l ipoproteins and proteases.
NA NA N/A N/A
ST6GALNAC4
ST6 (alpha-N-acetyl-
neuraminyl-2,3-beta-
galactosyl-1,3)-N-
acetylgalactosaminide alpha- Type II membrane protein
Located in the golgi apparatus and functions to catalyse the transfer of sialic 
acid from CMP-sialic acid to galactose-containing substrates.
SNORA12
small nucleolar RNA, H/ACA 
box 12 Small nucleolar RNA Small noncoding RNA involved in RNA processing 
NA NA N/A N/A
GUSBP2 glucuronidase, beta Pseudogene No information found
NA NA N/A N/A
CD79A
CD79a molecule, 
immunoglobulin-associated 
alpha
Associated with membrane-
bound immunoglobulin in B 
cells
Encodes the Ig-alpha protein of the B-cell  receptor antigen component. Needed 
in cooperation with CD79B for initiation of the signal transduction cascade 
downstream of the BCR. Also required for BCR surface expression and 
differentiation of pro- and pre- B cells. Stimulates SYK autophosphprylation 
and interacts with Src-family kinases. 
NA NA N/A N/A
NA NA N/A N/A
NA NA N/A N/A
ITGB7 integrin, beta 7 Integrin
Dimerises with other proteins to form a homing receptor for migration of 
lymphocytes to the intestinal mucosa and Peyer's patches. 
TAF1
TAF1 RNA polymerase II, TATA 
box binding protein (TBP)-
associated factor, 250kDa
Transcription factor complex 
protein
Facil itates transcription by acting as a large subunit of the transcription 
factor TFIID.
SQLE squalene epoxidase Enzyme Cataluses the first oxygenation step in sterol synthesis
KRI1 KRI1 homolog (S. cerevisiae) No information found No information found
LCMT1
leucine carboxyl 
methyltransferase 1 Methyltransferase
Methylates the carboxyl group of the C-terminal leucine residue of protein 
phosphatase 2A catalytic subunits to form alpha-leucine ester residues
RN7SK RNA, 7SK small nuclear No information found No information found
CDK5RAP3
CDK5 regulatory subunit 
associated protein 3 No information found
Associated with signalling pathways involved in transcriptional regulation 
and the cell  cycle (potential regulator of CDK5). May be linked to 
tumourigenesis and metastasis. 
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FAM102A
family with sequence 
similarity 102, member A No information found May play a role in oestrogen action
SDF4 stromal cell  derived factor 4 Calcium binding protein
Encodes a stromal cell  derived factor that is localised in the Golgi lumen and 
may regulate calcium-dependent processes.
SNORD96A small nucleolar RNA, C/D box Small nucleolar RNA Small noncoding RNA involved in RNA processing 
NA NA N/A N/A
ADAP1
ArfGAP with dual PH domains 
1
GTPase-activating protein 
GTPase-activating protein for the ADP ribosylation factor family. Binds 
PtdInsP3 and InsP4). Diseases associated include childhood leukaemia and 
alzheimers disease
SCART1
scavenger receptor protein 
family member Type I transmembrane molecule Scavenger receptor cysteine-rich type I transmembrane molecule.
NA NA N/A N/A
RBM39 RNA binding motif protein 39 Transcriptional coactivator
Involved in transcription of steroid hormones and is a transcriptional 
coregulator of the viral oncoprotein v-Rel. 
RBM38 RNA binding motif protein 38 RNA-binding protein Binds CDKN1A transcripts to mediate p53/TP53
NA NA N/A N/A
SNORD56 small nucleolar RNA, C/D box Small nucleolar RNA Small noncoding RNA involved in RNA processing 
DDIT3
DNA-damage-inducible 
transcript 3
Transcription factor
This gene encodes a member of the C/EBP family of transcription factors. The 
protein functions as a dominant negative inhibitor. This multifunctional 
transcription factor is involved in the ER stress response and plays a wide 
role in cell  stresses and induces cell  cycle arrest and apoptosis in response to 
ER stress. Negatively regulates expression of BCL2, ATF4-dependent 
transcriptional activation of asparagine synthetase and other genes. Inhibits 
Wnt signalling and plays a role in the inflammatory response through the 
induction of caspase 11. 
NLRP7
NLR family, pyrin domain 
containing 7 Leucine rich repeat protein
Encodes a protein involved in the activation of proinflammatory cytokines
IDI1
isopentenyl-diphosphate 
delta isomerase 1 Isocitrate dehydrogenase
Functions by catalysing the oxidative decarboxylation of isocitrate to 2-
oxoglutarate. 
PPM1K
protein phosphatase, 
Mg2+/Mn2+ dependent, 1K Phosphatase
Regulation of the mitochondrial permeability transition pore and is essential 
for cell  survival and development.  
NA NA N/A N/A
RAB5C
RAB5C, member RAS 
oncogene family Small GTPase Involved in endocytosis and the Ras signalling pathway
SNHG4
small nucleolar RNA host 
gene 4 (non-protein coding) Non-coding gene N/A
PLEKHA2
pleckstrin homology domain 
containing, family A 
(phosphoinositide binding 
specific) member 2 No information found
Recruits proteins to the plasma membrane and is associated with the PI3K 
and B-cell  receptor signalling pathways
ANP32AP1
acidic (leucine-rich) nuclear 
phosphoprotein 32 family, 
member A pseudogene 1 Pseudogene No information found
DHCR7 7-dehydrocholesterol 
MSMO1 methylsterol monooxygenase Enzyme Cholesterol synthesis
LSP1
lymphocyte-specific protein 
1
Intracellular F-actin binding 
protein Regulates chemotaxis
POU2F2 POU class 2 homeobox 2 Transcription factor
Binds octomer sequences which are common in immunoglobulin gene 
promoters. Associated with B-cell  receptor signalling pathways. Diseases 
associated include nodular lymphocyte predominant hodgkin lymphoma.
FST follistatin Gonadal protein
Inhibits foll icle-stimulating hormone release. Diseases associated include 
endometriosis
TSC22D3 TSC22 domain family, Transcriptional regulator Known to inhibit NF-kappa B DNA binding activity
RALGPS2
Ral GEF with PH domain and 
SH3 binding motif 2
Guanine nucleotide exchange 
factor
A guanine nucleotide exchange factor for the small GTPase RALA. May be 
involved in cytoskeletal organisation and the stimulation of transcription in 
a Ras-independent way. Diseases associated are tonsil l itus and Alzheimers 
disease
NLRP7
NLR family, pyrin domain 
containing 7 Leucine rich repeat protein
Encodes a protein involved in the activation of proinflammatory cytokines
NA NA N/A N/A
PRKCSH protein kinase C substrate Enzyme Associated with l iver disease
DHCR7 7-dehydrocholesterol Enzyme Cholesterol synthesis
NA NA N/A N/A
NA NA N/A N/A
TMEM159 transmembrane protein 159 Transmembrane protein No information found
DDX17
DEAD (Asp-Glu-Ala-Asp) box 
helicase 17
RNA helicase
DEAD box proteins are characterised by the conserved motif Asp-Glu-Ala-Asp 
and their role as RNA helicases allows them to aid initiation of translation 
and assembly of ribosomes and splicesosome. Some family members are 
thought to have a role in cellular growth and division.  
MEF2BNB-MEF2B
MEF2BNB-MEF2B 
readthrough
Non-coding nonsense-mediated 
decay candidates. 
MEF2C is an important paralog of this gene.
NA NA N/A N/A
UBE2E1
ubiquitin-conjugating 
enzyme E2E 1
E2 ubiquitin-conjugating 
enzyme
Accepts ubiquitin from the E1 complex and catalyses its covalent attachment 
to other proteins,
LDLR low density l ipoprotein Lipoprotein receptor Binds low density l ipoprotein receptor and transports it into cells.
KPNA6
karyopherin alpha 6 
(importin alpha 7) Nuclear import protein
Functions in nuclear import of proteins by acting as an adapter protein for 
nuclear receptor KPNB1
AP1S1
adaptor-related protein 
complex 1, sigma 1 subunit
Component of the clathrin coat 
assembly complex Plays a role in protein sorting in the Golgi.
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FADS1 fatty acid desaturase 1 Fatty acid desaturase Regulates unsaturation of fatty acids.
DDX17
DEAD (Asp-Glu-Ala-Asp) box 
helicase 17
RNA helicase
DEAD box proteins are characterised by the conserved motif Asp-Glu-Ala-Asp 
and their role as RNA helicases allows them to aid initiation of translation 
and assembly of ribosomes and splicesosome. Some family members are 
thought to have a role in cellular growth and division.  
FBXW7
F-box and WD repeat domain 
containing 7, E3 ubiquitin 
protein ligase
Component of the E3 ubiquitin 
l igase complex 
Mediates the ubiquitination of proteins including MYC and JUN. 
RALGPS2
Ral GEF with PH domain and 
SH3 binding motif 2
Guanine nucleotide exchange 
factor
Guanine nucleotide exchange factor for the small GTPase RALA, involved in 
metabolism.
NA NA N/A N/A
CCDC71 coiled-coil domain No information found No information found
AP1S1
adaptor-related protein 
complex 1, sigma 1 subunit
Component of the clathrin coat 
assembly complex Plays a role in protein sorting in the Golgi.
KIAA1524 KIAA1524 Phosphatase
Known to be an oncoprotein that stabilises MYC in human malignancies. Also 
known to promote tumour formation and cell growth.
MSMO1 methylsterol monooxygenase Enzyme Role in cholesterol biosynthesis
COPG2
coatomer protein complex, 
subunit gamma 2 Coatomer
Encodes a cytosolic protein complex which associates with the golgi and 
mediates protein transport from the ER
TSC22D3 TSC22 domain family, Transcriptional regulator Known to inhibit NF-kappa B DNA binding activity
SFN stratifin Adaptor protein
Adaptor protein implicated in the regulation of a large spectrum of both 
general and specialised signalling pathways. Binds to a large number of 
partners and usually results in the modulation of activity of the binding 
partner. Involved in stimulation of the AkT/mTOR pathway and may activate 
p53 via MDM2 regulation. Diseases associated include phlebotomus fever 
and bladder squamous cell carcinoma
PPP3R1
protein phosphatase 3, 
regulatory subunit B, alpha Phosphatase Associated with the PI3K and MAPK pathways.
ROCK1
Rho-associated, coiled-coil 
containing protein kinase 1 Serine/threonine kinase
Activated when bound to the GTP-bound form of Rho, allowing it to activate 
LIM kinase which phosphorylates cofil in and therefore inhibiting actin-
depolymerisation.
CTSZ cathepsin Z Carboxypeptidase
Encodes a lysosomal cysteine proteinase and is expressed ubiquitously in 
tumours and may be involved in tumourigenesis.
NA NA N/A N/A
Appendix Table 8 (Continued from previous four pages). Description of statistically significant 
genes differentially expressed in HLY-1 cells treated with CsA for 6hrs (paired data analysis). 
Columns indicate the gene symbols, names, family and function for statistically significant genes 
(adjusted P-value <0.05) differentially expressed upon treatment with CsA. Data in orange indicates 
genes downregulated by CsA and data in blue indicates genes upregulated by CsA. Data includes genes 
marked as N/A. 
symbol name Family Information based on GeneCard (www.genecards.org)
UPF3B
UPF3 regulator of nonsense 
transcripts homolog B 
Component of a post-
splicing multiprotein Involved in mRNA nuclear export and immunsurveillance
SNORD96A small nucleolar RNA, C/D Small nucleolar RNA Plays a role in the processing of ribosomal RNA precursors.
DNAJB11
DnaJ (Hsp40) homolog, 
subfamily B, member 11 Glycoprotein
Co-chaperone for binding immunoglobulin protein in the ER lumen 
HSPA5
heat shock 70kDa protein 5 
(glucose-regulated protein, Heat shock protein
Encodes a protein involved in protein folding and degradation of misfolded 
proteins.
WSU-NHL 6hr (unpaired data analysis) 
Appendix Table 9. Description of statistically significant genes differentially expressed in WSU-
NHL cells treated with CsA for 6hrs (unpaired data analysis). Columns indicate the gene symbols, 
names, family and function for statistically significant genes (adjusted P-value <0.05) differentially 
expressed upon treatment with CsA. Data in orange indicates genes downregulated by CsA and data in 
blue indicates genes upregulated by CsA. Data includes genes marked as N/A. 
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CCL4L1 
SLA  
CCL4L2  
TNF  
CCL3L1  PRRG4  
U2932 2hr (unpaired data analysis) 
Appendix Figure 3. The top 6 statistically significant genes (ranked by adjusted P-value) 
downregulated in U2932 cells treated with CsA for 2 hours (unpaired analysis). Each bubble in the 
figure represents one of most highly significant genes differentially expressed upon treatment with CsA. 
The larger the bubble the lower the adjusted P-value. Data excludes genes marked as N/A. 
GCSAM     
Appendix Figure 4. The top statistically significant gene (ranked by adjusted P-value) 
upregulated in U2932 cells treated with CsA for 2 hours (unpaired analysis). Each bubble in the 
figure represents one of most highly significant genes differentially expressed upon treatment with CsA. 
The larger the bubble the lower the adjusted P-value. Data excludes genes marked as N/A. 
PhD Thesis  Holly White 
 
282 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCL4L2   
U2932 2hr (paired data analysis) 
Appendix Figure 5. The top statistically significant gene (ranked by adjusted P-value) 
downregulated in U2932 cells treated with CsA for 2 hours (paired analysis). Each bubble in the 
figure represents one of most highly significant genes differentially expressed upon treatment with CsA. 
The larger the bubble the lower the adjusted P-value. Data excludes genes marked as N/A. 
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CCL4L1  
CCL4L2  
SLA  
NFATC1  
RILPL2  
UPF3B 
 
BSPR
Y 
CD58 
LOC2
85628 
LOC73010
1 
CLDN1
4 
CLEC
1 
W
DR
CST
F3 
ZB
TB
32 
U2932 6hr (unpaired data analysis) 
Appendix Figure 6. The top 15 statistically significant genes (ranked by adjusted P-value) 
downregulated in U2932 cells treated with CsA for 6 hours (unpaired analysis). Each bubble in the 
figure represents one of most highly significant genes differentially expressed upon treatment with CsA. 
The larger the bubble the lower the adjusted P-value. Data excludes genes marked as N/A. 
PSAT1  
SSR1  
CTH  
MTHFD2  
PCK2  
DDIT3  
GNL3  
MTHFD
1L  
ERLEC
1 
PSPH 
SLC1
0A7 
 
VIMP ST
T3
DNA
JB9 
 
PD1
A4 
Appendix Figure 7. The top 15 statistically significant genes (ranked by adjusted P-value) 
upregulated in U2932 cells treated with CsA for 6 hours (unpaired analysis). Each bubble in the 
figure represents one of most highly significant genes differentially expressed upon treatment with CsA. 
The larger the bubble the lower the adjusted P-value. Data excludes genes marked as N/A. 
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CCL3L3 
LOC285
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MAP3
K8 
EGR2 
BAT
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IA  
U2932 6hr (paired data analysis) 
Appendix Figure 8. The top 15 statistically significant genes (ranked by adjusted P-value) 
downregulated in U2932 cells treated with CsA for 6 hours (paired analysis). Each bubble in the 
figure represents one of most highly significant genes differentially expressed upon treatment with CsA. 
The larger the bubble the lower the adjusted P-value. Data excludes genes marked as N/A. 
DNAJB9 
 PSAT1 
 CTH 
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GPT2 
TRIB3  
DEPTO
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EDE
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Appendix Figure 9. The top 15 statistically significant genes (ranked by adjusted P-value) 
upregulated in U2932 cells treated with CsA for 6 hours (paired analysis). Each bubble in the figure 
represents one of most highly significant genes differentially expressed upon treatment with CsA. The 
larger the bubble the lower the adjusted P-value. Data excludes genes marked as N/A. 
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Appendix Figure 10. The top 11 statistically significant genes (ranked by adjusted P-value) 
downregulated in HLY-1 cells treated with CsA for 2 hours (unpaired analysis). Each bubble in 
the figure represents one of most highly significant genes differentially expressed upon treatment with 
CsA. The larger the bubble the lower the adjusted P-value. Data excludes genes marked as N/A. 
NUAK2    SOCS3    
Appendix Figure 11. The top 2 statistically significant genes (ranked by adjusted P-value) 
upregulated in HLY-1 cells treated with CsA for 2 hours (unpaired analysis). Each bubble in the 
figure represents one of most highly significant genes differentially expressed upon treatment with CsA. 
The larger the bubble the lower the adjusted P-value. Data excludes genes marked as N/A. 
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EGR2 
CCL3L3 
CCL4L2 
CCL4L1 
CCL3 
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PAX9 
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RAB11
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EVI2
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AT
HLY-1 2hr (paired data analysis) 
Appendix Figure 12. The top 15 statistically significant genes (ranked by adjusted P-value) 
downregulated in HLY-1 cells treated with CsA for 2 hours (paired analysis). Each bubble in the 
figure represents one of most highly significant genes differentially expressed upon treatment with CsA. 
The larger the bubble the lower the adjusted P-value. Data excludes genes marked as N/A. 
ID3 
TXNIP 
KLHL42 
DCAF5 
NUAK2 
SOCS3 
RGS12 
Appendix Figure 13. The top 7 statistically significant genes (ranked by adjusted P-value) 
upregulated in HLY-1 cells treated with CsA for 2 hours (paired analysis). Each bubble in the 
figure represents one of most highly significant genes differentially expressed upon treatment with CsA. 
The larger the bubble the lower the adjusted P-value. Data excludes genes marked as N/A. 
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HLY-1 6hr (unpaired data analysis) 
Appendix Figure 14. The top 15 statistically significant genes (ranked by adjusted P-value) 
downregulated in HLY-1 cells treated with CsA for 6 hours (unpaired analysis). Each bubble in 
the figure represents one of most highly significant genes differentially expressed upon treatment with 
CsA. The larger the bubble the lower the adjusted P-value. Data excludes genes marked as N/A. 
RALGPS2 
SFN 
SCN2A 
SNORD96
A 
SCART1  
GUSBP1
1 
RALGPS
2 
DDX1
7 
Appendix Figure 15. The top 8 statistically significant genes (ranked by adjusted P-value) 
upregulated in HLY-1 cells treated with CsA for 6 hours (unpaired analysis). Each bubble in the 
figure represents one of most highly significant genes differentially expressed upon treatment with CsA. 
The larger the bubble the lower the adjusted P-value. Data excludes genes marked as N/A. 
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HLY-1 6hr (paired data analysis) 
Appendix Figure 16. The top 15 statistically significant genes (ranked by adjusted P-value) 
downregulated in HLY-1 cells treated with CsA for 6 hours (paired analysis). Each bubble in the 
figure represents one of most highly significant genes differentially expressed upon treatment with CsA. 
The larger the bubble the lower the adjusted P-value Data excludes genes marked as N/A.. 
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Appendix Figure 17. The top 15 statistically significant genes (ranked by P-value) upregulated in 
HLY-1 cells treated with CsA for 6 hours (paired analysis). Each bubble in the figure represents one 
of most highly significant genes differentially expressed upon treatment with CsA. The larger the bubble 
the lower the adjusted P-value. Data excludes genes marked as N/A. 
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UPF3B   
WSU-NHL 6hr (unpaired data analysis) 
Appendix Figure 18. The top statistically significant gene (ranked by adjusted P-value) 
downregulated in WSU-NHL cells treated with CsA for 6 hours (unpaired analysis). Each bubble 
in the figure represents one of most highly significant genes differentially expressed upon treatment 
with CsA. The larger the bubble the lower the adjusted P-value. Data excludes genes marked as N/A. 
SNORD96A  
HSPA5  
DNAJB11  
Appendix Figure 19. The top 3 statistically significant genes (ranked by adjusted P-value) 
upregulated in WSU-NHL cells treated with CsA for 6 hours (unpaired analysis). Each bubble in 
the figure represents one of most highly significant genes differentially expressed upon treatment with 
CsA. The larger the bubble the lower the adjusted P-value. Data excludes genes marked as N/A. 
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Cell line Cell type
24 hours induction NS virus 
(%  RFP positive)
72 hours induction NS virus 
(%  RFP positive)
SUDHL-1 T-cell 32% 83%
Jurkat T-cell 26% 90%
HLY-1 B-cell 5% 9%
OCI-Ly3 B-cell 0% 0%
U2932 B-cell 0% 5%
SUDHL-4 B-cell 4% 32%
Farage B-cell 0% 0%
WSU-NHL B-cell 1% 5%
SUDHL-6 B-cell 0% 0%
OCI-Ly18 B-cell 0% 19%
a) 
b) c) 
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d) 
e) 
Appendix Figure 21 (Continued from previous page). shRNA knockdown of NFAT2 in DLBCL 
cell lines. (a) The transducibility of B-cells and T cells were compared by spinfection of a potent non-
silencing (NS) virus into cells, followed by induction by 2μg/ml doxycycline (dox) for 24 and 72 hours. 
The percentage RFP-positive cells were analysed by FACs analysis as a measure of transduction. Data 
is from one experiment (b-c) Fully transduced HLY-1 and WSU-NHL cells which stably expressed the 
shRNA construct were induced with 2μg/ml dox for one week before the level of NFAT2 protein was 
analysed by Western blot analysis. α-tubulin was used as a positive loading control. Data is 
representative of three individual experiments. (d) The expression of NFAT2 mRNA in HLY-1 cells 
was analysed by qRT-PCR analysis following one week induction with 2μg/ml dox. (e) The effect of 
NFAT2 knockdown on TNFα mRNA expression was analysed by qRT-PCR analysis following one 
week induction with 2μg/ml dox. For d-e, expression is relative to the uninduced control sample and 
data were normalised to the house-keeping gene GAPDH. Data is representative of one experiment from 
three independent experiments.  
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